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Abstract 
Ovarian cancer is the fifth most common cancer in women in developed countries and is 
associated with poor survival due to late diagnoses. Strategies focusing on detecting the 
disease in the earliest stages and/or improving risk prediction may represent effective clinical 
intervention reducing disease burden. Women at the greatest risk of epithelial ovarian 
cancer (EOC) can be offered prophylactic risk-reducing salpingo-oopherectomy (RRSO), 
which is currently only offered to women with mutations in the highly penetrant susceptibility 
genes BRCA1 or BRCA2. Previous studies show that 46% of familial cases of EOC carry a 
deleterious mutation in BRCA1 (37%) or BRCA2 (9%). The residual proportion of familial risk 
is likely to be attributable to other genetic variants providing a rationale for identifying 
additional susceptibility alleles using rapid high-throughput next generation sequencing 
(NGS) in large samples sizes.  
A pilot study determines the principle of NGS in mutation detection sequencing BRCA1 gene 
in 12 DNA samples with known mutations. The 11bp deletion, missed in the analysis, is 
detected by altering the bioinformatics. The second study sequences 1506 cases and 1130 
healthy controls using Fluidigm microfluidic technology and Illumina HiSeq2000 in 6 DNA 
repair genes (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3 and SLX4). 94% of the 
targeted region is sequenced with >30 reads. 23 cases and 1 control show a putative 
protein-truncating variant in 5 genes. Many missense variants are detected in cases and 
controls suggesting these are not pathogenic.  Epidemiological data shows that women with 
family history and a deleterious mutation develop EOC on average 10 years younger. 
Interestingly, half of those women with detected mutations have no family history.   
A final study uses the established NGS approach to characterise the mutation prevalence in 
4 known and 5 candidate EOC susceptibility genes in 2300 unaffected women from high-risk 
breast-ovarian cancer families. BRCA1 and BRCA2 deleterious mutations are identified in 53 
and 49 women respectively. Deleterious mutations are detected in 6 additional genes, 
BRIP1 (n=5), RAD51C (n=3), RAD51D (n=1) PALB2 (n=5), BARD1 (n=1) and NBN (n=3). 
Importantly, a bioinformatics pipeline is refined to maximise variant detection sensitivity with 
zero false negatives where read depth is >30X. Further large case-control studies are 
recommended to examine the population frequencies in these novel genes. These studies 
demonstrate the potential of targeted NGS approaches for population-wide risk prediction 
and early detection of EOC.  
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Chapter One  
 
Introduction 
 
1.1 The Genetic susceptibility to cancer 
 
Research into genetic susceptibility and cancer has been a highly valuable objective 
within cancer research for several decades.  The discovery of cancer susceptibility 
syndromes that result from a genetic predisposition to a variety of cancer types has 
guided research into novel treatment targets and provided greater insight into the 
biological mechanisms in tumour development (Fletcher & Houlston 2010).   
 
Figure 1.1 Susceptibility to all cancers  
Around 80% of cancers are likely to be sporadic, with 15-20% being familial (i.e. those cancers caused by 
a combination of low penetrance variants and environmental factors) and those that are truly inherited (i.e. 
caused by rare inherited high penetrance variants) are likely to be around 5-10% of all cancer (Adapted 
and re-drawn from Nagy et al 2004; Oncogene (2004) 23, 6445–6470). 
 
Cancers that occur sporadically account for the majority of diagnoses (~80%).  These 
randomly occurring cancers include those without a family link or gene alterations that 
result in an elevated cancer risk.  Around 15-20% of cancers are considered familial, 
i.e. they result from a combination of low penetrance variants and environmental 
factors.  Cancers that are truly inherited (i.e. they are caused by rare moderate-high 
penetrance gene variants) account for the smallest proportion of around 5-10% and 
often exhibit an autosomal dominant pattern of inheritance.  
 
1.2 Cancer susceptibility models 
 
The earliest model of cancer susceptibility dates back to the end of the 1960s with the 
idea that cancers clustering in families are due to genetic changes inherited between 
80% 
15% 
5% 
All Cancer 
Sporadic
Familial
Inherited
 27 
relatives that result in a carcinogenic ‘hit’ that increases the risk of cancer developing.  
Ashley (1969) examined colon cancer in patients with the hereditary condition 
polyposis coli proposing that those patients positive for the polyposis coli gene were 
predisposed to develop colon cancer as they already had one ‘hit’. Thus, they required 
one or two fewer hits to develop the disease.  Ashley based this conclusion on 
examination of the ratio of age-specific incidence of colon cancer patients in the 
general population against the age-specific prevalence in patients positive for the 
polyposis coli gene.  Ashley’s (1969) data showed these ratios reducing as the 
patient’s age increased. The ‘two-hit’ model is now considered an early milestone in 
cancer research with this model forming the basis of some autosomal dominant cancer 
syndromes, including familial adenomatous polyposis (FAP). 
 
1.2.1 High penetrance – rare variant model 
 
High-penetrant cancer susceptibility genes lead to a high risk of developing cancer.  
The predominant high-penetrant genes, discovered from the end of the 1980s through 
to the early 1990s mostly use linkage analysis and positional cloning. The genes 
discovered at this time are breast cancer 1, early onset (BRCA1) and breast cancer 2, 
early onset (BRCA2) (for breast and ovarian cancer), adenomatous polyposis coli 
(APC), MLH1 and MSH2 (for colorectal cancer) and cyclin-dependent kinase inhibitor 
2A (CDKN2A) (for malignant melanoma).  Continued attempts to detect other high-risk 
genes for colorectal cancer and for breast cancer have not been fruitful. Therefore, it is 
likely that the familial risk that is not attributable to the existing high-risk genes could be 
due to the inheritance of multiple variants with a moderate increase in risk (Fletcher & 
Houlston 2010).  For breast cancer, deleterious variants in BRCA1, BRCA2 and TP53 
occur in less than 0.5% of the population (Gayther 2012), but can increase the risk of 
developing the disease 10-20 fold compared to the risk for the general population 
without these mutations (Stratton & Rahman 2008).  
 
1.2.2 Moderate penetrance – rare variant model 
 
This polygenic model of cancer susceptibility proposes that several rare variants exist 
that confer a more moderate increase in cancer risk. Rare variants in this model 
include SNPs (Single Nucleotide Polymorphisms with minor allele frequencies of ≥1% 
but, <5%), sub-polymorphic variants (SNPs with minor allele frequencies of ≤1%) and 
deleterious mutations, such as insertions and deletions ranging from 1 base to many 
bases.  Such susceptibility variants are detected in breast cancer using DNA 
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sequencing technologies in which candidate genes are examined in studies comparing 
cases with healthy controls.  In breast cancer susceptibility, rare variants in this 
category include ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHK2), 
BRCA1 interacting protein C-terminal helicase 1 (BRIP1) and partner and localiser of 
BRCA2 (PALB2), occurring in the population at rate of <0.6%; these rare variants are 
estimated to result in an increased risk of breast cancer of 2-4 times that of the general 
population (Stratton & Rahman 2008). 
 
1.2.3 Low penetrance – common variant model 
 
The low penetrance – common variant susceptibility alleles are also included as part of 
the polygenic model.  This model suggests several commonly occurring (with minor 
allele frequencies >5%) SNPs associate together to increase the risk of cancer by a 
small extent, perhaps up to 3 times an increase compared to the general population.  
The predominant method employed in this model is the Genome Wide Association 
Study (GWAS).  These genetic association studies, which examine vast numbers of 
polymorphic variants distributed throughout the genome, are used to identify loci for 
cancer susceptibility (i.e. specific chromosomal regions that are linked to an increased 
risk in cancer) (Gayther & Pharoah 2010). Tag SNPs are located in genomic regions of 
high linkage disequilibrium (that is alleles that are non-randomly linked at more than 
two genomic loci) and are useful in GWAS to identify these cancer susceptibility loci.  
SNPs associated with breast cancer, which are found in the population at a rate of 5-
10%, are discovered to increase breast cancer risk by around 1.25 x that of the rest of 
the population with differences being noted in those individuals with homozygous or 
heterozygous SNPs (Stratton & Rahman 2008). 
 
1.3 Familial cancer syndromes 
 
Mutated tumour suppressor genes (TSG), genome stability genes or (rarely) 
oncogenes are the cause of familial cancer syndromes. Familial cancer syndromes 
often follow an autosomal dominant, but sometimes a recessive pattern of inheritance 
and exhibit complete or incomplete penetrance.  Familial cancer syndromes frequently 
exhibit specific characteristics that indicate their distinction from sporadic cancers.  
These observations include: more than one primary tumour in the same anatomical 
region, for example, contralateral breast cancer, earlier onset disease, rare histological 
tumour subtypes, and affected first degree relative(s) (FDR) with similar characteristics 
(Weber et al 2001). 
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Some of the most highly penetrant syndromes include: Cowden Syndrome, familial 
adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC) 
also known as Lynch Syndrome, hereditary breast-ovarian cancer syndrome, 
retinoblastoma, Li-Fraumeni syndrome and Peutz-Jeghers syndrome.  All of these are 
very rare syndromes with penetrance levels of 70-100% (Nagy et al 2004). 
 
Mutated tumour suppressor genes (TSG) result in a downregulation of gene function.  
Mutated oncogenes result in an up regulation of function or function when its normal 
counterpart would be inactive. Genome stability genes are involved in maintaining the 
integrity of the cell.  This is achieved through DNA repair efficiency via several types of 
DNA repair mechanism; for example, base excision repair (BER), nucleotide excision 
repair (NER), mismatch repair (MMR) and homologous recombination (HR) (Vogelstein 
& Kinzler 2004). However, in principle they act in a similar manner to classical tumour 
suppressor genes in that their mutations lead to loss of function. 
 
The genetic basis of cancer pathogenesis is reasonably well established.  If 
tumourigenesis arises due to uncontrolled cell growth and proliferation, then mutations 
in both oncogenes and tumour suppressor genes are necessary.  Genome stability 
genes however, function in cell maintenance and are involved in the repair of genetic 
alterations in other genes, thus if genes in this class are mutated it can result in an 
increase in mutations in the other classes of genes.  Tumour suppressor genes and 
genome stability genes have to be inactivated in order to result in downregulated, or 
non-functioning, genes so both alleles of a gene must be lost or inactivated.  Thus, if 
an individual has a germline mutation in BRCA1 (a stability gene) then they will be 
predisposed to develop tumours; but cancer will only develop if they incur a somatic 
mutation rendering the wild type allele also inactive. Oncogenes, however, need to be 
activated (upregulated); therefore, a mutation in just one allele is all that is required.   
 
1.3.1 Tumour suppressor genes 
 
Hereditary retinoblastoma is caused by mutations in the retinoblastoma 1 (RB1) gene, 
most of which are large or small deletions; retinoblastoma follows an autosomal 
dominant pattern of inheritance and almost complete penetrance of 90%.   
 
Familial adenomatous polyposis (FAP, OMIM 175100) is a cancer syndrome causing 
colorectal cancer.  It is caused by mutations in the APC gene and results in many 
adenomatous polyps through the colorectum.  FAP follows an autosomal dominant 
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pattern of inheritance with penetrance greater than 95% (Nagy et al 2004).  Cowden’s 
Syndrome (CS) is also an autosomal dominant disease caused by mutations in the 
phosphatase and tensin homolog (PTEN) gene and results in a number of different 
clinical features often identified in the general unaffected populations for example, 
fibrocystic breast disease or leiomyoma. However, CS patients are also at an 
increased risk of developing breast, thyroid or endometrial cancers.  
 
Li-Fraumeni syndrome (LFS, OMIM 151623) is caused by a heterozygous mutation in 
tumour protein 53 gene (TP53) and clinically causes multiple cancers including breast 
cancer, sarcomas, brain tumours, leukaemias and adrenocortical carcinoma.  LFS 
follows an autosomal dominant pattern of inheritance with virtually complete 
penetrance that appears to vary according to gender. In males penetrance is 
approximately 68% and in females 93%. Females with LFS also tend to be diagnosed 
with cancers at a much younger age as children or young adults. Germline gene 
variants in TP53 are noted in more than half of all LFS families. 
 
Peutz-Jeghers syndrome (PJS OMIM 175200) is caused by mutations in the threonine 
kinase 11 gene (STK11).  The syndrome presents as polyps through the 
gastrointestinal tract including, the colon, duodenum, stomach and jejunum. PJS has 
an autosomal dominant pattern of inheritance.  The syndrome is extremely rare 
occurring in 0.0005% of the population with penetrance at around 100%. 
 
1.3.2 Genome stability genes 
 
Hereditary breast-ovarian cancer (HBOC, OMIM 113705) is largely caused by 
mutations in genes BRCA1 and BRCA2 and has an autosomal dominant pattern of 
inheritance with incomplete penetrance. The penetrance estimates of BRCA1 and 
BRCA2 reduce with advancing age and vary between breast and ovarian cancer.  
Antoniou et al (2003) estimate average breast cancer risks by the age of 70 to be 
between 45-65% and ovarian cancer to be between 11-39%, with BRCA1 conferring 
higher cancer risks for both diseases. 
 
Lynch syndrome (OMIM 120435), which is also known as hereditary non-polyposis 
colorectal cancer (HNPCC), results from heterozygous mutations in DNA mismatch 
repair (MMR) genes.  HNPCC is caused by mutations in the gene mutS homolog 2, 
colon cancer nonpolyposis type 1 (MSH2). HNPCC is often diagnosed at an early age 
and colorectal cancers are more commonly located in a proximal region.  The 
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syndrome is characterised by multiple primary cancers.  Genes involved in HNPCC are 
postmeiotic segregation increased 2 (PMS2), mutL homolog 1, colon cancer 
nonpolyposis type 2 (MLH1) and (MSH2), mutS homolog 6 (MSH6). 
 
Lynch syndrome follows an autosomal dominant pattern of inheritance.  Prevalence of 
Lynch syndrome is estimated to be in the region of 0.05% at the general population 
level and around 1-3% in patients affected by endometrial or colorectal cancer.  
Lifetime (up to age 70) penetrance estimates of colorectal cancer are close to 100% in 
men with Lynch syndrome. In women, the lifetime penetrance estimates of endometrial 
cancer are up to 60% and colorectal cancer up to 54% by age 70 (Nagy et al 2004).   
 
Fanconi Anaemia (FA, OMIM 227650) is a highly heterogeneous syndrome caused by 
a several FANC and FANC- like genes.  The syndrome results in increased risks of 
cancers especially acute myeloid leukaemia.  FA has an autosomal recessive pattern 
of inheritance. 
 
1.3.3 Oncogenes 
 
Multiple endocrine neoplasia type 2 (MEN2) is caused by the oncogene ret proto-
oncogene (RET) and follows an autosomal dominant pattern of inheritance with almost 
complete penetrance.  MEN2 leads to conditions including medullary thyroid carcinoma 
(MTC), hyperparathyroidism (HPT) or parathyroid adenomas and phaeochromocytoma 
(PC) which are tumours involving the adrenal chromaffin cells. 
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1.4 The genetic susceptibility to ovarian cancer 
 
1.4.1 Ovarian cancer epidemiology and aetiology 
 
Ovarian cancer is the fifth most common cancer in women in developed countries. In 
the UK around 6,500 women are diagnosed and 4,400 women die from the disease 
each year meaning that ovarian cancer causes 6% of deaths in women from cancer.  
Globally, the figure is likely to be around 225,000 new cases diagnosed annually 
(2008). Extensive geographical variation is noted between different regions 
internationally as disease incidence rates appear to differ dramatically between 
developing and developed countries.  Regions with the highest incidence rates are 
Northern, Central and Eastern Europe with Africa and regions of Asia showing the 
lower incidence rates.  In Europe 65,000 new diagnoses were made in 2008 and 
21,500 new cases diagnosed in the US in the same year (Cancer Research UK 2008 
statistics). 
 
There has been some progress in survival rates in the 30 years between the early 
1970s until the early 2000s for short-term survival.  In 1971 women diagnosed with 
ovarian cancer had a survival probability of 42% (1 years) and 21% (5 years). In 2003 
these survival rates were 70% (1 year) and 41% (5 years).  However, the long-term 
survival rates remain low, even with current improved treatments the five-year survival 
rate is still less than 50%. This is likely to be attributable to late diagnosis of the 
disease.  The stage at diagnosis is key in survival rate: diagnoses at stage I disease 
show a five year survival rate of ~90%, compared to diagnoses made at stage IV 
where five year survival rate is as low as 5%.   
 
Essential in improving these bleak statistics are the introduction of superior approaches 
to risk prediction and earlier detection.  In addition, risk prediction will improve survival 
rates as identifying women at increased risk can be offered risk-reducing surgery 
known as risk-reducing salpingo-oophorectomy (RRSO).  This is currently offered to 
women with mutations in BRCA1 or BRCA2 and is a successful prophylactic in these 
cases reducing the risk of developing ovarian carcinomas. 
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Figure 1.2 A graphical representation of the proportion of sporadic (78%) and inherited (22%) 
causes of ovarian cancer.  This pie chart demonstrates the large proportion of sporadic ovarian cancers 
compared to the small proportion of inherited ovarian cancers. 
 
Studies in twins estimate that around 78% of ovarian cancer is sporadic, with the 
remaining 22% being due to inherited genetics (Figure 1.2) (Lichtenstein et al 2000).  
An individual with a first degree relative (FDR) has a 3-fold increase in risk of 
developing ovarian cancer.  Ramus et al (2007) show that in cases where there are 
more than two familial cases of epithelial ovarian cancer (EOC) in either first or second 
degree relatives, 46% are found to have probable deleterious mutations in BRCA1 
(37%) or BRCA2 (9%). 
 
 
Figure 1.3 A graphical representation of the residual unknown proportion of ovarian cancer 
susceptibility.  This pie chart demonstrates that half of inherited ovarian cancers are attributable to 
moderate penetrance variants other than BRCA1 or BRCA2. 
  
BRCA1 and BRCA2 have previously been shown to be the main (high penetrant) 
ovarian cancer susceptibility genes, accounting for ~50% of ovarian cancers. Hoskings 
et al (2011) suggests that in breast cancer common low penetrant variants are likely to 
account for ~8% of familial risk; it is plausible then that a similar contribution can be 
estimated in ovarian cancer.  Therefore, the large residual proportion of inherited 
ovarian cancer risk (around 46%) may be attributable to additional rare gene variants 
22 
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(Figure 1.3).  This provides a strong rationale for researching additional moderate to 
high penetrant gene variants in epithelial ovarian cancer (EOC).  These gene variants 
can be discovered via large scale sequencing studies of candidate genes or exome 
sequencing.  
 
Additional rare variants involved in ovarian cancer may follow a similar pattern to those 
identified in breast cancer; in which these rare variants can be subdivided into high-
penetrance and moderate-penetrance variants.  Investigating the BRCA1 and BRCA2 
molecular pathways lead to the identification of additional rare variants of moderate 
penetrance, namely ATM, CHK2, BRIP1, PALB2 and Nijmegen breakage syndrome 1 
(NBS1).  These variants are all identified as implicated in DNA repair and linked to the 
BRCA1 and BRCA2 network. These variants have an estimated frequency of ≤0.6% 
(Stratton & Rahman 2008). To study the contribution of mutations in these moderate-
penetrance genes to ovarian cancer would require extremely large cohorts since not 
only are these variants very rare they confer a lower risk of cancer; as such finding 
affected women would be problematical.  However, this could be achieved via 
international collaboration initiatives (Stratton & Rahman 2008).   
 
Figure 1.4 Allele frequency and breast cancer risk 
 
Figure 1.4 Allele frequency and breast cancer risk.  This diagram illustrates the relationship between 
breast cancer risk and allele frequency in the general population adapted from: Hollestelle et al Current 
Opinion in Genetics & Development 2010, 20:268–276 
 
Figure 1.4 demonstrates the association between genes conferring high, low and 
moderate cancer risk and the allelic frequency amongst the population.  High 
penetrance genes are rare within the population, whereas low penetrant genes are 
more common.  Moderate risk genes are rare in occurrence (Hollestelle et al 2010). 
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Hollestelle et al (2010) suggest that the high penetrant genes BRCA1 and BRCA2 
occur at a frequency of <0.1% in the population, where other estimates suggest <0.5% 
(Gayther 2012). It is likely that the genetic predisposition to ovarian cancer follows a 
similar pattern to breast cancer and that whilst the high penetrant rare alleles have 
been discovered through genetic linkage analysis; the moderate risk rare variants are 
probably best identified using DNA sequencing of large cohorts of cancer cases and 
controls (Li & Leal 2009). 
 
1.4.2 Family history 
 
Ramus & Gayther (2009) review the frequency of BRCA1 and BRCA2 mutations 
detected in breast and ovarian cancer or ovarian cancer families comparing a number 
of different studies conducted around the world.  They report a disparity in frequencies 
between studies.  These frequencies range from 34% to 84% for the presence of a 
mutation in either gene.  This apparent disparity may be due to a number of issues 
including, mutation detection methods, cohort recruitment biases (i.e. some studies 
may include only those families with >2 ovarian cancer cases whilst others >1 case 
was sufficient to be included), the presence of founder mutation cohorts, differences in 
protocols adopted by laboratories, size of cohort and finally, some studies screen all 
possible mutations where others do not include large genomic rearrangements.  
Ramus & Gayther (2009) note that within ovarian cancer families mutation frequencies 
vary between two cancer syndromes; hereditary breast and ovarian cancer (HBOC) 
syndrome and site-specific ovarian cancer (ovarian cancer only).  Detected mutation 
frequencies are higher in HBOC families (81%) compared to ovarian cancer only 
families (63%).  These data are derived from two familial ovarian cancer registries 
(Ramus & Gayther 2009).  In addition, these data also demonstrate that when there 
are more ovarian cancer cases within a family the frequency by which mutations are 
detected also increases.  Finally, Ramus & Gayther (2009) note that the proportion of 
BRCA1 mutations in families with ovarian cancer cases is higher than BRCA2 
mutations detected in these families.   
 
1.4.3 High penetrance genes 
 
BRCA1 and BRCA2 are likely to be responsible for around 13% of high-grade serous 
ovarian adenocarcinomas (The Cancer Genome Atlas 2011, Risch et al 2006).  
Hereditary breast/ovarian cancer syndrome (HBOC) is probably one of the most widely 
documented hereditary cancer syndromes.  Within the general population prevalence 
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figures are estimated to be in the region of 1:800 for a BRCA1 mutation and 1:500 for 
BRCA2 mutations (Antoniou et al 2008).  These figures vary extensively from study to 
study as the prevalence statistics vary between populations examined.  Inherited 
mutations in BRCA1/2 genes also increase the likelihood of other cancers developing, 
for example cancers of the pancreas, fallopian tube, stomach, larynx and prostate 
(Nagy et al 2004). Penetrance figures also fluctuate between populations, which may 
be the result of additional altering environmental factors or additional gene variants or 
due to variations in risk between different gene variants (Nagy et al 2004).  The 
penetrance rate in high-risk families (i.e. several cases within the family) is estimated to 
be 70% breast cancer by age 70 in those with BRCA1 or BRCA2 mutations.  Antoniou 
et al (2003) calculate accurate figures for the risk of developing breast or ovarian 
cancer with an inherited mutation in either gene.  In this study, they collect data from 
22 different studies, which include 8139 cancer index cases concluding that the 
cumulative EOC risk for women with mutations in BRCA1 is between 44% and 63% by 
70 years and in those with mutations in BRCA2 is between 27% and 31% by 70 years. 
 
1.4.4 Mismatch Repair genes in Lynch syndrome (HNPCC) 
 
A significant cause of inherited ovarian cancer is the familial cancer syndrome 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC).  Mutations in mismatch repair 
(MMR) genes may be responsible for up to 10% of inherited ovarian cancer.  Barrow et 
al (2009) examine 121 families with Lynch syndrome calculating the cumulative lifetime 
incidence for women with mutations in the Lynch Syndrome genes as 32.5% for 
gynaecological cancers (endometrial and ovarian).  The risk of endometrial cancer 
being much higher than ovarian cancer; in the study they quote the average cumulative 
ovarian cancer incidence of 6.1% by age 70. Lu & Daniels (2013) report the lifetime 
incidence of ovarian cancer in Lynch syndrome as between 6% and 8%. 
 
1.4.5 RAD51C and RAD51D as ovarian cancer susceptibility genes 
 
In the last two years two new ovarian cancer susceptibility genes have been identified.  
Meindl et al (2010) examine the gDNA of 480 women with HBOC finding 6 
heterozygous deleterious mutations in RAD51 homolog C (S. cerevisiae) (RAD51C) 
occurring at a rate of 1.3% in the study population.  This compares to zero mutations 
detected in women with breast cancer only.  Meindl et al (2010) also examine the 
RAD51 locus in tumour tissues finding they exhibit loss of heterozygosity suggesting 
RAD51C is a tumour suppressor.  Loveday et al (2011) analyse RAD51D for germline 
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mutations in 911 women from HBOC families and 1,060 matched healthy controls.  
They find 8 deleterious mutations in the cases and just one in the controls.  Loveday et 
al (2011) report the link between RAD51D and cancer is more significant in ovarian 
cancer cases than breast cancer, calculating the relative risks to be 6.30 and 1.32 for 
ovarian and breast cancer respectively. 
 
1.4.6 Genetic modifiers of cancer risk (CIMBA)  
 
The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) is an 
international collaboration initiative set up to investigate genetic modifiers.  This 
consortium includes several consortia with similar aims, for example EMBRACE 
(Epidemiological study of BRCA1 and BRCA2 mutation carriers) and Modifiers and 
Genetics in Cancer (MAGIC).  The creation of CIMBA allows for studies to be 
conducted with improved accuracy as collaboration results in increased sample 
numbers in studies. CIMBA includes groups that have access to a minimum of 100 
BRCA1 and BRCA2 positive women (with or without cancer) and are able to provide 
data on genotype, phenotype and epidemiological risk in those samples.  Groups 
follow standardised protocols for SNP genotyping. 
 
Genome wide association studies (GWAS) have identified SNPs in the general 
population that affects risk of developing ovarian cancer.  One SNP rs3814113 at 
9p22.2 is linked to a decreased risk in ovarian cancer (Goode et al 2010).  Within 
BRCA1 and BRCA2 mutation carriers this SNP also lowers the risk of ovarian cancer. 
There are a number of signs that indicate the existence of genetic modifiers to ovarian 
cancer risk.  These include variability seen in penetrance figures both within mutation 
positive pedigrees and between different families (Milne & Antoniou 2011).  Milne & 
Antoniou (2011) review the evidence on genetic modifiers in BRCA1 and BRCA2 
positive breast and ovarian cancer.  For example, they report that 2 SNPs (rs8170 and 
rs2363956) located at 19p13 are linked to increased risk of ovarian cancer or breast 
cancer within the general population and an increased risk of breast cancer only in 
patients positive for BRCA1.  Interestingly, when breast and ovarian cancer are 
examined together these SNPs do not affect risk.  Much of the work of CIMBA group 
members is currently being conducted and more evidence is required to confirm that 
19p13 is linked to increased risk of ovarian cancer in women positive for mutations in 
BRCA1. 
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A further candidate for a genetic modifier is the polymorphism known as CASP8-
D302H, which appears to result in a reduced risk of ovarian cancer in patients with 
BRCA1 mutations.  This reduction is estimated to be around 30%.  This effect is only 
seen in patients with BRCA1 mutations not in BRCA2 (Engel et al 2010) 
 
1.4.7 Hormonal and environmental modifiers of ovarian cancer risk in BRCA1 and 
BRCA2 women 
 
Barnes & Antoniou (2011) report on a number of studies that examine non-genetic 
modifiers.  They find that several factors can alter the cancer risks.  These factors 
include oral contraceptive use, which is shown to both increase and decrease risk of 
breast cancer in different studies.  In ovarian cancer a decrease in risk is noted in 
women using oral contraceptives.  Nulliparous women show an increase in risk of 
breast cancer.  Risk-reducing salpingo-oophorectomy (RRSO) is demonstrated to 
markedly reduce the risk of developing breast cancer in women positive for mutations 
in BRCA1 or BRCA2.  Radiation exposure during chest x-rays is demonstrated to 
increase the risk of developing breast cancer in BRCA1/2 positive patients.  The risk of 
breast cancer in women with high mammographic density and BRCA1/2 positive is 
estimated to be doubled compared to women with low mammographic density. 
 
1.5 Molecular pathogenesis of epithelial ovarian cancer 
 
1.5.1 Clinical features of epithelial ovarian Cancer – histological subtypes 
 
There are a number of different histological subtypes of epithelial ovarian cancer: 
endometrioid, mucinous, clear cell, transitional and serous.  These histological types 
represent very different diseases.  However, the main bulk of ovarian carcinomas fall 
into the high-grade serous category. The site of origin of ovarian cancer appears to be 
mesothelium of the ovary that forms inclusion cysts within the surrounding stroma.  It is 
these inclusion cysts that transform into malignant cells.  The ovarian carcinoma first 
metastasises to surrounding structures including the pelvis, abdomen and later more 
distant regions.  If ovarian carcinoma is detected early before metastasising outside of 
the ovary then survival rates are much improved.  Treatments generally include 
surgery and chemotherapy to prevent this spread.  One of the difficulties in treatment 
success has been the vast heterogeneity of the disease. 
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1.5.2 A model of histological categories of ovarian cancer 
 
Kurman & Shih (2010) suggest a model that categorises ovarian cancer based on 
molecular genetic and morphological characteristics. This model suggests there are 
two types of ovarian cancer, type I and type II. 
 
Type I tumours are slow developing and present at an earlier stage.  They are often 
borderline tumours with characteristics of both benign cysts and carcinoma.  In this 
category are the low-grade serous and low-grade endometrioid, clear cell and 
mucinous carcinomas.  In terms of the genetic characteristics, most low-grade serous 
tumours have mutations in vi-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and v-erb-b2 
erythroblastic leukaemia viral oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian) (ERBB2).  Mutations in TP53 are very uncommon in type I 
tumours.  In the low-grade endometrioid tumours mutations in catenin (cadherin-
associated protein), beta 1 (CTNNB1), phosphatase and tensin homolog (PTEN), and 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) occur 
commonly, whereas mucinous tumours show mutations in KRAS.   
 
Type II tumours are high-grade serous and high-grade endometrioid and also tend to 
be undifferentiated.  They usually present at a later stage and are aggressive tumours.  
High-grade serous tumours have mutations in TP53 in the majority of cases.  
Interestingly, type II tumours only very rarely show mutations in those genes commonly 
found occurring in type I tumours.   
 
1.5.3 The cell of origin of epithelial ovarian cancer 
 
Debate on the origin of epithelial ovarian cancer (EOC) continues.  Discerning the cell 
of origin of EOC is relevant in research as this may shed further light upon 
pathogenesis of the disease and assist in earlier detection and development of new 
biomarkers.  To date no clear precursors to the disease are discovered. Whilst the site 
of origin of ovarian cancer appears to be the mesothelium of the ovary, the cell of origin 
is still debated.  The starting point is that the cell of origin is also the mesothelial cell of 
the ovary and that metaplastic alterations result in the transformation of these cells into 
the different histological subtypes of endometrioid, serous, mucinous, transitional and 
clear cell. The endometrioid subtype has the appearance of endometrial epithelium and 
the serous subtype is similar to the epithelium of the fallopian tube.  Clear cell tumours 
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look like the epithelium of the gastrointestinal tract, with mucinous like the epithelium of 
the endocervix.   
 
The cervix, endometrium and fallopian tubes originate from the Mullerian ducts, 
whereas the ovaries arise from the urogenital ridge, which is composed of 
mesothelium.  Thus, it can be suggested that tumours resembling tissues derived from 
Mullerian ducts are not derived from the surface epithelium of the ovary, but from the 
columnar epithelium of the Mullerian tissues.  It is possible then, that high-grade serous 
carcinomas originate from the fallopian tube and metastasise locally first to the ovary. 
Kurman & Shih (2010) review theories on the ovarian cancer cell of origin in an attempt 
to further elucidate the pathogenesis of ovarian cancer. 
 
1.5.4 Mesothelium as the cell of origin 
 
Histologically, the subtypes, serous, mucinous, endometrioid and clear cell do not look 
as though they have originated from the mesothelium of the ovary.  One explanation 
for this is that metaplastic alterations of inclusion cysts arise following the invagination 
of the mesothelium of the ovary within the ovarian stromal tissues.  These metaplastic 
changes may result in the transformation of the mesothelial cells to Mullerian duct type 
epithelial cells (Kurman & Shih 2010). 
 
1.5.5 Mullerian duct as the origin of ovarian cancer  
 
Precursor lesions in paratubal and paraovarian cysts that appear like serous, 
endometrioid, and mucinous or clear cell have not been discovered. In addition, 
mucinous type cancers appear to be more like gastrointestinal cells than Mullerian. 
 
A number of studies, in women with a genetic susceptibility (i.e. BRCA mutation 
positive) to ovarian cancer demonstrate that in fact early lesions appear in the fallopian 
tube in this group of women.  Later it was discovered that the majority of sporadic high-
grade serous tumours display some involvement of the tubal mucosa.  Thus, it is 
possible that serous tubal intraepithelial carcinoma (STIC), which is thought to derive 
from the fimbria, may also be the origin of high-grade serous carcinoma. In addition, 
the vast majority of STICs reveal mutations in TP53. 
 
Louis Dubeau (2008) has studied the cell of origin for ovarian cancer extensively. He 
purports that epithelial ovarian tumours, rather than arising from the ovarian 
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mesothelium, are in fact derived from the tissues of the Mullerian duct. He goes further 
to suggest that the primary tumours of the fallopian tube, peritoneum and ovary are, 
essentially one single disease with Mullerian origins.  Dubeau (2008) sites a number of 
arguments to support his theory including molecular biology, embryology and tumour 
morphology.  Dubeau (2008) proposes that these tumours should be reclassified as 
‘extrauterine Mullerian cystadenomas or carcinomas’ and that these should be sub-
classified based on histology (i.e. serous, mucinous, endometrioid, clear cell).  In terms 
of those patients with a mutated BRCA1 or BRCA2 gene this re-classification could 
have implications in prophylactic treatment in which cases surgery could exclude some 
of the ovarian cortex thus enabling women to remain fertile. 
 
1.5.6 Gene Variants and Tissue Types 
 
EOC is highly heterogeneous. Kurman & Shih’s (2010) model, based on two main 
types of ovarian cancer, may well be oversimplified.  EOC is likely to be several 
different diseases that share a similar anatomical location. The molecular genetics of 
type I and type II tumours are distinctly different.  Type I tumours rarely display 
mutations in TP53 and >60% of low-grade endometrioid tumours exhibit mutations in 
KRAS, BRAF and ERBB2.  Alterations of the gene encoding β-catenin CTNNB1 or 
PTEN have also been found in a number of studies (Bell 2005). By contrast, type II 
tumours such as high-grade serous carcinoma (HGSOC) commonly display mutations 
in TP53 and amplification of the gene cyclin E1 (CCNE1).   The Cancer Genome Atlas 
(TCGA) data revealed that within type II tumours the different subtypes also display 
distinct molecular signatures.  TCGA researchers conduct exome sequencing on the 
tumour DNA of 316 high-grade serous ovarian cancer (HGSOC) specimens comparing 
the tissue samples of matched normal control samples.  They find that TP53 is 
somatically altered in >96% of samples and that 9% of cases exhibit a germline 
mutation in BRCA1 or 8% in BRCA2.  In addition somatic alteration in BRCA1/2 was 
noted in another 3% of samples. These data show that in ~50% of EOC, genes in 
homologous recombination (HR) are somatically altered. 
 
Type I tumours rarely show mutations in genes mutated in type II tumours and vice 
versa.  Mutations in KRAS are detected in both borderline and mucinous tumours; 
however, TP53 mutations are very rare in these tumour types.  Further elucidation of 
the molecular signatures of EOC are likely to lead to more accurate and detailed 
models of the disease and lead to more accurate, effective and targeted treatments for 
the disease. 
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1.5.7 The effect of inherited BRCA1 and BRCA2 mutations on pathology of EOC 
 
Lakhani et al (2004) examine the histopathology of tumour samples of patients with 
BRCA1 or BRCA2 mutations as many studies have previously reported conflicting 
results.  They investigate two groups of tumours: one includes 223 tumours from 
women with family history and the other 235 tumours from women unselected for a 
familial link.  The family history cases have a minimum of one first-degree relative 
(FDR) or one second-degree relative (SDR) with ovarian cancer.  Within the family 
history group 173 women are positive for mutations in BRCA1 and 29 have a mutation 
in BRCA2, the remaining number (16) are not positive for a mutation in BRCA1 or 
BRCA2 and are excluded for the rest of the study.  The mutation positive carriers 
include only those that have a deleterious mutation as defined by the Breast Cancer 
Information Core (BIC).  These deleterious mutations result in a truncated protein 
product due to a frameshift or nonsense mutation.  Also, included are large 
rearrangements, splice site variants or missense mutations that are clinically relevant 
as assessed by the BIC.   
 
Tumour samples are assessed for histological subtype and tumour grade as well as 
the evidence of psammoma bodies (clusters of calcium seen through a microscope), 
vascular involvement, necrosis, mitotic index and amount of solid tumour.  In addition, 
tumour samples are examined immunohistochemically for p53 and ERBB2 (also known 
as HER2).  In terms of age the patients with BRCA1 mutations 84% are between 30-59 
years old with only 16% above 60 years old.  For BRCA2 mutation carriers, 48% are 
40-59 years old with the remaining 52% being over 60 years old.  Tumour grade and 
histological subtype varies between BRCA1 and BRCA2 mutations carriers and 
controls.  Samples from patients with BRCA1 mutations are more often found to exhibit 
tumours of serous histology (44% of tumours) compared to controls (31% had serous 
histology).  This translates to an odds ratio (OR) of 1.84 in patients with BRCA1 
mutations having a serous histological result.  BRCA2 positive patients have the 
highest level of serous histology tumours at 48%.  Tumour grade also varies between 
groups.  72% of BRCA1 mutation positive patient samples exhibit tumours that are high 
grade (poorly differentiated or undifferentiated) compared to 81% of BRCA2 mutation 
positive patient samples and 55% of controls.  It is noted that the BRCA2 mutation 
positive patients include a group of women who are substantially older than the BRCA1 
group and this could have an affect upon tumour grade. They find TP53 
immunohistochemical staining is more often strong in BRCA1/2 tumours and this 
validates similar findings by Ramus et al (1999).   
 43 
Evans et al (2008) perform a large study examining ovarian cancer within families.   
They find that pathology of tumours affects the rate of identification of gene mutations.  
They combine the results of five studies and find that mucinous tumours very rarely 
exhibit mutations in BRCA1 or BRCA2; the combined total for these studies is only 2% 
mucinous and 2% for borderline.    
 
Piek et al (2001) conduct research to review the histopathology of fallopian tubes that 
are surgically removed from women that had a genetic susceptibility to ovarian cancer.  
They find that fallopian tubes demonstrate dysplastic and hyperplastic lesions and 
alterations in proteins involved in cell-cycle control and apoptosis are often evident.  
This implies a possible phenotype of a pre-malignant stage.  
 
1.5.8 Effect of inherited mutations in RAD51C or RAD51D on pathology of EOC 
 
How inherited mutations RAD51C or RAD51D affect the pathology of ovarian is yet to 
be elucidated.   There appears to be no existing research on specific histology of 
tumours of women with germline mutations in either of these genes.  It could be 
postulated that these might be more likely to be high-grade serous adenocarcinomas 
as they are known to interact with the BRCA1 DNA repair network and as they are 
involved in DNA repair via homologous recombination. This research may go some 
way in revealing insight into this area as cases in these studies are enriched for high-
grade serous adenocarcinoma. 
 
1.6 Clinical relevance 
 
1.6.1 The effect of gene variants on survival and chemosensitivity in ovarian cancer 
 
The assessment of clinical relevance of variants in BRCA1/2 in ovarian cancer cases 
reveals inconsistent data.  In an effort to resolve this researchers (Yang et al 2011) use 
data from The Cancer Genome Atlas (TCGA) to examine the effect of harbouring faulty 
BRCA1 or BRCA2 genes on overall survival, progression free survival and 
chemosensitivity.  Patients are considered to have a faulty BRCA1 or BRCA2 gene if 
found to be positive for a deleterious mutation or with hypermethlyation of the promoter 
region of either gene.  Overall survival is defined as the period of time from the original 
surgery to resect the tumour up to death and progression free survival is defined as the 
period of time from original surgery up to recurrence or progression of disease.  
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1.6.2 Survival analysis in BRCA1 and BRCA2 mutation carriers 
 
BRCA1 or BRCA2 mutation positive patients with high-grade serous ovarian carcinoma 
show improved survival to those negative for mutations in either gene; those with 
mutations in BRCA2 show a better survival rate than those with BRCA1 (Yang et al 
2011, Bolton et al 2012).  Interestingly, those patients with epigenetic alterations in 
BRCA1 that result in gene silencing show survival rates equivalent to those negative 
for a mutation in either gene.   
 
1.6.3 Survival in novel variants 
 
As yet, there is very little survival data on new variants (for example RAD51C and 
RAD51D) that are found related to ovarian cancer.  Walsh et al (2011) do not find a 
significant association between overall survival and mutation status amongst their 
cohort.  However, they do find a general tendency to better survival in those with 
mutations than those without.  As more studies are conducted and statistics combined 
for newly discovered variants, survival in novel variants will be more accurately 
estimated. 
 
1.6.4 Chemosensitivity in patients with BRCA1 or BRCA2 mutations  
 
Yang et al (2011) investigate chemosensitivity by examining at two main points: 1, 
primary response to treatment (platinum based chemotherapy) and 2, time interval free 
of treatment after initial primary response.  In the primary response a patient can be 
described as either chemo-sensitive or chemo-resistant depending on whether she has 
a response (partial or complete) to chemotherapy or no response (i.e. disease 
remained or progressed). Yang et al (2011) find that in High Grade Serous Ovarian 
Cancer (HGSOC) patients are more chemo-sensitive if positive for BRCA2 mutations 
compared to patients either BRCA1 positive or BRCA negative. 
 
1.6.5 Targeted chemotherapeutic treatments 
 
Detection of novel gene variants may lead to a greater understanding of the biological 
pathways involved and result in the identification of new treatment targets.  This has 
already been the case for patients with BRCA1 or BRCA2 related breast cancer.  In 
addition, many BRCA1 breast cancers are triple negative. Interestingly, TCGA notes 
the parallels between basal-like breast cancers (that are generally triple negative) and 
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high-grade serous ovarian carcinoma.  Uncovering the gene variants specific to this 
subtype might reveal that the chemotherapeutic treatments are also transferable. 
 
1.6.6 PARP inhibitors 
 
Poly (ADP-ribose) polymerase (PARP) is a DNA repair enzyme with a specific role in 
ssDNA break (SSB) repair.   It initiates a signaling cascade on detection of SSBs.  
Chemical inhibition of one of the two isoforms (PARP1 and PARP2) has been shown to 
be lethal only to those cells that are deficient in proteins of DNA repair via homologous 
recombination (for example, BRCA1 and BRCA2).  The action of PARP inhibition 
(Figure 1.5, page 46) works simply by forcing homologous recombination deficient cells 
to go through an alternative DNA repair pathway; cells without this genetic deficiency 
follow the normal repair pathway and are spared (Ashworth 2008).  The HR deficient 
tumour cells only are targeted and result in the selective death of those tumour cells.  
In addition, PARP inhibitors, currently in phase III clinical trials, show efficacy on 
tumours that inherently express BRCA1/2 deficient characteristics.  This phenomenon 
is known as BRACness (TCGA).  Those tumours with epigenetic silencing of BRCA1 
are also sensitive to PARP inhibitors. 
 
Figure 1.5.  BRCA1 or BRCA2 deficient cells are sensitive to PARP inhibitors; 
normal cells are not 
 
Figure 1.5. PARP inhibitors. PARP inhibitors affect BRCA1 or BRCA2 deficient cells only, because 
following DNA damage cells are forced into alternative DNA repair pathways.  These pathways are error 
prone and result in either the death of BRCA deficient cells or in their survival with gross chromosomal 
aberrations.  Normal cells are not sensitive to PARP inhibitors as they are able to follow the homologous 
recombination pathway following DNA damage (Ashworth, A 2008 J Clin Oncol 26:3785-3790). 
HR=homologous recombination, NHEJ=non-homologous end joining, SSA=single-strand annealing 
pathway. 
 46 
A research group has designed a laboratory test that can assay the sensitivity of cells 
to PARP inhibition.  Mukhopadhyay et al (2010) develop a laboratory test that can 
predict the sensitivity of cells to PARP inhibition. The assay is developed to test EOC 
tumour cells for deficiencies in Rad51 foci formation.  They find that 93% of cells 
deficient in homologous recombination are sensitive to PARP inhibition and that failure 
to form Rad51 foci is a good predication of homologous recombination deficiency.  
 
1.7 An overview of DNA sequencing technology for mutation detection 
 
Frederick Sanger won the Nobel Prize in Chemistry in 1980 for developing one of the 
first methods in DNA sequencing; the ‘Sanger Method’ is also known as the chain 
termination or dideoxy method and came into use in 1977.  DNA sequencing involves 
copying the original DNA sequence numerous times.  The original Sanger method is a 
four-tube reaction; into each tube DNA template, primer, polymerase, free nucleotides 
and one of 4 radioactive dideoxynucleotides are added.  First the template DNA is 
denatured into single stranded DNA.  The primer is hybridised to the template strand 
and is the starting point for sequencing.   The DNA polymerase anneals to the primer 
and synthesises another DNA strand complimentary to the original template by adding 
the free nucleotides in the tube.  Since the tube also contains one of the radioactive 
dideoxynucleotides the growing DNA chain is terminated as this modified nucleotide is 
missing the 3’OH group required to form the phosphodiester bond with the next 
nucleotide.  This results in numerous copied fragments of DNA of different lengths that 
end in a radioactive dideoxynucleotide (ddNTP).  Each tube has a different ddNTP; 
thus when the reaction products of each tube are separated on adjacent lanes on an 
electrophoretic polyacrylamide gel the length of fragment (smaller DNA molecules 
migrate faster) indicates the position of the nucleotide and the fluorescence indicates 
the base.  The gel is visualised under ultra-violet light or by autoradiography and read 
from the bottom upwards (Sanger et al 1977). 
 
Determining the order of the four bases in DNA heralds a new era in which knowledge 
of genetic variation is now more accessible, opening up greater opportunity to discern 
disease aetiology and epidemiology; and drive new insights into human evolution. DNA 
sequencing methodology has evolved rapidly over the last decade, during which time 
the draft reference sequence of the human genome was sequenced by the huge 
international collaborative efforts of the Human Genome Project in 2001.  Figure 1.6 
depicts the progress of DNA sequencing technology throughout the last 10 years. 
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Figure 1.6.  The progress of DNA sequencing during the last 10 years.   
 
Figure 1.6.  The progress of DNA sequencing during the last 10 years.  This image is a graphical 
representation of the rapid progress made in DNA sequencing technology throughout the last decade.  
Adapted from: Strannenheim & Lundeberg (2012) Stepping stones in DNA sequencing. Biotechnol J. 2012 
Sep;7(9):1063-73 
 
1.7.2 DNA sequencing by capillary electrophoresis 
 
DNA sequencing by Capillary Electrophoresis, still recognised as the gold standard, is 
a modification of the Sanger Method. It employs dye-terminating chemistry to allow for 
one sequencing reaction to take place instead of four.  The fragments of copied DNA 
are separated by capillary electrophoresis and each of the 4 ddNTPs is fluorescently 
labelled with a different coloured dye; laser excitation enables their identification. The 
trace output produced is a four-colour system that represents each of the 4 bases 
(Figure 1.7 overleaf).  
 
 
 
 48 
Figure 1.7 Capillary electrophoresis trace output.   
Figure 1.7 Capillary electrophoresis trace output.  This image shows the output from DNA sequencing 
using capillary electrophoresis. Red = Thymine, Blue = Cystosine, Black = Guanine and Green = Adenine.  
 
1.7.3 Next generation sequencing (NGS) 
 
Next generation sequencing, also known as massively parallel sequencing or second-
generation sequencing, can effectively sequence DNA templates in the order of 
kilobases (Kb) to megabases (Mb) simultaneously.   Up to 600 Gb per run in around 10 
days are achievable with the latest Illumina HiSeq2000; this, coupled with a high-
throughput per run, results in a highly cost effective sequencing method (Mamanova et 
al 2010).  Today’s NGS technology is able to sequence more than 5 whole human 
genomes simultaneously at a depth of 30 X with the latest dual flow cell Illumina 
HiSeq2000 or sequence 100 exomes in a single run.  However, when sequencing large 
numbers of subject DNA samples and if the researcher’s interest is in only a few genes 
this could be highly wasteful.  To circumvent this problem target enrichment 
approaches are employed to isolate and enrich the genomic region of interest and 
enable just those regions to be sequenced.  This increases sample throughput to 
unprecedented scales, depending on the size of genomic region targeted. 
 
1.7.4 Next generation sequencing system technologies 
 
These systems vary in terms of sequencing chemistry, throughput and cost.  All have 
similar library preparation protocols, during which the template sample is prepared for 
sequencing. 
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1.7.5 Illumina Genome Analyzer IIx (GAIIx) and Illumina HiSeq2000 
 
Figure 1.8. The Illumina HiSeq2000 
 
Figure 1.8. The Illumina HiSeq2000. This image describes some of the features in this technology 
including the dual flow cell and streamlined plug and play reagents.  Nevertheless, this instrument requires 
a large amount of space in the laboratory and a separate C-bot instrument for cluster generation. Image 
sourced from http://www.illumina.com/systems/hiseq_2000_1000.ilmn. 
 
 
The Illumina HiSeq2000 system is the successor to the GAIIx. This instrument 
amplifies by generating clusters of the original template immobilised on a glass slide 
(known as a flow cell).  The clusters are sequenced using fluorescently labelled 
reversible dNTPs and ‘sequencing-by-synthesis’ to produce 150bp reads at 600 Gb 
data per run at a rate of 81 Gb per day.  This new sequencer has a dual flow cell 
system to allow for reading sequences from both sides of the flow cell.  Essentially, this 
doubles the number of reads (a detected string of nucleotides) to enable sequencing of 
more genes and more samples.  The HiSeq2000 also has two independent flow cells, 
which allows for the simultaneous running of different experiments.   Thus, one cancer 
genome and one whole genome can be sequenced in just one week.  The new Illumina 
system also improves throughput.  More streamlined sample preparation involves 
master mixed reagents, the elimination of 75% of the purification steps and simplified 
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indexing protocols.  At the end of 2010 new robotics systems were introduced for 
library preparation, which enables 400 samples to be prepared in just one week.  
These changes to the system are improving scalability of the method as well as 
accuracy due to the minimisation of pipetting errors. 
 
1.7.6 Roche 454 system 
 
Produces on average 700bp reads at 700 Mb data in a 23 hour run. It uses capture 
bead-based technology, on which one fragment of DNA template is immobilised.  
These beads are amplified by emulsion PCR, which results in several million copies of 
each fragment per bead. The beads are then added to a PicoTiter plate that will only 
accept one bead in each well.  Then sequencing enzymes are added and the 
nucleotides are washed over in a set sequence and if one is complimentary to those on 
the beads, the Charge Couple Device (CCD) camera detects fluorescence.  Data 
analysis is performed examining the intensity of signal and the position of the signal on 
the PicoTiter plate (Tucker et al 2009). 
 
1.7.7 SOLiD (sequencing by oligonucleotide detection) 
 
This system by Applied Biosystems produces 300 Gb of data per run in 14 days for 
paired end (sequencing each end of a DNA sequence in both forward and reverse 
directions) 75bp reads.  SOLiD uses bead based technology and emulsion PCR.  
Sequencing is achieved by ligation of 4 differently labelled ligation probes that ligate to 
the sequencing primer competitively; the sequence is determined by identification of 
the first and second base in each reaction.  A ligation-detection-cleavage cycle is 
repeated numerous times to extend the sequencing primer; these multiple cycles are 
repeated again with a universal primer following cleavage of the first primer.  This 
results in each base being detected twice, thus it has an inbuilt error correction system 
(Tucker et al 2009). 
 
Massively parallel sequencing can also be achieved by sequencing single DNA 
molecules in a system known as Helicos. This system does not amplify the original 
template, but instead sequences each molecule and identifies it via fluorescence 
immediately. 
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1.7.8 Complete Genomics 
 
The Complete Genomics method sequences whole genomes by technology known as 
sequencing by unchained ligation. Template DNA is initially fragmented into 500bp 
segments into which four adapters are included using intramolecular ligation and 
restriction enzymes that cut at repeat intervals.  This produces ‘DNA nanoballs’, which 
are amplified circles of ssDNA that are exact copies of the original template.  This 
method of amplification is known as restriction/circularisation or rolling circle 
amplification (RCA).  The DNA nanoballs are hybridised to the surface of a DNA 
nanoball microarray, which contains complimentary DNA.  The DNA sequence is 
determined by fluorescence as the complementary DNA contains fluorescent detection 
probes that are hybridised to the anchor probes.  The anchor probes search for the 
four adapters within the DNA nanoballs (Strannenheim & Lundeberg 2012). 
 
1.7.9 Ion Torrent 
 
The Ion Torrent system works differently to the previous methods as it uses an 
electrical detection system as opposed to fluorescence.  The Ion Torrent library 
preparation is similar to the Roche 454 system in which the template is amplified using 
a bead based emulsion PCR method.  The beads from the emulsion PCR are added to 
the wells of an ion chip, which has the ability to distinguish free protons.  Hydrogen 
ions are released when DNA polymerase adds nucleotides, this leads to a change in 
the free protons, which is distinguished by a sensor in the ion chip and converted to an 
electrical signal (Strannenheim & Lundeberg 2012). 
 
Each of these systems has advantages and disadvantages. For example, Illumina and 
SOLiD produce many short reads and this has clear disadvantages compared to the 
longer read length of the 454 system; in that a proportion (around 10-20%) of the reads 
produced by Illumina are not of sufficient quality to be usable.  SOLiD has a similar 
problem with a fraction of reads not reaching usable quality levels. However, this issue 
can be overcome by increasing read depth.  The cluster amplification of template 
strands on the Illumina system produces 1,000 copies of the original template, enabling 
the simultaneous sequencing of the same DNA strand.  The 454 system produces 
fewer longer reads of higher quality ~95% align to the reference sequence 
(Harismendy et al 2009).  This system is however, a lot more expensive per base, 
more than 10 times more expensive in fact (Tucker et al 2009).  A major disadvantage 
of the Complete Genomics system is that it is not available for sale; the company 
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keeps the system as an in-house platform offering DNA sequencing services.  Thus, 
the system is not a financially competitive one.  One obvious advantage of Ion Torrent 
is the use of an electrical detection system in comparison to detection by fluorescence 
as this can massively reduce costs by eliminating the requirement of optics and 
modified nucleotides.  In addition, data stored as fluorescent images requires additional 
processing to become meaningful.  One clear disadvantage of this system is that it 
produces very short reads (200 bp) and errors in detecting indels can be evident 
(Strannenheim & Lundeberg 2012). 
 
1.7.10 Third generation sequencing systems  
 
A new generation of DNA sequencing threatens to supersede massively parallel 
sequencing.  These technologies use single molecule DNA sequencing, which has the 
advantage of longer read lengths (> several hundred base pairs) enabling easier read 
alignment and sequence assembly and improved accuracy in variant detection.  This 
coupled with greatly reduced run times; result in even higher likelihood for the use of 
this technology for genetic screening.  Two main companies are developing third 
generation technologies.  These are PacBio and Life Technologies, each of which has 
their own advantages and disadvantages.  Both technologies utilise the same camera 
technology to record data output.  The charge coupled diode (CCD) system uses CCD 
array technology that currently has a limited size and results in throughput no higher 
than that of Illumina or SOLiD technologies (Munroe & Harris 2010). At the present 
time, most laboratories do not have this technology available.  
 
1.7.11 Challenges for second-generation sequencing technology 
 
The last decade has seen massive progression in sequencing technology in terms of 
increased throughput, reduced cost and time.  However, this progress brings additional 
challenges in that the library preparation and bioinformatics required needs to keep up 
with this accelerated advancement in technology.  This has produced bottlenecks at 
each end of the sequencing process.  Many of the library preparation issues are now 
being addressed, with increased multiplexing, sample barcoding and library 
preparation automation systems.  The downstream analyses, bioinformatics and data 
storage are still demanding, however, improvements are being introduced in these 
areas.  Certainly, the most important first step in sequence analysis is the mapping 
stage (also known as read alignment to the reference genome) and this requires 
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greater speed and accuracy than at present to be able to use the full capacity of 
current sequencing technologies.   
 
1.7.12 Whole exome sequencing  
 
Whole exome sequencing is the sequencing of the coding sequence of all protein 
coding genes.  Jones et al (2009) identify PALB2 as a susceptibility gene in pancreatic 
cancer using whole exome sequencing.  They narrow down the search to three 
candidates as these three contain deleterious mutations with the loss of both alleles.  
The likely causative mutation is in partner and localiser of BRCA2 (PALB2) gene, as 
the other two serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2) 
and renal tumour antigen (RAGE) are found to typically contain stop codons within the 
general population and PALB2 is already linked with breast cancer susceptibility. In 
addition, PALB2 is one of the Fanconi Anaemia pathway genes (also known as 
FANCN).  Once the likely candidate is identified, Jones et al (2009) use DNA 
sequencing to examine PALB2 in a larger group of pancreatic patients whom are 
enriched for family history.  Jones et al (2009) conclude that PALB2 is probably a 
pancreatic cancer susceptibility gene as it is commonly mutated in hereditary forms of 
the disease.  Thus, whole exome sequencing is one approach to the identification of 
cancer predisposition genes. Exome sequencing in cancer cases and controls may be 
an appropriate method for the detection of new cancer predisposition genes, however, 
in the clinical setting it may be more economically and practically feasible to sequence 
the specific genes that confer high disease risk for the purposes of risk prediction and 
early detection of disease. 
 
1.8 Genetic testing for familial ovarian cancer 
  
1.8.1 UK Guidelines for genetic testing 
 
NICE (National Institute for Health and Clinical Excellence) is an organisation set up to 
independently issue guidelines and quality standards for NHS practices.  The first 
familial breast cancer guidance was delivered in 2004, known as NICE clinical 
guidance [CG14], and this focuses on the care of women with an increased risk of 
breast cancer.  This first guidance defines care at primary, secondary and tertiary 
levels of the health system.  This was further updated in 2006 when guidance was 
issued on clinical screening management of women with an elevated breast cancer 
risk.  
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This guidance is concerned with providing care for women with an elevated risk of 
developing breast cancer due to family history of the disease or other relevant cancers 
(sarcoma in family member under 45 years, glioma or childhood adrenal cortical 
carcinomas and families with multiple cancers at an early age of onset).   
 
The key points in the NICE 2006 [CG14] guidance concerning policy for clinical 
management of women with elevated breast cancer risk are summarised in Table 1.1. 
 
Table 1.1 Key policy points for clinical management of women with elevated 
breast cancer risk  
Table 1.1 Key policy points for clinical management of women with elevated breast cancer risk. 
NICE clinical guidance CG41.  
 
An assessed high-risk level includes women with a 10 year risk >8% at 40-49 years 
and an overall lifetime risk of >30%; this risk level also includes women with a >20% 
probability of being a mutation carrier in one of the genes BRCA1, BRCA2 and/or 
TP53. A moderate risk level includes those women with a 10-year risk level of 3-8% at 
40-49 years and an overall lifetime risk of 17-30%.  Population risk level is considered 
to be a 10-year risk of <3% and an overall lifetime risk of <17%.  It is not recommended 
that women with elevated risk should be sought, that only those women whom 
approach primary care with anxieties about their risk level should be assessed.  In the 
first instance a family history is taken looking at both first and second-degree relatives 
(NICE 2006 CG14).  The guidance was further updated in June 2013 [CG164].  Now 
genetic testing is extended to those without a cancer diagnosis or a living affected 
relative if they have an assessed 10% probability of a mutation in one of the high 
penetrant genes (BRCA1, BRCA2 or TP53). 
 
1.8.2 Intervention strategies and risk reduction 
 
The strategies for clinical intervention in women assessed as high risk include regular 
screening, chemoprevention and risk reducing surgery.  For breast cancer risk surgery 
Assessed level 
of risk High Raised/moderate Population 
Appropriate 
level of care 
Referral to a specialist 
genetic clinic in tertiary care. 
Genetic counselling offered. 
Secondary Care Primary Care 
Clinical 
management 
Women offered annual MRI 
30-39 years 
Women 40-49 offered annual 
mammography and/or annual 
MRI 
None 
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includes mastectomy or annual MRI.  However, for ovarian cancer risk current 
adequate screening is not available so risk-reducing salpingo-oophorectomy (RRSO) is 
performed if women have completed their families and have a mutation in BRCA1 or 
BRCA2 (Domcheck et al 2010). 
 
Domcheck et al (2010) perform a prospective analysis on a large cohort of 4,255 
BRCA1 and/or BRCA2 positive women that received risk-reducing surgery.  They 
examine mutation type, type of surgery (mastectomy or RRSO) and cancer history.   
The main findings of the study are summarised as follows: 
 
1.  In women who have risk-reducing mastectomy none have a breast cancer diagnosis 
in the subsequent 3 years of follow-up; this compares to 7% cancer diagnoses in 
women whom do not have mastectomy.   
 
2.  In women who have RRSO the hazard ratios (HR) for BRCA1 mutation carriers are 
0.31 and no BRCA2 carriers have a cancer diagnosis during 6 years of follow-up; this 
compares to 3% cancer diagnoses in women whom do not have RRSO. 
 
3.  In women that have RRSO and are previously diagnosed with breast cancer the HR 
are 0.15 reduction in risk in BRCA1 mutation positive patients; and zero further cancer 
diagnoses are confirmed in women with BRCA2 mutations.  
 
4.  In women that have never been diagnosed with breast cancer the HR associated 
with RRSO in BRCA1 mutation positive women are 0.63 and 0.36 in those with BRCA2 
mutations.  
 
5.  If women have RRSO <50 years old the risk reduction HR is 0.51 however, if RRSO 
is performed >50 years there is no observed reduction in risk.   
 
6.  In both BRCA1 and BRCA2 positive women no reduction in risk is observed in the 
subsequent diagnosis of a second primary breast cancer. 
 
7.  Mortality is reduced in women who have RRSO and no previous breast cancer 
diagnosis (HR 0.45) this compares to those who have previously had a breast cancer 
diagnosis (HR 0.30). 
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1.8.3 Risk prediction models 
 
A number of clinical criteria could indicate the presence of BRCA1 or BRCA2 mutation.  
These include early onset disease (under 50 years at diagnosis for breast cancer and 
under 60 years for ovarian cancer), diagnosis of contralateral breast cancer or ovarian 
and breast cancer, male breast cancer, triple negative breast cancer diagnosed under 
50 years and in a specific population group (e.g. Ashkenazi Jewish).   
 
Several models designed for the prediction of germline BRCA1 or BRCA2 mutation 
status have been developed since the late 1990s.  The main models in current use are 
BRCAPRO, BOADICEA, the Myriad Prevalence tables and Tyrer-Cuzick models.  
These models have been extensively assessed in terms of validity in predicting the 
presence of mutations based on family history of breast and/or ovarian cancer of the 
proband.  BRCAPRO and BOADICEA are similar models and appear to perform 
equally well in terms of both sensitivity and specificity (Schneegans et al 2011). 
 
BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm) is a genetic risk model for mathematically estimating the probability of the 
presence of a mutation in BRCA1 or BRCA2 and in addition the probability of 
developing breast and or ovarian cancer.  BOADICEA does not estimate the probability 
of detecting a mutation, however as this also involves the sensitivity of the mutation 
detection method.  The BOADICEA risk model is useful for assessing further need for 
genetic counseling or genetic testing.  This model takes a polygenic approach to risk 
prediction (Antoniou et al 2004).  
 
BRCAPRO is a similar Bayesian based model that uses family history of breast and 
ovarian cancer; it also includes family history of male breast cancer and diagnoses of 
bilateral breast cancer within the family (BayesMendel Lab 2012) 
 
1.9 Research aims 
 
1. Almost half of inherited EOC risk is due to moderate to high penetrant gene 
variants other than BRCA1 and BRCA2.  The aim of this research is to examine the 
contribution of six candidate genes to EOC. 
 
2. Discovering gene variants within the missing 46% will lead to improved risk 
prediction and early detection.  Using the most up to date sequencing technology to 
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detect these variants will assist in meeting this aim.  There is a translational 
element to this research.  If gene variants can be detected swiftly and cheaply then 
this will result in a larger population of women being tested; thus enabling superior 
risk prediction and earlier detection of disease (or disease potential).  
 
1.10 Hypotheses 
 
 
1. The missing proportion of genetic predisposition to inherited/familial ovarian cancer 
is due to rare variants in moderate to high penetrance genes. 
 
2. Next generation sequencing of large sample sets of cancer cases and healthy 
matched controls is an appropriate method to detect rare variants in moderate 
penetrance genes. 
 
3. Recently discovered rare variants in HR genes are validated in these data. 
 
4. Targeted re-sequencing using NGS technology is ready and suitable for use in the 
Molecular Genetics Diagnostic laboratory. 
 
Including novel rare variants in moderate to high penetrance genes that confer a high 
risk of ovarian cancer will give a more accurate prediction of ovarian cancer risk.  
Genetic risk models for mathematically estimating the probability of developing ovarian 
cancer should include these newly discovered variants. 
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Chapter Two 
Establishing new technology: The application of next generation sequencing for 
the detection of germline gene mutations  
2.0 Introduction  
2.1 BRCA1 and BRCA2 in ovarian cancer susceptibility 
Ovarian cancer is the predominant cause of death from gynaecological malignancy and 
ranked fourth in the UK for cancer death amongst women.  Globally, ovarian cancer is 
the cause of death of ~125,000 women annually (Cancer Research UK statistics, 
2009). The detection of ovarian cancer at an advanced stage results in a poorer 
prognosis for patients. Only a small proportion of ovarian cancers are detected in the 
early stages when survival rates are best.  One third of women diagnosed present with 
distant metastases and the five-year survival rates for these patients are only 15% 
(Cancer Research UK statistics, 2009). Inherited ovarian cancers constitute ~10% of all 
invasive ovarian carcinomas (Stratton et al 1998).   Penetrance estimates in BRCA1 
and BRCA2 genes vary widely amongst studies and this variability is likely to be due to 
the cohort studied (i.e. from breast-ovarian cancer families or studies unselected for 
family history). Gayther (2012) reports that the cumulative risk of epithelial ovarian 
cancer to age 70 is between 40% and 50% for BRCA1 mutation positive women and 
between 20% and 30% for BRCA2 mutation positive women. Antoniou et al (2003) 
estimate ovarian cancer risks due to BRCA1 or BRCA2 genes by combining data from 
22 studies that included cases not selected for family history.  They conclude that the 
average cumulative lifetime (by age 70) ovarian cancer risk in BRCA1 positive women 
is 39% and for BRCA2 is 11%. 
New methods that can detect ovarian cancer at an earlier stage are vital to improve 
survival rate for the disease.  Next generation sequencing (NGS) technology is an 
advancing method that could be employed to identify quickly, cheaply and accurately 
biologically relevant genetic variants enabling early detection of women at high risk of 
developing ovarian cancer.  This proof of principle study aims to re-sequence BRCA1 
in 12 ovarian cancer patients with known positive BRCA1 mutations.  Long Range PCR 
(LR-PCR) is used as a target enrichment strategy to amplify BRCA1 from 12 ovarian 
cancer patient samples.  The study successfully multiplexes 11 samples in one lane of 
an Illumina flow cell to re-sequence the whole of BRCA1 in these 11 samples.  I am 
blinded to the known mutations in each sample and all mutations are accurately 
identified. The study concludes that multiplexed sequencing protocols can be 
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employed for the targeted re-sequencing of multiple patient samples in each lane of the 
Illumina flow cell and that scaling up of these methods will ensure that this technology 
is ready for use in the diagnostic clinic. 
2.2 The research questions 
1.  Can Massively Parallel Sequencing (MPS) technology be applied for use as a 
clinical tool for the detection of germline gene mutations in BRCA1? 
2.  Can MPS be employed as a research tool to identify additional rare variants that 
confer a moderate increase in cancer risk?  
2.2.1 The research questions in context - why is the research important?   
As women with germline mutations in BRCA1 or BRCA2 have a high lifetime ovarian 
(Antoniou et al 2003).  The introduction of better genetic screening for the identification 
of women with inherited mutations is required to improve survival rates for the disease.  
Early disease detection benefits survival as detection at stage I disease the 5 year 
survival rate is ~90% (Cancer Research UK statistics 2006).  Improved survival is 
achieved by earlier intervention with, for example, prophylactic or risk reducing surgery 
or early monitoring in patients identified at high risk.   
The National Institute for Health and Clinical Excellence (NICE) guidelines on genetic 
testing report that women should be tested for BRCA1 or BRCA2 mutations if they 
have a 20% or more assessed risk of having a mutation (NICE 2006 
recommendations).  The guidance states that ‘Genetic testing is only appropriate for a 
small proportion of women who are from high-risk families’. This risk is assessed on 
family history of disease and only those with a living affected relative are tested.  NICE 
guidelines [CG164] were recently updated to include those without cancer or a living 
affected relative if they have an assessed risk of 10% of a BRCA1 or BRCA2 mutation. 
In a population-based study Soegaard et al (2008) find that age is as significant a 
predictor of the presence of BRCA1 or BRCA2 mutations as family history. In patients 
found to have a mutation in either gene more than half are diagnosed with ovarian 
cancer under 50 years old compared to <20% diagnosed with cancer that are found to 
have a negative mutation status. Antoniou et al (2003) find that age is a significant risk 
factor for development of breast or ovarian cancer in women positive for mutations in 
BRCA1 or BRCA2; and that two additional factors modified the risk of breast or ovarian 
cancer. The location of the mutation is relevant in altering the risk of developing 
disease and the year of birth also has a significant effect in that the earlier that women 
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were born the lower their risk of developing cancer.  King et al (2003) investigate the 
impact of BRCA1 and BRCA2 mutations on breast and ovarian cancer risk.  
Interestingly, they find that 50% of their 1,008 breast and ovarian cancer patients with 
detected BRCA1 or BRCA2 mutations are from ‘low incidence families’ that have no 
disease in female relatives on their maternal side.  They report that this is because 
these are small families and that the mutations are inherited from their paternal side.  
Walsh et al (2010) report that women, without an apparent family history, positive for 
BRCA1 or BRCA2 mutations are equally at high risk of ovarian or breast cancer as 
those with a strong family history.  Family history can only arbitrarily be assessed and 
subsequently, many women with BRCA1 or BRCA2 mutations are not offered genetic 
testing.   
Genetic screening will improve disease management by refining the classification 
system for serous carcinoma.  The further sub-classification of High Grade Serous 
Carcinoma (HGSC) according to BRCA mutation status could lead to earlier detection 
and thus improve the prognosis for these specific ovarian cancer patients (Press et al 
2008).  Routine use of genetic testing for all women diagnosed with breast cancer or 
ovarian cancer could improve treatment options.  The introduction of PARP inhibitors, 
for the treatment of BRCA associated tumours is likely to introduce a more targeted 
therapy for these specific tumours that should effectively reduce toxicity and increase 
specificity (Farmer et al 2005).   
Dr Ranjit Manchanda of the Institute for Women’s Health, University College London 
(UCL) is leading a trial into genetic screening for BRCA1 and BRCA2 mutations in the 
Ashkenazi Jewish population.  The study known as Genetic Cancer Prediction through 
population screening (GCaPPS) will assess the viability of screening an entire 
population in order to determine who in that population has a higher risk of developing 
cancers related to germline mutations in BRCA1 or BRCA2. The trial will examine the 
effects of population-based screening and weigh up these against the existing protocol 
of family history based screening.  The results of this trial will be very interesting and 
may influence how the prediction of genetic susceptibility to cancer is assessed in 
clinical practice for a wider population. Genetic screening for a wider population would 
require in an increase in counselling on the results of that screening. 
To date an expedient BRCA1/2 mutation-screening tool has not been developed that is 
rapid and cheap enough per patient to allow for testing patients without family history.  
Next generation sequencing (NGS) technology could be applied to the detection of 
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BRCA1 and BRCA2 as well as other gene variants linked to the genetic predisposition 
to ovarian cancer.   
2.3 BRCA1 and BRCA2 Genes: structure and function 
Figure 2.1. The structure of BRCA1 and BRCA2 genes 
 
Figure 2.1 The structure of BRCA1 and BRCA2 genes. This schematic representation shows the 
structure of BRCA1 and BRCA2 genes.  Red blocks are coding exons and yellow represent non-coding 
exons 
BRCA1 is located at chromosome 17q21 and comprises a region 81 Kb in size with 24 
exons, 22 of which are coding exons. BRCA2 is located at 13q12-q13 and comprises a 
region 84 Kb in size with 27 exons, 26 of which are coding exons  (Figure 9).  BRCA1 
and BRCA2 have translational start sites in exon 2.  
Brown et al (1996) found a genomic region of chromosome 17 that includes BRCA1 
with a 30 kb duplication, which leads to two copies of exon 1 and exon 2 of BRCA1, 
two copies of exon 1 and 3 of NBR1 (Neighbour of BRCA1 Gene 1) and in addition two 
copies of an intergenic region 295 bp in size; Brown et al (1996) suggest these multiple 
exons are in fact duplicated pseudogenes. A large proportion (41%) of BRCA1 
contains Alu repeat sequences that are 69-231 bp in length (Smith et al 1996); and 
these occur approximately every 650 bp throughout the entire sequence of the gene 
(Tancredi et al 2004). The size of the introns of BRCA1 varies between 403 bp to 9.2 
Kb.  
BRCA2, like BRCA1 has a very large exon 11. BRCA1 and BRCA2 contain AT rich 
sequences in their coding regions and translational start sites are situated in exon 2 of 
each gene (Tavtigian et al 1996).  A region of BRCA2 has been designated by Gayther 
et al (1997) as the ‘ovarian cancer cluster region’ (OCCR) and this region is situated 
between nucleotides 3035 and 6629 spanning 3.3 Kb of exon 11. Gayther et al (1997) 
found that breast and ovarian cancer families had a higher ratio of ovarian cancer 
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cases to breast cancer cases if mutations resided in this portion of BRCA2.  
Interestingly, the RAD51 binding domain resides in this region of BRCA2 (Thompson & 
Easton 2001). 
The protein product encoded by BRCA1 is relatively large consisting of 1,863 amino 
acid residues (Huen et al 2010).  At its amino terminal the BRCA1 protein has a 
conserved RING domain and at its carboxyl terminal are tandem BRCT domains.  
RING domains are recognised as regions involved in the ubiquitination of proteins, a 
process involving the tagging of proteins for their degradation. By contrast the BRCT 
domains are regions implicated in the binding of phosphorylated proteins.  These 
domains are regularly observed in proteins concerned with the DNA damage response. 
The functions of BRCA1 and BRCA2 continue to be elucidated.  BRCA1 is probably 
the better known of the two, with roles in the mechanisms of DNA repair, cell-cycle 
regulation, chromatin remodelling, protein ubiquitination and transcriptional regulation 
(Narod & Foulkes 2004).   The diagram (Figure 2.2) depicts the role of BRCA1 in the 
DNA damage response.  DNA damage is detected via sensors.  These sensors are 
kinases, for example Ataxia Telangiectasia Mutated (ATM) that once activated 
phosphorylate checkpoint kinase 2 (CHK2), which in turn phosphorylates BRCA1 and 
results in the cessation of cell division.  BRCA1 further phosphorylates downstream 
targets involved in cell cycle control, including p53 and Rb.  The protein products of 
BRCA1 interact and form complexes with other proteins in the BRCA network to bring 
about its various functions.  For example, BRCA1 forms a heterodimer with BRCA1 
associated RING domain 1 (BARD1) to result in ubiquitin ligation of downstream 
targets.  S-phase or G2 arrest are brought about via the complexing of BRCA2 and 
RAD51, which in turn interacts with Fanconi Anaemia complementation group D2 
(FANCD2) and its subsequent annealing to BRCA1 (Narod & Foulkes 2004).  
Homologous recombination and transcriptional regulation are controlled by BRCA1-
associated surveillance complex, which includes genes: Bloom syndrome, RecQ 
helicase-like (BLM), MSH2-MSH6 and MRE11-RAD50-NBS1).  BRCA1 also has some 
involvement in non-homologous end joining, in the regulation of chromatin remodelling 
and in the regulation of apoptosis (Narod & Foulkes 2004). 
The predominant function of BRCA2 is in homologous recombination (HR) in which the 
BRCA2 protein binds RAD51 protein at its binding domain, which is a region of eight 
BRC repeats.  RAD51 protein is an enzyme that instigates the exchange between 
homologous DNA molecules via the formation of a nucleoprotein filament that covers 
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ssDNA molecules.  Essentially, BRCA2 regulates RAD51 recombinase (Venkitaraman 
2002).  
Figure 2.2 The BRCA1 network in response to DNA damage 
 
Figure 2.2. The BRCA1 Network in Response to DNA Damage. Adapted from: Narod, S.A. & Foulkes, 
W.D. (2004) Nat.Rev.Cancer, (4):665-676. 
 
2.4 Frequency of BRCA1 and BRCA2 mutations in specific populations 
 
There are large variations in the frequency of BRCA1 and BRCA2 mutations detected 
within specific populations. A founder mutation can be defined as one that persistently 
arises within one haplotype in a specific population (Fackenthal & Olopade 2007).  A 
haplotype is a set of genetic markers (usually Single Nucleotide Polymorphisms or 
microsatellite markers) that are inherited together as a block.  Haplotypes arise through 
meiotic recombination during which fragments of chromosomes are mixed.  
Interbreeding leads to the same fragments appearing in a number of different 
individuals.  When recombination is random, these fragments would be dispersed over 
time (International HapMap Project 2011). Founder mutations may continue to be 
evident within the specific population or may become incorporated within a wider 
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community such as a particular geographic region due to historical relocation of the 
community in which the founder mutation occurred. 
Ramus & Gayther (2009) report vast differences in the frequency of particular 
mutations detected in diverse populations.  Founder mutations are evident in specific 
ethnic groups or in localised global areas.  The presence of founder mutations is 
relevant in the genetic screening laboratory in that, in those populations containing a 
large percentage of founder mutations, screening could be specifically targeted for 
those identified mutations.  For example, in the Ashkenazi Jewish population there are 
three identified mutations that explain most of the specific founder mutations 
recognised in this ethnic group. In this population the prevalence rate of one of three 
mutations in BRCA1/2 is 2.6% compared to the general population rate of 0.1-0.2%.  
These three mutations are 185delAG (BRCA1), which has a prevalence rate of 1%; 
5382insC (BRCA1) with a prevalence rate of 0.13 % and 6174delT (BRCA2), which 
has a prevalence rate of 1.52 % (Ferla et al 2007). Together these three mutations 
constitute 98-99% of all mutations within the Ashkenazi Jewish population (Phelan et al 
2002).  Thus, mutation specific screening for the Ashkenazi Jewish population is widely 
accepted in routine clinical use (Ramus & Gayther 2009).  In specific regions or 
isolated countries around the world similar clinical screening is employed for other 
distinct founder mutations. For example, the Icelandic BRCA2 mutation 999del5 
causes most of the HBOC or familial ovarian cancer only cases attributable to BRCA1 
or BRCA2 genes. 
 
In Iceland the most prevalent founder mutation is in BRCA2 gene (995del5), which 
occurs at a rate of 0.4% of the population. However, this mutation occurs at a rate of 
7.9% in breast cancer patients and at a rate of 8.5% in ovarian cancer patients. Also in 
Iceland is the more rare, but still significant founder mutation G1593A in BRCA1, which 
is identified in 1% of breast and/or ovarian cancer patients. The Table 2.1 below 
defines the key founder mutations within Europe in BRCA1 and BRCA2 genes.   
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2.4.1 The key founder mutations  
Table 2.1 Key founder mutations in European populations 
Name of 
Population 
BRCA1/BRCA2 
mutation 
Prevalence in 
named 
population (%) 
Contribution to BRCA1/2 mutations 
Ashkenazi 
Jewish 
BRCA1 185delAG 1.00 16-20% breast cancer diagnosed under 50 years 
BRCA1 5382insC 0.13  
BRCA2 617delT 1.52 
8% women diagnosed with breast cancer 
under 42 years and 7% women diagnosed 
with breast cancer 42-50 years that have 
a strong family history 
Icelandic 
BRCA1 G5193A rare 1% breast/ovarian cancer diagnoses 
BRCA2 995delT 0.4% 8.5% breast cancer patients and 7.9% ovarian cancer patients 
Norwegian 
BRCA1 1675delA 
BRCA1 816delGT 
BRCA1 3347delAG 
 These 3 account for 68% of all the BRCA1/2 mutations 
BRCA1 1135insA  Found in 3% of ovarian cancer 
Finnish 
BRCA1 
IVS11+3A>G 
BRCA2 9345+1G>A 
BRCA2 C7708T 
BRCA2 T8555G 
 These 4 mutations constitute 84% of all BRCA1/2 mutations 
Swedish BRCA1 317ins5  70% of BRCA1/2 mutations in one region (west of Sweden) 
French BRCA1 3600del11 BRCA1 G1570X  52% of BRCA1/2 mutations 
Dutch 
BRCA1 2804delAA 
BRCA1 IVS12-
1643del 3835 
BRCA2 5579insA 
BRCA2 delTT 
 
All 4 mutations constitute 24% of 
BRCA1/2. 
Both BRCA2 mutations constitute 62% of 
those with strong family history 
Italian 
(Calabria) BRCA1 5083del19   
Italian  
(Sardinia) BRCA2 8765delAG  1.7% in breast cancer patients 
Polish 
BRCA1 5382insC 
BRCA1 C61G 
BRCA1 4153delA 
 Sourced from Gorski et al (2004) 
Table 2.1 Key founder mutations in named European populations. This table describes the key 
founder mutations in European populations, including prevalence within breast/ovarian cancer patients, if 
known. Table adapted and re-drawn from Ferla et al (2007). Annals of Oncology 18 (Supplement 6) vi93-
vi98. 
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Table 2.2 Key founder mutations identified in non-European populations 
Name of population BRCA1/BRCA2 mutation 
French-Canadian 
BRCA1 C4446T 
BRCA1 R1443X 
BRCA2 8756delG 
BRCA2 3398delAAAAG 
Hispanic 
(South Carolina) 
BRCA1 S995X 
BRCA1 2552delC 
Hispanic (Columbia) 
BRCA1 3450delCAAG 
BRCA1 A1708E 
BRCA2 3034delACAA 
African-American 
BRCA1 943ins10 
BRCA1 1832del5 
BRCA1 5296del4 
BRCA2 IVS13 + 1G>A 
South African BRCA1 E881X 
Jewish (Iraq/Iran) BRCA1 Tyr978X 
Chinese BRCA1 1081delG 
Japanese 
BRCA1 Q934X 
BRCA1 L64X 
BRCA2 5802delAATT 
Malaysian BRCA1 2846insA 
Filipino 
BRCA1 5454delC 
BRCA2 4265delCT 
BRCA2 4859delA 
Pakistani BRCA1 S1503X BRCA1 R1835X 
Afrikaner BRCA2 8162delG (sourced from Schoeman et al 2013) 
Table 2.2 Key founder mutations identified in named non-European populations. This table 
describes the key founder mutations in non-European populations.  Adapted and re-drawn from Ferla et al 
(2007). Annals of Oncology 18 (Supplement 6) vi93-vi98. 
Screening for founder mutations is straightforward and raises the possibility of rapid 
population level targeted genetic testing.  This would also be cost effective in that only 
the specific variants in certain populations are screened and allows for the possibility of 
extending genetic testing to specific populations rather than restricting testing to cases 
with a strong family history of the disease, which is currently the case. Using this 
approach more accurate prevalence and penetrance estimates can be made within 
these populations (Ferla et al 2007). Widening research to new populations, screening 
additional genes and examining for large rearrangements may uncover further founder 
mutations. 
2.5 Mutations in BRCA1 and BRCA2 and ovarian cancer susceptibility 
The predominant ovarian tumours are epithelial carcinomas.  Of these the most 
common histological sub-type is high-grade serous carcinoma (Gilks & Prat 2009), 
which notoriously presents at a late stage when metastatic lesions are already evident.  
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The majority of high-grade serous carcinomas reveal aberrations in BRCA1 or BRCA2, 
these alterations include, epigenetic changes as well as germline and somatic 
alterations.  In addition, often p53 is mutated or lost.  Genomic instability results from 
the non-repair of DNA damage (Gilks & Prat 2009).  
2.5.1 Mutation detection in BRCA1 and BRCA2 
Germline mutations are distributed throughout BRCA1 and BRCA2 coding regions and 
are of various types, including small mutations, insertions and deletions that result in a 
frameshift (i.e. alteration of the gene’s reading frame and a non-functioning protein) 
and nonsense mutations (i.e. that result in the addition of a stop codon and again a 
truncated non-functioning protein product).  Thousands of pathogenic mutations have 
been found in BRCA1 and BRCA2 genes (Breast Cancer Information Core BIC).  
These mutations include protein-truncating mutations that result in a loss of protein 
function; for example, nonsense and frameshift mutations.  A proportion of these 
variants are missense mutations, of which a small subset are deleterious, however, 
many are variants of uncertain significance (VUS).  Interestingly, certain pathogenic 
mutations have been found in higher density in exon 11 of BRCA2 and these reveal an 
elevated ovarian cancer risk compared to breast cancer.  This region is now referred to 
as the ovarian cancer cluster region (OCCR) of BRCA2 (Gayther et al 1997).   
2.5.2 Mutation types 
Genetic variation or changes in the DNA sequence can take many forms and may or 
may not be pathogenic.  These changes may or may not result in an alteration of the 
amino acid.  Pathogenic mutations can range in size and type, for example, point 
mutations (deletions or insertions) or larger genomic rearrangements including 
deletions, insertions and duplications.  Different types of variants give rise to different 
consequences and may or may not affect gene expression.  For example, the 
inactivation of tumour suppressor genes can result from missense, frameshift or 
nonsense mutations since these can lead to a truncated and non-functioning protein 
product.  Frameshift mutations involve the addition or loss of base pairs that lead to an 
alteration in the gene’s reading frame.  As a result the grouping of bases is shifted so 
that the amino acid code is altered and ultimately means a non-functioning protein.  
Missense mutations are an alteration in one base pair that leads to the substitution of 
one amino acid for another.  Nonsense mutations are an alteration of one base pair 
that lead to the insertion of a stop codon and therefore, a truncated non-functioning 
protein.  Splice-site mutations occurring at splice sites have various consequences; for 
example, these can result in exon skipping; or the exploitation of cryptic spice sites 
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resulting in aberrant mRNA that results in the insertion of a stop codon and a truncated 
non-functioning protein product (Speicher et al 2010)  
The first mutations to be identified in these two genes were protein-truncating 
mutations, mostly nonsense, small insertions or deletions.  The Breast Cancer 
Information core (BIC) is a database, for BRCA1 and BRCA2, of both type of mutation 
and their occurrence.  Initially, the majority of mutations identified were protein 
truncating therefore, most research centred on the use of the protein-truncation test 
(PTT); however, this test does not identify small mutations, particularly those in small 
exons.  The PTT will not identify mutations within the regulatory regions or intronic 
regions that may affect RNA stability (Narod & Foulkes 2004) or mutations that lead to 
protein product that does function albeit in an altered fashion. 
Early attempts to detect mutations in BRCA1 and BRCA2 focus on the coding regions 
and splice site of both genes.  This is undoubtedly due to the sequencing methods 
available at the time.  These experiments identified many disease-causing mutations in 
both genes. However, these leave some gaps in the sequencing of the entire genomic 
regions of these genes in that the intronic and regulatory regions are yet to be 
sequenced and mutational analyses conducted.  
Ramus et al (2007) investigate the contribution of BRCA1 and BRCA2 mutations to 
inherited ovarian cancer.  This is achieved by analysing 283 epithelial ovarian cancer 
families for mutations in BRCA1 and BRCA2. Various mutation detection methods are 
used, including Multiplex Ligation Probe Amplification (MLPA), Heteroduplex Analysis 
(HA) and capillary electrophoresis, to screen the coding regions and splice sites of both 
genes. They report the prevalence of mutations in BRCA1 as 37% and in BRCA2 as 
9%. The predominant mutations they detect are frameshift and nonsense mutations 
with the majority of these residing in a central portion of each gene. This central portion 
of BRCA2 has been known previously as the ovarian cancer cluster region (OCCR) 
(Gayther et al 1997).  In the Ramus et al (2007) study they report that 85% of the 
detected BRCA2 mutations are located in this 3.5 Kb central section of the gene. They 
conclude that overall the stronger the family history of breast/ovarian cancer, the higher 
the likelihood of BRCA1 or BRCA2 mutations. 
Genetic linkage analysis is the examination of genetic markers that have been 
inherited together.  Ramus et al (2007) examine genetic linkage to BRCA1 or BRCA2 
loci, using microsatellite markers, in those epithelial ovarian cancer families that do not 
have mutations in either BRCA1 or BRCA2 genes.  This is achieved by combining 
linkage analysis in the family and loss of heterozygosity (LOH) analysis in tumours.  
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Interestingly, 5/9 non-BRCA1 or BRCA2 families are shown to be linked to BRCA1 or 
BRCA2 loci, suggesting the possibility that mutations may be present that are missed 
by screening.  However, as 4/9 families reveal no linkage to BRCA1 or BRCA2 
mutations, this proposes the likelihood that other susceptibility genes exist. 
In order to build on the work by Ramus et al (2007), using the latest next generation 
sequencing technology (NGS), these two genes can now be sequenced in their 
entirety, including all intronic and regulatory regions. NGS can also be used to 
sequence other candidate susceptibility genes identified from genome wide association 
studies or those involved in the DNA repair pathway.  This may involve sequencing 
large numbers of cases and controls in ovarian cancer and/or breast cancer. 
Morgan et al (2010) use NGS to sequence the coding regions of TP53, BRCA1 and 
BRCA2.  Long Range PCR is used as a target enrichment method and Illumina GAII to 
sequence the coding regions plus an additional 20nt either side of each exon for both 
genes. This is achieved by amplifying TP53 in 2 fragments of 3,289 bp (exons 2-9) and 
12,346 bp (exons 10-11); BRCA1 and BRCA2 are amplified in 22 fragments ranging in 
size from 1,221 bp to 5834 bp. This paper is useful in that it demonstrates the viability 
to translate this technology into the diagnostic clinical setting; however, it does omit 
regulatory and intronic regions and there is no linkage analysis alongside it to 
demonstrate if there are missed mutations or if there are additional susceptibility 
genes.  The research being undertaken here could fill these gaps and answer 
questions vital in the translation of research into the diagnostic clinic.  The research 
uses robust and reproducible experimental design, indicating that Long Range PCR 
(LR-PCR) is a good target enrichment strategy for smaller genomic regions.  However, 
its relatively small cohort size of 55 breast cancer patients does not allow for the 
accurate assessment of the contribution of BRCA1 to familial breast cancer.  One final 
point is that it may be possible to use genomic enrichment with NGS (rather than LR-
PCR and MPS) to detect large genomic rearrangements, including larger deletions and 
insertions by analysing read depth of coverage (Yoon et al 2009).  This will make the 
translation of this technology to the diagnostic setting more feasible as it will not be 
necessary to use additional techniques such as MLPA to detect larger genomic 
rearrangements.  
 
 
 
 70 
2.6 Target enrichment strategies 
2.6.1 Long Range PCR 
Target enrichment essentially isolates and amplifies the genomic region of interest.  
There are a number of target enrichment methods available and each has advantages 
and disadvantages.  These methods include Long Range PCR (LR-PCR), Molecular 
Inversion Probes (MIP) and Hybrid Capture. 
Long Range Polymerase Chain Reaction (LR-PCR) is a modification of PCR and has 
been one of the most commonly used techniques as it does not require expensive 
equipment and is suited to all the various massively parallel sequencing platforms. 
Polymerase Chain Reaction (PCR) is a method for amplifying a target DNA template. 
The technique takes the form of three cycles of reactions.  First, DNA denaturation, the 
separation of double stranded DNA (dsDNA).  Secondly, primer annealing, the binding 
of each primer to each end of the template strand revealed in the denaturation step. 
Finally, the extension cycle, during which a complimentary strand of nucleotides are 
synthesised by a thermostable Taq polymerase using dexoxynucleotidetriphosphates 
(dNTPs).  This results in amplification of the original template DNA sequence in an 
exponential fashion (Moody 2007).  In LR-PCR large amplicons are amplified; 
achieving this requires the use of another enzyme, in addition to the Taq polymerase, 
which is a high-fidelity polymerase with proof-reading 3’-5’ exonuclease ability in order 
to accurately amplify amplicons of ~10 Kb.   
There are numerous advantages in using PCR, including the uniformity of coverage 
with the use of overlapping long PCR amplicons.  PCRs of ~10kb in length are 
probably the maximum size to ensure a robust PCR product (Mamanova et al 2010).  
Another advantage is there is no need for high tech equipment, just a few primers is all 
that is required for each different PCR reaction. Primers are inexpensive, easy to 
acquire and PCR is well established in the laboratory.  
LR-PCR is not without its caveats, and these need to be addressed during 
experimental design.  LR-PCR is likely to be most efficient in amplifying amplicons up 
to 10 Kb in size. Therefore, it is probably only realistic to amplify targets up to ~200 Kb; 
much more than this would require a large number of PCR reactions and would result 
in inflated costs due to the amount of primers and other reagents required as well as 
the DNA input requirements for larger numbers of reactions. To guarantee full 
coverage of the desired region and to ensure that primer annealing is not in areas of 
SNPs, primers are designed so that they amplify overlapping PCR fragments of several 
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hundred base pairs. Normalisation of amplified PCR products is necessary because, all 
reactions will not result in the same yield, even under the same conditions with 
identical concentrations of starting material (Mamanova et al 2010).   
LR-PCR and the alternative methods for target enrichment can be assessed on several 
criteria, including specificity, or a measure of the amount of sequenced reads 
accurately mapping to the target region; sensitivity, illustrates the amount of bases 
covered by sequence reads; coverage uniformity, describes how consistent read depth 
is across the target region; reproducibility, assesses how well similar results can be 
achieved from repeat experiments; cost effectiveness; and input DNA requirement.  
Some of these parameters are interrelated in that a target enrichment method that 
shows both good coverage uniformity and specificity will be cheaper, since it would 
require reduced sequencing capacity.  Issues that need to be considered when 
identifying the most appropriate approach to target enrichment include the size of the 
target region and the quantity of samples to sequence (Mamanova et al 2010). 
2.6.2 Molecular Inversion Probes (MIP)  
Molecular inversion probes are an enzymatic solution to target enrichment.  
Oligonucleotides are constructed that are made up of a linker sequence and a target 
specific sequence on either side that then hybridise to the target region after which an 
extension step fills the gap between the two targets. Finally, a ligation step circularises 
the oligonucleotides (Figure 2.3).  This method is useful for capture of exons or few 
regions in which a large number of samples are to be sequenced, since scaling up is 
relatively easy. 
Figure 2.3 Molecular inversion probes 
 
Figure 2.3 Molecular inversion probes. Adapted from Mamanova et al (2010) Target enrichment 
strategies for next generation sequencing. Nat. Methods. Vol 7, No. 2.111-118. 
MIP demonstrate relatively poor coverage uniformity, but perform better on other 
parameters such as an input DNA requirement of as low as 200ng and sensitivity of 
more than 98%.   
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2.6.3 Hybrid capture 
Hybrid capture is a genomic sequence capture method developed by Roche 
Nimblegen and Agilent (Figure 2.4).  It can be performed on array or in solution.  In this 
method the DNA libraries are prepared first from genomic DNA, which is then annealed 
to probes specific to the target region.  The DNA that is not specific to the target 
sequence is simply washed away and the captured target DNA is eluted for 
sequencing. 
Figure 2.4 Hybrid capture on array or in solution 
 
Figure 2.4 Hybrid Capture on array or in solution. Adapted from Mamanova et al (2010) Target 
enrichment strategies for next generation sequencing. Nat. Methods. Vol 7, No. 2.111-118. 
The obvious advantage with this method of target enrichment is in its speed and ease 
of use, however coverage uniformity does not compare well with LR-PCR, at ~60%.  
Other parameters are good with small quantities of input DNA requirements and high 
sensitivity.  Specificity is below that achieved by the other methods at ~70-80% 
(Mamanova et al 2010). 
Whilst PCR is probably not suitable for larger regions, it is a highly specific method that 
can offer good coverage uniformity at a relatively low cost for smaller target regions.  If, 
however, the whole exome is required alternative methods of target enrichment, such 
as hybrid capture are more appropriate. 
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2.7 The Illumina Genome Analyser II (GAII) Platform  
Figure 2.5 Illumina GAII flow cell 
  
Figure 2.5 Illumina GAII Flow Cell.  This picture shows the Illumina GAII flow cell, which consists of a 
solid substrate, made of glass and silicon, with 8 discrete channels on to which millions of oligonucleotides 
are hybridised.   These oligonucleotides create a lawn across the surface of the flow cell and act as probes 
to which the prepared DNA fragments hybridise. (Image from www.illumina.com). 
 
2.7.1 Library Preparation  
Figure 2.6 Library preparation 
Figure 2.6 Library preparation.  This flow diagram shows the steps involved in library preparation from 
genomic DNA to prepared libraries ready for sequencing on the GAII. (Image from www.illumina.com). 
Sequencing libraries are prepared; one library for each sample analysed. This is done 
by first, fragmenting the template DNA into ~200-600bp sized fragments (A. Figure 2.6) 
via one of 2 possible methods (nebulisation or sonication). The template DNA used is 
the pool of LR-PCR fragments for each sample generated during target enrichment.  
Next the fragments are denatured and the ends of fragments repaired to form blunt 
ended fragments (B. Figure 14).  Then an ‘A’ base overhang is added (B. Figure 2.6), 
which allows for adapter sequences (complimentary to the oligonucleotides on the flow 
cell surface) to be ligated (C. Figure 2.6).   
If multiplexing, the 6 base index sequences are introduced at the PCR enrichment 
stage, during which the selected DNA fragments are enriched (D. Figure 2.6).  For a 
paired end (PE) read there are two primers for the PE read (one forward and one 
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reverse), plus one primer for the index.  These can be added to both samples and to 
genes, so that all of BRCA1 can be sequenced for multiple patients in one lane of one 
flow cell. During this pilot study Illumina supplied 12 index primers that contain no more 
than 3 positions the same between each index so that if there is an error in one the 
correct index can be identified. These 12 indexes can be used for each lane of the flow 
cell.  By the end of this pilot study Illumina increased multiplexing levels to 96 index 
sequences. 
2.7.2 Cluster Generation 
Figure 2.7 Cluster generation 
 
Figure 2.7 Cluster generation. This flow diagram describes the process of cluster generation of prepared 
libraries prior to sequencing on the GAII. (Image from www.illumina.com). 
Prior to sequencing, the prepared templates must be copied. The cluster station 
(recently upgraded to the ‘CBot’) is the separate fluidics apparatus that conducts this 
step.  The fragmented DNA is first denatured into single stranded fragments and 
attached to the surface of the flow cell (E. Figure 2.7).  A new strand is created with 
polymerase by extending the template strand.  The adapter sequences of the newly 
synthesised strand, of which there are two different ones (forward and reverse) arch 
over and anneal to a free oligonucleotide on the flow cell (F. Figure 2.7) This produces 
a bridge and a new position for the synthesis of another new strand.  Forward and 
reverse fragments are generated by repeating the process and produce 100s of 
millions of clusters each with ~1,000 copies of the original template (G. Figure 2.7).  
These clusters are denatured and cleaved to leave just the forward strand (for single 
read sequencing) allowing for many simultaneous sequencing reactions, hence the 
term ‘massively parallel’. Primers for sequencing are hybridised to templates and the 
flow cell is moved to the GAII (H. Figure 2.7) 
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2.7.3 Sequencing-by-synthesis (single read sequencing) 
Figure 2.8 Sequencing-by-synthesis 
 
Figure 2.8 Sequencing by synthesis.  This image describes sequencing by synthesis using reversible 
chain termination chemistry. (Image from www.illumina.com). 
Once the clusters are generated, the flow cell is moved to the GAII where the clusters 
are first denatured.  Then the polymerase, primers for sequencing and modified 
fluorescently labelled chemically modified nucleotides (reversible dye terminators) are 
included. It works as follows: the 4 fluorescently labelled nucleotides are modified so 
that the 3’OH can be chemically inactivated to permit reversible chain termination.  As 
each base is synthesised and the chain terminated due to the inactivation of the 3’OH 
in the nucleotide, this base is read and the blocking of the 3’OH is removed to allow for 
the next base to be synthesised.  The process is repeated and the flow cell surface is 
imaged following the addition of each base (Tucker et al 2009). Each of the fluorescent 
bases is detected via laser excitation.  
2.7.4 Paired-end sequencing 
Paired-end sequencing requires specialised additional equipment from Illumina, known 
as the paired-end module that is connected to the GAII.  The Paired-End Module is an 
additional piece of specialised equipment that is attached to the Genome Analyser.  
Figure 2.9 demonstrates how paired end sequencing is achieved; essentially both ends 
of the DNA template are sequenced and paired with genomic inserts of a known size.  
In the first read the reverse strand is re-synthesised from the forward strand, the 
forward strand is subsequently cleaved to allow for complimentary strands to be bridge 
amplified creating new clusters for the second read.  Sequencing primers SP1 and SP2 
are paired and sequencing-by-synthesis is performed in order. 
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Figure 2.9 Paired end sequencing flow diagram 
 
Figure 2.9 Paired end sequencing flow diagram. This diagram demonstrates how paired end 
sequencing is achieved, so that each DNA template is sequenced from each end in the forward 
and reverse directions. (Image from www.illumina.com). 
2.7.5 Multiplexed Sequencing 
The expected coverage on a 76bp single-end read for one channel of the flow cell is 
~30,000X.  This calculation is made using the Lander & Waternan (1988) formula: C = 
LN/G where C = coverage, L = read length (bp), N = number of reads and G = haploid 
length of the genome (bp).  So, C = 76 x 38x106 / 91,500 = 31,562X. Thus, it is logical 
to put this large sequencing capacity to full use.  Multiplexing using bar-coded index 
sequences enables several samples and several genes to be sequenced in one lane, 
improving efficiency by lowering the cost per sample as well as reducing the time taken 
to sequence several genes. To sequence 12 patient samples for two genes would give 
coverage of ~1,250X.  One issue that arises when pooling samples and LR-PCR 
amplicons is the possible loss of sequencing uniformity. Multiplexed sequencing is 
possible via the addition of tags (index sequences) enabling 12 samples to be 
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sequenced in each lane or 96 samples per flow cell.  The next diagram shows how this 
is achieved (Figure 2.10).                    
Figure 2.10 Multiplexed sequencing 
 
Figure 2.10 Multiplexed sequencing. Multiplexing is achieved via the addition of a 6 base index 
sequence at the PCR enrichment stage following ligation of adapter sequences as the final step in library 
preparation. (Image from www.illumina.com). 
 
2.8 Bioinformatics for data analysis and mutation detection 
2.8.1 Data analysis of DNA sequencing using Capillary Electrophoresis 
Sequence analysis for capillary electrophoresis is performed using either Applied 
Biosystems own program, SeqScape® or alternative programs that are available, for 
example, GeneScreen that has been developed by Ian Carr at the Leeds Institute of 
Molecular Medicine, University of Leeds (Carr et al 2011).  Both software programs 
have been designed to rapidly and accurately analyse capillary sequencing traces for 
variant detection or SNP analysis.  These methods assist in improving throughput for 
data analysis. 
To enable the identification of sequences produced by capillary sequencing freely 
available on line software programs are available to align sequences.  The NCBI tool 
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BLAST (Basic Local Alignment Search Tool) is one such tool that searches for 
sequences with homology to the input template sequence.   
2.8.2 Data analysis for DNA sequencing using Illumina GAII and HiSeq2000 
The data analysis pipeline for Illumina GAII can be divided into a number of separate 
steps.  These include: demultiplexing of indexed samples (for multiplex sequencing), 
read mapping (alignment of reads to the reference sequence), base calling and variant 
detection.  Bioinformatics analyses also include additional statistical information such 
as quality scores and depth of coverage.  
Data analysis of NGS data is a rapidly developing field with many modifications of 
existing approaches as well as new approaches emerging at an alarming rate.  Most of 
these modifications centre on the algorithms in use to align the multitude of short read 
sequences produced by MPS technology. Differences in these can result in differences 
in data output.   
2.8.3 Sample Demultiplexing 
If multiplexed sequencing is conducted, in which several samples are sequenced in 
each lane of the flow cell, the first step in data analysis is the demultiplexing of indexed 
reads to accurately assign reads to each sample.  The index sequences have no more 
than 3 bases that are the same between each of them; this ensures that if there is an 
error in one the correct index can still be identified and good quality reads do not get 
filtered out due to a mismatch in the bar code sequence.    
The diagram, Figure 2.11, shows the workflow of the analysis of NGS sequencing data. 
 
    Figure 2.11 NGS sequencing data analysis workflow 
 79 
2.8.4 Alignment of reads to the reference sequence (read mapping) 
The next step in analysis is the alignment of millions of short sequencing reads to the 
reference sequence.  This is possibly the most crucial step in NGS data analysis and 
the subsequent accurate detection of variants relies upon precise read alignment.  The 
previous methods to align sequences to the reference sequence, including BLAST, are 
not appropriate for mapping the abundant 76bp reads produced by Illumina GAII.  The 
GAII data will undoubtedly include gaps and these are dealt with by the clever use of 
algorithms.  In addition, algorithms need to be robust enough to deal with the abundant 
repetitive sequences in the genome. 
The Consensus Assessment of Sequence and Variation (CASAVA) is a package that 
includes read mapping using the mapping algorithm known as Efficient Large-Scale 
Alignment of Nucleotide Databases (ELAND).  ELAND identifies the location on the 
reference sequence of sequencing reads.  To do this ELAND divides a 32 bp read 
section (a ‘seed’) into 4 portions of 8 bp.  These 8 bp sections are called ‘substrings’.  
Substrings are then concatenated to form 32 bp seeds; with two mismatches permitted 
so that two (or more) of the 4 substrings will map to the reference sequence (Horner et 
al 2009).  This should allow for the accurate alignment of ‘gapped reads’.   
Alternative programs that use modified algorithms have been developed for read 
mapping.  The differences in these include, speed, amount of memory space required 
and the accuracy by which indels can be detected.  Size of allowable indels varies from 
program to program (Horner et al 2009). 
The Table 2.3 below outlines some of the available software programs for read 
alignment and variant detection.  Selecting which program to use will often depend on 
the available computer systems in terms of the memory capacity and whether gapped 
or ungapped read alignment is required.  In the case of variant detection, as opposed 
to de novo assembly, gapped read alignment is vital. 
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Table 2.3 A selection of the available software for NGS data analysis 
Program 
Name 
Description Reference/Website 
Bowtie Aligns reads to reference sequence 
– low memory requirements 
www.bowtie-bio.sourceforge.net 
CLC 
Genomics 
Workbench 
Complete integrated system 
including read alignment to reference 
sequence, SNP/indel detection, 
sequence viewer and statistical 
output 
www.clcbio.com 
ELAND Gapped read alignment program. 
Developed for Illumina sequencing 
platform probably one of the fastest 
alignment programs with economical 
memory requirements 
www.bioinfo.cgrb.oregonstate.edu/docs/solexa 
Exonerate Aligns reads to reference sequence www.ebi.ac.uk/~guy/exonerate 
MAQ Read alignment is fast but lacks the 
accuracy of other programs 
www.maq.sourceforge.net/index.shtml 
MOSAIK Gapped read alignment  
NextGENe Gapped read alignment as well as 
SNP/indel detection and alignment 
viewer.  
www.softgenetics.com 
NOVOALIGN Gapped read alignment www.novocraft.com/products.html 
RMAP Read alignment http://rulai.cshl.edu/rmap 
SHRiMP Read alignment http://compbio.cs.toronto.edu/shrimp 
SOAP Alignment program – fast and 
accurate but requires a large amount 
of memory capacity 
www.soap.genomics.org 
ZOOM Similar to ELAND, faster – but 
requiring more memory capacity 
 
Table 2.3 A selection of the available software for NGS data analysis. Information sourced from 
Horner et al (2009) Briefings in Bioinformatics vol 11. No 2 181-197.  
  
2.8.5 Base calling and variant detection 
Once reads are mapped to the reference sequence those that match are stored as the 
‘Final Read Set’ (CASAVA); one or two allele calls are made by the allele caller with a 
quality score (i.e. PHRED score divided by 10) assigned to each allele call.  For a SNP 
to be called homozygous no reference allele must be seen; for a SNP to be 
heterozygous the second allele must score ≤ 6 (i.e. PHRED score 60) and the ratio 
between the two alleles must be ≤ 3 (i.e. PHRED score 30).  Indels are detected by 
assembling reads that align; those that do not align fully (known as ‘shadow reads’) are 
assembled into contigs.  Assembled contigs are aligned to the reference sequence 
again to produce candidate indels, which are compared to the reference to determine 
homozygosity, heterozygosity or no indel (CASAVA v 1.6 User Guide). 
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2.9 Clinical genetic screening for rare high-penetrance ovarian cancer and breast 
cancer susceptibility genes BRCA1 and BRCA2  
There are three main reasons for genetic testing for mutations in BRCA1 and BRCA2.  
Firstly, for the assessment of an individual’s cancer risk, secondly, to initiate a strategy 
for early prevention, including, prophylactic therapy (chemoprevention or risk reducing 
surgery) and early monitoring and thirdly, for the use of targeted treatments for patients 
with a cancer diagnosis. For example, cancer patients positive for BRCA1 or BRCA2 
mutations have been found to be highly sensitive to PARP inhibitor drugs (Farmer 
2005). These treatments are likely to be less toxic and more specific than the current 
chemotherapies. 
The existing recommendations for genetic screening for BRCA1 and BRCA2 in the 
clinic are to test women for mutations if they have a 20% or more assessed risk of 
having a mutation (NICE 2006).  Therefore, testing is currently only offered to women 
assessed as having a very strong family history.  In addition, women with a strong 
family history of breast cancer or ovarian cancer must have either, a living affected 
relative that can be tested for mutation status; or be a patient with ovarian cancer or 
breast cancer to be offered genetic screening. Research has shown that a large 
proportion of women from low-risk families are positive for mutations (Walsh et al 
2010); therefore, these patients would be missed in screening.  Currently, one of the 
main reasons why a wider population of women are not tested is because the cost of 
screening makes it prohibitive. 
2.9.1 Advantages and disadvantages of BRCA genetic testing 
The main advantages of BRCA genetic testing include the identification of women at 
high risk of developing breast or ovarian cancer, which will allow for the introduction of 
targeted strategies for cancer prevention and early detection. It may also be 
advantageous to identify those that are not carriers of BRCA mutations; and this may 
relieve anxiety in those with a strong family history of disease.  However, BRCA testing 
is not without drawbacks; it is likely that not all mutations will be detected, resulting in 
false negatives. The abundant variants of uncertain significance that are identified in 
these genes may in fact increase anxiety in individuals. Those patients diagnosed as 
negative for BRCA mutations would still be at risk from sporadic cancers.  Some of the 
interventions for those diagnosed as BRCA mutation carriers, such as early screening, 
have not been adequately proven.  Potentially, there could be a level of social or 
financial harm in having a test for a gene mutation as this may affect mortgage or life 
insurance applications. 
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When the diagnosis of a BRCA mutation is made the patient must make a decision on 
what measures to take; these often include screening and/or risk reducing surgery.  In 
pre-menopausal women annual breast MRI scans are offered and possibly 
mastectomy.  In BRCA mutation carriers there is also the option for pre-implantation 
genetic diagnosis (PGD) to test for BRCA mutations in embryos prior to in-vitro 
fertilisation (IVF).  
The current method for genetic testing of BRCA1 and BRCA2 is PCR of specific exons 
and capillary electrophoresis to sequence for mutation detection. In addition, the use of 
multiplex ligation probe amplification (MLPA) for the detection of large genomic 
rearrangements. The regulatory regions and intronic non-coding regions are not 
currently included in routine testing.  The cost for NHS clinical mutation testing in 
BRCA1 and BRCA2 during this study (conducted in 2010) is ~£700-£1,000, including 
all the coding regions of both genes and MLPA for large rearrangements. This cost has 
since reduced to ~£500 in 2014.  
Genetic testing will be extended to those with an ovarian cancer or breast cancer 
diagnosis without family history and those with a strong family history without a cancer 
diagnosis, when the cost of mutation detection significantly reduces.  A clinical genetics 
Department in Leeds suggest they can test the coding regions of BRCA1 and BRCA2 
using LR-PCR and MPS for EU62.5 (~£50) (Morgan et al 2010).  However, this cost 
does not include the intronic and regulatory regions. A group in US report that it cost 
US$1,500 (~£1000) to sequence multiple genes in their entirety using genomic capture 
and MPS and they suggest that this cost could be reduced to $500 if using multiplexed 
protocols (Walsh et al 2010).  Using the protocols outlined in this report, Long PCR and 
MPS and multiplexing at 96 samples in one lane of a flow cell, it could possible re-
sequence the whole of three genes for ~£320. The ‘Discussion’ section gives a full 
breakdown and comparison of costs for different sequencing methods in both research 
and clinical settings at the time of writing in 2010. 
2.10 Identification of additional rare moderate-penetrance gene variants using 
NGS 
Although, BRCA1 and BRCA2 are the two predominant high-penetrance genes in 
ovarian and breast cancer susceptibility these do not explain all inherited ovarian 
cancers and breast cancers.  Five moderate-penetrance genes are identified as linked 
to a genetic predisposition to breast cancer, ATM, BRIP1, CHK2, PALB2 and NBS1.  
These are detected by sequencing candidate genes for pathogenic mutations. It is 
highly plausible that these are also linked to epithelial ovarian cancer and that there are 
 83 
other cancer susceptibility genes in this category, which could be successfully 
identified using NGS to sequence candidate genes in large cohorts of ovarian cancer 
cases and controls.  These genes may also be identified with whole exome sequencing 
(i.e. sequencing the complete set of coding regions) in affected families. 
2.11 Research aims  
To conduct a pilot study screening for known mutations in 12 BRCA1 mutation positive 
cancer patient DNA samples and demonstrate that Long Range PCR and NGS are as 
accurate as the current method (Sanger sequencing). 
1. To conduct a pilot study that will include screening for mutations in regulatory and 
intronic regions of BRCA1. 
2. To establish that, in principle, multiplexed NGS technology can be used to detect 
gene variants that predispose to an increased risk in ovarian cancer or breast 
cancer. 
3. To conduct an assessment of the viability of Long Range PCR and NGS as a 
clinical screening method.  This assessment will examine cost and time efficiency.  
The pilot study aims to establish the protocols for multiplexed mutation detection, which 
will allow for the scaling up in follow on studies of larger cohorts of patients in which 
additional susceptibility genes will be analysed. 
2.12 Hypotheses  
1. NGS technology detects all known germline BRCA1 variants in 12 mutation positive 
ovarian cancer patient control DNA samples. 
2. It is hypothesised that NGS technology could be used as a clinical tool to detect 
gene variants that predispose to an increased risk in breast cancer or ovarian 
cancer.  
3. This technology could be employed to identify rare variants in other genes that 
confer a moderate increase in cancer risk. 
4. NGS is scalable for high-throughput research studies. 
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2.13 Results 
(Refer to Chapter 6 Materials and Methods page 250) 
Long Range PCR (LR-PCR) is used as a target enrichment method to amplify the 
whole genomic region of BRCA1 gene.  11 overlapping primer pairs are designed 
using GenBank sequence L78833.1 Homo sapiens BRCA1 (BRCA1) gene, complete 
coding sequence.  12 DNA samples with known mutations in BRCA1 are prepared for 
sequencing on the Illumina GAII.  Several commercially available DNA polymerases 
are tested to find the best performing enzyme.  One library is prepared for each sample 
and these samples are pooled in equimolar quantities and indexed with one of 12 
unique barcode sequences.  76bp single read sequencing is performed on the GAII.  
Resulting data are analysed three times using different methods to identify all known 
mutations in the study DNA samples. 
2.13.1 DNA samples 
12 DNA samples are identified that have a variety of known mutations in BRCA1 from 
cancer patients with breast, ovarian or prostate cancer.  These mutations are not 
revealed to the author. This is done so that mutation detection can be conducted 
blinded to ensure good quality controls for the study. 
2.13.2 The search for the best performing DNA polymerase for Long Range PCR 
 
Figure 2.12 Fermentas Long Range PCR DNA polymerase.  Gel electrophoresis images of the same 
pooled control DNA sample using BRCA1 primers for one 6880 bp amplicon.  Lanes 1-4, 6-9, 11-14 
positive controls. Lanes 5, 10, and 15 negative controls. 
Figure 2.12 shows multiple bands and smearing for most lanes.  Two tests are 
conducted on this enzyme using higher annealing temperatures on the second test. 
 
 
 
Fermentas LR PCR Test 1 Fermentas LR PCR Test 2 
L   1   2   3   4    5  6   7   8   9 10 11 12 13 14 15                                 
 
L  1 2  3  4 5  6  7   8  9 1011 12 13 14 15 L                             
 
6 Kb 
10 Kb 6 Kb 
10 Kb 
6 Kb 
10 Kb 
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Figure 2.13 Kapa Biosystems HiFi Hot Start Long Range 
 
Figure 2.13 Kapa HiFi Hot Start Long Range.  Gel electrophoresis image of one example of 3 similar 
electrophoresis gels for three Kapa Biosystems enzymes tests using BRCA1 primers.  Lanes 1-4, 6-9 and 
11-14 positive controls; lanes 5 and 10 negative controls. This gel represents the PCR products of one 
6880 bp amplicon in BRCA1 
Figure 2.13 shows multiple bands and smearing for all positive control lanes using the 
Kapa Biosystems range of DNA polymerases suitable for LR-PCR on a pooled control 
female DNA sample.   
Figure 2.14 Phusion Hot Start Finnzymes  
 
Figure 2.14 Phusion Hot Start from Finnzymes. Gel electrophoresis image Phustion Hot Start Long 
Range PCR test using BRCA1 primers for one amplicon of 6880 bp.  Lanes 1-4, 6-9 and 11-14 positive 
controls; lanes 5 and 10 negative controls. 
Figure 2.14 shows multiple bands and smearing for all positive control lanes using the 
Finnzymes enzymes Phusion Hot Start.   
 
 
 
 
 
 
 
 
L       1     2      3     4     5      6      7     8     9   10     11   12   13    14                            
 
L       1     2      3     4     5      6      7     8     9   10     11   12   13    14                            
 
L       1     2      3     4     5      6      7     8     9   10     11   12   13    14                            
 
6 Kb 
10 Kb 
6 Kb 
10 Kb 
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Figure 2.15 Invitrogen SequalPrep™ Long PCR Kit with dNTPs 
 
Figure 2.15 Sequal Prep Long PCR Kit with dNTPs.  Gel electrophoresis testing Invitrogen sequal prep 
Long PCR Kit.  Lanes 1-6 positive controls using BRCA1 primers for 1 amplicon (intron 1 to intron 2); lane 
7 negative control, lanes 8-13 positive controls using BRCA1 primers for 1 amplicon (intron 14 to 1)6. 
Lanes 8-13 show a PCR product of 6880bp. 
Figure 2.15 shows faint multiple bands for BRCA1 primers intron 1 to intron 2 and clear 
bands for intron 14 to 16; lanes 11-13 show clearer and more specific bands using a 
higher annealing temperature.  The SequalPrep Long PCR kit with dNTPs is chosen to 
amplify DNA samples from patients with known mutations in BRCA1, blinded to the 
author, to test the efficiency of this product on varying DNA samples.  The Sequal Prep 
Kit is tested to see if DNA quality, assessed by age of the DNA sample, affects 
performance of the LR-PCR kit.  37 DNA samples, varying in quality, from both BRCA1 
mutation carrier samples and non-carrier samples are tested.  Table 2.4 demonstrates 
these samples showing which reveal a good PCR result and which fail PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   L     1      2     3     4     5      6      7      8      9     10     11    12    13                    
 
6 Kb 
10 Kb 
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Table 2.4 LR PCR enzyme efficiency and DNA quality 
 
Table 2.4 LR-PCR enzyme efficiency and DNA quality.  This table shows that DNA quality appears to 
affect LR-PCR performance.  NK= DNA age not known. 
The final samples chosen for sequencing are selected from those that produce a good 
LR-PCR product.  It is important to note that DNA quality appears to affect LR PCR 
performance and that although the Invitrogen enzyme is a relatively robust product it 
performs best when using good quality DNA samples.  A final set of 17 samples are 
chosen that work well for two fragments (6.436 Kb and 10 Kb), see Figure 2.17.  Then 
these are amplified on all 11 fragments for BRCA1.  The final 12 samples are chosen 
as those that amplified in all 11 fragments.   
 
No DNA Age 
in years 
Sample ID PCR 
Product 
Y/N 
1 23 OV001.306b Y 
2 19 OV002.304a N 
3 19 OV002.304b N 
4 19 OV025.515C Y 
5 21 OV034.411a Y 
6 16 OV034.411c Y 
7 18 OV099.402a N 
8 4 OV250.404 N 
9 11 OV371.304 N 
10 4 OV401.307 Y 
11 2 OV133.301b Y 
12 2 OV069.301b Y 
13 Degraded PRY0861 N 
14 Degraded PRY1145 N 
15 Degraded PRY0777 N 
16 Degraded PRS0625 N 
17 N/K PRS0673 Y 
18 N/K PRM4585 Y 
19 N/K PRY1541 Y 
20 N/K PRY0925 Y 
21 N/K PRY3217 Y 
22 N/K PRY3194 Y 
23 N/K Pr_B1 Y 
24 N/K Pr_B2 Y 
25 N/K Pr_B3 Y 
26 N/K Pr_B4 Y 
27 N/K Pr_B5 Y 
28 N/K Pr_B6 Y 
29 N/K Pr_B7 Y 
30 N/K Pr_B8 Y 
31 N/K Pr_B9 Y 
32 N/K Pr_B10 Y 
33 N/K OV089.305b Y 
34 N/K OV110.201c Y 
35 N/K OV110.303b Y 
36 N/K OV205.404 N 
37 N/K OV362.403 N 
12 carrier 
DNAs 
15 carrier 
DNAs 
Non- carrier 
DNAs 
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2.14 Target enrichment – Long Range PCR 
The whole of each gene is amplified in 11 overlapping fragments.  The diagrams below 
show where these fragments are located in each gene and where and by how many 
base pairs they overlap. 
Figure 2.16 Long Range PCR amplification of BRCA1 
 
Figure 2.16 Diagram of Position and Size of Long Range PCR fragments that amplify the whole of 
BRCA1 gene. 
Long Range PCR amplification of BRCA1
Schematic diagram showing exonic (yellow blocks) and intronic (black lines) regions of BRCA1
Black arrows represent amplified fragments
BRCA1_1 Forward primer is 3222 bp upstream of start of exon 1 to encompass promoter region 
BRCA1_9 Reverse primer is 2651 bp downstream of  3’ UTR 
Sequence: GenBank: L78833.1 
1 2
nt 122
9.5Kb
5 6
9.5Kb
208bp overlap 
in intron 2
5.009kb 
11
8.415Kb
9.411Kb
6.047Kb
6.436kb 
9.2Kb
247bp 
overlap 
i  i t 12
10Kb
30bp overlap 
in intron 19
10Kb
nt 87078
140bp overlap 
in intron 20
3'UTR5 'UTR
Scale
10Kb
112bp overlap 
in intron 13
14bp overlap 
in intron 16
328bp 
overlap 
i   11
5.771Kb
78bp overlap 
in intron 3
46bp overlap 
in exon 6
891bp 
overlap 
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Figure 2.17 Long Range PCR Gel Electrophoresis 
 
Figure 2.17 Two representative examples of gel electrophoresis images for two fragments for 17 
patient samples.  The final 12 samples are taken from these 17 samples. Lanes labelled P and N are 
Positive and Negative control lanes.  All other lanes are patient DNA samples labelled with numbers 
corresponding to DNA sample numbers in Table 2.4  
Agarose gels are run for each fragment in 17 patient samples.  The final 12 patient 
samples are selected from these.  Figure 2.17 above are two representative gels.  
 
 
 
 
 
 
 
 
   L              1     4    5     6   10   11  12   23  24  25   26  27   28   29   31  32  33                L 
   L      1     4     5      6   10   11   12    23   24   25   26   27   28   29   31   32   33                 L              
L 
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2.14.1 PCR product normalisation  
 
Table 2.5 Normalisation and pooling of PCR products 
Table 2.5 Normalisation and pooling of PCR Products.  PCR products are normalised and pooled in 
equimolar quantities each pool includes 11 BRCA1 amplicons. Each row represents one amplicon of 
BRCA1 Amplicon 1 to 11.  
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PCR products are pooled in normalised (equalised) quantities to minimise biases in 
sequencing.  This is done, as PCR reactions may not amplify template DNA with equal 
efficiency.  Table 2.5 details how this is achieved. 
 
2.14.2 Library validation 
 
Following library preparation the libraries are validated using Agilent Bioanalyzer 2100.  
This measures DNA concentration and size of fragments in base pairs (bp).  Figure 
2.18 below is the output from the Agilent Bioanalyzer 2100, in these 12 samples the 
middle peak represents the DNA fragment size (in bp) and the concentration of DNA in 
each sample in nmol/l.  The other two peaks represent DNA markers.  Each of the 
samples are quantified in triplicate and the mean is used to calculate the DNA 
concentration required for pooling of 12 samples.   
Figure 2.18 Library validation by Agilent Bioanalyzer 2100 
 
 
Figure 2.18 Library validation by Agilent Bioanalyzer 2100. 
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11 out of 12 libraries are validated on the Agilent Bioanalyzer 2100.  Sample 3 is 
unfortunately not validated and this sample failed the library preparation.  This is shown 
in Figure 2.18 where there is no peak at 300-400bp size band.  The full Agilent trace 
output for triplicate repeats is in Appendix I.  Quantitation and sizing is performed in 
triplicate and mean calculations used for normalisation. 
 
2.14.3 Library normalisation  
 
Table 2.6 Normalisation sheet for pooling 11 prepared libraries 
 
Table 2.6 Normalisation sheet for pooling 11 prepared samples. 
 
The results of the library validation are used to calculate the DNA input required to 
normalise samples for pooling.  Table 2.6 describes the DNA quantities to create 
POOL1 of 11 patient DNA samples in equivalent quantities.   
2.14.4 Agilent results for pool (concentration) 
Following normalisation, the DNA concentration and size of fragments are analysed 
using the Agilent Bioanalyzer 2100 (Figure 2.19).  This is performed in triplicate.  This 
quality control shows that POOL1 has a mean molarity of 58.1 nmol/l at a mean size of 
422 bp.  This analysis is required to calculate DNA input for flow cell generation. 
 
 
 
 
 
Pool ID
Internal ID - 
External ID Size nM nM nM Average nM
Pool 
Factor DNA
Pool 
Volume Index
Guideline Final 
concentration of 
Pool
Actual Final 
concentration of 
Pool
SOL567-1 390 18.5 21.7 20.10 78 3.88 23.08 1 50.03 58.13
SOL568-2 344 46.5 45.5 44.2 45.40 78 1.72 2
SOL570-4 372 16.4 19.9 18.15 78 4.30 4
SOL571-5 404 64.5 68 66.25 78 1.18 5
SOL572-6 399 68.9 73.6 71.25 78 1.09 6
SOL573-7 478 19.7 17.5 18.60 78 4.19 7
SOL574-8 435 53.3 57.9 55.60 78 1.40 8
SOL575-9 464 59.6 70.8 65.20 78 1.20 9
SOL576-10 471 65.3 84 74.65 78 1.04 10
SOL577-11 464 76.1 78.7 77.40 78 1.01 11
SOL578-12 580 31 44.5 37.75 78 2.07 12
1
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Figure 2.19 Quantitation of DNA concentration and sizing of pooled fragments 
     
 
Figure 2.19 Quantitation of DNA concentration and sizing of pooled fragments. 
2.14.5 Flow cell worksheet 
Table 2.7 Library dilutions and DNA input for Pool 
 
Table 2.7 Library dilutions and DNA input for pool 
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Table 2.8 Flow cell Generation 
 
Table 2.8 Flow cell Generation 
The results from the Agilent Bioanalyzer 2100 are entered into a flow cell worksheet 
and final run volumes are calculated for DNA input.  Note POOL1 is lane one of the 
flow cell.  PhiX is lane 8 and is the control lane.   The other six lanes are for another, 
unrelated, project. 
2.14.5 Clustering results 
Figure 2.20 Cluster density report 
 
Figure 2.20 Cluster density report.  This cluster density report shows that the mean cluster density is 
635,000 clusters per mm2. 
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In Figure 2.20 the first plot is the cluster density of POOL1.  This shows that there is a 
minimum cluster density of 556,000 mm2 and a maximum of 678,000 mm2.  To 
calculate the actual cluster density per tile, multiply this number by 0.53.  So, 600,000 
mm2 x 0.53 = 318,000 clusters per tile and 38 million reads for lane one.  There are 
120 tiles per lane on Illumina GAIIx. 
2.14.6 GAII Results 
Table 2.9 The First base report 
 
Table 2.9 The first base report.  This report is produced as an initial quality control before continuing with 
the sequencing run.  
The Genome Analyser generates the first base report; this is produced so that quality 
control metrics can be assessed before continuing with the sequencing run.  This 
report shows the number of clusters and the intensity of clusters for each of the 4 
nucleotides. 
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2.15 Data analysis 
2.15.1 Alignment of reads to human reference 
Read alignment is performed using software Consensus Assessment of Sequence and 
Variation (CASAVA).  This program is part of the Illumina GA data analysis workflow 
and converts the raw image data from the GA into aligned reads with base calls and 
quality control metrics.      
2.15.2 Detection of variants using SAMtools (Sequence Alignment Map) 
Table 2.10 Blinded causative mutations detected in NGS data. 
Sample Mutation Exon Mutation Type HGVS Nomenclature 
001. 
OVO25.515c L78833.1:g37067del AA 11 Frameshift 3984delAA 
002. 
Pr_B9 L78833.1:g35269delA 11 Frameshift 2187delA 
003. 
Pr_B10 L78833.1:g36529delAAGC 11 Frameshift 3447del4 
004. 
Pr_B1 Missing mutation    
005. 
OVO69.301b L78833.1:g35079delAGTC 11 Frameshift 1997del4 
006. 
OVO401.307 L78833.1:g34044delCTCA 11 Frameshift 962del4 
007. 
Pr_B2 L78833.1:g24598G>T 7 Nonsense E143X 
008. 
OVO133.301b L78833.1:g35854delTC 11 Frameshift 2773delTC 
009. 
OVO89.305b L78833.1:g34130delA 11 Frameshift 1048delA 
010. 
OVO01.306b L78833.1:g35154delA 11 Frameshift 2071delA 
011. 
Pr_B7 L78833.1:g71668insC 20 Frameshift 5382insC 
012. 
OVO34.411a Library failed    
Table 2.10 Blinded causative mutations detected using NGS.  One library failed and 1 mutation is 
missed in one sample. 
On the second analysis using CASAVA and SAMtools the parameters are altered to 
include reads that are in regions of lower coverage (i.e. < 30 X).  Table 2.10 shows the 
variants detected in the coding regions of BRCA1 following the second analysis. 
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 Table 2.11 All coding variants as identified by CASAVA software   
Sample Mutation Exon Amino Acid Change 
Mutation 
Type 
BIC 
Nomenclature 
001. 
OVO25.515c 
L78833.1:g37067del AA 
L78833.1:g34953T>G 
L78833.1:g35589A>G 
L78833.1:g35801A>G 
L78833.1:g36320G>A 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
L78833.1:g36429A>T 
L78833.1:g36905A>G 
 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
 
 
 
 
 
Ser1040Asn 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
 
 
FS 
 
 
 
MS 
MS 
MS 
MS 
MS 
 
 
 
3984delAA 
1871T>G 
2507A>G 
2719A>G 
3238G>A 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
3347A>T 
3822A>G 
 
002. 
Pr_B9 
L78833.1:g35269delA 
L78833.1:g35283C>T 
L78833.1:g35512T>C 
L78833.1:g35813C>T 
L78833.1:g36314A>G 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
L78833.1:g36749A>G 
L78833.1:g46278T>C 
L78833.1:g57655A>G 
 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
13 
16 
 
 
 
 
Pro871Leu 
Glu1038Gly 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
Lys1183Arg 
 
Ser1613Gly 
 
FS 
 
 
MS 
MS 
MS 
MS 
MS 
MS 
MS 
 
MS 
 
2187delA 
2201C>T 
2430T>C 
2731C>T 
3232A>G 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
3667A>G 
4427T>C 
4956A>G 
 
003. 
Pr_B10 
L78833.1:g35283C>T 
L78833.1:g35512T>C 
L78833.1:g35813C>T 
L78833.1:g36314A>G 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
L78833.1:g36529delAAGC 
L78833.1:g36749A>G 
L78833.1:g46278T>C 
L78833.1:g57655A>G 
 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
13 
16 
 
 
Pro871Leu 
Glu1038Gly 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
Gln1069Leu 
Lys1183Arg 
 
Ser1613Gly 
 
 
MS 
MS 
MS 
MS 
MS 
MS 
FS 
MS 
 
MS 
 
2201C>T 
2403T>C 
2731C>T 
3232A>G 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
3447del4 
3667A>G 
4427T>C 
4956A>G 
 
004. 
Pr_B1 
Missing mutation 
L78833.1:g4708T>G 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
 
 
2 
11 
11 
11 
11 
 
 
Cys24Gly 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
 
MS 
MS 
MS 
MS 
MS 
 
 
189T>G 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
 
005. 
OVO69.301b 
L78833.1:g34268A>G 
L78833.1:g35079delAGTC 
L78833.1:g35283C>T 
L78833.1:g35512T>C 
L78833.1:g35813C>T 
L78833.1:g36314A>G 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
 
Gln365Arg 
 
 
 
Pro871Leu 
Glu1038Gly 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
MS 
FS 
 
 
MS 
MS 
MS 
MS 
MS 
MS 
 
1186A>G 
1997del4 
2201T>C 
2430T>C 
2731C>T 
3232A>G 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
 
006. 
OVO401.307 
L78833.1:g34044delCTCA 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
 
11 
11 
11 
11 
11 
 
 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
FS 
MS 
MS 
MS 
MS 
 
962del4 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
 
 98 
Sample Mutation Exon Amino Acid Change 
Mutation 
Type 
BIC 
Nomenclature 
007. 
Pr_B2 
L78833.1:g24598G>T 
L78833.1:g36388T>C 
L78833.1:g36389C>A 
L78833.1:g36391A>T 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
 
7 
11 
11 
11 
11 
11 
11 
11 
 
Glu to Stop 
Ser to Pro 
Ser to Tyr 
Ser to Cys 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
NS 
MS 
MS 
MS 
MS 
MS 
MS 
MS 
 
E143X 
3306T>C 
3307C>A 
3309A>T 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
 
008. 
OVO133.301b 
L78833.1:g35854delTC 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
 
11 
11 
11 
11 
11 
 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
FS 
MS 
MS 
MS 
MS 
 
2773delTC 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
 
009. 
OVO89.305b 
L78833.1:g34130delA 
L78833.1:g35283C>T 
L78833.1:g35512T>C 
L78833.1:g35813C>T 
L78833.1:g36314A>G 
L78833.1:g36396T>A 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
L78833.1:g36749A>G 
L78833.1:g46278T>C 
L78833.1:g57655A>G 
 
11 
11 
11 
11 
11 
11 
11 
11 
11 
11 
13 
16 
 
 
 
 
Pro871Leu 
Glu1038Gly 
Asp1065Glu 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
Lys1183Arg 
 
Ser1613Gly 
 
FS 
 
 
MS 
MS 
MS 
MS 
MS 
MS 
MS 
 
MS 
 
1048delA 
2201C>T 
2403T>C 
2731C>T 
3232A>G 
3314T>A 
3322T>A 
3323T>G 
3325A>T 
3667A>G 
4427T>C 
4956A>G 
 
010. 
OVO01.306b 
L78833.1:g35154delA 
L78833.1:g35283C>T 
L78833.1:g35512T>C 
L78833.1:g35813C>T 
L78833.1:g36314A>G 
L78833.1:g36749A>G 
L78833.1:g46169T>C 
L78833.1:g46173A>G 
L78833.1:g46278T>C 
L78833.1:g57655A>G 
 
11 
11 
11 
11 
11 
11 
13 
13 
13 
16 
 
 
 
Pro871Leu 
Glu1038Gly 
Lys1183Arg 
 
 
 
 
FS 
 
 
MS 
MS 
MS 
 
 
 
 
 
2071delA 
2201C>T 
2403T>C 
2731C>T 
3232A>G 
3667A>G 
4318T>C 
4322A>G 
4427T>C 
4956A>G 
 
011. 
Pr_B7 
L78833.1:g36404T>A 
L78833.1:g36405T>G 
L78833.1:g36407A>T 
L78833.1:g71668insC 
 
11 
11 
11 
20 
 
Ile1068Asn 
Ile1068Met 
Gln1069Leu 
 
 
MS 
MS 
MS 
FS 
 
3322T>A 
3323T>G 
3325A>T 
5382insC 
 
012. 
OVO34.411a Library failed     
Table 2.11 All coding variants as identified by CASAVA software. Likely sequencing artefacts are 
highlighted in red. MS = missense, FS = Frameshift, NS = Nonsense 
 
The Table 2.11 shows a list of all coding variants that are detected by NGS.  Many of 
these are likely to be sequencing artefacts and these are evident as the parameters 
are changed to include all variants in regions that are below 30X depth of coverage.  
These are considered artefacts as either they are in sequence next to each other i.e. 
each nucleotide in a sequence is called as single base change or they are repeated in 
many samples.  This suggests that the alignment is incorrect.  Interestingly, where 
there is a missing mutation in exon 2 of sample Pr_B1, CASAVA has called a single 
base change in that position.  It is likely that this is part of the missing mutation and that 
it is missed due to incorrect alignment during read mapping. In addition, no minimum 
percentage for alternate allele is set.  These issues are addressed in the next study. 
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2.15.3 Detection of unclassified variants in regulatory and intronic regions 
 
Many unclassified variants are detected, including insertions and deletions in the 
promoter region and 3’ UTR, as well as in introns. These large data sets are available 
as excel files; however, the files are too large to print as each sample has ~300-400 
novel variants in non-coding regions.  Many of these are single base changes and are 
repeated in several samples.  The Table 2.12 describes unclassified intronic variants, 
which are insertions or deletions of bases 2-5 bp in size that are unique to samples. 
Table 2.12 Unclassified intronic variants 
 
Sample 
 
Intronic variant Intron 
001. 
OVO25.515c 
22806insCTTG 
42620delTA 
5 
12 
002. 
Pr_B9 
9446delTT 
32346insTTTC 
42616insTGTT 
60880insAAC 
74964delTTC 
2 
9 
12 
16 
20 
005. 
OVO69.301b 69249insGTA 19 
007. 
Pr_B2 5359delCA 2 
008. 
OVO133.301b 37797delGT 12 
009. 
OVO89.305b 
4827insGGG 
79985insGG 
82163delTAA 
13 
22 
23 
010. 
OVO01.306b 
21495insAC 
22806insCTCA 
4827insTGGG 
60603insTT 
73746delCC 
3 
5 
13 
16 
20 
011. 
Pr_B7 
27768delCT 
28683delCC 
54064del AT 
69250insTTT 
7 
7 
15 
19 
Table 2.12 Unclassified intronic variants. Variants selected are those that are 2-5 bp indels.  The table 
shows the nucleotides inserted or deleted and the location of the variant.  
 
The Table 2.12 above details some examples of changes found in intronic regions of 
BRCA1.  The significance of these is difficult to determine here and their relevance in 
cancer susceptibility is uncertain unless RNA testing is conducted to determine if these 
intronic changes result in a shorted RNA transcript.  In addition, many of these may be 
artefacts of the sequencing technology. 
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2.15.4 Capillary sequencing of exon 2 in sample Pr_B1 
Figure 2.21 Capillary sequencing trace of the end of exon 2 
 
Figure 2.21 Capillary sequencing trace of the end of exon 2.  This trace shows the deletion of the last 
11bp of exon 2 in sample Pr_B1 
One mutation is not detected by NGS.  To troubleshoot this missing mutation capillary 
sequencing of the region is performed to verify the mutation in the sample, which is 
confirmed. Figure 2.21 shows the mutation 189del11 in sample Pr_B1. 
2.15.5 A revised analysis pipeline for the re-analysis of Exon 2 in sample Pr_B1 
The overwhelming growth in the sequencing capacity of massively parallel sequencing 
technologies has resulted in the necessary development of new computational 
methods to analyse resultant large sequencing data sets.  These tools are continually 
being refined and developed at an astounding rate.  Many of these tools are 
specifically designed for certain tasks, i.e. one for read mapping, another for SNP 
detection and another for indel detection.  One difficulty with this is that they may not 
be compatible on all platforms.  Sequencing capacity and data analysis are not 
developing at an equal rate, meaning that data analysis methods are not easily 
extracting the required information to answer specific biological questions.  
Downstream analysis requires the manipulation of sequencing data in order to extract 
answers to these complex questions.  It follows that in any analysis pipeline there must 
be adaptability that allows for programming to be performed thus, tailoring the analysis 
to the individual experiment (McKenna et al 2010). 
Almost certainly the most crucial step in analysing massively parallel sequencing data 
is the first one that involves mapping millions of short 100bp reads individually to the 
reference sequence.  Immediately, it is obvious that if reads contain an indel they run 
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the risk of being incorrectly mapped.  Although each base is assigned a quality score 
that calculates the likelihood that the base is the correct sequenced base, this cannot 
be relied upon.  These quality scores are renowned for their imprecision (DePristo et al 
2011).  Both of these major flaws can have serious consequences and produce 
inaccuracies in variant detection. The main obstacle to overcome in the analysis of 
NGS data is discerning genuine genetic variation from artefacts of the sequencing 
technology. 
To resolve these issues analysis tools are available to filter reads on the basis of 
certain parameters.  For example, variants detected in regions of too high or too low 
coverage can be filtered out.  In this study, it is shown that both of these pose a 
problem. In the regions of very high coverage due to excess sequencing capacity and 
the use of Long Range PCR, filters are changed to allow for the detection of several 
variants. 
A new analysis pipeline is used for the investigation of the missing 189del11 mutation 
in sample Pr_B1.  This revised analysis pipeline is performed on sample Pr_B1.  The 
analysis pipeline of the pilot study and the revised pipeline are described in the 
following flow diagrams: 
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Figure 2.22 Original analysis pipeline: pilot study 
 
 
 
 
 
 
 
 
 
Figure 2.22 The original analysis pipeline.  This format is used in first analysis. 
 
Figure 2.23 Revised analysis pipeline  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23  The revised analysis pipeline.  This is the format used in the re-analysis of exon 
2 sample Pr_B1. 
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2.15.6 Re-analysis of Pr_B1 exon 2 with an alternative analysis pipeline 
2.15.6.1 FastQC 
FastQC performs quality control (QC) analysis on raw data generated from high-
throughput sequencing. This program effectively highlights any areas of concern in the 
data.  This Java based program analyses the raw data and graphically reports a 
detailed image of sequence quality specifically for high-throughput sequencing data.  
QC data are displayed and the following describes the information provided by the 
program: 
1.  Basic Statistics 
These statistics (Table 2.13) give brief information on sequence ID, library sequence 
length, number of sequences and GC% content of sequences. 
 
2.  Per base sequence quality 
This displays quality scores per base (Figure 2.24); scores should be high and at least 
over 20.  Yellow blocks show the 25th to 75th percentile and the blue line is the mean. 
 
3.  Per sequence quality scores 
This shows the mean across all bases and plots the distribution of means (Figure 2.25) 
 
4.  Per base sequence content 
This graph shows per base sequence content and will demonstrate if the position of a 
base in the sequence influences base calls.  Lines should be roughly parallel, as 
position should not influence base call (Figure 2.26). 
 
5.  Per base GC content 
This line should be flat, as % GC content should not vary through sequence reads 
(Figure 2.27). 
 
6.  Per sequence GC content 
This graph should show a normal distribution (Figure 2.28).  Peaks could demonstrate 
contaminants. 
 
7.  Per base N content 
This should be a flat line at 0% to show that no base calls were N, meaning that a base 
is not identified (Figure 2.29). 
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8.  Sequence length distribution 
This plot demonstrates if all sequences are the same length i.e. 76 bp (Figure 2.30) 
 
9.  Sequence duplication levels 
This plot shows how unique sequences are (Figure 2.31).  A duplication level of 1 
shows that it is mostly unique and a duplication level of 10 is 10 x duplicated and so is 
not unique. 
 
10. Overrepresented sequences 
This table (Table 2.14) shows a list of those overrepresented sequences with the 
percentage of each sequence making up the library. 
 
2.15.6.2 Burrows Wheeler Aligner (BWA) 
 
The Burrows-Wheeler Aligner (BWA) is a read-mapping program that effectively aligns 
short reads (up to 200 bp) against a reference sequence (Li & Durbin 2009). It allows 
for gapped alignment, which is crucial when aligning single read sequences that may 
include insertions and deletions.  BWA is used in a third analysis of just one sample 
Pr_B1 in order to troubleshoot the missing mutation in exon 2 that is not identified in 
previous analyses. 
2.15.6.3 SAM (Sequence Alignment Map) Format and SAMtools 
The SAM format is a universal format that stores NGS reads that are aligned using 
read mapping programs.  These various read mapping programs produce read 
alignment data in many different, and incompatible, formats.  Converting aligned reads 
to SAM format allows for the further downstream analysis of sequencing data to 
effectively detect gene variation.  These downstream analyses can be performed using 
SAMtools and Picard.  SAM has a corresponding binary format known as BAM, which 
enables compression of data.  
2.15.6.4 Picard 
Picard is a tool that can manipulate files in SAM format. Following alignment with BWA, 
Picard is used to remove the duplicate sequences. These duplicate sequences include 
the indexes used to identify individual samples.  They also include the overrepresented 
sequences that appear to be duplicated at each end of the LR-PCR fragment.  These 
sequences can be cleaned up (i.e. removed) by Picard and realigned using the 
Genome Analysis Toolkit developed by the Broad Institute.    
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2.15.6.5 Genome Analysis Toolkit (GATK) Broad Institute 
The GATK is a programming structure designed to provide tools that enable the more 
refined analysis of next generation sequencing data using the programming model 
MapReduce (DePristo et al 2011).  This software framework facilitates the writing of 
analysis tools for MPS resequencing data.  GATK has been used for the analysis of the 
1000 Genome Project data and the Cancer Genome Atlas.  
2.15.6.6 Realignment with GATK IndelRealigner 
Local realignment is often required around regions that include indels. The Multiple 
Sequence Alignment (MSA) tool realigns reads to reduce the number of mismatched 
bases across the read.  If these mismatches are not removed they can be erroneously 
identified as SNPs.  This is the case in this study as the CASAVA program identifies 
two single base changes in the region that the 11 bp deletion resides rather than 
identifying the mutation.  This is due to the incorrect alignment of reads containing the 
deletion. Once local realignment is performed the resulting reads are clean and can be 
put through the variant detection program (Unified Genotyper, which is a tool available 
from GATK). 
Local realignment is performed in two stages: first is to establish intervals that may 
require realignment. So, in this case exon 2 is identified because, the indel is expected 
be located in exon 2. Second, the realigner is run over the established interval (exon 
2).  In the re-analysis of exon 2 Pr_B1 100bp intervals are used and run through the 
realigner.   
2.15.6.7 Variant detection using GATK Unified Genotyper 
This tool calls SNPs and indels from both single sample and multi-sample data.  It 
attempts to establish both the likely genotypes and the allele frequencies within the 
input population of samples. 
2.15.6.8 Integrative Genomics Viewer (IGV) 
The Integrative Genomics Viewer is a data visualisation tool, also from the Broad 
Institute, that is fully compatible with GATK.  BAM or SAM files can be imported directly 
and visualised alongside RefSeq genes.  This tool allows the user to interrogate data 
sets from genomics experiments, including sequencing, copy number variation and 
gene expression data (Robinson et al 2011) 
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2.15.7 Fast QC data 
Table 2.13. Basic statistics 
 
Measure Value 
Filename s_1_sequence.txt 
File type Conventional base calls 
Total 
Sequences 795819 
Sequence 
length 76 
%GC 44 
 
Table 2.13 Basic statistics table. This table shows that the sample file contains 795,819 sequences of 76 
bp in length. 
Figure 2.24 Per base sequence quality 
 
Figure 2.24 Per base sequence quality.  This image shows that mean quality scores are all high. 
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Figure 2.25 Per sequence quality scores 
 
 
Figure 2.25 Per sequence quality scores.  This image shows that the mean quality scores are high 
Figure 2.26 Per base sequence content 
 
Figure 2.26 Per base sequence content.  This image shows that the position of the base does not 
influence base call.  The four bases are equally called. 
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Figure 2.27 Per base GC content 
 
 
Figure 2.27 Per base GC content. This image shows that the per base GC content does not vary 
between reads. 
Figure 2.28 Per sequence GC content 
 
 
Figure 2.28  Per sequence GC content. This image shows that the distribution is roughly a normal 
distribution.  The small peak on the right indicates a level of contamination. 
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Figure 2.29 Per Base N content 
 
 
Figure 2.29 Per Base N content.  This image shows that the N content is minimal; most bases are called. 
Figure 2.30 Sequence length distribution 
 
 
Figure 2.30 Sequence length distribution. This image shows that sequences are all the same length 
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Figure 2.31 Sequence duplication levels 
 
 
Figure 2.31 Sequence duplication levels.  This plot demonstrates that 55.32% of the 
sequences are not unique.   
 
Table 2.14 Overrepresented sequences 
 
Sequence Count Percentage Possible Source 
AGCCTTGTCTCAGCTGGGTGTCTTTATTTACTCTGTCTTAAAGT
GTTCCTTTTATTATCATTATTATTTTTTAATC 2328 0.29252882879147146 No Hit 
GGCTTGTAAGAATGCCCTGCCACTTCTGCCCTGCAATATCCCT
TGCTATTAGGATTTTGGCATCACCTTGGGTCCT 2177 0.2735546650683133 No Hit 
ACAATTCAGAGCAGGGGTAGGGAGGAAATTCCCTTATGATAGT
ACTGCAGAATATAGTACAGTAGAGTGACAAGCT 1871 0.2351037107684034 No Hit 
GCAGGGCAGAAGTGGCAGGGCATTCTTACAAGCCAGGATGAA
AACAAACACTAGAGAAATGCTACTATCTGGCAGT 1769 0.22228672600176674 No Hit 
TGTATAGACTACAGCACGAGACAGCTTAGCTTGTCACTCTACT
GTACTATATTCTGCAGTACTATCATAAGGGAAT 1767 0.22203541257496992 No Hit 
CCAGACATTTTAGTGTGTAAATTCCTGGGCATTTTTTCCAGGCA
TCATACATGTTAGCTGACTGATGATGGTCAAT 1733 0.2177630843194244 No Hit 
ACAGCACTTGAGTTGCATTCTTGGGATATTCAACACTTACACTC
CAAACCTGTGTCAAGCTGAAAAGCACAAATGA 1712 0.21512429333805802 No Hit 
CCTAGTGCCCAGAACACAGTAGGCTCCCAATAAATAGCCACTG
AATAAAAGTTAAAACCAACAAAAATAATCATTT 1573 0.19765801017568063 No Hit 
 111 
CACTGTGAAGAAAACAAGCTAGCAGAACATTTTGTTTCCTCACT
AAGGTGATGTTCCTGAGATGCCTTTGCCAATA 1438 0.18069435386689686 No Hit 
AGAGGAGACAAGGAGCATGTACACCTAAAATCAACATAGACCC
CTCTGTTGATGGGGTCATAGTGAGTACTTGAGG 1165 0.14639007110913413 No Hit 
AGCCCTTTCACCCATACACATTTGGCTCAGGGTTACCGAAGAG
GGGCCAAGAAATTAGAGTCCTCAGAAGAGAACT 1090 0.13696581760425422 No Hit 
ACGACTAACCTGGCAGTGTGACAAGAATGTGGTTTTTTCCTTAA
ATATTTAACTTTTTAGAAAAGGATCACAAGGG 1067 0.13407571319609107 No Hit 
CAGGTTATGTTGCATGGTATCCCTCTGCTTCAAAAACGATAAAT
GGCACCAAGAAAATGAAATACTTTGAGAAGCT 1052 0.1321908624951151 No Hit 
CAGGTTGCTGGCCCCACCTGTCTGGGATTCAGTGGGTCTGGG
AATTTGCATATCTAACAAATTCCTAGGTGATGGT 1004 0.126159340251992 No Hit 
CCAGACATTTTAGTGTGTAAATTCCTGGGTTCTGCTAGCTTGTT
TTCTTCACAGTGAGATCGGAAGAGCACACGTC 987 0.12402317612421919 No Hit 
CAGGTTGCTGGCCCCACCTGTCTGGGCTGTCTCAACAGTTTTG
GGTTTGCCTGGATTTCACTGCATCTTGAGCTGG 870 0.10932134065660659 No Hit 
CACTGTGAAGAAAACAAGCTAGCAGAACCCAGGAATTTACACA
CTAAAATGTCTGGAGATCGGAAGAGCACACGTC 836 0.10504901240106104 No Hit 
AGTGTCACCACCCCAAGGACTCTCTCTCATTTTCTTTGCCTGG
GCCCTCTTTCTACTGAGGAGTCGTGGCCTTCCA 831 0.10442072883406907 No Hit 
Table 2.14 Overrepresented sequences. This table shows the sequences that are overrepresented. 
The sequences in Table 2.14 are those that are overrepresented.  On closer inspection 
of these sequences they are the beginning of LR-PCR amplicons.   
Following QC checks, the reads from sample Pr_B1 are aligned with BWA, and then 
duplicate sequences are removed with Picard tools.  Next the cleaned up sequences 
are re-aligned with GATK IndelRealigner and variant detection is performed on exon 2 
Pr_B1 using GATK.  The Figure 2.32 overleaf shows the reads using the Integrative 
Genome Viewer (IGV).  Here the 11 bp deletion at the 3’ end of exon 2 is clearly 
identified.  The second IGV image in Figure 2.33 shows the table zoomed out and 
demonstrates that there are 7 high quality reads that identify the 11bp deletion. 
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Figure 2.32 The Integrative Genomics Viewer (IGV) 
 
Figure 2.32 The Integrative Genomics Viewer (IGV).  This image shows the 11 bp deletion at the end of 
exon 2. 
 
Figure 2.33 The Integrative Genomics Viewer (IGV) 
 
Figure 2.33 The Integrative Genomics Viewer (IGV). This view of IGV is zoomed out, with clearly visible 
7 high quality reads containing the 11 bp deletion.   
  
Exon 2 BRCA1 
11 bp deletion 
3’end of exon 2 
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2.15.8 Troubleshooting the missing 11 bp deletion in Pr_B1 
A third Analysis of Exon 2 of sample Pr_B1 is conducted to ascertain if the 11 bp 
deletion in exon 2 of Pr_B1 can be detected in the Illumina GAIIx sequencing data.  
This analysis is based on the alternative pipeline outlined in the Methodology chapter. 
The Fast QC checks for Pr_B1 are mostly passed, however one highlighted warning is 
the number of repeated sequences (Table 2.14).  Pr_B1 results show that 55.32% of 
the sequences are duplicated, meaning they were not unique sequences.  On closer 
examination of the individual sequences the overrepresented sequences are the 
beginning of LR-PCR amplicons.  Other researchers using LR-PCR and Illumina 
sequencing observe this; in that the 50 bp at each end of LR-PCR fragment can 
represent in excess of 50% of the sequenced bases (Harismendy & Frazer 2009).  
Reducing the overrepresentation of amplicon ends will improve coverage uniformity 
and result in an overall increase in sequencing depth across the sequencing target. 
The new analysis pipeline cleans up duplicated sequences before realigning reads.  
This results in the detection of the 11bp indel in the sample. This demonstrates that by 
using a different analysis pipeline the missing mutation in the pilot study is in fact 
detected.  This allows more confidence in the data analysis as this study detected 
100% of mutations in samples sequenced using Illumina GAIIx.   
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2.15.9 Coverage data 
Figure 2.34 Coverage data for one patient sample 
 
 
 
Figure 2.34 Coverage data for one patient sample.  These diagrams show the coverage data for one 
patient sample 
 115 
One amplicon appears to show very low coverage across most samples.  This is the 
region exon 6 to exon 8.  Figure 2.34 illustrates this region in the middle graph labelled 
‘intron 6 to intron 8’.    
2.15.10 Coverage statistics 
Table 2.15 coverage statistics 
Sample Coverage >30x 
001 94.5% 
002 96.5% 
003 95.4% 
004 94.3% 
005 95.2% 
006 95.2% 
007 95.2% 
008 94.9% 
009 95.3% 
010 67.3% 
011 86.0% 
Table 2.15 coverage statistics.  This table shows the coverage statistics for each of the 11 samples 
sequenced. 
Coverage statistics show the percentage of the target region covered for each sample 
(Table 2.15).  9/11 samples show coverage of more than 30X for over 94% of the 
target region.  For two samples coverage of more than 30X was lower at 86% and 
67.3%. 
2.15.11 Phred scores 
Phred scores are assigned to each base call giving a quality score for each base.  
Scores are all over 50; this demonstrates a probability of a base call being incorrect as 
1:100,000. 
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2.16 Discussion 
2.16.1 Detection of blinded causative mutations in 12 patient samples  
This study uses LR-PCR and the Illumina GAII to sequence the whole of BRCA1 gene 
in 12 patient DNA samples demonstrating that, in principle, NGS can be used in the 
clinic, to detect deleterious mutations in cancer susceptibility genes.  The entire 
genomic region of BRCA1 is sequenced in 11 samples (1 failed library preparation) on 
Illumina GAII platform using a multiplex sequencing protocol that pooled and 
sequenced all samples on one lane of a flow cell.  LR-PCR is found to be an 
appropriate target enrichment method for the size of target region and the number of 
samples. 
9 small insertions and deletions (indels) and 1 nonsense mutation are accurately 
detected in the correct samples.  The 9 indels result in a frameshift mutation. 
Frameshift mutations result in an alteration of the gene’s reading frame and a shift in 
the grouping of bases that leads to an altered or non-functioning protein product. The 
size of indels ranges from 1bp to 4bp.  The nonsense mutation results from a single 
base substitution in which there is an amino acid change from Glutamic Acid to a Stop 
Codon.  The reason the one 11bp indel is not detected in one of the samples may be 
because the alignment software is not able to detect indels of this size.  Morgan et al 
(2010) note that the alignment and variation software program CASAVA does not 
detect insertions or deletions.  Capillary sequencing is employed to investigate this 
sample for an indel in exon 2.  This demonstrates that the sample is positive for the 
188del11 mutation in exon 2. This may be remedied with the use of alternative 
software (NextGENe) or with the use of paired-end sequencing, which should improve 
accuracy in base calling. Numerous single base changes are detected; many of these 
are missense mutations that result in a substitution of one amino acid for another, 
however the functional impact of these is not assessed.  In the next study this limitation 
is addressed with the use of functional prediction software programs.  15 coding non-
synonymous single base changes are identified; 10 coding synonymous single base 
changes are detected.  A very large number of unclassified variants are detected in the 
regulatory and intronic regions of BRCA1.  These include indels of 1bp to 5bp and 
single base substitutions.  Many of these are repeated in several samples and some 
are unique to specific samples, however, the functional effect of these cannot easily be 
assessed; indeed many may be sequencing artefacts.  Moreover, as these samples 
are positive for deleterious coding mutations, it is likely that these are of little 
significance here.  Nevertheless, detecting these intronic changes is important as this 
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shows that the methodology used here is able to identify small changes in a very large 
genomic region. 
2.16.2 Scaling up 
In order to increase the scale of targeted re-sequencing to that required in a diagnostic 
laboratory or for use in very large scale direct sequencing of candidate cancer 
susceptibility genes, a number of issues need to be addressed.  There are a number of 
areas where bottlenecks in the protocol create an obstacle in increasing throughput.  
Overcoming these will ensure streamlined procedures and allow for scaling up.  This 
study identifies the first bottleneck prior to library preparation during normalisation of 
the PCR products. For 12 patients for one gene it involved 132 different PCR products.  
If this is calculated for 48 samples for 3 genes (2 at 11 fragments and 1 at 7 
fragments), it will require 1392 PCR products.  The PCR amplification can be 
automated which could reduce the risk of pipetting errors or contamination.  The 
purification of PCR products prior to quantitation for normalisation and pooling can be 
done in 96 well plates using SPRI beads.  The protocol for this is outlined as 
‘supplementary protocol 1 in the paper by Mamanova et al (2010) in which an 
alternative library preparation protocols is described.  The quantitation of PCR products 
for normalisation would require automation to reduce the risk of pipetting errors.  Other 
methods of quantitation and normalisation will be investigated, for example, PicoGreen 
or qPCR.   
It took several days to prepare 12 libraries; therefore, preparing 48 will take around 3 
weeks. There are new automated systems available for library preparation.  For 
example, SPRIworks Fragment Library System by Beckman Coulter Genomics 
advertises that 20 libraries can be prepared in just one day compared to 4 libraries in 
one day when done manually.  Automated systems obviate the need for certain steps 
in the current protocols, such as size selecting by cutting out gels.  As throughput 
requirements increase the cost of sequencing may reduce, however, the cost of the 
library preparation will inflate with the use of more reagents and indexes for 
multiplexing.   
The first step in library preparation is fragmentation of DNA samples. This step, 
performed using the Bioruptor to sonicate samples will take 2-3 days to fragment 48 
samples. Using a Covaris AFA (Adaptive Focused Acoustics) machine to fragment 
samples results in improved more uniform fragments and removes the need to size 
select so that 48 samples would take 2 hours (Mamanova et al 2010).   
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The purification steps required between each step in library preparation could be done 
using QiaQuick 96 well plates rather than the spin columns used in this pilot study; this 
will improve the procedure, save time and be more streamlined.  96 well plates will also 
be used for the purification steps in the next studies. 
2.16.3 Coverage uniformity 
Sensitivity and specificity in base calling is achieved with sequencing coverage 
uniformity.  However, variation in sequence uniformity has been identified in previous 
literature when using LR-PCR as a target enrichment strategy (Harismendy & Frazer 
2009).  In this study, depth of coverage is highly variable both between and within 
samples.  There are a number of reasons why coverage is uneven including 
normalisation, design of multiplexed library preparation protocols and the LR-PCR 
itself.  
 
If normalisation of LR-PCR fragments is not calculated accurately then this could lead 
to biases in sequencing coverage.  In this study, quantitation of DNA concentration in 
PCR products is measured individually using the Qubit Fluorometer, and as such may 
not be accurate enough.  An alternative quantitation method that could be automated 
for scaling up in the next follow on project may be more appropriate, such as 
quantitative PCR (qPCR). It is difficult to assess the effect of the omission of one 
sample in the final pooling; it is possible that this may have a negative effect on 
coverage uniformity.   
 
Mamanova et al (2010) note that tagging fragmented DNA with indexes for bar-coding 
results in uneven coverage and their protocol for preparing libraries in 96-well plates 
includes the index sequence in a mid-region of the reverse PCR primer at the PCR 
enrichment stage.  Another modification to the protocols to achieve improved uniformity 
is to use 5’ blocked primers.  Harismendy & Fraser (2009) suggest that using LR-PCR 
as target enrichment produces an overrepresentation at the ends of amplicons, 
specifically a 50bp region at the 5’ends.  They suggest that the use of 5’ blocked 
primers improves coverage uniformity. 
 
Coverage of 30X is considered to be the minimum for accurate base calling.  Very high 
coverage could also cause difficulty in base calling as some software programs apply 
filters that effectively exclude bases in areas of very high coverage.  One crucial point 
in depth of coverage is highly accurate quantitation of DNA concentration in PCR 
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products and thus accurate normalisation.  In the results section coverage statistics are 
outlined; 9 of the 11 samples show >30X coverage of >94% of the amplified sequence.  
One amplicon (intron 6 to intron 8) shows low coverage across the majority of samples. 
This could be due to incorrect calculation of DNA concentration for normalisation 
purposes or due to the region being rich in A-T repeat sequences.  Harismendy et al 
(2009) make comparisons between the three main NGS platforms.  They advise that 
the SOLiD and Illumina systems both show areas of low or no coverage and that these 
regions are noted for their A-T rich repeat sequences.  The clear benefit of improving 
uniformity of coverage is that it increases depth of coverage throughout the entire 
target region.  Therefore, refinement of library preparation protocols will not only 
increase throughput, but will also improve quality control. 
2.16.4 Single-read vs. paired-end read sequencing data 
Single read (SR) sequencing data is likely to show marginally less accuracy when 
compared to paired-end sequencing (PE) data.  PE data is advanced in terms of 
precision and accuracy in detecting insertions and deletions.  The read length 
generated via PE sequencing is clearly twice as long as that of SR.  This will be crucial 
if sequencing larger genomes or those containing large regions of repeat sequences, 
since it will be very difficult to align data accurately through these if using short SR 
data.  For example, if the short SR data sequence appears in several areas in the gene 
and if this sequence has a mutation within it, then it will not be possible to ascertain the 
position of the mutation.  With PE sequencing the two read sequence pairs are a 
known distance apart, thus ascertaining their position should be more possible.  In 
addition, if the single read sequence includes repeats, then this read may be aligned 
anywhere within the repeat sequence.  Since PE reads essentially double the read 
length then it is more likely that, at least, a portion of the reads will include regions 
outside of these repeat sequences.   
In order to detect larger indels it will be necessary to use PE reads.  In this pilot study 
single reads of 76bp are performed.  It is known that BRCA1 comprises 41.5% Alu 
repeat sequences, with one Alu repeat sequence occurring approximately every 650bp 
throughout the entire sequence of the gene (Tancredi et al 2004).  In order to detect 
larger insertions and deletions it will be imperative to use PE sequencing.  If these Alu 
sequences are 69-231 bp in length (Smith et al 1996), and the SR length is just 76bp 
then it is clear that this could be problematic and that aligning some 76bp reads against 
the reference genome sequence would be almost impossible.  With 2 x 100bp (the new 
HiSeq2000) paired reads that are a known distance apart (i.e. insert sizes of ~300bp) 
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this will make alignment to the reference sequence much more precise.  It may be 
possible to improve accuracy in alignment of reads by reducing the selected fragment 
size, however, this could increase the time it will take to analyse these data.   
Using overlapping PE reads could further increase the accuracy of sequencing data 
produced.  This is achieved by size selecting fragments of a smaller size than the 
combined read length.  This is probably best accomplished using the longest read 
lengths available with the Illumina GAII.  The additional read depth attained with PE 
sequencing will also increase coverage across the region sequenced, thus increasing 
the accuracy of mutation detection.  Finally, the new HiSeq2000 system will also 
increase coverage depth. This system has a dual flow cell in which reads are taken 
from both sides of the flow cell, effectively doubling the number of reads per flow cell.  
This system is capable of the slightly longer read length of 100bp, which will increase 
accuracy of alignment further. 
2.16.4 Quality controls  
Quality controls are in place at all stages.  These include the quantitation and validation 
of libraries using the Agilent Bioanalyzer 2100; the cluster density report produced by 
the Genome Analyzer; coverage data produced by analysis software; and Phred 
scores for base call quality produced by the analysis software.  Phred scores are 
assigned for each base call and this system demonstrates that quality is in the region 
of 50-60 for each base call; which signifies that there is a probability of 1:100,000 that a 
base call is incorrect. 
2.16.5 Cost comparison of sequencing methods 
 
Table 2.16 shows a comparison of sequencing costs for different sequencing methods 
(2010 costs); these are for the current method used in the genetics clinic (Sanger 
sequencing) for diagnosis of BRCA1 or BRCA2 mutations and the method used in this 
study (LR-PCR and NGS).  This table also gives an estimated cost if the next study 
were to sequence 48 samples in 3 genes.  The Illumina costs are based on one lane of 
a flow cell and the current research costs are based on PCR and capillary sequencing 
at the current (2010) price.  The current clinical costs are derived from the cost charged 
by NHS centres and this price includes MLPA for both genes. 
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Table 2.16. A comparison of costs of sequencing methods 
 
Table 2.16 A comparison of sequencing methods costs.  This table compares the sequencing costs for 
different sequencing methods (2010 costs). 
 
2.16.6 Rejecting the use of Long Range PCR as target enrichment method 
LR-PCR is a highly effective method of enriching a large genomic region in a small 
number of samples.  However, it is debateable that the inclusion of all regions of genes 
is necessary in order to assess risk. Deleterious changes in BRCA1 or BRCA2 genes 
are generally considered to be those that result in a non-functioning protein product.   
Therefore, those that reside in non-coding regions or that do not result in amino acid 
changes in coding regions cannot be classified in terms of their influence on breast or 
ovarian cancer susceptibility.  In addition, in the clinical setting both variants of 
uncertain significance and non-coding changes are currently ignored. 
The discovery of genetic alleles for ovarian cancer will require interrogating very large 
sample sets; therefore, increasing throughput is of paramount importance.  Thus, it is 
considered prudent to change the experimental design to only include a specific highly 
targeted region (the coding regions) of the genome that are most likely to be relevant in 
protein function.  These coding regions can be directly related to the clinical setting as 
their probable pathogenic impact can be more accurately assessed.     
2.16.7 Dealing with technical sequencing artefacts  
In the studies that follow on from this pilot study, issues in distinguishing technical 
artefacts from real genetic changes need to be addressed to improve specificity and 
sensitivity in mutation detection.  This will be addressed in two ways: firstly, in the use 
of paired-end sequencing which results in improved alignment and secondly, in the 
Current Clinic Current Research
BRCA1/2 BRCA1/2
PCR £1 x 44  + 5% £1 x 12  + 5% £1 x 29 +5%
£46.20 £138.60 £1,461.00
Lib Prep £250 x 12 £250 x 48
£3,000.00 £12,000.00
Sequencing
£1,000.00 £217.80 £1,330.00 £4,000.00
£1,000.00 £264.00 £372.38 £363.77
£500.00 £132.00 £372.38 £121.25
Time to 
sequence only
No. Samples N/K 12 48
Region covered coding only Coding only
regulatory regions, 
coding, inronic 
regulatory regions, 
coding, inronic 
Pilot Study 12 
samples. BRCA1 
only GAII
Follow-on 48 
samples. 3 Genes. 
HiSeq2000
Total cost per 
sample
Total cost per 
gene
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data analysis steps in filtering out multiple reads and likely variants using 
computational methods and improved data analysis pipelines. 
2.17 Conclusion 
To conclude, all known mutations are identified using LR-PCR and sequencing on the 
Illumina GAII platform with the exception of one 11bp indel and one causative mutation 
in the sample that failed at library preparation stage that could not be sequenced.  The 
accuracy and sensitivity of mutation detection using this protocol is dependent upon 
experimental design of sequencing as well as improvements in bioinformatics and data 
analysis. The use of paired-end sequencing to improve read mapping is a fundamental 
step. Filtering out duplicate reads and devising methodology to discern and remove 
technical sequencing artefacts are necessary in order to conclude that Long Range 
PCR and multiplexed NGS for mutation detection are as accurate as PCR enrichment 
and Sanger sequencing.  However, these issues are not insurmountable. NGS is a 
rapidly advancing technology with increasingly more streamlined sample preparation 
whilst simultaneously becoming cheaper and faster with increasing sequencing 
capacity. The cost and throughput capabilities of NGS mean that it could be used to 
test a wider population than are currently tested under NICE recommendations.  The 
potential benefits of next generation sequencing approaches within research and 
diagnostics are vast.  This thesis will develop next generation sequencing approaches 
still further.  At the same time focus will be given to scaling up research to use this 
established technology in mutation detection and examine the frequency of both known 
and novel cancer susceptibility genes in large sample sets of cancer cases and 
controls.   
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Chapter Three 
 
A high throughput targeted sequencing approach to evaluate the penetrance and 
prevalence of germline mutations in 6 DNA repair genes in epithelial ovarian 
cancer 
 
3.1 Introduction 
There is a strong rationale that gene variants, additional to BRCA1 and BRCA2, of 
moderate to high penetrance exist for epithelial ovarian cancer, which can be 
discovered using massively parallel next generation sequencing approaches to scan 
the whole genome, or whole exome or targeted regions of the genome.  It is known that 
the most significant factor for the development of epithelial ovarian cancer is family 
history of the disease. A single first-degree relative (FDR) affected by ovarian cancer 
confers an elevated disease risk in women two-three times greater than the general 
population (Stratton et al 1998). Lichtenstein et al (2000) suggest, from studies of 
twins, that the inherited component of ovarian cancer risk could be as high as 22%.   
The highly penetrant genes, BRCA1 and BRCA2 are most often found in families 
where there are several cases of ovarian cancer and/or breast cancer. BRCA1 
mutation carriers show penetrance levels of 40% to 50% for ovarian cancer. BRCA2 
mutation carriers show penetrance levels of 20% to 30% for ovarian cancer (Ford et al 
1998; Ramus et al 2007).  Other highly penetrant genes identified include the genes 
associated with Lynch syndrome (the DNA mismatch repair genes), which show 
average cumulative lifetime (to age 70) penetrance levels of 6% to 12% for ovarian 
cancer (Aarnio et al 1999; Lu & Daniels 2013). Research conducted in the last few 
years identifies additional high-moderate penetrant genes in ovarian cancer (as well as 
breast-ovarian cancer familial syndromes). These include genes that function in the 
BRCA1 network of DNA double strand break repair.  Meindl et al (2010) detect rare 
variants in RAD51C and Loveday et al (2011) find deleterious variants in RAD51D, in 
ovarian cancer cases negative for BRCA1 or BRCA2. A study by Rafnar et al (2011) 
finds BRIP1 deleterious variants also result in an increased risk of ovarian cancer. 
Whilst linkage studies have not revealed genes with the level of penetrance as high as 
BRCA1 or BRCA2, recent sequencing studies are finding genes that result in a 
considerable increase in ovarian cancer risk (>10x more than those without variants in 
these genes).  Estimates suggest that these highly penetrant genes comprise up to 
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40% of the familial ovarian cancer risk (Holschneider & Berek 2000).   It is likely that 
the remaining, currently unidentified, susceptibility alleles for ovarian cancer are 
attributable to genes at the moderate to low penetrance level.  This study will establish 
a novel system for library preparation, which will allow for scaling up to very high-
throughput levels; and at the same time will identify both known and unknown epithelial 
ovarian cancer susceptibility genes.  This will include validating recently discovered 
breast-ovarian cancer susceptibility genes and detecting novel candidate genes in a 
set of 5 interacting DNA repair genes, plus 1 stand-alone DNA repair gene. 
Since around half of the inherited susceptibility to epithelial ovarian cancer is 
attributable to genes other than BRCA1 or BRCA2, discovering these remaining rare 
variants is required to enable improved risk prediction and early detection of disease. 
Identifying these rare variants requires large scale sequencing studies of either a few 
targeted candidate genes or whole exome sequencing. This study uses a candidate 
gene approach to investigate the contribution of six DNA repair genes to epithelial 
ovarian cancer.   
3.1.1 Technological advances in next generation sequencing approaches for mutation 
detection  
The previous chapter established the requirement to address issues of library 
preparation bottlenecks in scaling-up research to fully utilise the capabilities of next 
generation sequencing technologies in mutation detection for identifying cancer 
susceptibility genes.  This chapter introduces and evaluates a novel approach to library 
preparation demonstrating its use in large scale mutation detection studies in ovarian 
cancer.  
3.1.2 Introducing a novel library preparation system – Fluidigm Access Array 
Large-scale population based screening studies are required to discover novel ovarian 
cancer susceptibility genes. The main hurdle to increasing throughput is the bottleneck 
that exists at the library preparation stage. The cost of library preparation and the time 
to isolate the region of interest and prepare DNA libraries is the predominant limitation 
preventing the full use of Illumina sequencing capacity.  Library preparation is time 
consuming and expensive. The Fluidigm Access Array system is a microfluidic platform 
that can perform target enrichment and library preparation simultaneously in a high 
throughput format.  This system essentially removes this bottleneck reducing the time 
and cost in sample preparation for very high throughput re-sequencing projects.  
Expensive library preparation kits are not necessary with the Fluidigm platform and the 
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input DNA quantities are greatly reduced in comparison to genomic capture methods.   
At the same time, multiplexing at 384 samples uses the increased capacity of the 
HiSeq2000.  This study uses the Fluidigm Access Array, which is a complete sample 
preparation system to combine target enrichment and library preparation into one 
platform.  
Figure 3.1 Target enrichment using the Fluidigm Access Array system 
 
 
Figure 3.1 Target enrichment using the Fluidigm Access Array system.  Fluidigm Access Array 
System is capable of preparing 48 samples with 48 PCR reactions simultaneously resulting in 2,304 
reactions and final PCR product pools of 48 for each of 48 samples. 
 
The Fluidigm Access Array system is a method for target enrichment and library 
preparation that simultaneously prepares multiple targeted re-sequencing libraries 
using multiplex PCR on a microfluidic platform (Figure 3.1).  The Access Array can be 
used to prepare 48 libraries in around 5 hours.  48 PCR amplicons are generated for 
each of 48 samples on the 48.48 Integrated Fluidic Circuit (IFC).  At the same time 
each sample can be indexed to produce PCR products that are immediately ready for 
re-sequencing.  This circumvents the time consuming and costly library preparation 
step and effectively eliminates the bottleneck at this stage noted in re-sequencing 
studies. 
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Figure 3.2 Overview of the Fluidigm Access Array protocol 
  
 
 
Figure 3.2 An overview of the Fluidigm Access Array protocol. The required regions of interest (ROI) 
are identified and PCR primers are designed to include adaptor sequences and sample specific indexes to 
produce tagged amplicons ready for cluster generation on the Illumina platform. This essentially eliminates 
the library preparation step 
 
The design by Fluidigm included a wet validation of primers and a gel like image to 
demonstrate that the primers successfully amplify the regions of interest (Figure 3.3). 
 
Figure 3.3 Wet-test amplification results 
 
Figure 3.3 Wet-test amplification results. This gel-like image shows the PCR reactions for each of 48 
amplicons and demonstrates successful PCR reactions 
Forward and reverse primers are supplied in a 96-well plate format to enable ease and 
speed of multiplex PCR set up. Through the PCR reaction sample specific index 
primers and Illumina sequencing adapters are adjoined to PCR amplicons. Four primer 
sequences are used to prepare samples for sequencing with an Illumina HiSeq2000.  
The custom adapter sequence tag (CS1) is joined to the target specific primer 
sequence (TS) to form one primer sequence.  The Illumina PE sequence tag (PE1) is 
also joined to the TS.  The other two are the same, except reverse sequences.  A fifth 
primer is needed (index SP) to read the index sequences.  As sample specific indexes 
are adjoined the resultant 2,304 PCR amplicons are ready for pooling and multiplex 
sequencing on one lane of the Illumina HiSeq2000. 
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Figure 3.4: Overview of the 4-primer PCR protocol 
 
Figure 3.4 Overview of the 4-primer PCR protocol.  AS1 = Adaptor sequence tag 1; AS2 = Adaptor 
sequence tag 2; TS = Target-specific primer sequence; PE1 = Paired end sequence 1; PE2 = Paired end 
sequence 2; BC = Barcode sequence. Note that in this study custom sequencing tags (CS1 and CS2 were 
used because custom indices for 384 per lane multiplexing were used instead of standard 96 multiplexing 
indices). 
 
It is possible to multiplex further with the Fluidigm Access Array to include up to 10 
primers in each well (10Plex).  To do this successfully requires following specific rules 
on primer pair mixing.  It is important to mix primer pairs that do not produce an 
overlapping PCR amplicon, such as primer pairs that overlap to amplify one larger 
exon.  The mixed primer pairs should amplify regions that are at least 5 Kb apart.  
Primer sets should ideally amplify products that are all within 20% of the average pool 
size.  For example, if the pool size average is 200 bp, then all primers should produce 
PCR products of 160 bp to 240 bp.  Mixed primer pairs should produce amplicons of a 
similar GC content. Primers with multiple annealing sites should be avoided and primer 
pools are best tested for primer-dimer formation before use and avoided. 
 
Multiplexing PCR reactions in each well results in an increase in sample throughput on 
the 48.48 Access Array. In a single plex reaction design the 48.48 IFC can prepare 48 
samples and one PCR reaction for each sample, which results in 48 PCR reactions for 
each sample and a total of 2,304 PCR reactions per Access Array chip.  Multiplexing at 
3plex, on the 48.48, means that 3 PCR reactions are performed in each well for 48 
samples and 48 wells.  Thus, 144 PCR reactions are performed for each of 48 samples 
and a total of 6,912 PCR reactions can be achieved for each Access Array chip; 
resulting in an impressive reduction in time, labour and cost.  Multiplexing at 3plex 
means that all amplicons to cover the whole coding region of the 6 candidate genes 
can be prepared for 384 samples in each chip which reduces the total number of chips 
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and reagents used as well as the time taken to prepare the chips by 3. The only 
possible caveat here would be whether these reactions could successfully be mixed in 
each well.  If inappropriate amplicons are mixed then those that do not sequence will 
have to be repeated.  This could make multiplexing prohibitive, as it would be 
necessary to re-amplify and then to re-sequence the failed products. 
 
3.2 Recently discovered ovarian cancer susceptibility genes 
The study by Meindl (2010) detects 6 heterozygous pathogenic mutations in RAD51C 
and reveals that these occur in 1.3% of affected cases from breast and ovarian cancer 
families compared to no pathogenic mutations in the unaffected controls or in those 
families with breast cancer only. A study, published during this project, by Loveday et al 
(2011) which analyses RAD51D for germline mutations in breast and ovarian cancer 
families finds 8 pathogenic mutations in cases and only 1 in the unaffected controls this 
study suggests that risk estimates for RAD51D mutations are 6.30 for ovarian cancer 
and 1.32 for breast cancer.  In this way, looking at one gene at a time, discovering the 
remaining heritability to ovarian cancer will take an extremely long time; therefore, it is 
important to use technology that will analyse multiple genes in large sample sizes. 
3.3 The research questions  
1. Does the Fluidigm Access Array system offer a viable solution to addressing the 
bottleneck in library preparation? 
2. Is Fluidigm microfluidic technology both an accurate and rapid method for 
sequencing library preparation in a large sample set for cases and controls? 
This will be assessed by evaluating time to prepare libraries, depth of coverage, 
evenness of coverage and mutation detection sensitivity.  
3. Is this system able to characterise the mutation frequency of 6 DNA repair 
genes in ovarian cancer?  
 
3.3.1 The research questions in context: how this research impacts on the health of the 
population. 
Strategies that focus on early detection and improved risk prediction in ovarian cancer 
are being suggested as an effective clinical intervention in breast and ovarian cancer.  
Indeed, genetic testing is already in place in order to identify women at high risk of 
developing breast or ovarian cancer and these women are offered early screening or 
risk reduction surgery.  Developing a technology that is capable of identifying additional 
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genes in epithelial ovarian cancer will have a direct translational impact by validating 
the means by which cancer susceptibility alleles can be found.  At the same time, this 
novel approach that increases throughput by such an extent will undoubtedly result in a 
wider population of women being able to benefit from genetic screening for ovarian 
cancer.  
Identifying risk genes and risk factors provides further insight into the causes of ovarian 
cancer susceptibility.  This knowledge will be invaluable in the refinement of risk 
prediction strategies allowing for earlier detection and prevention of disease.  These 
studies could indicate elusive biomarkers for ovarian cancer detection.  The 
establishment of high-throughput NGS approaches and improvements in technology 
during the progress of this research will lead to a wider population of women being 
offered genetic testing and assessment of cancer risk.  Discovering the cause for the 
remaining ovarian cancer susceptibility will result in more women being offered 
prophylactic surgery that reduces the risk of development of ovarian cancer by more 
than 90%.  This will result in individual personalised care and treatment tailored to an 
individual woman’s level of risk and allow for a greater informed choice (prophylactic 
surgery or early surveillance and monitoring) than is currently available. 
3.4 DNA repair and cancer susceptibility  
The DNA damage response is a molecular signalling kinase cascade that is initiated 
following detection of DNA damage.  This response involves the transcriptional 
regulation of genes implicated in repair and replication of DNA. DNA damage includes 
double strand breaks (DSB), nicks, gaps and genetic changes that prevent the 
replication of DNA. ATM and ataxia telangiectasia and Rad3 related (ATR) code for 
protein kinases that detect DNA damage.  ATM exists in an inactive dimer state and 
has a role of specifically detecting DSBs, where ATM separates into active monomers 
once recruited to subsequently phosphorylate downstream targets. 
Double strand break DNA repair mechanisms include homologous recombination (HR), 
non-homologous end joining (NHEJ) and microhomology-mediated end joining (MHEJ).  
In addition to DSB, homologous recombination is also the mechanism for the repair of 
stalled replication forks and DNA interstrand cross-links.  Mutations that result in an 
inactivation of genes involved in HR have been identified as increasing the 
susceptibility to certain cancers. The recent discoveries of novel genes (RAD51C and 
RAD51D) further support the view that additional rare variants with moderate 
penetrance exist.  By re-sequencing candidate genes in large cohorts of ovarian cancer 
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cases and equal numbers of healthy matched controls it should be possible to identify 
the likely pathogenic variants in novel cancer susceptibility genes.  
3.5 Study candidate genes – 6 DNA repair genes 
Six candidate genes are selected for targeted re-sequencing in a large series of 
ovarian cancer cases and controls.  The five interacting genes being analysed are 
RAD51 paralog B (RAD51B),  RAD51 paralog C (RAD51C), RAD51 paralog D 
(RAD51D), X-ray repair complementing defective repair in Chinese hamster cells 2 
(XRCC2) and X-ray repair complementing defective repair in Chinese hamster cells 3 
(XRCC3).  The five interacting genes (RAD51B, RAC51C, RAD51D, XRCC2 and 
XRCC3) are involved in homologous recombination and the sixth one SLX4 structure-
specific endonuclease subunit homolog (SLX4) is linked to homologous recombination 
and Fanconi Anaemia.  These candidate genes are associated with BRCA1 or BRCA2 
and are involved in the BRCA1 network in double strand break repair.  These genes 
may be associated with high-grade serous ovarian carcinoma as they are involved in 
homologous recombination (TCGA data 2011).  DNA samples include both patients of 
unknown mutation status as well as those already identified as negative or positive for 
mutations in BRCA1 or BRCA2.  The rationale for choosing these candidates is 
explained below in Figure 3.5. 
Figure 3.5 The interaction between the RAD51 associated proteins 
 
 DNA double strand break 
Figure 3.5 The interaction between the RAD51 associated proteins. Two distinct complexes are 
formed within this group of proteins.  1) RAD51C complexes with XRCC3; and 2) RAD51B, RAD51C, 
RAD51D and XRCC2 complex to form a complex known as BCDX2 complex.  These complexes are 
recruited to DNA double strand breaks with BCDX2 functioning to bind gaps in one strand of a double 
strand DNA molecule.   
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The RAD51 group of proteins (Figure 3.5) consists of RAD51 plus 5 RA51-like proteins 
RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3. The primary function of this group 
of proteins is in homologous recombination repair of DNA double strand breaks. They 
form two complexes 1) RAD51C complexes with XRCC3 to form a heterodimer and 2) 
RAD51B, C, D, XRCC2 form a heterotetramer known as BCDX2; along with RAD51 
both of these complexes play a role in strand invasion during homologous 
recombination (Miller et al 2004, Liu et al 2002). 
Figure 3.6 Schematic representation of RAD51B (RAD51 paralog B) gene 
 
Figure 3.6 Schematic representation of RAD51B.  RAD51B is located at 14q24.1 Genomic co-
ordinates: 14:68,286,495-69,062,737 (build GRCh37/hg19) 
 
RAD51B is involved in the hydrolysis of adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP) as its structure (that includes nucleotide-binding motifs) implies that 
it is an ATPase.  Expression of the protein encoded by RAD51B is observed in peak 
levels in the ovary, testis, thymus and spleen. Rice et al (1997) demonstrate that cells 
damaged by ionizing radiation express RAD51B, whereas cells that are not show no 
distinguishable levels of the protein.  
Alternative splicing leads to the production of three transcripts, the largest of which is 
2596 bp with an encoded protein product of 384 amino acid residues.  RAD51B 
complexes with RAD51C; this heterodimer is involved in DNA double strand break 
repair via homologous recombination along with RAD51 and BRCA2.  The protein 
product of RAD51B forms a complex with protein products of RAD51C, RAD51D and 
XRCC2 to form a heterotetramer; this is known as the BCDX2 complex.  BCDX2 binds 
gaps in one strand of a dsDNA molecule (Figure 3.5). 
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Figure 3.7 Schematic representation of RAD51C (RAD51 paralog C) gene 
 
Figure 3.7 Schematic representation of RAD51C.  RAD52C is located at 17q22 genomic coordinates: 
17:56,769,962-56,811,691 (build GRCh37/hg19) 
 
RAD51C protein forms a heterodimer with XRCC3, complexes with RAD51B and is 
critical in homologous recombination.  Masson et al (2001) find that RAD51C and 
XRCC3 form a complex when co-purified and that the heterodimer only anneals single 
stranded DNA molecules. RAD51C is also part of the BCDX2 complex and is most 
likely to be involved in resolution of Holliday junctions. Liu et al (2004) find diminished 
Holliday junction resolvase activity in cells harbouring mutations in either RAD51C or 
XRCC3. The RAD51C transcript is 1322 bp producing a protein product of 376 amino 
acid residues with two isoforms.  RAD51C assists in the phosphorylation of checkpoint 
kinase 2 (CHK2) which itself phosphorylates BRCA1 which in turn phosphorylates its 
downstream targets, such as p53 and Rb, which are involved in cell cycle control.  
 
Figure 3.8 Schematic representation of RAD51D (RAD51 paralog D) gene 
 
Figure 3.8 Schematic representation of RAD51D.  RAD51D is located at 17q12 genomic coordinates: 
17:33,426,810-33,446,887 (build GRCh37/hg19) 
 
The protein encoded by RAD51D gene forms a complex with XRCC2 and is included in 
the BCDX2 heterotetramer, which binds gaps in one strand of a dsDNA molecule and 
as such has a role in homologous recombination.  Several transcripts arise from 
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alternative splicing.  The largest transcript is 2404 bp producing protein of 328 amino 
acid residues. 
Braybrooke et al (2000) demonstrate that recombinant RAD51D hydrolyses ATP when 
Mg2+ is available.  Braybrooke et al (2000) also note an association between XRCC2 
and RAD51D.  Loveday et al (2011), in a case-control study, detect 8 deleterious 
mutations in cases and 1 in the healthy age-matched controls.  Similar to RAD51C, the 
incidence of these mutations is found to be higher in ovarian cancer than breast 
cancer; calculating the relative risk of ovarian cancer to be 6.3 (95% CI 2.86-13.85, 
p=4.8 x 10-6). Moreover, they demonstrate a higher prevalence of mutations amongst 
those cases with more than one case of ovarian cancer in their family.  Interestingly, 
Loveday et al (2011) use functional assays to examine the effect of the loss of 
RAD51D function in tumour cells and their sensitivity to PARP inhibitors.  Using short 
interfering RNA (siRNA) to silence RAD51D in tumour cells, they detect sensitivity to 
PARP inhibitors to be consistent with that noted in cells with non-functioning BRCA2. 
This suggests that PARP inhibitors may be valuable in the clinic for RAD51D positive 
patients along with those with BRCA1 or BRCA2 mutations. 
Figure 3.9 Schematic representation of XRCC2 (X-ray repair complementing 
defective repair in Chinese hamster cells 2) gene 
 
Figure 3.9 Schematic representation of XRCC2.  XRCC2 is located at 7q36.1 with genomic coordinates: 
7: 512,343,582-152,373,249 (build GRCh37/hg19) 
 
XRCC2 has a role in the repair of DNA double strand breaks via homologous 
recombination (Johnson et al 1999).  This was first noted in hamster cells that were 
lacking the protein encoded by the gene.  The protein also has a role in the repair of 
chromosomal fragmentation, translocation and deletions.  It is part of the BCDX2 
complex, which binds gaps in one strand of a dsDNA molecule.  The transcript is 3067 
bp and the encoded protein is 280 amino acid residues. 
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Figure 3.10 Schematic representation of XRCC3 (X-ray repair complementing 
defective repair in Chinese hamster cells 3) gene 
 
Figure 3.10 Schematic representation of XRCC3.  XRCC3 is located at 14q32.33 with genomic 
coordinates: 14:104,163,953-104,181,822 (build GRCh37/hg19) 
 
 
XRCC3 has a role in the repair of DNA double strand breaks via homologous 
recombination.  In addition, the encoded protein has a role in the repair of 
chromosomal fragmentation, translocation and deletion.  The protein product that is 
encoded by this gene interacts with RAD51 in homologous recombination (Liu 1998).  
XRCC3 also forms a complex with other proteins including BRCA2, FANCD2 and 
FANCG (Wilson 2008). There are two transcripts, 2622 bp and 2439 bp that arise from 
alternative splicing producing a protein of 346 amino acid residues. 
Figure 3.11 Schematic representation of SLX4 (SLX4 structure specific 
endonuclease subunit) gene 
 
Figure 3.11 Schematic representation of SLX4.  SLX4 is located at 16p13.3 with genomic coordinates 
(GRCh37): 16:3,631,181–3,661,584(build GRCh37/hg19) 
 
SLX4 (SLX4 structure-specific endonuclease subunit) is previously known as BTBD12 
(BTB/POZ domain-containing protein 12).  Svendsen et al (2009) report the 
multiprotein complex that includes SLX4 is necessary for the repair of particular 
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categories of DNA damage and is key in resolving replication fork failure.  SLX4 is a 
scaffold protein key in the formation of a multiprotein complex of enzymes required in 
the repair of DNA. 
Cleavage of DNA strands and subsequent re-joining during DNA repair processes is 
necessary; this is coordinated through a number of structure specific endonucleases.  
SLX4 is an identified downstream target of ataxia telangiectasia mutated and ataxia 
telangiectasia and Rad3 related (ATM/ATR) (Svendsen et al 2009), both are protein 
kinases that have roles as DNA damage sensors and as such are pivotal in the 
initiation of the DNA damage response.   
The protein product of SLX4 gene is a regulatory subunit that co-ordinates the activity 
of various structure-specific endonucleases by increasing their activity. SLX4 has a 
clear role in genome protection in DNA repair.  SLX4 forms multiprotein complexes with 
excision repair cross-complementing rodent repair deficiency, complementation group 
4-1 (ERCC4-ERCC1) and MUS81 structure-specific endonuclease subunit (MUS81) 
and essential meiotic structure-specific endonuclease subunit (EME1) and SLX1 (SLX1 
structure-specific endonuclease subunit).  Moreover, the protein interacts with 
telomeric repeat binding factor 2 (TERF2) and its associated interacting protein 
TERF2IP.  Other protein interactions include protein polo-like kinase 1 (PLK1) and 
mismatch repair proteins (MSH2-MSH3). These other endonucleases have roles in 
repairing specific types of DNA damage that arise through homologous recombination 
and repair.  For example, SLX4 assists in the resolution of Holliday Junctions (HJ) 
produced during homologous recombination.  SLX4 is also involved in repair of stalled 
replication forks and acts as a docking platform for the construction of various structure 
specific endonucleases.  In vitro, SLX4 resolves Holliday Junctions (HJ) and in vivo 
they play a role in the repair of double strand breaks in homologous recombination 
(Svendsen 2009).  SLX4 has 15 exons, 14 of which are coding exons.  Translation start 
site is in exon 2. The SLX4 transcript is 7307 bp in length and its protein product is 
comprised of 1834 amino acid residues. During the progress of this project, 
researchers in Spain (de Garibay et al 2012) perform mutation screening in breast and 
ovarian cancer patients screen negative for BRCA1 or BRCA2.  They use high 
resolution melting analysis to scan the full coding region of SLX4 along with the 
flanking sequences to search for germline variants in a cohort of 486 breast or ovarian 
cancer cases.  They conclude that loss of function mutations in SLX4 are very low in 
non-BRCA1 or BRCA2 breast and or ovarian cancer families.  
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The FA complex is recruited to sites of interstrand cross-link for ubiquitination by 
FANCD2 and FANCI; together these proteins localise to DNA damage sites along with 
BRCA2 (FANCD1), BRIP1 and PALB2.  The following stage of repair is HR which 
involves RAD51 and associated proteins, as previously described. 
Figure 3.12 A schematic representation of the FA-BRCA DNA repair pathway 
 
Figure 3.12 A schematic representation of the FA-BRCA DNA repair pathway re-drawn and adapted 
from Levy-Lahad (2010) Fanconi anaemia and breast cancer susceptibility meet again. Nature Genetics. 
Vol 42. No. 5. 368-369 
 
3.6 Summary table of samples for next generation sequencing  
3.6.1 Samples in the study 
The cases and controls included here are drawn from a number of different sources 
internationally.  They are from a population based case control series and two familial 
ovarian cancer registries and a polish familial cancer case study.   The table overleaf 
(Table 1.1) gives details of the origins of samples. 
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Table 3.1 Summary of samples sourced from ovarian cancer studies or familial 
ovarian cancer registries 
Registry FH/Genetic/Histology No. Cases No. Controls 
GRFOCR (Glider 
Radner Familial 
Ovarian Cancer 
Registry) 
All (except 20) screened 
negative for BRCA1/2. 
All have FH (>2 OC) and 
Serous histology 
175  
MALOVA 
(Malignant ovarian 
cancer study)  
FH 
 44 
192 
Serous histology 192 
UKOPS (UK 
ovarian cancer 
population study) 
FH + Serous histology 579 384 
UKFOCR > 1 FDR with ovarian cancer 50  
POL (NCI ovarian 
case control study 
in Poland 
> 1 FDR with ovarian 
cancer 96  
JAC Polish ovarian 
cancer study 
Polish healthy control 
samples  96 
AOCS (Australian 
Ovarian Cancer 
Study) 
Serous histology 421 460 
Totals 
 
1557 1131 
Table 3.1 Summary of samples sourced from other ovarian cancer studies or familial ovarian 
cancer registries. FH = family history, FDR = first degree relative 
All of these samples are screened negative for mutations in BRCA1 or BRCA2, except 
for 336 cases in UKOPS population study.  Therefore, the purpose of re-sequencing 
these samples is to answer the question “do these candidate genes account for a 
proportion of familial susceptibility to ovarian cancer?”  This study will aim to identify 
additional ovarian cancer susceptibility genes that could result in new routine tests 
being available in the clinical setting.  If the risks are calculated to be high, then this 
could impact upon the management of ovarian cancer risk to identify rapidly and cost 
efficiently those women at increased risk of developing ovarian cancer.  This is a case-
control study, in which the controls are women unaffected by ovarian cancer, and age 
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matched to the cases. At the beginning of this study, only RAD51C gene is known to 
have mutations; this study includes 6 blinded RAD51C positive controls as a means of 
assessing the sequencing approach.     
3.6.1 Gilder Radner Familial Ovarian Cancer Registry (GRFOCR) 
This registry was established in 1981 in the US with the aim of researching novel 
genes linked to familial ovarian cancer.  This self-referral registry includes families 
containing at least 2 ovarian cancer cases.  The registry is based within the Roswell 
Park Cancer Institute Gynaecologic Oncology Department and collates familial cancer 
information.   
There are four main aims of the GRFOCR:   
1) To collect family history data from ovarian cancer patients within families with 
at least 2 cases of ovarian cancer or individuals with a related cancer 
syndrome.   
2) To record the incidence of cancer, by referring to pathologists and medical 
records of tissue samples.  
3) To build a bio bank of biological samples drawn from volunteers in the 
registry.  
4) To allow the use of these biological samples for approved research. 
 
Volunteers in the registry are selected if they meet at least one of the criteria listed 
here: 
1) At least 2 cases of ovarian cancer in the family. 
2) 1 ovarian cancer plus 2 other cancers  
3) At least 1 woman in the family with at least 2 primary cancers, one of which 
must be ovarian cancer 
4) At least two cases of cancer in the family with 1 being ovarian and the other 
diagnosed under 45 years (early onset). 
 
Volunteers must also sign consent forms agreeing to allow access to medical records; 
family history data is obtained via written forms. Once volunteers are accepted as 
members into the registry they complete blood forms for giving blood samples.  The 
registry requests permission to contact the relatives of registry members and these are 
invited to take part. More than 2,616 families are part of GRFOCR and 2,011 of these 
families contain 2 or more cases of epithelial ovarian cancer.  The whole registry 
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includes 4,987 women whom have had epithelial ovarian cancer (Piver et al 1984, 
Greggi et al 1991) 
3.6.2 UK Familial Ovarian Cancer Registry (UKFOCR) 
The UK Familial Ovarian Cancer Registry (UKFOCR) is a UK based study originally 
known as the UK Co-ordinating Committee for Cancer Research (UKCCR) that began 
in 1991.  The registry includes information on 391 ovarian cancer families containing at 
least 2 cases of epithelial ovarian cancer in first or second-degree relatives.  Within 
these families there are 1,433 cases of cancer.   
For both GRFOCR and UKFOCR, information gathered includes family history of 
cancer, reproductive records and other medical data, including medical history, use of 
oral contraceptives and/or hormone replacement therapy (HRT); blood as well as 
breast and ovarian tumour tissue samples are also stored for a proportion of the 
registry members.   
3.6.3 Australian Ovarian Cancer Study (AOCS) 
AOCS was established in 2001 and is a collaborative effort between institutions within 
Australia including University of Melbourne, Queensland Institute of Medical Research, 
Peter McCallum Cancer Institute Melbourne and Westmead Hospital Sydney.  This 
population-based case-control study recruited women throughout Australia with a 
diagnosis of invasive or low malignant potential epithelial ovarian cancer between 
January 2002 and June 2005.  All women are aged between 18 and 79 years at 
recruitment.  The study consists of 2,319 cases of epithelial ovarian cancer and 1,509 
healthy age-matched controls.  Full epidemiological data are held on study participants 
to include general health and lifestyle, family history of cancer, medical history data and 
details on reproductive history (Merritt et al 2008) 
3.6.4 UK Ovarian Cancer Population Study (UKOPS).   
UKOPS is a UK case-control bio-banking study (Principal Investigators, Usha Menon, 
Simon Gayther and Ian Jacobs) with three mains aims: 
1. To identify moderate penetrance genes for epithelial ovarian cancer using SNP 
analysis. 
2. Evaluation of biomarkers for ovarian cancer cases, including pre- and post-surgery 
and subsequent to chemotherapy.  
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3. Classification of common medical conditions and symptoms in women with ovarian 
cancer compared to those without. 
Criteria for inclusion as cases in UKOPS: 
1. Women diagnosed with a primary invasive ovarian cancer or fallopian tube 
carcinoma. 
2. Women diagnosed with a borderline ovarian cancer 
3. Women pre-surgery diagnosed with an adnexal mass that may be ovarian cancer 
4. Women not having surgery for a likely ovarian cancer 
Criteria for inclusion as control in UKOPS: 
1. Women that are part of the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) that are undergoing annual screening and appearing healthy. 
2. Women with a benign or borderline adnexal mass 
The study (two years in duration) includes 10 UK Gynaecological Clinics.  Follow-up is 
being conducted for 15 years and is due to end in 2020.  Blood and tissue samples are 
stored with medical records of surgery, chemotherapy and histology reports.  Health 
questionnaires are sent to participants periodically throughout the follow-up (Institute 
for Women’s Health, UCL website accessed 02-08-2013) 
3.6.5 Polish ovarian cancer studies 
The Polish Ovarian Cancer Case Control Study (NCI POL) and the Polish Ovarian 
Cancer Study (JAC) are studies sponsored by the National Cancer Institute (NCI) in the 
USA.   The National Cancer Institute (NCI) Polish Ovarian Cancer Case Control Study 
is a population based case-control study and includes ovarian and endometrial cancer 
cases diagnosed in women from Warsaw and Lodz in Poland between 2001 and 2003.  
Blood, urine and tumour samples are stored for each participant and the control women 
are healthy women age and location matched in proportion.  The study includes 347 
invasive ovarian cancer cases and 555 endometrial cancer cases.  2,798 healthy 
controls are included for breast, ovarian and endometrial cancer cases.  DNA from 
tumours is also extracted and stored ready for appropriate studies (NCI Division of 
Cancer Epidemiology and Genetics website accessed 02-08-2013). The Polish ovarian 
cancer case control study is a hospital based case control study, which includes 423 
cases and 417 healthy age-matched controls. Both of these studies examine the 
molecular epidemiology of Polish breast, ovarian and endometrial cancer and includes 
family history data, histology, stage and grade (Permuth-Wey et al 2013). 
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3.6.6 Malignant Ovarian Cancer Study (MALOVA) 
The MALOVA study is conducted in Denmark and involves a multidisciplinary approach 
to the study of ovarian cancer including, molecular biology, epidemiology and 
biochemistry with the primary goal to ascertain accurate risk prediction and prognosis 
of the disease.  Several Gynaecological centres throughout Denmark are included.  
Cases are women between 35 and 79 years with recruitment prior to surgery for 
suspected ovarian cancer identified between December 1994 and May 1999.  The 
study includes 698 ovarian cancer cases, 219 ovarian borderline tumours and 450 
benign ovarian tumours.  Blood is taken prior to surgery and tumour samples stored 
from surgical procedures. All tumours have histopathology classification reviewed 
separately by two pathologists.  International Federation of Gynaecology and 
Obstetrics (FIGO) staging of tumours, which is the standard staging for ovarian cancer, 
is recorded for each case (Hogdall et al 2003). 
3.7 Study designs in population based genetic studies 
This study is a population-based case-control study, which employs a candidate gene 
approach to identify gene variants for epithelial ovarian cancer.   The genomic DNA of 
individuals, unrelated to each other, is analysed for changes in 6 DNA repair genes.    
The frequency of gene variants in cases is compared to the frequency observed in 
controls.  This is in contrast to family-based designs in which families are analysed and 
controls within families are unaffected family members.  Family-based studies are 
useful for the identification of highly penetrant genes within high-risk families; where 
population-based studies are useful for finding alleles with a low to moderate increase 
in risk in a wider population (Daly & Day 2001). Population-based design has the clear 
advantage that collecting samples is simpler and more likely to produce the larger 
samples sizes required to increase statistical power (Li et al 2010).  
3.8 Research aims  
The four main aims of this study are:  
1. To establish a novel approach for target enrichment for high-throughput targeted 
NGS; this will represent an increase in scale compared to the pilot study, by using 
the increased capacity of Illumina HiSeq2000 technology. 
2. To use this novel approach to characterise the mutation prevalence in 2,688 
subjects from ovarian cancer case-control studies for 5 interacting genes in the 
DNA double strand break repair pathway (namely, RAD51B, RAD51C, RAD51D, 
XRCC2 and XRCC3) that interact with BRCA1 and BRCA2 
 142 
3. To use NGS to characterise the mutation prevalence in the same 2,636 subjects of 
1 additional DNA repair gene linked to Fanconi Anaemia in epithelial ovarian 
cancer (namely SLX4). 
4. To evaluate the suitability of the Fluidigm Access Array platform and NGS in the 
clinical diagnostic genetics laboratory.  
The fundamental aim of this study is to expand on the pilot study to re-sequence 6 
DNA double strand break repair genes. A high-throughput population based case-
control study design is being used and includes DNA samples from a variety of 
international ovarian cancer epidemiological case-control studies and familial ovarian 
cancer registers.  Samples are identified that have previously tested negative for 
BRCA1 or BRCA2 mutations and some are sourced from patients with high-grade 
serous adenocarcinoma of the ovary (HGSOC).  
3.9 Hypotheses under investigation 
1. Fluidigm Access Array platform and highly multiplexed Illumina sequencing 
technologies are accurate, affordable and rapid methods for identifying genetic 
alleles in cancer susceptibility genes. 
2. This novel method of mutation detection will be able to assess the mutation 
frequency in 6 DNA repair genes in a large series of ovarian cancer cases and 
controls. 
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3.10 Results 
 
(Refer to Chapter 6 Materials and Methods page 255) 
 
3.10.1 Study Design - A population based case-control study 
 
This population based case-control study uses a novel highly multiplexed DNA 
sequencing approach to identify ovarian cancer susceptibility alleles.  The 6 candidate 
ovarian cancer susceptibility genes are selected because they interact in the BRCA1 
and BRCA2 pathways.  These are RAD51B, RAD51C, RAD51D, XRCC2, XRCC3 and 
SLX4. Cases are drawn from a several population based ovarian cancer case-control 
studies, and from two familial ovarian cancer registries. A proportion of the cases are 
previously analysed for mutations in BRCA1 and BRCA2, in which case only 
individuals negative for pathogenic mutations in these genes are selected for further 
analysis.  The study successfully sequences 1506 cases and 1130 healthy age-
matched controls. 
 
3.11 Target enrichment  
 
Note: I prepared libraries for 3 sequencing lanes (1152 samples and 24 Access Array 
chips) at Great Ormond Street Molecular Genetics Laboratory.  Maria Intermaggio and 
Andre Kim at USC prepared the remaining 4 lanes (1,536 samples and 32 Access 
Array chips). 
 
Sequencing the coding region of 6 candidate genes from the human genome requires 
a method to select and enrich the regions of interest.  The available methods for target 
enrichment are described in chapter 2.  This study uses the Fluidigm Access Array 
System for both target enrichment and preparation of DNA sequencing libraries for the 
Illumina HiSeq2000 platform.  The Fluidigm Access array is a PCR based method that 
generates sequencing ready, tagged amplicons that are 200 bp or less; thus the 
amplicons can be sequenced with 100 bp paired end reads.  These tagged amplicons 
include both sequencing adaptors and individual indices for Illumina flow cell 
multiplexing. 
 
Where exons are larger than 200 bp overlapping amplicons are designed to fully cover 
the coding region and flanking regions. Table 3.2 below describes the number of 
amplicons in the whole experiment and a breakdown of these showing numbers of 
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amplicons for each gene.  It also gives a calculation of the percentage of the coding 
region covered for each gene by the amplicons.  The genomic co-ordinates for each 
amplicon in each gene are given in the Appendix IV and an image, which maps the 
location of amplicons, is given in appendix V. The reference assembly used here is the 
Genome Reference Consortium Human genome build 37 (GRCh37/hg19) from 
February 2009.  The National Centre for Biotechnology Information (NCBI) accession 
numbers for each gene are RAD51B (NM_133510.3), RAD51C (NM_058216.1), 
RAD51D (NM_002878.3), XRCC2 (NM_005431.1), XRCC3 (NM_005432.3) and SLX4 
(NM_032444.2). 
 
Table 3.2 A breakdown of amplicons per gene 
Gene No. Amplicons % of coding region included 
5’UTR included (in 
bp) 
3’UTR included 
(in bp) 
RAD51B 18 100 99 93 
RAD51C 17 100 52 60 
RAD51D 15 100 31 67 
XRCC2 11 100 63 49 
XRCC3 13 100 48 80 
SLX4 70 100 161 71 
Total 144 100   
Table 3.2 A breakdown of amplicons per gene.  This table details the number of amplicons in the whole 
experiment, with the number for each gene and the percentage of the coding region included; the number 
of bases into 3’ and 5’ UTR for each gene is also given. Where there are more than 1 amplicon per exon 
amplicons are overlapping by more than the length of the primer sequence to ensure that all bases can be 
sequenced.  Amplicons overlap into the flanking intronic regions by more bases than the length of primer 
sequences to include all the coding exons and splice sites.  
 
 
3.12 Library preparation  
 
48 sequencing libraries are prepared on each Fluidigm Access Array chip.  This 
includes the full coding region of all 6 candidate genes i.e. 144 PCR reactions are 
performed for 48 samples per chip.  To reach this 3 PCR reactions are conducted in 
each well of the Access Array chip.  PCR products are harvested and a second PCR is 
conducted to attach sample specific barcodes to each.  Then each Access Array chip 
is then pooled to create a pool of 48 barcoded prepared libraries.  Then 8 chips are 
pooled in equimolar quantities to form a pool of 384 individually barcoded libraries.  
The pools of 384 libraries are run in each flow cell lane on the Illumina HiSeq2000.  
The whole sequencing study is performed using 7 lanes of the HiSeq2000. 
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3.12.1 Quantitation of pools 
 
As an initial quality control step, a proportion of the prepared libraries are quantified on 
the Agilent Bioanalyzer DNA 1000 chips using 1 μl of the library.  This is performed to 
ensure that all samples have amplified prior to pooling.  Images and results from these 
Agilent Bioanalyzer chips are included in Appendix VI.  An example is given below in 
the gel-like image Figure 3.13. 
 
Figure 3.13 Quantitation of Lane 4 (control samples) 
 
Figure 3.13 Quantitation for lane 4 (controls samples) using the Agilent Bioanalyzer.  A 300bp 
product is created that includes the target specific insert, the Illumina adapter sequences and the sample 
specific index sequences. This image shows the quantitation of 8 pools of Access Array chips each with 48 
libraries.  L = DNA Ladder, 1-8 = chips 1-8, the purple and green bands are the DNA markers. 
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3.12.2 Normalisation of pools 
 
For each Illumina flow cell lane pools of 8 chips are pooled in equimolar quantities and 
the final concentration is calculated to allow for dilution of pools to the correct 
concentration for the Illumina Flow cell.  
 
Table 3.3 Normalisation table for pooling prepared libraries from 8 Fluidigm 
Access Array chips into one Illumina flow cell lane 
Access Array Chip Number Average Molarity of 10nM stock Pool 1 
Pooling Volume 
(µl) 
Access Array Chip 1 47.30 
Pool 1 
21.1 
Access Array Chip 2 49.60 20.2 
Access Array chip 3 28.00 35.7 
Access Array Chip 4 29.70 33.7 
Access Array Chip 5 40.60 24.6 
Access Array Chip 6 44.00 22.7 
Access Array Chip 7 33.90 29.5 
Access Array Chip 8 27.50 36.4 
Table 3.3 Normalisation table for pooling prepared libraries. This table shows an example of one 
pooled lane.  The pools of 48 libraries, prepared using the Fluidigm Access Array, are pooled in equimolar 
quantities. 
 
Table 3.3 shows that the level of variation in molarity between pools for each chip is 
normalised to ensure that equal concentrations of samples are sequenced in each 
lane. 
 
3.12.3. Final concentration 
 
The final concentration required for the flow cell is 10nM in a total volume of 50 µl. The 
dilution factor is calculated from the initial molarity divided by the required final molarity.  
The volume of DNA to add is calculated by final volume divided by dilution factor.  The 
volume water was added to reach 50 µl.  Tables are in Appendices VII and VIII to show 
the final concentrations and dilutions for each lane. 
 
3.13 Sequencing Quality Control 
 
3.13.1 Phred scores (Q scores) 
 
Quality control scores in next generation sequencing data are necessary for assessing 
the accuracy of data and for filtering sequencing artefacts.  The Phred scoring system 
is used to assess base call accuracy. The Q score is a related to probability that a base 
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call is incorrect.  Thus, Q = -10  log10 (P); this means that a Q score of 10 reveals that 
the probability that the base call is incorrect is 1 in 10 and the accuracy is 90%.  A Q 
score of 30 means that the probability that the base call is incorrect is 1 in 1,000 and 
the accuracy is then 99.9%.  Q30 is considered the standard minimum level of 
accuracy as this means that the majority of base calls are correct.   
 
3.13.2 Read depth 
 
Read depth, sometimes referred to as coverage, can be defined as the number of 
times a read is aligned to the reference.  This is important in next generation 
sequencing to assess certainty in variant call accuracy.  In the research setting a read 
depth of 30X (i.e. each of 30 reads are aligned to the reference sequence) is 
considered to be the benchmark for confident variant call accuracy.  In the diagnostic 
clinic read depth of 50X is aimed for. 
 
Table 3.4 Phred quality scores and read depth summary table 
Lane 
Mean 
Quality 
Score 
Bases > 
Q30 (%) 
Total number 
of reads in 
lane 
Minimum 
Read 
Depth 
(X) 
Maximum 
Read 
Depth 
(X) 
Mean 
Read 
Depth per 
sample (X) 
1 N/A N/A 182,960,682 306 4248 1813 
2 20.5 48.91 394,728,316 60 6829 3807 
3 32.0 79.58 214,132,200 8 5437 2184 
4 20.72 49.54 390,879,886 2 10443 3770 
5 20.23 48.27 415,876,556 52 6284 4021 
6 34.90 89.17 417,894,038 0 7214 4030 
7 34.65 88.45 409,879,152 0 7525 3984 
Table 3.4 Phred quality scores and read depth summary table. This table summarises the quality 
scores, total number of reads in each lane, mean read depth for each lane and minimum and maximum 
read depth for each lane. X = number of reads, Q = Phred score, N/A=data not available 
 
The table above (Table 3.4) summarises the quality scores, mean read depth and the 
minimum and maximum read depth for each lane in the study. The table also includes 
Phred quality scores for each lane.   
 
Phred quality scores were very good for lanes 3, 6 and 7 with 80% or more samples 
receiving a quality score of Q30 or more.  None of the lanes are assigned quality 
scores below Q20, which means that there is a 1 in 100 chance that a base call is 
incorrect in these lanes. In other words there is a base call accuracy rate of 99% (Q20) 
and 99.9% (Q30). 
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In addition, figures 3.14 to 3.20 plot the individual sample read depths for each lane.  
This shows that, whilst in lanes 6 and 7 the minimum read depth is zero, very few 
samples failed in the whole study.  
 
Figure 3.14 Graph plotting mean read depth per sample for lane 1 
 
Figure 3.14 Graph plotting mean read depth per sample for lane 1.  This graph shows the minimum 
mean read depth is 306 X and the maximum mean read depth is 4248 X 
  
Figure 3.15 Graph plotting mean read depth per sample for lane 2 
 
 
Figure 3.15 Graph plotting mean read depth per sample for lane 2.  This graph shows the minimum 
mean read depth is 60 X and the maximum mean read depth is 6829 X 
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Figure 3.16 Graph plotting mean read depth per sample for lane 3 
 
Figure 3.16 Graph plotting mean read depth per sample for lane 3.  This graph shows the minimum 
mean read depth is 8 X and the maximum mean read depth is 5437 X.  3 samples fall below read depth of 
30 X. 
 
Figure 3.17 Graph plotting mean read depth per sample for lane 4 
 
 
Figure 3.17 Graph plotting mean read depth per sample for lane 4.  This graph shows the minimum 
mean read depth is 2 X and the maximum mean read depth is 10443 X. 13 samples fall below read depth 
30 X 
 
 
 
0
1000
2000
3000
4000
5000
6000
0 50 100 150 200 250 300 350 400
R
ea
d 
D
ep
th
 
Samples 
Lane 3 
0
2000
4000
6000
8000
10000
12000
0 50 100 150 200 250 300 350 400 450
R
ea
d 
D
ep
th
 
Samples 
Lane 4 
 150 
Figure 3.18 Graph plotting mean read depth per sample for lane 5 
 
Figure 3.18 Graph plotting mean read depth per sample for lane 5.  This graph shows the minimum 
mean read depth is 52 X and the maximum mean read depth is 6284 X.  
 
 
Figure 3.19 Graph plotting mean read depth per sample for lane 6  
Figure 3.19 Graph plotting mean read depth per sample for lane 6.  This graph shows the minimum 
mean read depth is 71 X and the maximum mean read depth is 7214 X. The sample that shows read 
depth 0 X is the non-template control (NTC) 
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Figure 3.20 Graph plotting mean read depth per sample for lane 7 
 
Figure 3.20 Graph plotting mean read depth per sample for lane 7.  This graph shows the minimum 
mean read depth is 206 X and the maximum mean read depth is 7525 X. The samples showing read 
depths 0 X are the non-template controls (NTC) 
 
In Figures 3.14 to 3.20 these graphs demonstrate that depth of coverage is generally 
even between samples and that most samples are sequenced at a read depth of that 
required for diagnostic mutation testing (i.e. 50X).  Lane 4 is the least well performing 
lane as 13 samples failed to sequence and the coverage varies widely between 
samples.  Lanes 6 and 7 are the best performing lanes as the majority of samples are 
sequenced with a mean read depth hovering around 4000 X with fewer outliers high or 
low.  There are several reasons why these differences may be seen.  It may be that 
there are differences in amplification between samples at the library preparation stage 
in lanes 3, 4 and 5 and in lane 6 and 7 the amplification may have been more even.  
The normalisation of samples is very important prior to amplification using the Access 
Array and this could be the reason for the unevenness in coverage.   A second 
possibility is the normalisation and pooling of samples following library preparation and 
prior to loading on the C-bot for cluster generation. 
 
Further analyses are conducted on read depth per amplicon.  Each of the 144 
amplicons are split into two, one for the forward read and one for the reverse read, 
which gives a total of 288 ‘amplicons’ for each of 7 lanes.  This means the total number 
of possible ‘amplicons’ is 2,016. For each ‘amplicon’ 50% of samples must be 
sequenced at a minimum of 30X coverage to be assessed as ‘passed’. Table 3.5 gives 
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a breakdown of the number of failed and passed amplicons in each gene.  This shows 
that overall 96.53% of amplicons are sequenced at a depth greater than 30X.  The best 
performing gene is XRCC2 with 99.35% sequenced at read depth greater than 30X 
and the poorest performing gene is SLX4 with 95.2% sequenced at read depth greater 
than 30X. 
 
Table 3.5 The number of passed and failed amplicons in each gene for the whole 
study 
Gene Passed Failed Total % Passed 
RAD51B 247 5 252 98.02 
RAD51C 233 5 238 97.90 
RAD51D 204 6 210 97.14 
XRCC2 153 1 154 99.35 
XRCC3 176 6 182 96.70 
SLX4 933 47 980 95.20 
Total 1946 70 2016 96.53 
Table 3.5 The number of passed and failed amplicons in each gene for the whole study.  This table 
gives data for all possible ‘amplicons’ in the study.  For each lane there are 288 possible ‘amplicons’ 
(forward and reverse reads) with a total of 2,016 across all 7 lanes.  This table also shows the proportion 
of passing amplicons for each gene. For an 'amplicon’ to pass >50% of samples must show a read depth 
of >30X. (Data supplied by Dr Honglin Song at Strangeways Research Laboratory, Cambridge UK). 
 
Further in depth analyses are conducted per sample; samples are considered ‘failed’ if 
greater than 80% of the sample has a read depth under 30X.  Using these parameters, 
51 samples are considered failed.  For the remaining samples that are considered 
‘passed’ the overall median depth of coverage is 2,264X (interquartile range is 1,502 – 
3251). 
 
For each gene the number of passed samples per gene is calculated to give a 
sensitivity figure for each gene and across all 6 genes.  The Table 3.6 shows the 
sensitivity for the whole study, that is the proportion of samples in each gene 
sequenced at a read depth of >30X.  
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Table 3.6 Proportion of samples in each gene with a read depth >30X  
Gene Proportion >30X (%) 
RAD51B 93 
RAD51C 94 
RAD51D 95 
XRCC2 95 
XRCC3 93 
SLX4 93 
Table 3.6 Proportion of samples with read depth >30X for each gene.  The overall mean sensitivity 
across all 6 genes is 94%. (Data supplied by Dr Honglin Song at Strangeways Research Laboratory, 
Cambridge UK). 
 
3.14 Genetic variant prevalence and characteristics  
 
Genetic variants or changes in the DNA sequence may or may not cause disease 
(deleterious or pathogenic).  Common polymorphisms are gene variants that occur in 
more than 1% of the population and rare variants occur at a rate less than 1% in the 
population.  Common polymorphisms are generally considered to be non-pathogenic, 
thus in this study the common polymorphisms, as assessed either on dbSNP or 
through the frequency detected in the study, are filtered out and excluded as predicted 
neutral variants.  Variants that are predicted to result in protein-truncation, i.e. those 
introducing a stop codon, frameshift insertions and deletions and variants at splice 
sites are considered predicted pathogenic variants for the purpose of this study. For 
definitive biological effect of novel variants detected functional assays would be 
required, therefore, these are referred to as predicted pathogenic variants. 
 
3.14.1 Variant detection sensitivity and specificity 
 
Variant detection sensitivity can be broadly defined as the proportion of variants 
detected and specificity as the proportion of false positives found in the data.    
Variants detected in NGS are validated here using Sanger sequencing to assess the 
false positives in the NGS approach.  The positive controls spiked in for RAD51C is 
used to assess the accuracy of the NGS approach and to assess the accuracy of the 
multiplexing.  Read filtering is conducted to filter out sequencing artefacts.  
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3.14.2 Blinded positive controls 
 
6 blinded positive controls for RAD51C are spiked into these data as an assessment of 
variant detection sensitivity.  5 of these are accurately detected by NGS and the 6th 
control is not detected due to zero coverage for the region in which the variant resides.  
Figures 3.21 to 3.26 are a series of images representing the reads for each of the 
positive controls at the variant position. 
 
Figure 3.21 Integrative Genome Viewer generated image for control No1 RAD51C 
c.-26C>T 
 
Figure 3.21 Integrative Genome Viewer generated image for control No1. RAD51C c.-26C>T. The 
variant is clearly seen in the forward reads shaded pink and highlighted by parallel vertical dotted lines in 
the image  
 
Figure 3.22 Integrative Genome Viewer generated image for control No2 RAD51C 
c.374G>T 
 
Figure 3.22 Integrative Genome Viewer generated image for control No2 RAD51C c.374G>T. The 
variant is seen in the reverse reads shaded blue and highlighted by dotted parallel vertical lines  
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Figure 3.23 Integrative Genome Viewer generated images control No3 RAD51C 
c.687C>T 
 
Figure 3.23 Integrative Genome Viewer generated images control No3 RAD51C c.687C>T.  The 
variant is seen in the reverse reads shaded blue and highlighted by dotted parallel vertical lines  
 
 
 
Figure 3.24 Integrative Genome Viewer generated images control No4 RAD51C 
c.IVS6(-19)T>C 
 
Figure 3.24 Integrative Genome Viewer generated images control No4 RAD51C c.IVS6(-19)T>C. The 
variant is clearly seen in the forward reads shaded pink and highlighted by parallel vertical dotted lines in 
the image  
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Figure 3.25 Integrative Genome Viewer generated images control No5 RAD51C 
c.790G>A 
 
Figure 3.25 Integrative Genome Viewer generated images control No5 RAD51C c.790G>A. The 
variant is seen in the reverse reads shaded blue and highlighted by dotted parallel vertical lines  
 
 
 
Figure 3.26 Integrative Genome Viewer generated image for control No6 RAD51C 
c.1097G>A 
 
Figure 3.26 Integrative Genome Viewer generated image of control No.6. RAD51C c.1097G>A.  The 
image demonstrates that there is zero depth of coverage in the region highlighted with the parallel dotted 
lines in which the variant should be located.  Therefore, this variant was missed due to no coverage. 
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3.14.3 Filtering by read depth and alternate allele frequency 
 
Filtering is performed to distinguish sequencing artefacts from real variants.  The 
following parameters are used to filter out spurious variant calls.  Variants detected are 
accepted if read depth is 15X or more and the alternate allele frequency is 40% or 
more; or if the read depth is 30X or more and the alternate allele frequency is 30% or 
more.  Where variants are detected in regions that do not meet these criteria then 
variants are rejected.  Table 3.7 gives the numbers of variants detected prior to filtering 
(unfiltered data) and the number of variants post filtering (filtered data) 
 
Table 3.7 Filtering variants by lane 
Lane Unfiltered or Filtered No.Variants 
Lane 1 
Unfiltered 1432 
Filtered 1354 
Lane 2 
Unfiltered 1482 
Filtered 1448 
Lane 3 
Unfiltered 1300 
Filtered 1167 
Lane 4 
Unfiltered 8684 
Filtered 2985 
Lane 5 
Unfiltered 1473 
Filtered 1295 
Lane 6 
Unfiltered 1539 
Filtered 1465 
Lane 7 
Unfiltered 1756 
Filtered 1616 
Table 3.7 Filtering variants by lane.  Variants are filtered out according to read depth and alternate allele 
frequencies.  Where read depth is greater than 15X alternate allele frequency must be greater than 40% 
and where read depth is greater than 30X alternate allele frequency must be greater than 30%. 
 
3.14.4 Filtering out silent variants 
 
Following filtering by read depth and alternate allele frequency all synonymous single 
nucleotide variants (S-SNV) that do not result in a change in amino acid are removed 
in the next stage of the analysis.  This leaves only the non-synonymous single 
nucleotide variants (NS-SNV) that result in a change in amino acid and the insertions 
and deletions (INDELs). Table 3.8 details the total number of remaining variants that 
lead to a change in amino acid, some of which are the same variant in different 
samples.  
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Table 3.8 Number of remaining variants following removal of silent variants 
Lane No. remaining variants post removal of silent variants 
Lane 1 802 
Lane 2 855 
Lane 3 692 
Lane 4 2168 
Lane 5 846 
Lane 6 887 
Lane 7 1048 
Table 3.8 Number of remaining variants following removal of silent variants.  All synonymous single 
nucleotide variants are removed in this stage of the analysis. Note that some of these variants are the 
same change in different samples 
 
 
3.14.5 Summary of genetic variants detected according to variant type.   
 
Following filtering of S-SNVs, variants are subdivided into non-synonymous single 
nucleotide variants (NS-SNVs), frameshift insertions and deletions, nonsense variants 
and splice site variants. The table 3.9 summarises all variants detected in the study by 
gene giving number of different variants of each type.   
 
Table 3.9 Summary of genetic variants detected according to variant type 
Gene Nonsense Frameshift Splice site NS-SNV 
RAD51B 1 0 0 13 
RAD51C 4 2 2 18 
RAD51D 3 1 0 16 
XRCC2 0 1 0 11 
XRCC3 0 0 1 18 
SLX4 2 1 0 27 
Total 10 5 3 103 
Table 3.9 Summary of genetic variants detected according to variant type.  This table gives detail on 
the total number of different variants detected by variant type for the whole study. (NS-SNV = non-
synonymous single nucleotide variant) 
 
3.15 Predicted deleterious variants detected in the 6 genes. 
 
Nonsense, frameshift and splice site variants are assumed to be predicted deleterious 
variants as these are anticipated to result in protein truncation.  The NS-SNVs are not 
assumed to be deleterious and the functional effects of these are predicted using two 
software programs PROVEAN and PolyPhen-2. 
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3.15.1 Predicted protein-truncating variants 
 
Table 3.10 Predicted protein-truncating variants 
Gene Function Variant cDNA Exon 
No. 
cases or 
controls 
Novel 
or 
known 
Sanger 
sequencing 
validation 
Yes/No 
RAD51B Nonsense c.489T>G 6 1 case Novel Yes 
RAD51C FS Del c.497delT 3 1 case Novel Yes 
RAD51C FS Del c.651_652del 4 1 case Novel Yes 
RAD51C Nonsense c.577C>T 4 2 cases Known Yes 
RAD51C Nonsense c.955C>T 7 2 cases Novel Yes 
RAD51C Splicing c.706-2A>G 5 2 cases Known Yes 
RAD51C Splicing c.905-2delAG 7 1 case Known Yes 
RAD51C Nonsense c.1005C>A 8 1 case Novel No 
RAD51C Nonsense c.312T>A 2 1 case Novel Unknown 
RAD51D FS Del c.565_568del 6 2 cases Novel Yes 
RAD51D Nonsense c.478C>T 5 1 case Novel Yes 
RAD51D Nonsense c.620C>A 7 1 case Novel Yes 
RAD51D Nonsense c.898C>T 9 1 control Novel Yes 
XRCC2 FS Del c.96delT 2 2 cases Novel Yes 
XRCC3 Splicing c.194-2A>G 7 1 case Novel Yes 
SLX4 FS Del c.2497_2498del 12 1 Case Novel Yes 
SLX4 Nonsense c.4386_4387insAGGATGAACGAGGCCGC 12 2 Cases Novel Yes 
SLX4 Nonsense c.1976C>A 9 1 case Novel No 
SLX4 Non FS Del c.3919_3921del 12 1 control Novel Yes 
Table 3.10 Predicted protein-truncating variants.  This table gives details of all predicted protein-
truncating variants detected in all 6 genes in the whole study.  Variants are named according to the cDNA 
sequence of each gene.  There are 19 different variants of which Sanger sequencing validates 16.  16 
variants are novel with 3 previously reported in literature.  20 cases have validated predicted protein-
truncating variants; 1 case has a predicted protein-truncating variant with unknown validation status; 2 
cases with predicted protein-truncating variants are not validated by Sanger sequencing and 1 control has 
a predicted protein-truncating variant and 1 control has a non-frameshift deletion. 
 
The predicted protein-truncating variants for the whole study are described in the table 
3.10.  This table gives details of type of variants detected in each gene and if they are 
novel or known.  Table 3.10 also gives the number of variants in cases and controls.  
There are 19 different variants in total with 16 of those validated by Sanger 
sequencing.  3 variants are previously reported in literature: the nonsense variant in 
RAD51C c.577C>T and the splice site variant c.905-2delAG have been published by 
Coulet et al (2012) and the splice site variant in RAD51C 706-2A>G is published by 
Loveday et al (2012).  All other variants are previously unknown. 
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3.15.2 Predicted deleterious non-synonymous single nucleotide variants 
 
In addition to predicted protein truncating variants in the 6 genes under study, several 
other genetic variants, including putative functional missense alterations and known 
polymorphisms are identified in these data. Table 3.11 gives the results from two 
functional prediction programs (PROVEAN and PolyPhen-2). 
 
Table 3.11 Results from PROVEAN and PolyPhen-2 software functional 
prediction programs for each of the non-synonymous single nucleotide variants 
Gene Variant PROVEAN PolyPhen-2 
RAD51B L172W Neutral Possibly damaging 
 K243R Neutral Possibly damaging 
 V207L Neutral Benign 
 C185G Deleterious Possibly damaging 
 Y180C Neutral Benign 
 R217G Deleterious Probably damaging 
 A89T Neutral Benign 
 E340Q Neutral Benign 
 M120T Neutral Benign 
 A295V Deleterious Probably damaging 
 D142G Deleterious Probably damaging 
 S250A Neutral Benign 
 V343A Neutral Possibly damaging 
RAD51C G264S Deleterious Benign 
 T287A Deleterious Probably damaging 
 G125V Deleterious Probably damaging 
 A126T Neutral Benign 
 L226P Deleterious Probably damaging 
 A354V Neutral Benign 
 D318N Neutral Benign 
 V169G Deleterious Possibly damaging 
 K84N Neutral Benign 
 L27P Deleterious Probably damaging 
 L262V Neutral Possibly damaging 
 T174S Neutral Benign 
 E67K Neutral Benign 
 L91F Deleterious Probably damaging 
 P43S Deleterious Possibly damaging 
 Q222K Neutral Possibly damaging 
 Q268H Neutral Possibly damaging 
 Q11R Neutral Possibly damaging 
RAD51D R165Q Neutral Benign 
 A210V Deleterious Probably damaging 
 C119R Neutral Possibly damaging 
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 C117S Deleterious Probably damaging 
 C9S Deleterious Possibly damaging 
 H23Y Neutral Benign 
 Q115R Deleterious Probably damaging 
 R165W Deleterious Probably damaging 
 R239W Deleterious Probably damaging 
 T313A Neutral Benign 
 L164P Deleterious Probably damaging 
 M308V Neutral Benign 
 G44A Neutral Benign 
 I251M Neutral Benign 
 E233G Deleterious Probably damaging 
 V56G Deleterious Possibly damaging 
XRCC2 R188H Neutral Benign 
 D36N Neutral Benign 
 V118E Deleterious Benign 
 E207G Neutral Benign 
 R214Q Neutral Benign 
 K229R Neutral Benign 
 T94R Neutral Possibly damaging 
 V39M Neutral Possibly damaging 
 F240L Neutral Benign 
 F32V Deleterious Probably damaging 
 L90F Deleterious Benign 
XRCC3 T241M Neutral Possibly damaging 
 A262T Neutral Benign 
 V194M Neutral Possibly damaging 
 R108C Neutral Benign 
 R162C Deleterious Probably damaging 
 K17N Neutral Possibly damaging 
 R94H Neutral Benign 
 R302H Neutral Benign 
 K22R Neutral Benign 
 S110L Deleterious Probably damaging 
 V124M Deleterious Probably damaging 
 V165I Neutral Benign 
 R58W Deleterious Probably damaging 
 P230L Neutral Benign 
 P230S Neutral Benign 
 R313W Deleterious Probably damaging 
 R231K Neutral Probably damaging 
 M263V Neutral Benign 
SLX4 A424V Deleterious Probably damaging 
 A535V Deleterious Probably damaging 
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 D1802N Deleterious Probably damaging 
 E787K Deleterious Possibly damaging 
 K354N Deleterious Probably damaging 
 K458E Deleterious Probably damaging 
 L472S Deleterious Probably damaging 
 L497S Deleterious Probably damaging 
 P1122L Deleterious Benign 
 P1381S Deleterious Possibly damaging 
 P1624A Deleterious Benign 
 P504R Deleterious Probably damaging 
 Q273H Deleterious Probably damaging 
 Q355L Deleterious Probably damaging 
 R1341I Deleterious Possibly damaging 
 R1550L Deleterious Possibly damaging 
 R1550W Deleterious Benign 
 R1814C Deleterious Probably damaging 
 R204C Deleterious Probably damaging 
 R278W Deleterious Probably damaging 
 R811T Deleterious Probably damaging 
 S1123Y Deleterious Possibly damaging 
 S1271F Deleterious Probably damaging 
 S1492Y Deleterious Probably damaging 
 S498F Deleterious Probably damaging 
 T757I Deleterious Probably damaging 
 V362A Deleterious Probably damaging 
Table 3.11 Putative functional missense mutations in the 6 genes under study: two software 
programs PROVEAN and PolyPhen-2 are used to predict the putative functional effects of missense 
variants.  Results suggest that there is a high degree of concordance between deleterious prediction by 
PROVEAN and probably damaging by PolyPhen-2.  Differences are seen in the additional level for 
PolyPhen-2 the ‘Possibly damaging’ subset. 
 
 
A final set of 56 predicted functional missense variants for all 6 genes under 
investigation is compiled in Table 3.12. Sanger sequencing validation results are 
available for 5 of these variants; this is due to the high costs that would have incurred 
in full validation as there are very large numbers of samples involved.  4 out of 5 
Sanger sequenced variants are confirmed and these are highlighted Table 3.12 
(green=validated and pink=not validated).  Table 3.12 also gives details on dbSNP 
listing with rs SNP numbers where known and minor allele frequencies (MAF) if known.  
MAF is taken from 1000 Genomes data. 
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Table 3.12 Predicted functional missense variants 
Gene Variant (Protein) 
Variant 
(gDNA) 
Position 
(Exon 
No.) 
Frequency (%) 
rs dbSNP MAF Source if known 
Sanger 
Validation 
Y/N/Unknown Cases Controls 
RAD51B C185G c.553T>G 6 0.07 0 Novel   Unknown 
RAD51B R217G c.649A>G 7 0.07 0 Novel   Unknown 
RAD51B A295V c.884C>T 9 0 0.09 Novel   Unknown 
RAD51B D142G c.425A>G 5 0 0.09 Novel   Unknown 
RAD51C G264S c.790G>A 5 0.60 0.62 rs147241704 N/A dbSNP Unknown 
RAD51C T287A c.859A>G 6 1.39 0.97 rs28363317 G=0.006 1000 Genomes Unknown 
RAD51C G125V c.374G>T 2 0.07 0.27 rs267606998 N/A Meindl et al (2010) Unknown 
RAD51C L226P c.677T>C 4 0.07 0 Novel   Yes 
RAD51C V169G c.506T>G 3 0.13 0 Novel   No 
RAD51C L27P c.80T>C 1 0.07 0 Novel   Unknown 
RAD51C L91F c.271C>T 2 0.07 0 Novel   Unknown 
RAD51C P43S c.1271C>T 1 0.07 0 Novel   Unknown 
RAD51D Q115R c.344A>G 4 0.07 0 Novel   Unknown 
RAD51D C117S c.349T>A 5 0.07 0 Novel   Unknown 
RAD51D C9S c.26G>C 1 0.20 0 rs1408257595   Unknown 
RAD51D A210V c.629C>T 7 0.13 0 Novel   Unknown 
RAD51D R165W c.493C>T 6 0 0.18 Novel   Unknown 
RAD51D R239W c.715C>T 10 0.07 0 Novel   Unknown 
RAD51D L164P c.491T>C 6 0.07 0 Novel   Yes 
RAD51D E233G c.698A>G 8 2.99 1.24 rs28363284 C=0.006 1000 Genomes Unknown 
RAD51D V56G c.167T>G 3 0.13 0 Novel   Unknown 
XRCC2 F32V c.94T>G 2 0.13 0 Novel   Yes 
XRCC2 V118E c.353T>C 3 0 0.09 rs185815454 G=0.001 1000 Genomes Unknown 
XRCC2 L90F c.286C>T 3 0.07 0 Novel   Unknown 
XRCC3 R162C c.484C>T 7 0.07 0 Novel   Unknown 
XRCC3 S110L c.329C>T 6 0.07 0 Novel   Yes 
XRCC3 R58W c.172C>T 5 0 0.09 rs143410843 NA Unknown Unknown 
XRCC3 V124M c.370G>A 6 0.07 0 Novel   Unknown 
XRCC3 R313W c.937C>T 10 0.07 0 Novel   Unknown 
SLX4 A424V c.1271C>T 6 0.07 0 Novel   Unknown 
SLX4 A535V c.1604C>T 7 0.07 0 Novel   Unknown 
SLX4 D1802N c.5404G>A 15 0.07 0.09 Novel   Unknown 
SLX4 E787K c.2359G>A 12 0.27 0.18 rs140600202 NA Unknown Unknown 
SLX4 K354N c.1062G>T 5 0 0.09 Novel   Unknown 
SLX4 K458E c.1372A>G 7 0.07 0 rs149126845 0.000 1000 Genomes Unknown 
SLX4 L472S c.1415T>C 7 0.13 0 Novel   Unknown 
SLX4 L497S c.1409T>C 7 0.07 0 Novel   Unknown 
SLX4 P1122L c.3365C>T 12 14.94 12.21 rs714181 A=0.197 1000 Genomes Unknown 
SLX4 P1381S c.4141C>T 12 0 0.09 Novel   Unknown 
SLX4 P1624A c.4870C>G 14 0 0.18 Novel   Unknown 
SLX4 P504R c.1511C>G 7 0 0.09 Novel   Unknown 
SLX4 Q273H c.819G>C 4 0.07 0 Novel   Unknown 
SLX4 Q355L c.1064A>T 5 0 0.09 Novel   Unknown 
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SLX4 P1341I c.4022G>T 12 0.07 0 Novel   Unknown 
SLX4 R1550L c.4649G>T 13 0 0.62 Novel   Unknown 
SLX4 R1550W c.4648C>T 4 0.66 0.71 rs77021998 A=0.002 1000 Genomes Unknown 
SLX4 R1814C c.5440C>T 15 0 0.09 Novel   Unknown 
SLX4 R204C c.610C>T 3 12.22 11.33 Novel   Unknown 
SLX4 R278W c.832C>T 4 0.07 0 Novel   Unknown 
SLX4 R811T c.2432G>C 12 0.07 0 Novel   Unknown 
SLX4 S1123Y c.3368C>A 12 0.20 0 Novel   Unknown 
SLX4 S1271F c.3812C>T 12 6.44 5.04 Novel   Unknown 
SLX4 S149Y c.4475C>A 12 0.07 0 Novel   Unknown 
SLX4 S498F c.1493C>T 7 0.07 0 Novel   Unknown 
SLX4 T757I c.2270C>T 11 0.07 0 Novel   Unknown 
SLX4 V362A c.1085T>C 5 0.27 0.09 Novel   Unknown 
Table 3.12 Predicted functional missense variants. This table describes all predicted functional 
missense variants detected in all 6 genes with frequency of each variant in cases and controls.  The 
protein names are included as these are used in the functional prediction programs.  Sanger sequencing 
validation is performed on a subset of 5 variants due to the large number of samples involved.  4 out of 5 
variants are confirmed via Sanger sequencing. rsSNP number is included where these are known.  MAF 
(Minor Allele Frequency) is given for the second most commonly occurring allele according to dbSNP in 
order to differentiate rare variants from common polymorphisms.  MAF is based on frequency in 1000 
genomes data and MAF G=0.008 means that allele G occurs at a frequency of 0.8% in the 1094 samples 
sequenced in 1000 Genomes data in 2011. 
 
 
3.16 Summary of variant prevalence and characteristics including position of 
variants in each gene 
 
NGS data identifies 23 ovarian cancer cases and 1 control as having a predicted 
protein-truncating variant in one of the 6 genes.  Of these Sanger sequencing 
validation confirms 20 cases and 1 control with predicted protein-truncating variants.  In 
addition, 1 control sample is detected with a non-frameshift deletion. These variants 
include, 1 nonsense variant in RAD51B, 2 nonsense and 2 splice site variants in 
RAD51C, 1 frameshift and 3 nonsense variants in RAD51D, 1 frameshift deletion in 
XRCC2, 1 splice site variant in XRCC3 and 1 frameshift deletion, 1 nonsense and 1 
non-frameshift deletion in SLX4.  In all 6 genes in the study 1.33% of cases have a 
predicted protein-truncating variant and just 0.09% of control samples have a predicted 
protein-truncating variant in one of the 6 genes. 
 
The figure 3.27 is an image demonstrating the position of variants in each gene.  This 
illustrates that variants have been detected throughout the coding region of each gene.  
This figure also shows which variants are novel and which were previously identified. 
 
 
 165 
Figure 3.27 Images of each gene with position of predicted protein truncating 
variants 
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Figure 3.27 Images of each gene with position of predicted protein truncating variants. The variant 
in RAD51B is in exon 6, RAD51C has the most variants and these are positioned in exons 2, 3, 4, 5, 6 and 
7, RAD51D has the second most frequently occurring variants and these are located in exons 5, 6, 7 and 9 
only. XRCC2 and XRCC3 have only 1 variant in each gene. SLX4 has 2 variants and both of these are 
located in exon 12, the largest exon in the gene.  Red = Nonsense.  Blue = splicing.  Purple = frameshift. 
The previously reported mutations are indicated with a star 
 
 
3.17 Summary of Sanger sequencing validation  
 
Sanger sequencing validation confirms 20 cases with predicted protein-truncating 
variants and 1 predicted protein-truncating variant in 1 control sample.  Figures 3.28 to 
3.33 show images of examples of comparisons of Sanger sequencing data and NGS 
data for the same variant and sample. Integrative Genome Viewer (IGV) images of 
NGS data were generated and compared to the Sanger sequencing trace images. 
 
Figure 3.28 Sanger sequencing trace and NGS IGV generated image for variant 
RAD51B c.489T>G 
 A B 
Figure 3.28 Sanger sequencing trace and NGS IGV generated image for variant RAD51B c.489T>G 
This figure shows images of the same RAD51B (c.489T>G) nonsense mutation, A. Sanger sequencing 
trace and B. NGS IGV generated image. The NGS image (B) shows reads ‘squished’ demonstrating that 
the mutation is detected in both directions (red = forward, blue = reverse). 
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Figure 3.29 Sanger sequencing trace and NGS IGV generated image for variant 
RAD51C c.577C>T 
 A B 
Figure 3.29 Sanger sequencing trace and NGS IGV generated image for variant RAD51C c.577C>T.  
This figure shows images of the same RAD51C (c.577C>T) nonsense mutation, A. Sanger sequencing 
trace and B. NGS IGV generated image.  The NGS image clearly shows the variant is heterozygous, with 
approximately half of the reads showing each allele. 
 
 
Figure 3.30 Sanger sequencing trace and NGS IGV generated image for variant 
RAD51C c.905-2delAG 
  A       B          
Figure 3.30 Sanger sequencing trace and NGS IGV generated image for variant RAD51C c.905-
2delAG.  This figure shows images of the same RAD51C (905-2delAG) spice site mutation, A. Sanger 
sequencing trace and B. NGS IGV generated image.  The NGS image clearly shows the 2 base pair 
deletion in the forward read direction.  The grey boxes show the read depth at half the surrounding 
sequence showing that this is a heterozygous deletion. 
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Figure 3.31 Sanger sequencing trace and NGS IGV generated image for variant 
RAD51D c.478C>T 
    B 
Figure 3.31 Sanger sequencing trace and NGS IGV generated image for variant RAD51D c.478C>T.  
This figure shows images of the same RAD51D (c.478C>T) nonsense mutation, A. Sanger sequencing 
trace and B. NGS IGV generated image.  The NGS image shows this is an heterozygous single base 
change with approximately half of the reads for each base (G = brown and A = green).  The read is the 
forward direction and the gene is on the reverse strand. 
 
Figure 3.32 Sanger sequencing trace and NGS IGV generated image for variant 
XRCC2 c.96delT 
A  B 
Figure 3.32 Sanger sequencing trace and NGS IGV generated image for variant XRCC2 c.96delT.  
This figure shows images of the same XRCC2 (96delT) frameshift deletion, A. Sanger sequencing trace 
and B. NGS IGV generated image.  The NGS image shows that approximately half of the forward reads 
contain the single base deletion and half do not suggesting a heterozygous single base deletion. Two 
reads show a red outline and this suggests they are poorer quality than the other reads. 
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Figure 3.33 Sanger sequencing trace and NGS IGV generated image for variant 
XRCC3 c.194-2A>G 
A  B 
Figure 3.33 Sanger sequencing trace and NGS IGV generated image for variant XRCC3 c.194-2A>G. 
This figure shows images of the same XRCC3 (194-2A>G) splice site mutation, A. Sanger sequencing 
trace and B. NGS IGV generated image.  The NGS image has been set to ‘squished’ reads mode so that 
the reads containing the variant are visualised.  There are clearly approximately half the number of reads 
with a T base (red) and half with the C base (blue).  These reads are the reverse direction reads. 
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3.18 Epidemiological data  
 
Table 3.13 Epidemiological data for samples with predicted protein-truncating 
variants 
Gene Variant Type Variant 
Epidemiological Data 
Race Age at diagnosis Histology Grade 
FIGO 
Staging 
Final 
status at 
follow-up 
Family 
history 
Source of 
sample 
RAD51B Nonsense c.489T>G Unknown 62 Serous Poorly differentiated IIIC 
Deceased 
368 days Unknown AOCS 
RAD51C Frameshift deletion c.497delT White 52 Serous 
Poorly 
differentiated IIIC 
Deceased 
1716 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
MALOVA 
RAD51C Frameshift deletion 651_652del White 64 Serous 
Poorly 
differentiated IIIC 
Deceased 
1031 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
AOCS 
RAD51C Nonsense c.577C>T Unknown 60 
Other (i.e. 
not serous, 
endometrioid 
or mucinous) 
Unknown Unknown Unknown 
Maternal 
Aunt had 
ovarian 
and 
breast 
cancer 
PFH 
RAD51C Nonsense c.577C>T Unknown 41 Serous 
Moderate to 
poorly 
differentiated 
Unknown Unknown 
Sister 
had 
ovarian 
cancer 
PFH 
RAD51C Nonsense c.955C>T Unknown 40 Serous Moderately differentiated IIIC 
Alive 
2107 
days 
Father 
had 
breast 
cancer 
AOCS 
RAD51C Nonsense c.955C>T White 74 Serous Poorly differentiated IIIC 
Alive 
2664 
days 
Sister 
had 
breast 
cancer 
AOCS 
RAD51C Splicing c.706-2A>G Unknown Unknown Unknown Unknown Unknown Unknown 
One 
case of 
ovarian 
cancer 
(not 
FDR) 
UKFOCR 
RAD51C Splicing c.706-2A>G White 64 Serous Poorly differentiated IIB 
Alive 
1418 
days 
Mother 
and 
sister 
had 
ovarian 
cancer 
UKOPS 
RAD51C Splicing c.905-2delAG Unknown 52 Endometrioid Unknown IIB Unknown 
Mother 
ovarian 
cancer 
PFH 
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RAD51C Nonsense c.312T>A White 49 Serous Poorly differentiated IIIC 
Alive 
3062 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
AOCS 
RAD51D Frameshift deletion c.565_568del White 59 Serous 
Moderately 
differentiated IIIC 
Deceased 
2408 
No 
history of 
breast or 
ovarian 
cancer in 
family 
MALOVA 
RAD51D Frameshift deletion c.565_568del White 76 Serous 
Poorly 
differentiated IIA 
Deceased 
564 
No 
history of 
breast or 
ovarian 
cancer in 
family 
MALOVA 
RAD51D Nonsense c.478C>T Unknown Unknown Unknown Unknown Unknown Unknown 
One 
case of 
ovarian 
cancer 
(not 
FDR) 
UKFOCR 
RAD51D Nonsense c.620C>A White 59 Serous Moderately differentiated IB 
Alive 
1246 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
UKOPS 
RAD51D Nonsense c.898C>T White 49 at interview 
Control no 
ovarian 
cancer 
NA NA NA 
Sister 
had 
ovarian 
cancer 
AOCS 
XRCC2 Frameshift deletion c.96delT White 50 Serous Unknown Unknown 
Deceased 
days 
unknown 
One 
case of 
ovarian 
cancer 
(not 
FDR) 
GRFOCR 
XRCC2 Frameshift deletion c.96delT Unknown 40 Mucinous 
Well 
differentiated IA Unknown 
1st cousin 
had 
ovarian 
cancer 
(maternal 
side) 
PFH 
XRCC3 Splicing c.194-2A>G Unknown 64 Serous Poorly differentiated IIIC 
Alive 
3513 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
AOCS 
SLX4 Frameshift deletion c.2497_2498del White 56 Serous 
Moderately 
differentiated IIIC 
Deceased 
1950 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
MALOVA 
SLX4 Nonsense 
c.4386_insAGG 
ATGAACGAGG 
CCGC 
White 61 Serous Poorly differentiated IIB 
Alive 
1153 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
UKOPS 
SLX4 Nonsense 
c.4386_insAGG 
ATGAACGAGG 
CCGC 
White 51 Serous Moderately differentiated IIIC 
Deceased 
2354 
days 
No 
history of 
breast or 
ovarian 
cancer in 
family 
UKOPS 
Table 3.13 Epidemiological data for samples with predicted protein-truncating variants. FDR = First-
degree relative. FIGO (International Federation of Gynaecology and Obstetrics) is the standard staging for 
epithelial ovarian cancer. The majority of cases are diagnosed at stage IIIC all of which are serous 
histology. The majority of cases are serous in histology, with only 1 mucinous and 1 endometrioid and 1 
other.  Age at diagnosis ranges from 40 to 76 years, with 11 cases being diagnosed under the age of 60 
years and 8 over 60 years; the mean age at diagnosis is 57 years. Final status gives detail on whether the 
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woman is alive or deceased at the final follow-up with the number of days from diagnosis to final follow-up. 
Survival ranges from 1 year to 9.6 years. Family history information is included giving details on which 
family member(s) are affected; 10 cases do not have family history of breast or ovarian cancer and a 
further 5 have family history that is not in a FDR; 5 cases have family history in at least 1 FDR. 
 
Epidemiological data are given for samples with predicted protein-truncating variants. 
Table 3.13 gives epidemiological data for each of these samples including race, age at 
diagnosis, histology, grade, International Federation of Gynaecology and Obstetrics 
(FIGO) staging, which is the standard tumour staging system for epithelial ovarian 
cancer (Table 3.14 gives a description of FIGO staging for the tumour stages described 
in these data), final status at follow-up (deceased or alive) with number of days from 
diagnosis to final follow-up, family history and source of sample. 
 
16 cases have known FIGO staging classification. In 10 cases diagnoses are made at 
FIGO stage IIIC (Table 3.14), with all of the IIIC staged tumours being of serous 
histology.  3 are made at stage IIB and 1 each at stage IA, IIA and IB.  Stage IIIC is the 
more advanced stage with metastases evident beyond the pelvis.  Only stages IA and 
IB are localised to 1 or both ovaries.  13 cases show tumour staging as extending 
beyond the ovaries at diagnosis.  
 
For 19 cases histology is known; of these 16 are serous histology (84.2%), 1 is 
mucinous, 1 is endometrioid and 1 is classified as other (i.e. not described as serous, 
mucinous or endometrioid).  This is in keeping with known prevalence statistics for 
serous histological subtype, which is estimated to be 80-85% in the Western world 
(Seidman et al 2004).  In 16 cases tumour grade is known; of these 9 are the highest 
grade, poorly differentiated (56.2%), 1 is moderate to poorly differentiated and 5 are 
moderately differentiated.  Just 1 case is the lower grade of well differentiated. 
 
Age at diagnosis ranges from 40 to 76 years old with the mean age at diagnosis being 
57 years.  11 cases are diagnosed in women under 60 years with 8 diagnoses over 60 
years.  Follow-up time ranges from 1 year to 9.6 years with 7 still living at final follow-up 
and 8 deceased at final follow-up.  Of the women deceased, the shortest survival time 
was 1 year and the longest 6.6 years. 
 
Family history data is available for the majority of cases.  10 cases have no family 
history of breast or ovarian cancer; 5 cases have family history of breast or ovarian 
cancer in relatives that are not first-degree relatives and 5 cases have family history of 
breast and/or ovarian cancer in 1 FDR or more.  This means that 50% of cases with a 
predicted protein-truncating variant do not have family history of breast or ovarian 
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cancer; 25% have family history of ovarian and/or breast cancer in at least 1 FDR and 
25% have family history of breast and/or ovarian cancer in a relative other than a FDR.  
For the 11 women diagnosed under the age of 60 years only 3 (27%) have family 
history of breast or ovarian cancer in a FDR; 6 (54%) have no family history and the 
remaining 2 (18%) have family history of breast and/or ovarian cancer in a relative 
other than a FDR.  For the women with family history in FDRs diagnoses are made at 
40, 41 and 52 years (mean age at diagnosis is 44.3 years).  For the women without 
family history the youngest diagnosis is 49 and the oldest 59 (mean age at diagnosis is 
54.3 years) and for the women with family history other than a FDR the two diagnoses 
were made at 40 and 50 years (mean age at diagnosis is 45 years).   
 
Table 3.14 International Federation of Gynaecology and Obstetrics (FIGO)  
Stage Description 
IA 
Tumour growth is limited to one ovary, no ascites containing malignant 
cells.  No tumour on external surface; capsule intact 
IB 
Tumour growth is limited to both ovaries, no ascites containing 
malignant cells.  No tumour on external surface; capsule intact 
IIA 
Tumour extension and/or metastases to the uterus and/or fallopian 
tubes 
IIB Tumour extension to other pelvic tissues 
IIIC 
Metastasis evident beyond the pelvis >2cm in diameter and/or positive 
regional lymph node involvement 
Table 3.14 International Federation of Gynaecology and Obstetrics (FIGO). FIGO is the standard 
staging for tumour stages included in these data.  Adapted from FIGO Committee on Gynecologic 
Oncology Int J Gynaecol Obstet 105 (1): 3-4, 2009. 
 
3.19 Ovarian cancer risks associated with predicted deleterious variants in 
candidate susceptibility genes 
 
In order to evaluate the clinical significance of these findings it is necessary to evaluate 
the disease risks that are associated with deleterious mutations in these 6 genes for 
the population under study.  These predicted deleterious variants are interpreted in the 
context of the available genetic epidemiological data and in the clinical characteristics 
of disease in the affected individuals.  These data suggest that whilst family history of 
breast or ovarian cancer is not the overriding factor in ovarian cancer development it 
does appear to influence age of onset in that the mean age of diagnosis in women with 
family history is 10 years younger than those without family history.  This information 
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has clinical relevance in that risk prediction and early detection strategies may be most 
beneficial for women with family history of breast and/or ovarian cancer beginning at 
the age of 40 (or less depending on the level of risk calculated within the family). 
 
In the 5 youngest diagnoses (40 to 50 years), 3 of these have nonsense variants in 
RAD51C; interestingly all 3 diagnoses were made when women were in their 50th 
decade.  2 women have the same frameshift deletion in XRCC2 of which 1 was 40 
years and 1 was 50 years at diagnosis. These 2 cases with XRCC2 variants are from 
the same small population from the Polish Family History study, suggesting either 
possible founder mutations or that these are distantly related to each other.  
 
Of the 10 with FIGO tumour staging at the most advanced stage (IIIC), 1 has a 
predicted nonsense variant in RAD51B, 5 have predicted protein-truncating variants in 
RAD51C (2 frameshift deletions and 3 nonsense variants), 1 has a predicted splice site 
variant in XRCC3 and 2 have predicted protein-truncating variants in SLX4 (1 
nonsense and 1 frameshift deletion).  These data suggest that these particular gene 
variants may increase the risk of developing more aggressive disease; of the women in 
this study where FIGO staging is known, 62.5% are diagnosed at stage IIIC.  All 
women diagnosed at stage IIIC have serous histological subtype tumours and the 
mean age of diagnosis in this subset is 57.1 years.  Interestingly, of those women with 
IIIC stage tumours, 7 (70%) have no family history of breast or ovarian cancer, 2 have 
family history in a FDR (20%) and for 1 family history is unknown (10%).  
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3.20 Statistical analysis of data  
 
3.20.1 Predicted protein-truncating variants 
 
Odds ratios (OR) are calculated for predicted protein-truncating variant and predicted 
functional missense variants.  OR is chosen over relative risk due to the low 
prevalence figures for these variants.  OR is calculated to give an impression of the 
disease odds for those with a predicted deleterious variant, it measures the association 
between the presence of a positive variant and disease status.  OR is calculated using 
the formula: 
 
OR=(a/b)/(c/d) with 95% Confidence Intervals (CI) = OR ± 1.96 SE 
 
A 2 X 2 contingency table is created as follows: 
 
                           
 
 
 
 
 
a = number of cases positive for a predicted deleterious variant 
b = number of controls positive for a predicted deleterious variant 
c = number of cases negative for a predicted deleterious variant 
d = number of controls negative for a predicted deleterious variant 
 
Upper and lower 95% confidence intervals are calculated from the standard error (SE) 
for the log OR as follows:  
 
SE (logOR) = √ 1 ⁄ a + 1 ⁄ b +1 ⁄ c +1 ⁄ d 
 
Thus, the 95% CI for the logOR is ±1.96 SE. To the find the 95% CI for the OR the 
antilog is found using exp(logOR ±1.96) SE. 
 
To test the significance of the OR and ascertain the p-value, the z-statistic is used. This 
z-statistic is a measure of the standard deviation and from this the p=value obtained by 
looking up the z-statistic in standard tables.  
 Case Control 
Positive a b 
Negative c d 
Disease Status 
Variant Status 
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Table 3.15 Calculated Odds Ratios for predicted protein-truncating variants 
Predicted protein-truncating variants 
Gene 
Mutation 
status 
Cases Controls 
Odds 
Ratio 
95%CI 
(Lower) 
95% 
(Upper) 
Z 
statistic 
P 
value 
RAD51B 
Positive 1 0 
     
Negative 1505 1130 
RAD51C 
Positive 10 0 
     
Negative 1496 1130 
RAD51D 
Positive 4 1 
3.0 0.33 26.94 0.984 0.325 
Negative 1502 1129 
XRCC2 
Positive 2 0 
     
Negative 1504 1130 
XRCC3 
Positive 1 0 
     
Negative 1505 1130 
SLX4 
Positive 3 1 
2.25 0.23 21.69 0.703 0.481 
Negative 1503 1129 
Table 3.15 Calculated odds ratios (OR) for predicted protein-truncating variants. OR could only be 
calculated for RAD51D and SLX4 as these are the only genes where there is an occurrence of a predicted 
protein-truncating variant in the control group. 95% CI are large and neither of these are statistically 
significant at the p=0.05 level.  
 
Predicted protein-truncating variants in all 6 genes are detected in cases only for 
RAD51B, RAD51C, XRCC2 and XRCC3. In RAD51D and SLX4 each has one 
predicted protein-truncating variant in a control sample (Table 3.15).  OR can only be 
calculated for RAD51D and SLX4 because there are no predicted protein-truncating 
variants in controls in the other 4 genes.  Neither of these is statistically significant and 
the 95% CI are large due to the rare prevalence of these variants and the sample size 
in this study. Increasing statistical power would require larger sample sizes. This 
suggests that the variants in RAD51B, RAD51C, RAD51D, XRCC2, XRCC3 and SLX4 
are very rare. The likely risk curves for variants in these genes compared to BRCA1 
and BRCA2 are represented in Figure 3.34. 
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3.21 Discussion 
In this study a high throughput targeted next generation sequencing (NGS) approach is 
used to evaluate the prevalence and penetrance of germline functional mutations of a 
series of candidate susceptibility genes in 1506 ovarian cancer cases compared to 
1130 controls.  The NGS technology used here enables study sample sizes to reach 
levels required for the detection of rare or very rare variants in population-based case 
control studies.  The Fluidigm Access Array system is used as a high-throughput, rapid 
and affordable method for NGS target enrichment and library preparation.  This 
effectively removes the library preparation step previously required for sequencing on 
the Illumina HiSeq2000  
3.22 Evaluation of the high-throughput NGS approach established in this study 
3.22.1 Target enrichment and library preparation 
The simple and streamlined workflow of the Fluidigm Access Array platform makes it 
ideal for use in large-scale research projects as well as in clinical diagnostic 
laboratories.  The Long Range PCR (LR-PCR) method (previously described in 
Chapter 2) involves several weeks of LR-PCR experiments as target enrichment to 
amplify 1 gene in 11 samples.   The standard Illumina library preparation kit (in 2010) 
requires several days for completion for all 11 samples that are run in 1 Illumina flow 
cell lane. In this study 48 samples are prepared in 1 day, including both target 
enrichment and library preparation for the coding region of all six genes.  Therefore, in 
just 8 days all 384 samples that are run in 1 Illumina flow cell lane are prepared.  This 
platform produces sequence-ready libraries with Illumina sequencing adapters and 
primers attached.  The multiplexing barcode index sequences are also included in this 
one-day protocol.  Not only does this result in rapid target amplification and library 
preparation, it also means huge reductions in costs, estimated at around £4 per sample 
for all regions sequenced, then adding a cost for analysis results gives a final price of 
around £15 per sample.  This cost is likely to continue to reduce as multiplexing levels 
are increased further.  However, it is important to note that for the diagnostic setting, 
whilst this is a good streamlined method for target enrichment and library preparation, 
in order to reach the lower costs there is a requirement for preparing large numbers of 
samples, which a diagnostic clinic may not receive on an on-going basis. 
This study employs the use of a PCR based targeted capture approach to select the 
coding region only for the 6 target genes of interest. One limitation in this approach is 
that this method does not allow for the detection of larger genomic rearrangements (i.e. 
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large deletions and duplications). This is because this PCR based targeted capture 
method creates overlapping amplicons of around 200 bp each. Therefore, if a large 
deleterious deletion is present, for example of a few kilo base pairs (Kb), the PCR 
primers will not be annealing to the mutant copy of the genes, unless they span a 
breakpoint that lies within the coding region. This problem can be circumvented using 
capture techniques that do not rely on short PCR fragments. In a paper by Walsh et al 
(2010) they assess the efficacy of genomic capture as a target enrichment method to 
enable the isolation of 21 genes they expect to be implicated in inherited ovarian 
cancer.  Their method includes the coding sequence as well as the intronic sequences 
plus an additional region of 10 Kb upstream (5’) and downstream (3’) for each gene.  
This way they are able to detect 4 large rearrangements in BRCA1 and 2 in BRCA2.  
Of these, they describe 5 as deletions and 1 as a duplication.  They achieve this by 
calculating the read depth at each base pair for individual samples and make a 
comparison with the mean read depth for the same bases for all samples.  If the 
calculation is less than 60% or over 140% of the mean depth for all samples in the 
study then they assume that these samples are not diploid. If less than 60% then they 
suggest there is a large deletion and where mean depth is over 140% they suggest a 
duplication.  Walsh et al (2010) use Sanger sequencing to validate the breakpoints of 
large deletions and duplications and conclude that 12.5% of BRCA1 mutations are 
large deletions that result in inactivation of BRCA1 protein. However, the main 
argument for not using a genomic capture method in this study is due to the high costs 
for library preparation and the large quantity of DNA required; Walsh et al (2010) report 
that 3 μg of genomic DNA are required for each individual’s library preparation.  This 
compares to the 100ng required per sample using the protocol in this study. 
3.22.2 Sequencing quality controls (QC) – sequence coverage 
An important factor affecting sequencing data quality is the sequence depth of 
coverage or read depth; that is the number of times each individual base is sequenced. 
The requirement for varying depths of coverage specifically relates to the allele 
frequency of variants under investigation. Very common variants, i.e. those with minor 
allele frequencies between 5% and 50% (Cirulli & Goldstein 2010) are relatively easy to 
detect (see Figure 3.34 in Results) especially with large samples sizes in this study.  
Therefore, relatively low coverage (e.g. 10X) will be sufficient to detect the vast majority 
of these variants.  However, highly penetrant variants such as those in BRCA1 and 
BRCA2 are very rare in the general population. In a paper by Whitmore et al (2004) 
they estimate minor allele frequencies of 0.24% in a white European non-Ashkenazi 
Jewish population.  The abundant different non-founder functional variants identified in 
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these genes, means that the frequency of each individual variant in the population is 
extremely rare. Sequence coverage >50X is often regarded as the lower threshold in 
sequencing data to be sure of detecting the alterations of this frequency. For recently 
published population based studies that have identified susceptibility genes for ovarian 
cancers (e.g. RAD51C and RAD51D), the frequency of mutations in these genes 
appears to be even lower than for BRCA1 and BRCA2 (<1% in familial ovarian/breast 
cancer cases) and so depth of sequencing coverage becomes even more of an issue. 
The Illumina HiSeq2000 NGS approach sequences PCR amplified DNA molecules and 
this can introduce amplification bias in sequencing data resulting in false negatives.  
Thus, the appropriate level of coverage is required to enable the accurate detection of 
variants.  The level required depends both on allele frequencies and read filtering 
parameters. In terms of detecting heterozygous variants (i.e. where there will be 50% 
of reads for each allele) a read depth of 1X will mean that only 0.5 of variants will be 
detected.  Moreover, as read depth increases the probability of detecting variants also 
increases; as reads are filtered out though due to quality scores, then even a read 
depth of 15X will miss a proportion of variants.   In this study a read depth of 30X is 
considered the minimum level for confident variant detection, however in the diagnostic 
clinic this level is considered to be 50X to reduce further the possibility of a variant call 
error.  Morgan et al (2010) look at read depth and calculate that this positively 
correlates with variant detection.  In their LR-PCR study they simulate lower read 
depths and calculate that at a minimum read depth of 50X they are confident that no 
variants are missed.  
For the current study, the overall coverage across samples is shown to be relatively 
even both between samples and throughout the regions sequenced. Compared to LR-
PCR, this is a far superior approach since in the LR-PCR method some regions have 
very low or no coverage and the minimum threshold for mutation detection (i.e. 30X) is 
not always attained.  In this study a mean sensitivity of 94% >30X depth is observed 
across all 6 genes; and the overall median coverage for samples is 2,264X.  This 
suggests that a larger region could be included to still reach acceptable read depth for 
accurate mutation detection.  A small proportion (1.93%) of samples failed (n=51 with 
read depths <30X for 80% of the sample); this may be due to DNA quality and as such, 
a level of failure can be anticipated.  The de-multiplexing step is proven to work well as 
verified through positive control samples that are accurately identified. 
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3.22.3 Primer chopping 
The sequencing primers are chopped out during the analysis meaning that bases are 
removed from one end of reads. Following this the read co-ordinates are adjusted, but 
this does not require re-alignment of reads.  This can pose a problem if bases are not 
incorporated, during sequencing reactions, at the end of primers or if additional bases 
are added.  If there was a deletion or insertion in a region to which a primer annealed 
then this could result in an alteration of the position of reads following primer chopping. 
3.22.4 Variant detection sensitivity  
Sanger sequencing is still considered the  ‘gold standard’ in variant detection 
(Davidson et al 2012).  However, this method is limited in terms of cost and throughput, 
and is not suitable for the large-scale epidemiological based approaches that include 
the thousands of subjects that are needed to detect rare susceptibility variants in the 
population. It is for this reason that NGS is an attractive alternative and therefore, an 
evaluation in the variant detection sensitivity and specificity of the approach is 
essential.  
Many variants are removed at the read filtering stage. This is due to minimum 
thresholds at minor allele frequency rates that allow for confident variant detection. At a 
read depth of >15X the minor allele frequency must be a minimum of 40% to remain in 
the data set; at a read depth of >30X the minor allele frequency must be a minimum of 
30% to remain in the data set. Variants not meeting these criteria are filtered out.  The 
performance of lanes, in terms of the proportion of remaining variants post-filtering 
ranges from 34.4% (lane 4) to 97.7% (lane 2). In lanes 1, 3, 5, 6 and 7 there are 
94.5%, 89.8%, 87.9% and 92% respectively remaining variants post-filtering. Looking 
at performance of samples in terms of read depth, between 93% and 95% of samples 
are sequenced at >30X depth across all 6 genes, suggesting very good rates of 
sensitivity.  That is, there is a very high probability that the sequencing will detect all 
variants. 
The mutation detection sensitivity can be viewed as an estimate of the false negative 
rate i.e. of the number of mutations missed by the sequencing approach. This is difficult 
to calculate since not all samples can be analysed by Sanger sequencing. However, an 
evaluation can be made using positive control samples. These positive controls are 
‘spiked‘ into the experiment and blinded for the purpose of calculating sensitivity as well 
as for assessing the multiplexing accuracy in the study as a whole. Variant detection 
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sensitivity is defined as the proportion of known mutation positive controls correctly 
identified as positive by NGS. The following formula calculates the sensitivity rate: 
No. True positive variant calls 
÷ 
No. Positive variant calls + false negatives 
 
This gives a measurement of the true positive rate. In this study there are 6 positive 
controls and 5 of these are accurately detected giving a mutation detection sensitivity 
rate of 83.3%. The variant not detected is in a region of zero depth coverage. 
Therefore, where there is adequate coverage mutation detection sensitivity is 100%, 
however, the coverage for all genes >30X was 94% so this is the maximum possible 
sensitivity for the whole study.  The results section refers to these coverage data. In the 
clinical setting false negatives are important to guard against, as we will not Sanger 
sequence all samples in a study or clinical setting.  We need to strive for 100% 
sensitivity in both research and diagnostic setting. 
In addition, it is possible to estimate the false negative rate in a study by making 
comparisons with known variants from a public database such as dbSNP.  The false 
negative rate can be calculated as the proportion of known variants that should be 
detected these data, but are not.  Illumina suggest that this can also be calculated as 
true positive rate subtracted from 100. Harismendy et al (2009) compare Illumina 
sequencing data to Sanger sequencing data to calculate false negative rates and in 
their data they find zero false negative variant calls. In addition, they find 100% 
agreement between SNP genotyping data and Illumina NGS data.  Furthermore, they 
suggest that at simulated low coverage, the rate of false negatives is still minimal. 
3.22.5 Mutation detection specificity 
Mutation detection specificity is defined as the true negative rate.  This is not possible 
to calculate as we cannot Sanger sequence all genes in all samples.  Therefore, it may 
be most appropriate to assess the false positive rate.  This is calculated using Sanger 
confirmation of a proportion of the variants detected. If variant detection specificity is 
viewed as the rate of true negative variant calls then the following formula would give 
this figure: 
No. True negative variant calls 
÷ 
No. True negative variant calls + false positive variant calls 
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The study includes a number of non-template controls, however this does not give an 
accurate figure for the specificity as the non-template controls only test for 
contamination during PCR or sequencing. In this study the large numbers of samples 
mean that it is prohibitive in terms of cost and time to validate all samples using Sanger 
sequencing. There are a number of studies that have examined the false positive rates 
for variant detection in NGS studies.  Ozcelik et al (2012) use LR-PCR and NGS to 
sequence the whole of BRCA1 and BRCA2 validating all 12 patient DNA samples with 
Sanger sequencing.  They report that both false negative and false positives are zero 
in their study.  
In this study, 28 NGS variants are Sanger sequenced for confirmation and 24 of these 
are detected with the remaining 4 being false positives. This means that 85.7% are 
confirmed. In the clinical setting false positives are less worrying than false negatives 
as currently all NGS positives are confirmed using Sanger sequencing, therefore, false 
positives would be eliminated.   
3.23 Evaluation of study design  
3.23.1 Targeted candidate gene approach versus whole exome sequencing  
Other studies suggest that candidate gene approaches are not finding rare variants in 
moderate penetrance genes (Thompson et al 2012) and that whole exome sequencing 
should instead be used to identify causal rare variants.  Whilst there have been 
substantial increases in capacity and throughput of NGS technologies in recent years 
there are still not enough high-throughput whole exome sequencing studies to support 
this approach; particularly of very large case-control studies with the aim of detecting 
rare or very rare variants. The place for exome sequencing may be in family-based 
studies, which can be informative of candidate genes for follow on case-control studies.  
The targeted candidate gene approach is still likely to be the most appropriate method 
for detecting rare or very rare variants in ovarian cancer susceptibility genes.  It may be 
appropriate in breast cancer to perform full exome sequencing on small pedigrees of 
breast cancer families and then re-sequence the genes discovered in large case-
control studies. Since we can draw on our existing knowledge of the biology of ovarian 
cancer it is possible to choose panels of likely gene candidates.  In order to increase 
the probability of finding rare variants in novel ovarian cancer susceptibility genes the 
best approach is likely to involve the most appropriate sample set, i.e. a genetically 
enriched sample set of women at very high risk of developing ovarian cancer.  The 
increasing capacity of NGS technology and improvements in bioinformatics and data 
analysis is allowing for the increase in size of these candidate gene panels.  Within 12 
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months it is possible to double the number of genes under investigation from 6 to 12 
genes.   
An advantage of targeted re-sequencing compared to whole exome or whole genome 
is in the number of samples that can be run in one experiment resulting in more cost 
effective experiments and furthermore, the depth of coverage is far higher in a targeted 
candidate gene approach.  Exome sequencing results in much lower depth of coverage 
and this is very likely to result in missing variants that are relevant (Walsh et al 2011). 
To characterise novel cancer susceptibility genes, exome sequencing could be most 
useful, as this would allow for narrowing down the number of genes interrogated.  
However, to ensure that variants are not missed or for use in a clinical setting, a 
targeted re-sequencing approach is likely to be the most appropriate, since this will 
increase sensitivity as well as allow for increasing sample throughput to levels where 
resulting data can be confidently applied to a wider population.  In addition, in the 
genetic clinic targeted re-sequencing of a panel of ovarian cancer genes can be 
screened with the aim of offering an ‘ovarian cancer risk’ percentage. 
Exome sequencing has many caveats compared to targeted re-sequencing studies.  
Whilst there is background noise in both exome and targeted sequencing studies, 
whole exome sequencing will have much higher levels of background noise simply 
because there are many more genes under investigation and many people have 
variants in many genes that appear not to be harmful.  This is particularly the case with 
complex diseases such as cancer.  Additionally, when searching for genes in 
autosomal dominant diseases then a higher coverage is required to confidently identify 
mutations.  The reason for this is that the search will be for heterozygous rather than 
homozygous variants and thus the need for double the level of coverage.  It can be 
estimated that to detect ~95% of single nucleotide variants in an exome sequencing 
study at least 20X depth is required; below this level of depth, studies are likely to miss 
many of the causative variants.  
 
3.23.2 Advantages and disadvantages of population based case control studies 
 
One of the main confounding issues in population-based studies is that of population 
stratification, in which allele frequencies differ between sub-populations.  This is due to 
the diversity in ancestry between individuals where minimal mating has occurred 
between these sub-populations meaning that allele differences are not shared between 
these groups (Li et al 2010, Foulkes 2009).  This study includes data on race and the 
samples are drawn from ovarian cancer registries and other ovarian cancer studies 
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worldwide.  To fully define the risk associated with gene variants in these types of 
studies, it would be necessary to correct for this type of confounding to guard against 
false-positive effects due to population stratification.  Whilst bioinformatics correction 
methods are available for this purpose, another way to surmount this caveat is to 
perform replication studies in which cases and controls are selected randomly from 
populations.  Since, data from many large international case control studies is likely to 
be combined to allow for full determination of ovarian cancer risks in these genes, 
population stratification should not result in false-positive effects. 
3.24 Genetic variant prevalence and characteristics  
In this study the combined prevalence of a deleterious mutations in all 6 genes is 
1.33% in ovarian cancer cases compared to 0.09% in the healthy controls. For the 
purpose of this analysis, deleterious mutations are classified as frameshift, nonsense 
and splice site alterations predicted to result in protein truncation. Missense mutations 
are identified in the 6 genes, although their functional significance is unclear, and 
variant prediction programs such as SIFT and Polyphen-2 are limited in their ability to 
predict function with confidence. However, when these variants are combined, the 
prevalence of predicted functional missense variants across all six genes in the set is 
42.63% (cases) and 34.5% (controls).  This suggests that most of these predicted 
missense variants are likely not to result in non-functional protein. Certainly, those 
missense variants that occur at high frequency in cases and controls can be eliminated 
as non-pathogenic. In those missense variants that are low frequency in controls it 
could be relevant to perform functional assays to assess the impact of these variants 
on the protein product and then calculate the combined prevalence in cases and 
controls.  
In 2011, The Cancer Genome Atlas (TCGA) published data on mutational analyses of 
316 high-grade serous ovarian carcinomas (HGSOC).  They report that half of these 
tumours are functionally deficient in one of the homologous recombination (HR) genes 
either by germline or somatic mutation or by hypermethlyation leading to gene 
silencing.  In terms of somatic mutations >3% of HGSOC tumours have mutations in 
BRCA1 or BRCA2, with a further 6 genes identified as significantly mutated in tumours.  
2 of these can be ruled out (FAT tumour suppressor homolog (FAT3) and Gamma-
Aminobutyric Acid (GABA) A receptor Alpha 6 (GABRA6) as they do not appear to be 
expressed either HGSOC or fallopian tube normal tissue. The 4 other genes include 
RB1 (a known tumour suppressor gene), neurofibromin 1 (NF1), cyclin-dependent 
kinase 12 (CDK12) and CUB and Sushi multiple domains 3 (CSMD3).  Of these, 2 
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(NF1 and CSMD3) do not appear to be expressed in ovarian or fallopian tube tissues 
(Online Mendelian Inheritance in Man - OMIM), leaving CDK12, which TCGA report 
has 5/9 predicted protein-truncating mutations with the remaining 4 predicted missense 
variants.  In addition, TCGA analyse somatic mutations detected in their data with 
those in OMIM and in the Catalogue of Somatic Mutations in Cancer databases.  From 
these analyses they suggest that other rare variants may be key players in ovarian, 
including BRAF, PIK3CA, KRAS and NRAS, interestingly these are all oncogenes, 
which are uncommon in inherited cancer syndromes (discussed in Chapter 1).  
Certainly, for future sequencing studies, candidate genes can be centred on the 
homologous recombination related genes, as these appear to be highly relevant in 
ovarian cancer.  
The majority of the predicted protein-truncating variants detected in this study are 
novel, with the exception of 3 variants that are previously reported in literature as 
associated with ovarian and/or breast cancer.  These are all in RAD51C and include a 
nonsense variant (c.577C>T) and a splice site variant (c.905-2delAG); both are 
published by Coulet et al (2012) and another splice site (c.706-2A>G) is published by 
Loveday et al (2012).  
Of the predicted protein-truncating variants in these data 3 variants (2 nonsense and 1 
splicing) are identified in more than one case.  For each, the cases are apparently 
unrelated, but from the same geographical region.  Variant RAD51C c.577C>T is a 
nonsense mutation in exon 4 and the two cases in which this is detected are both from 
Poland with family history of ovarian cancer.  There are only 96 polish family history 
cases in the whole study meaning that the prevalence in the study for this variant is 
2.1%; suggesting that this may be a novel founder mutation in this population or that 
these two cases may be distantly related to each other.  To confirm a founder mutation 
a series of cases from the same population would need to be analysed for this variant.  
Variant RAD51C c.955C>T is a nonsense mutation in exon 7 and both of these cases 
are detected in Australian ovarian cancer cases.  One of the splice site alterations 
(RAD51C c.706-2A>G) is detected in 2 UK cases from different studies one has family 
history of ovarian cancer in a FDR and the other has family history in a relative other 
than a FDR. 
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3.25 Analysis of clinical relevance of study findings 
 
In cases with predicted protein-truncating variants and staging information (n=16) 
62.5% are diagnosed at the more advanced stage of IIIC where distant metastases are 
already evident; and 81.2% are diagnosed with staging beyond the pelvis, suggesting 
that these variants may be relevant in more advanced disease.  In cases with known 
histology (n=19) 84.2% are serous histology, which further suggests that homologous 
genes are highly relevant in HGSOC.  Future studies may concentrate on both 
homologous recombination genes and HGSOC, especially since homologous 
recombination defective tumours are identified as sensitive to PARP inhibition 
(Mukhopadhyay et al 2012).   
An earlier age of onset appears to be suggestive of the presence of a gene mutation; of 
those cases with predicted protein-truncating variants the age at diagnosis ranges from 
40 to 76, with mean age at diagnosis being 57 years. This may be relevant clinically in 
the management of women with ovarian cancer in that for women diagnosed under 60 
years it may be relevant to undertake genetic screening analysis as these tumours may 
have a sensitivity to PARP inhibition.  
 
Interestingly, 50% of cases with predicted protein-truncating variants have no family 
history of breast or ovarian cancer, 25% have family history in a relative other than a 
FDR and 25% have family history in a FDR.  This suggests that factors other than 
family history are involved in these cases.  However, of particular importance is the 
observation that the mean age at diagnosis for those with family history is 10 years 
younger than those without. This factor is relevant in clinical management suggesting 
risk prediction and early detection measures should begin earlier for women with family 
history of breast and ovarian cancer.  Indeed, depending on the level of risk calculated 
within the family, early screening or genetic testing could be recommended before the 
age of 40 years.  
In a paper by Alsop et al (2012) they calculate the frequency of BRCA mutations in a 
cohort of women with non-mucinous ovarian cancer and analyse their response to 
treatment.  They report that 44% of women with a BRCA1 or BRCA2 mutation do not 
have family history and since these women appear to have specific treatment response 
and survival, Alsop et al (2012) suggest all women presenting with non-mucinous 
ovarian cancer should be offered genetic testing for BRCA1 or BRCA2 routinely even 
without family history. 
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To fully define the risk of ovarian cancer caused by germline mutations in these genes 
would require extremely large numbers of cases and controls and this is due to the low 
frequency of these variants within the population.  Loveday et al (2011) suggest this 
frequency to be around 0.1% in the population.  The figure 3.34 is a graphical 
representation of the association between allele frequency and risk of ovarian cancer, 
which suggests that the more rare a variant the larger the effect of that variant.  This 
figure can also give an indication as to the likely method of detection for finding these 
variants, in that common low-risk variants would most efficiently be detected via large 
Genome Wide Association Studies (GWAS), rare moderate-risk alleles are likely to 
detected via large studies of cases and controls in re-sequencing studies of defined 
candidate genes in specific disease phenotypes (e.g. HGSOC), perhaps alongside 
enrichment for family history and age of onset. Although, caution must be noted in 
calculation of odds ratios and inferring disease risk, especially in a single case control 
study, the odds ratio is given as an impression of disease association only.  In this 
study odds ratios are calculated for predicted-protein truncating variants only as the 
predicted missense variants show high frequencies in controls in addition to cases, 
suggesting that they are not pathogenic.  The low frequency of variants means that 
neither RAD51D nor SLX4 odds ratios are statistically significant.  Figure 3.34 places 
RAD51C amongst the rare moderate-risk alleles and if RAD51D, XRCC2 and XRCC3 
were also placed on this diagram they would inhabit a similar region on the graph. 
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Figure 3.34 Minor Allele Frequencies versus relative risk 
 
Figure 3.34 Minor allele frequencies versus relative risk.  This image is re-drawn and adapted from 
Harris & McCormick Nat. Rev. Clin. Oncol. 7, 251–265 (2010) with RAD51C and RAD51D added as new 
ovarian cancer rare moderate-risk susceptibility alleles. If XRCC2 and XRCC3 were new susceptibility 
genes then they would be situated close to RAD51D in terms of minor allele frequency, but below them in 
relative risk.  The very rare low-risk alleles are impossible to detect, as the number of cases required would 
be too large.  It is very unlikely that more common high-risk alleles exist, as these would have already 
been discovered.  It is likely that many more rare, moderate-risk alleles exist and these are best 
discovered using high throughput re-sequencing approaches in large studies of cancer cases and controls. 
 
3.26 Conclusion 
In conclusion, returning to the research questions outlined in the ‘Introduction’, the 
Fluidigm Access Array system, does offer a viable solution to the bottleneck seen in the 
library preparation step in Illumina sequencing.   This novel approach is an accurate, 
rapid and cost effective method for the accurate detection of gene variants that 
predispose to an increase in ovarian cancer risk.  This is demonstrated in the speed 
with which libraries are prepared, the depth and evenness of coverage, and the 
mutation detection sensitivity and specificity. This system accurately characterises the 
frequency of mutations occurring in the study population in the six genes under 
investigation in this study.  To this end the four aims of this research are successfully 
addressed.  This confirms the significance of RAD51C and RAD51D in ovarian cancer. 
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Whilst, no novel cancer susceptibility genes are among these candidates, this high-
throughput system is now fully established and evaluated to allow for follow on studies 
that will have the capacity to identify novel cancer susceptibility genes.  This research 
also suggests that these approaches could soon be introduced into the clinical setting 
meaning that a wider population of women could be offered genetic testing for early 
detection and prediction of risk.  The epidemiological and histological data presented 
here in combination with detected gene variants suggests that specific risk factors may 
indicate that a genetic variant is involved and that testing for validated gene variants 
may be a routine part of clinical management of cases.  This can be put into place once 
these gene variants are fully defined in terms of risk of ovarian cancer.   
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Chapter Four 
 
A characterisation of 9 ovarian cancer susceptibility genes in unaffected women 
from high-risk breast-ovarian cancer families 
 
 
4.0 Introduction 
 
The connection between DNA damage and tumourigenesis has been intricately studied 
and well documented (Bernstein et al 2002).  When DNA damage sensors detect DNA 
damage, the cell has a choice of going into either apoptosis or a temporary pause of 
the cell cycle during which time the damage is repaired. The biological mechanism that 
switches a cell between a pause in the cell cycle or apoptosis is crucial in cell 
protection from uncontrolled replication of damaged DNA and subsequent development 
of cancer.  During the pause in the cell cycle where an attempt is made to repair 
damaged DNA the cell either continues with the damage repaired or goes into 
apoptosis, if the damage is too great to allow for its repair.  If these cells are impervious 
to apoptosis this results in an increased production of cells with damaged DNA and a 
state of global genomic instability ensues; this leads to an elevated chance of 
carcinogenesis.  
 
This study uses the same NGS analysis as the case-control study to analyse a panel of 
candidate genes. These genes have roles in DNA repair via homologous 
recombination; are downstream targets of key players in the homologous 
recombination pathway (for example BRCA1 or BRCA2 related genes) or are part of 
the Fanconi anaemia-BRCA DNA repair pathway. 
 
4.1 DNA damage and the Fanconi anaemia pathway 
 
The Fanconi anaemia pathway is crucial in the repair of DNA interstrand crosslinks.  
Fanconi anaemia is an autosomal recessive condition that results in congenital defects 
and malfunction of bone marrow as well as an increased susceptibility to cancers.  This 
genetic disorder is very rare with an occurrence of around 1 in 100,000 births 
(D’Andrea & Grompe 2003). Some communities appear to show a higher incidence of 
the syndrome (for example, Ashkenazi Jewish and Afrikaners from South Africa).  The 
study of this syndrome has increased understanding of the genetic susceptibility to 
cancers amongst those that do not have the genetic disorder, namely those related to 
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inherited mutations in BRCA1 or BRCA2; as these genes are intimately related and 
involved in the response to DNA damage.  Most interestingly, the Fanconi anaemia 
pathway also includes genes, the protein products of which are important in the 
activation of DNA damage checkpoints and temporary cell cycle cessation whilst repair 
takes effect.  These include DNA damage sensor ATM in addition to NBS1 and 
RAD51.  The biological mechanism of these interrelated proteins sheds relevant insight 
on and direction towards appropriate candidate genes as targets for investigation in 
this high-throughput study.  
 
4.1.2 The intricate relationship between tumour suppression and the Fanconi anaemia 
pathway 
 
Fanconi anaemia patients with monoallelic mutations in the Fanconi anaemia pathway 
genes have an extremely elevated predisposition to many cancers including acute 
myeloid leukaemia (AML) and squamous cell carcinoma.  Four downstream players in 
the Fanconi anaemia pathway function in DNA repair via homologous recombination 
and result in an increased risk of development of ovarian and/or breast cancer.  
BRCA2 is also known as FANCD1.  Interestingly, mutations in RAD51C exhibit a 
Fanconi-like condition and this may soon be referred to as FANCO (Kottemann & 
Smogorzewska 2013).  Essentially, the predominant relevance of Fanconi anaemia 
pathway genes is in the interaction of these genes with BRCA2, meaning that 
homozygous mutations in Fanconi anaemia genes appear to affect the action of 
BRCA2 in a way to render BRCA2 inactive. 
 
4.2 Rationale for choice of genes in this study 
 
The 4 known genes in this study (BRCA1, BRCA2, RAD51C and RAD51D) are already 
identified as known ovarian and/or breast cancer susceptibility genes.  The 5 candidate 
genes are chosen as they are either related to these 4 genes or the DNA double 
strand-break repair mechanism via homologous recombination.  These 5 genes are 
RAD51B, PALB2, NBN, BRIP1 and BARD1.  The biology, structure and function of 
BRCA1, BRCA2, RAD51B, RAD51C and RAD51D are previously described in 
chapters 2 and 3 of this thesis.   The additional 4 candidate genes are described here.  
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4.2.1 The structure and function of PALB2   
 
The gene partner and localiser of BRCA2 (PALB2) NCBI Genbank accession number 
NM_024675.3 (OMIM 610355) is also referred to as FANCN gene and forms part of 
the Fanconi Anaemia (FA) pathway. It is located on chromosome 16 at 16p12.2 with 
genomic co-ordinates:chr16:23614483-23652678.  The proteins PALB2 and BRCA2 
co-localise forming nuclear foci, with PALB2 assisting in the stabilisation and 
localisation of BRCA2 within the nucleus and facilitating BRCA2 in its roles of 
checkpoint control and repair by homologous recombination. Tishcowitz & Xia (2010) 
report that harbouring heterozygous deleterious changes in this gene results in an 
increased risk of both breast and pancreatic cancer.  PALB2 is involved in tumour 
suppression as part of the BRCA complex of DNA repair via homologous 
recombination.   The protein product of this gene also appears to bind BRCA1 in 
addition to BRCA2.  The diagram (Figure 4.1) below describes the structure of PALB2 
and which regions are likely to bind BRCA1.    
 
The gene MORF-related gene 15 protein (MRG15) is also referred to as mortality 
factor 4 like 1 and is part of the histone acetyltransferase complex (HAT); the encoded 
protein functions in the transcription activation of specific genes, the relevance here is 
that it has a role in the localisation of PALB2/BRCA2/RAD51 to DNA damage foci. 
 
Figure 4.1 The structure of PALB2 with binding regions for interacting genes 
 
Figure 4.1 The structure of PALB2 with binding regions for interacting genes. This diagram 
demonstrates binding regions and relationships between PALB2 and BRCA1, BRCA2, RAD51 and 
MRG15.  Adapted from Tischkowitz & Xia (2010) Cancer Res; 70(19) October 1, 2010  
 
Tischkowitz & Xia (2010) report on the model in which the BRCA DNA repair complex 
assembles at regions of DNA double-strand breaks.  This core complex is composed of 
BRCA1/BRCA2/PALB2 as well as BRCA1 and BRCA1 C-terminus (BRCT) binding 
domain partners.  These protein partners are likely to include BRIP1, FANCJ, coiled-
coil domain-containing protein 98 (CCDC98-RaP80) or retinoblastoma binding protein 
8 (RBBP8).  There are two probable biological mechanisms by which BRCA1 is 
employed at detected regions of DNA damage.  The first possibility is that BRCA1 
interacts with the MRN complex (which includes MRE11/RAD50/NBS1) and the 
BRCA1 
Coiled-coil 
PALB2/FANCN 
MRG15 (611-764) BRCA2/RAD51 
WD repeats/β-
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second is that BRCA1 binds the CCDC98/RAP80 complex.  One or other of these is 
the route via which PALB2/BRCA2/RAD51 associates with BRCA1 at DNA damage 
sites.   
 
Figure 4.2 Schematic representation of PALB2 (Partner and localiser of BRCA2) 
gene 
 
Figure 4.2 A schematic representation of PALB2. PALB2 has 13 exons all of which are coding exons 
and includes a genomic region of 38,196 bp.   
 
Deleterious mutations in PALB2 are associated with the familial cancer syndrome 
Fanconi anaemia and with an inherited susceptibility to breast cancer. Resulting in a 
moderate increase in breast cancer risk of around 2-6 fold (Gage et al 2012). In 
addition, the functions of PALB2 and its relation to BRCA2 suggest it to be a likely 
candidate gene for EOC.  Genetic testing for variants in this gene is not currently 
performed in the genetics clinic, however PALB2 has been suggested to be the third 
breast cancer susceptibility gene and deleterious protein-truncating variants appear to 
affect the risk of developing breast cancer (Rahman et al 2007). 
 
Walsh et al (2011) investigate a group of 12 candidate genes in 326 women with 
ovarian cancer; the cohort are not enriched for family history or early onset disease 
and those patients referred for genetic risk are not included in the study.  In addition, 
patients diagnosed with recurrent disease are also excluded. They find that all 12 
genes have deleterious variants all of which are in the Fanconi anaemia pathway.  
Specifically, Walsh et al (2011) detect two deleterious mutations in PALB2 that are not 
previously associated with ovarian cancer. 
 
PALB2 is established as a breast cancer susceptibility gene.  Rahman et al (2007) 
examine PALB2 in breast cancer patients that are screened negative for BRCA1 or 
BRCA2 and discover deleterious mutations in around 1% of patients with familial 
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breast cancer, which leads to an elevated breast cancer risk of 2.3 x higher than 
controls.  These data are validated by Erkko et al (2007) who discover a deleterious 
mutation in a Finnish population that results in an increase in breast cancer in familial 
cases.  These deleterious mutations affect the functioning of BRCA2 and result in 
inadequate repair by homologous recombination. Erkko (2007) find that this deleterious 
variant is 4 times more likely to be present in cases compared to healthy age-matched 
controls.  Tischkowitz et al (2012) detect deleterious mutations in 0.9% of breast 
cancer patients diagnosed with bilateral disease; all of the patients with breast cancer 
in only one breast are negative for these PALB2 mutations.  Interestingly, this 
difference is only observed in patients with deleterious frameshift mutations and does 
not involve missense variants as these occur at the same frequency in both groups.  
The relative risk of breast cancer for patients with deleterious mutations in PALB2 is 
5.3.  
 
4.2.2 The structure and function of BRIP1 (BRCA1 interacting protein C-terminal 
helicase 1)  
 
The gene BRCA1 interacting protein C-terminal helicase 1 (BRIP1) NCBI Genbank 
accession number NM_032043 and OMIM 605882 is also known as Fanconi anaemia 
complementation group J (FANCJ) or BRCA1-associated C-terminal helicase 1 
(BACH1).  The gene has 20 exons, 19 of which are coding exons; the coding sequence 
starts in exon 2.  The gene is located on chromosome 17q23.2 with genomic co-
ordinates chr17:59756547-59940920 and includes a genomic region of 184, 374 bp.   
 
Figure 4.3 Schematic representation of BRIP1 (BRCA1 interacting protein C-
terminal helicase 1) gene 
 
Figure 4.3 Schematic representation of BRIP1.  BRIP1 has 20 exons 19 of which are coding exons and 
includes a genomic region of 184,374 bp 
 
The protein product of BRIP1 is an ATP dependent DNA helicase that forms a complex 
with BRCA1 protein binding between the two BRCT repeat regions at the C-terminal of 
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BRCA1 (Cantor et al 2001).  It functions in DNA repair directed by BRCA1 and is 
intimately related to BRCA1 with a role in BRCA1 checkpoint activation. The 
relationship between BRIP1 and BRCA1 is cell-cycle control via the phosphorylation of 
amino 990 (Ser residue) within BRIP1 and it is suggested that this interaction assists 
BRCA1 in its function in DNA double strand break repair and checkpoint control at the 
G2/M phase of the cell cycle (Cantor & Guillemette 2011).   This gene is shown to be a 
low-moderate breast cancer susceptibility gene (Cantor & Guillemette 2011). The 
encoded protein product of BRIP1 interacts with BRCA1 and germline mutations in 
BRIP1 gene affect the function of BRCA1 in homologous recombination. 
 
4.2.3 The structure and function of BARD1 (BRCA1-associated RING domain protein 
1)  
 
The gene BARD1 (BRCA1-associated RING domain protein 1) NCBI Genbank 
accession number NM_000465 OMIM 601593 is composed of 11 exons with all 11 as 
coding exons.  It is located on chromosome 2q35 with genomic co-ordinates 
chr2:215593275-215674428  and a genomic size of 81,154 bp. 
 
Figure 4.4 Schematic representation of BARD1 (BRCA1-associated RING domain 
protein 1) 
 
Figure 4.4 Schematic representation of BARD1.  BARD1 has 11 exons all of which are coding exons 
and includes a genomic region of 81,154 bp  
 
BARD1 binds the N-terminal of BRCA1 and possesses homologous regions with two 
regions in BRCA1 – the N-terminal RING domain and the C-terminal BRCT repeat 
domain.  A number of proteins involved in cell growth regulation contain RING motifs, 
which consist of cysteine rich sequences.  Studies show that this protein directly affects 
the function of BRCA1 and in fact the complex that is formed between BRCA1 and 
BARD1 may be key in the suppression of tumourigenesis (Wu et al 1996).  The BARD1 
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protein is located within the nucleus of the cell and its expression is elevated in cells 
actively proliferating, including ovary, breast as well as cells of the testes and spleen.  
When expression of BRCA1 is reduced this leads to an increase in BARD1 expression 
in the cytoplasm and in this state BARD1 functions in the activation of apoptosis 
(Ratajska et al 2013).  Thus, it follows that non-functioning BARD1 is very harmful to 
cells resulting in genomic instability.  Ratajska et al (2013) investigate the contribution 
of germline mutations in BARD1 in families negative for mutations in either BRCA1 or 
BRCA2.  They discover a number of novel variants including one protein truncating 
mutation, a splice site variant and a number of predicted deleterious variants. 
 
4.2.4 The structure and function of Nibrin (Nijmegen breakage syndrome)  
 
Figure 4.5 Schematic representation of Nibrin (Nijmegen breakage syndrome) 
 
 
Figure 4.5 Schematic representation of Nibrin.  Nibrin has 16 exons 15 of which are coding exons and 
includes a genomic region of 51,336 bp  
 
Nibrin (Nijmegen breakage syndrome) NCBI accession number NM_002485 OMIM 
602667.  Nibrin has 16 exons, all of which are coding exons.  It is located at 
chromosome 8q21.3 with genomic co-ordinates: chr8:90945564-90996899.  The 
protein product of this gene is involved in DNA double strand break repair as part of a 
heteropentamer known as MRE11/RAD50 complex (Zhong et al 1999).  This complex 
consists of 5 monomers and includes MRE11, RAD50, ATM, H2AX, TERF2 and 
BRCA1. It has a role in cell cycle checkpoint activation due to DNA breakage.  The 
Nijmegen breakage syndrome is an autosomal recessive disorder that causes 
chromosome instability and includes several consequences including susceptibility to 
various cancers.  The MRE11/RAD50 complex interacts with BRCA1 forming nuclear 
foci with RAD50 (Wang et al 2000). 
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4.3 Screening for ovarian cancer (CA-125) 
 
Bast et al (1981) report on the discovery of cancer antigen (CA)-125, which can be 
detected using a murine monoclonal antibody known as OC125.  This antibody reacts 
with six different epithelial ovarian carcinoma cell lines and tumour samples derived 
from ovarian cancer patients.  Bast et al (1981) suggest that a diverse range of normal 
tissues and normal cell lines do not bind the antibody OC125. Since this discovery 
much research time has gone into assessing CA-125 and the possibility of using it as a 
tumour marker and screening tool for ovarian cancer.  In addition to CA-125, 
transvaginal ultrasonography (TVS) made an entrance in an article by Campbell et al 
(1982).  This research evaluates how precisely TVS can quantify ovarian volume and 
assess ovarian morphology.  The researchers suggest that TVS has potential as a 
novel screening tool for ovarian cancer.  Since then TVS has been further refined and 
is of particular use in postmenopausal women when rates of false positives are 
substantially decreased.  Additionally, performing several sequential TVS scans further 
eliminates benign conditions of the ovary. Assessment of ultrasound results is 
improved following clinical screening trials, where follow up of those participants shows 
that unilocular cysts less than 10 cm in diameter suggest a very low risk of ovarian 
cancer; in contrast complex cysts not of uniform morphology or that appear to exhibit 
solid regions suggest a high risk of ovarian cancer.  Further, the use of TVS assists in 
understanding the levels of CA-125 in that an elevated CA-125 result coupled with 
abnormal ovarian morphology on TVS suggests a high risk of ovarian cancer (Lewis & 
Menon 2004).  Despite these improvements TVS and CA-125 appear to be useful in 
detecting late stage disease, but still lack the sensitivity to early detect lesions (Long & 
Kauff 2013).  It is the earlier detection of ovarian cancer that is required in order to 
improve the mortality rates.   
 
4.4 Samples for next generation sequencing 
 
The samples in the study are acquired from a large prospective screening trial 
conducted in the UK known as the UK Familial Ovarian Cancer Screening Study 
(UKFOCSS).  Screening involves a blood test measuring levels of CA-125 on 3 
occasions each year. In addition annual transvaginal ultrasound scans (TVS) are 
performed.  The principal aim of this study is to discover whether screening strategies 
can early detect ovarian cancers.  This trial aims to develop a novel screening 
approach for women at high risk of developing ovarian cancer due to an assessed 
genetic susceptibility or a very strong family history and to discover new biomarkers 
that can diagnose, stage and grade epithelial ovarian cancer and cancer of the 
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fallopian tube.  Women are included into the trial under specific criteria. In families 
affected by both ovarian and breast cancer the following is applicable: 
 
1. Women FDRs in families where two women or more were affected by ovarian 
cancer. 
2. Women FDRs in families with one ovarian and one breast cancer case diagnosed 
under 50 years 
3. Women FDRs in families with one ovarian and two breast cancer cases under 60 
years 
4. Breast cancer in the trial member under 45 years old and additionally having a 
mother with both breast and ovarian cancer. 
5. Breast cancer in a trial member under 40 years as well as a sister with both breast 
and ovarian cancer. 
6. Some of these criteria may be changed if there appears to be paternal transmission 
of inherited predisposition. 
 
The screening study includes families that contain a member with an assessed gene 
mutation that results in an increased risk of ovarian cancer, for example, BRCA1, 
BRCA2, MLH1, MSH2, MSH6, PMS1 and PMS2.  In the case of Lynch Syndrome 
families, the family has to include more than three members with a Lynch syndrome 
related cancer and be a FDR of this family with at least one case diagnosed under 50 
years old. The Lynch related cancers must involve more than one generation in the 
family.  For families with breast cancer only diagnoses there should be a minimum of 4 
cases of breast cancer in the family.  If the family contains only 3 breast cancer cases, 
then one must be under 30 years or all of them under 40 years or include one male 
breast cancer and one bilateral diagnosis.  If the screening volunteer has had breast 
cancer this must have been diagnosed under the age of 50 years and the individual 
must have a mother with breast cancer under 30 years or the volunteer is under 30 
years and the mother is under 50 at diagnosis.  If bilateral breast cancer was 
diagnosed in the volunteer’s mother, then diagnosis should be under the age of 40 
(Institute for Women’s Health website UKFOCSS eligibility criteria accessed 09-08-
2013). 
4.4.1 PROMISE 2016 
PROMISE 2016 is an acronym for ‘Predicting Risk of Ovarian Malignancies, Improved 
Screening and Early detection’.  It is a large international research effort with an overall 
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aim to reduce the number of deaths from ovarian cancer by 50% both in the UK and 
further afield.  This research aims to identify women within high-risk groups as well as 
discovering new technological methods to diagnose ovarian cancer.  Thus, PROMISE 
2016 aims to predict risk and improve diagnosis of ovarian cancer and to discover the 
optimum screening method specific to groups of women at risk.  Professor Ian Jacobs 
of University of Manchester is the leading investigator and includes an international 
collaboration of scientists at UCL, University of Cambridge, University of Southern 
California and Harvard Medical School. 
This study fits with the research ethos of PROMISE 2016 and as such draws on the 
sample bank of UKFOCSS in order to assist in the aims of the PROMISE study.  This 
study sequences 2,300 women in total.   
4.5 Study design 
This is a family-based study, which draws upon samples from a large prospective 
cohort of women whom are part of a UK wide familial ovarian cancer screening trial.  
The case-control study in Chapter 3 establishes and evaluates a high-throughput 
sequencing approach, which characterises the penetrance and prevalence of 6 
candidate genes.  This established technology is used here to sequence 9 known and 
novel candidate genes in ovarian cancer in women that are disease free at the time of 
inclusion in the study (PROMISE 2016 samples).  The women in this study are pre- 
and post-menopausal, unaffected and part of families with a history of ovarian cancer 
and breast cancer, therefore, putting them at high risk of developing the disease.  
 
4.6 Research Aims 
 
The 3 main aims of this study are: 
 
1. To use the established high-throughput DNA sequencing technology to 
characterise the mutation prevalence in 4 known ovarian cancer susceptibility 
genes (namely BRCA1 and BRCA2 and recently identified genes RAD51C and 
RAD51D) in 2,300 unaffected women from high-risk breast-ovarian cancer families. 
2. To use the established high-throughput NGS approach to examine the mutation 
prevalence of 5 novel candidate genes (namely RAD51B, PALB2, NBN, BRIP1 and 
BARD1) in the same cohort of 2,300 unaffected women from high-risk breast-
ovarian cancer families. 
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3. To increase throughput to include more genes and evaluate the sequencing 
coverage. 
 
The overall aim of this study is to discover if women with moderate-high risk mutations 
are more likely to develop ovarian cancer and if these mutations should be targeted for 
screening for early disease detection in future follow-up studies.    
 
4.7 Hypotheses under investigation 
 
1. Fluidigm Access Array platform and highly multiplexed Illumina sequencing 
technologies are scalable methods to enable identification of genetic alleles in 9 
known and novel susceptibility genes in ovarian cancer. 
2. This method of mutation detection will be able to evaluate the mutation prevalence 
in 9 known and novel genes in a large series of unaffected women from high-risk 
breast-ovarian cancer families. 
3. This method of mutation detection will be able to identify novel ovarian cancer 
susceptibility genes.  
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4.8 Results 
 
(Refer to Chapter 6 Materials and Methods page 279) 
 
4.8.1 Study Design – A prospective family-based study 
 
This prospective cohort study, of women at high-risk of developing ovarian cancer due 
to family history of breast and/or ovarian cancer, uses the previously established NGS 
DNA sequencing technology.  This research characterises the frequency of 4 genes 
(BRCA1, BRCA2, RAD51C and RAD51D) formerly identified as breast or ovarian 
cancer susceptibility genes, and 5 (RAD51B, PALB2, BRIP1, NBN and BARD1) novel 
candidate ovarian cancer susceptibility genes.  
 
4.9 Target enrichment 
 
Target enrichment and preparation of sequencing libraries is conducted using the 
Fluidigm Access Array platform. This is performed as previously described in Chapter 
3, however the Access Array multiplexing is performed at 10 PCR reactions per well 
(10 Plex) to enable enrichment and library preparation of the coding regions of all 9 
genes on 1 Access Array IFC. The tables in Appendix IX give details of the regions 
covered in each gene, including the genomic co-ordinates for each amplicon.  In 
Appendix X images are displayed mapping the location of each amplicon in each gene. 
Where exons are larger than 200bp then overlapping amplicons are designed to 
ensure that all the coding regions are amplified.  The reference assembly used here is 
the Genome Reference Consortium Human build 37 (GRCh37/hg19) from February 
2009.  The National Centre for Biotechnology Information (NCBI) accession numbers 
for each gene are, BRCA1 (NM_007294.3), BRCA2 (NM_000059.3), PALB2 
(NM_024675.3), BRIP1 (NM_032043.2), BARD1 (NM_000465.2), NBN 
(NM_002485.3), RAD51B (NM_133510.3), RAD51C (NM_058216.1) and RAD51D 
(NM_002878.3) 
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Table 4.1 Breakdown of amplicons per gene 
Gene No. Amplicons % Coding region included 
BRCA1 67 100 
BRCA2 118 100 
RAD51B 24 100 
RAD51C 19 100 
RAD51D 18 100 
PALB2 38 100 
BRIP1 45 100 
BARD1 25 100 
NBN 29 100 
Total 384  
Table 4.1 The breakdown of amplicons per gene.  This table details the number of amplicons in the 
whole experiment.  Where there is more than 1 amplicon per exon, amplicons overlap by more than the 
length of the primer sequence to ensure that all bases are included in the sequencing analysis.  Amplicons 
overlap into the flanking intronic regions by more bases than the length of primer sequences to include all 
the coding exons and splice sites. 
 
4.10 Library preparation – quantitation and normalisation of pools 
 
Note: I prepared libraries for 2 sequencing lanes (768 samples and 16 Access Array 
chips) at Great Ormond Street Molecular Genetics Laboratory.  Maria Intermaggio and 
Andre Kim at University of Southern California prepared the remaining 4 lanes (1,536 
samples and 32 Access Array chips) 
 
48 sequencing libraries are prepared on each Fluidigm Access Array chip.  This 
includes the full coding region for all 9 candidate genes i.e. 384 PCR reactions are 
performed for 48 samples per chip.  To reach this 10 PCR reactions are conducted in 
each well of the Access Array chip.  (Note that additional genes are included in these 
Access Array chips, however, only 9 genes are fully analysed).  Each Access Array is 
pooled to create a pool of 48 barcoded prepared libraries.  Then 8 chips are pooled in 
equimolar quantities to form a pool of 384 individually barcoded libraries.  The pools of 
384 libraries are run in each flow cell lane on the Illumina HiSeq2000.  The whole 
sequencing study is performed using 6 lanes. 
 
4.10.1 Quantitation of pools  
 
As an initial quality control step, a proportion of the prepared libraries are quantified 
using Agilent Bioanalyzer DNA 1000 chips with 1µl of each library to confirm that 
samples have amplified prior to pooling.  
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4.10.2 Normalisation of pools 
 
Normalisation of pools is performed in an identical manner as described in Chapter 3.  
For each Illumina flow cell lane, 8 pools of chips are pooled in equimolar quantities and 
the final concentration calculated to ensure dilution of pools to the correct 
concentration for the flow cell.   
 
4.10.3 Final concentration 
 
The final concentration required for the flow cell is 10nM in a total volume of 50µl. The 
dilution factor is calculated from the initial molarity/required final molarity.  The volume 
of DNA to add is calculated by final volume/dilution factor.  The appropriate volume of 
water is added to reach 50µl.   
 
4.10.4 Dilution and final QC for flow cell 
 
Once diluted each final pool was quantified in triplicate using the Agilent Bioanalyzer.  
The mean is calculated and used as the actual final molarity for pools 
 
4.11 Sequencing Quality Control 
 
4.11.1 Depth of coverage data  
 
For each gene sequenced the percentage of coding bases with read depth greater 
than 30X is calculated for each sample.  Table 4.2 gives the mean percentage of 
coding bases with greater than 30X coverage for each gene.  The table also describes 
the minimum and maximum percentage of reads sequenced at read depths greater 
than 30X for each gene. 
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Table 4.2 Mean and range of percentage of coding bases sequenced at greater 
than 30X coverage for each gene 
Gene 
Mean % coding bases sequenced at > 
30X depth 
Minimum-maximum % coding bases 
sequenced at >30X depth 
BRCA1 94.5 0.1-98.8 
BRCA2 93.1 1.0-98.1 
PALB2 96.9 0-100 
BRIP1 93.6 0-99.3 
NBN 93.6 0-100 
RAD51B 77.3 0-84.8 
RAD51C 90.4 0-96.3 
RAD51D 81.6 0-86.2 
BARD1 89.5 3.3-95.7 
Table 4.2 Mean and range of percentage of coding bases sequenced at greater than 30X coverage 
for each gene. This table shows that the read depth by gene is very good with the mean percentage of 
coding bases sequenced at a read depth exceeding 30X at more than 77% for each gene.  The table gives 
detail on the minimum and maximum percentage of reads that are sequenced at a read depth greater than 
30X for each gene. 
 
Table 4.3 Mean and range of percentage of coding bases sequenced at greater 
than 30X coverage for each gene for 2,200 samples 
Gene 
Mean % coding bases sequenced at > 
30X depth 
Minimum-maximum % coding bases 
sequenced at >30X depth 
BRCA1 96.1 78.5-98.8 
BRCA2 95.2 71.9-98.1 
PALB2 98.8 78.1-100 
BRIP1 96.1 53.2-99.3 
NBN 96.5 36-100 
RAD51B 79.2 43.7-84.8 
RAD51C 92.9 47.9-96.3 
RAD51D 82.9 55.2-86.2 
BARD1 91.5 48.7-95.7 
Table 4.3 Mean and range of percentage of coding bases sequenced at greater than 30X coverage 
for each gene for 2,200 samples.  This table describes the mean and maximum and minimum 
percentage of coding bases sequenced at a read depth greater than 30X for 2,200 samples.  The 100 
poorly performing samples are removed here and this demonstrates the good coverage statistics for the 
study.  The best coverage statistics are for genes BRCA1, BRCA2 and PALB2 where 70-100% of coding 
bases are sequenced at read depths exceeding 30X for 2,200 samples.  
 
The range for meeting the minimum read depth of 30X for each gene varies from 0.1% 
and 100%.  Analysis of the coverage data in greater detail shows a small subset of 
samples do not perform well.  If the 100 poorly performing samples are removed then 
all of the remaining 2,200 samples are sequenced with a read depth more than 30X for 
80% of the coding bases in BRCA1 and BRCA2 together.  Table 4.3 gives the mean 
percentage of coding bases with greater than 30X coverage and the minimum and 
 205 
maximum percentage of coding bases sequenced at greater than 30X for all genes if 
these 100 poorly performing samples are removed.  This table shows that sequencing 
performance is good for all genes, especially BRCA1, BRCA2 and PALB2 in which 70-
100% of coding bases are sequenced at read depths greater than 30X. 
 
4.11.2 Filtering out technical artefacts 
 
Reads are filtered based on a minimum read depth of 30X.  Following this Sanger 
validation is conducted on those variants detected where the alternate allele 
frequencies are ≥ 30%. 
 
4.11.3 Sanger sequencing validation 
 
Maria Intermaggio and Dr Susan Ramus at USC conduct Sanger sequencing validation 
on all protein-truncating and predicted protein-truncating variants detected by NGS.  
113 variants are Sanger sequenced where alternate allele frequencies are at least 
30%; of these 89 are validated. Then further Sanger sequencing validation is 
conducted on those variants where the depth is at least 30X, but the alternate allele 
frequency is between 20% and 30% and the quality scores are 99; one additional 
variant is Sanger sequenced in which the quality score is 99, depth 30X and alternate 
allele frequency is 10%.   
 
For those variants with a read depth of <30X Sanger sequencing is performed on all 
variants with quality scores of 99 and a read depth above 10X. One variant is the same 
as another variant, but with a quality score of less than 99 (81).  Of these 7 variants are 
Sanger sequenced and 14% of them are validated.  Images of Sanger sequencing 
results are given following the tables describing detailed results for protein-truncating 
and predicted protein-truncating variants detected in each gene. This results in 116 
variants in total being Sanger sequenced and 99 (85.4%) variants are validated.  This 
means that there are 17 false positive results. There is 1 Sanger sequencing trace 
representing 1 example variant for each gene (Figures 4.6, 4.8, 4.9, 4.10, 4.11 and 
4.12).  Further Sanger sequencing validation is conducted following the 2nd analysis, 
however these data are not available at the time of writing. 
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4.12 Genetic variant prevalence and characteristics following 1st analysis 
 
This sequencing analysis focuses on those variants predicted to result in protein-
truncation; these include, frameshift insertions, deletions and substitutions, nonsense, 
splice site and functional missense variants.  Many of the variants detected in BRCA1 
and BRCA2 are known and are included in the Breast Cancer Information Core (BIC) 
database.  The analysis is performed twice for two reasons: 1) the first analysis does 
not include an analysis of splice site changes and 2) the first analysis shows 
discordance with clinical testing results and therefore, the filtering parameters are 
relaxed in the 2nd analysis in order to detect the missing variants.  Table 4.4 is a 
summary of the genetic variants according to variant type detected at the 1st analysis.  
 
Table 4.4 Summary of genetic variants detected by gene and variant type at the 
1st analysis 
Gene Nonsense 
Frameshift 
deletion 
Frameshift 
insertion 
Percentage of 
protein-
truncating 
variants 
BRCA1 4 33 0 1.6 
BRCA2 3 37 3 1.9 
BRIP1 1 4 0 0.22 
PALB2 0 4 0 0.17 
NBN 0 3 0 0.13 
BARD1 0 1 0 0.04 
RAD51C 0 3 0 0.13 
RAD51D 0 1 0 0.04 
Table 4.4 Summary of genetic variants detected by gene and variant type at the 1st analysis. This 
table describes the protein truncating and predicted protein-truncating variants are found in 8 out of 9 
genes in the study. NB. Although 99 variants are validated, 2 of these are non-frameshift deletions and are 
therefore, not included in this table.   
 
Table 4.4 shows that 1.6 % (n=37) of samples are found to have a protein-truncating 
variant in BRCA1; 1.9% (n=43) of samples are found to have a protein-truncating 
variant in BRCA2.  0.73% of samples have a protein-truncating variant in one of the 
other genes, with around half of these being in BRIP1 (0.22%) and PALB2 (0.17%).   
 
4.12.1 Discordance with clinical testing results and splice site analysis 
 
Comparison with clinical testing results reveals that several mutations are not detected 
in the initial analysis with the filtering parameters used.  The stringency of these filters 
means that some variants are excluded; however, these cannot be considered false 
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negatives as they are in the Illumina data analysis when the filtering stringency is 
relaxed.   These variants are validated using Sanger sequencing. 
 
Using clinical data for the trial volunteers whom previously tested positive (n=73) for 
mutations in either BRCA1 or BRCA2, 14 of these were missed (9 BRCA1 and 5 
BRCA2) in the first analysis.  NGS data for these are re-investigated and all mutations 
are detected in NGS data except one variant, 185delAG, which is identified as a SNP 
in exon 2 rather than a 2bp deletion.  One sample is missed due to low coverage in the 
position of the mutation and the additional 12 are missed due to filtering of the variant 
annotations using the Genome Analysis Toolkit (GATK) set of analysis tools. 
 
Variant annotation filters from GATK that result in missing these 12 mutations include 
the following calculations; Haplotype Score, Read Pos Rank Sum Test, In breeding 
Coefficient, MQ, QD and MQ Rank Sum Test.  11/12 samples are missed due to high 
haplotype scores, which would suggest regions where alignments are poor leading to 
sequencing artefacts and false SNP or indel calls.  In this instance the use of this filter 
in variant annotation results in missing 11 mutations in the sequencing data.  The Read 
Pos Rank Sum Test makes a calculation of the distance the variant is located from the 
end of reads in the alternate allele.  If these alternate alleles are located repetitively at 
the end of reads this is filtered out as an artefact.   1/12 is missed solely due to low QD 
(low Quality Depth by Depth).  This filter calculates quality divided by unfiltered read 
depth and a low score suggests a false positive or sequencing artefact.  The 
Inbreeding Coefficient is an algorithm based on the Hardy-Weinberg test that suggests 
that in a randomly breeding population genotype frequency maintains equilibrium.  The 
MQ score calculates the mapping quality of variants called, filtering variants out if this 
score is low.  The MQ score is a comparison of the quality of reads that contain the 
reference allele and the quality of reads containing the alternate allele (Mckenna et al 
2010, DePristo et al 2011).  The initial analysis does not include variants residing in 
splice sites.  In the 2nd analysis 3 splice site changes are detected (Table 4.5 Final 
deleterious variants detected in candidate genes). 
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4.13 Genetic variant prevalence and characteristics following 2nd analysis 
 
Table 4.5 Final summary of predicted deleterious variants detected by gene and 
variant type at the 2nd analysis 
Gene Nonsense 
Frameshift 
deletion 
Frameshift 
insertion 
Frameshift 
substitution 
Missense 
Splice 
site 
S-SNV 
BRCA1 7 41 0 2 2 0 1 
BRCA2 7 37 3 0 1 1 0 
BRIP1 1 4 0 0 0 0 0 
PALB2 0 4 0 0 0 0 0 
NBN 0 3 0 0 0 2 0 
BARD1 0 1 0 0 0 0 0 
RAD51C 0 3 0 0 0 0 0 
RAD51D 0 1 0 0 0 0 0 
Table 4.5 Final summary of predicted deleterious variants detected by gene and variant type at the 
2nd analysis. NGS identifies 121 samples with predicted deleterious gene variants in 8 of the 9 genes.  
Sanger sequencing validation is performed on all 121 samples, however data from this validation are not 
available at the time of writing (September 2013). 
 
Table 4.5 shows that 2.26 % (n=52) of samples are found to have a predicted 
deleterious variant in BRCA1; 2.13% (n=49) of samples are found to have a predicted 
deleterious variant in BRCA2. In 0.82% of samples, a predicted deleterious variant is 
detected in one of the other genes, BRIP1 (0.22%, n=5), PALB2 (0.17%, n=4) and 
NBN (0.22%, n=5) and RAD51C (0.13% n=3); RAD51D and BARD1 (both 0.04%, 
n=1).   As the women here are unaffected and with a strong family history it could be 
argued that potentially the real prevalence of mutations might be doubled in affected 
cases.  This could be inferred if the inheritance pattern of these variants is autosomal 
dominant, in which case subjects would have a 50% chance of inheriting the mutation.  
Certainly, this is the case with BRCA1 and BRCA2 genes in Hereditary Breast Ovarian 
Cancer Syndrome.    
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Table 4.6 Detailed results table of predicted deleterious variants detected in 
BRCA1 
Gene Function BIC cDNA Protein Exon Frequency 
On 
BIC 
Y/N 
BRCA1 FS Del 5083del19-ter1658 c.4964_4982del19 p.Ser1655fs 15 1 Y 
 FS Del 4491_4507del17(STOP1469) c.4372_4388del17 p.Gln1458fs 13 1 Y 
 FS Del 4232delG c.4113delG p.Cys1372fs 11 1 Y 
 FS Del 4184_4187delTCAA(STOP1364) c.4065_4068delTCAA p.Asn1355fs 11 9 Y 
 FS Del 3875del4(STOP1262) c.3756_3759delGTCT p.Leu1252fs 11 5 Y 
 FS Del 3448del4(STOP1115) c.3329_3332delAGCA p.Lys1110fs 11 1 Y 
 FS Del 3121delA(STOP1023) c.3002_3002delA p.Glu1001fs 11 1 Y 
 FS Del 3006delA(STOP999) c.2887delA p.Thr963fs 11 1 Y 
 FS Del 2823delG c.2704delG p.Glu902fs 11 1 N 
 FS Del 2776_2777delCT c.2657_2658delCT p.Ser886fs 11 2 Y 
 FS Del 2246delT c.2127delT p.Phe709fs 11 1 N 
 FS Del 1624_1628del4 c.1505_1509delTAAAG p.Leu502fs 11 4 N 
 NS 1445T>A c.1326T>A p.Cys442X 11 1 N 
 FS Del 917delTT-ter285 c.798_799delTT p.Ser267fs 10 1 Y 
 FS Del 795delT-ter233 c.676delT p.Cys226fs 10 2 Y 
 NS 546G>T(E143X) c.427G>T p.Glu143X 6 3 Y 
 FS Del 221delT c.102delT p.Pro34fs 2 1 N 
 FS Del 185delAG c.67_67delinsAG p.Glu23Val 2 7 Y 
 FS Del 3274delA c.3155delA p.Asn1052fs 11 1 N 
 NS E1134X c.3400G>T p.Glu1134X 11 1 Y 
 NS-SNV L204F c.612G>C p.Leu204Phe 10 1 Y 
 NS-SNV M1775R c.5324T>G p.Met1775Arg 21 1 Y 
 FS Sub 2080insA c.1960_1962AAAG p.Lys654Lys 11 1 Y 
 NS W1718X c.5153G>A p.Trp1718X 18 2 Y 
 S-SNV Q1395Q c.4185G>A p.Gln1395= 12 1 Y 
 FS Sub 5386delinsCA c.5267_5267delinsCA pGln1756ProfxX74 20 1 N 
Table 4.6 Detailed results table of predicted deleterious variants detected in BRCA1.  This table 
describes details of predicted deleterious variants detected in BRCA1, including mutation type, frequency, 
position and if known on BIC database.  NS = nonsense (Stop Gain), FS Del = Frameshift deletion, FS 
Sub = Frameshift substitution, NS-SNV = non-synonymous single nucleotide variant, S-SNV = 
synonymous single nucleotide variant.  7 mutations were not previously recorded on the BIC database. 
 
 
Table 4.6 gives detailed results for NGS in BRCA1 gene.  26 different variants are 
detected in BRCA1 and 7 of these are not listed on the BIC database or on the NCBI 
dbSNP database; of these 5 are unknown frameshift deletions, 1 is an unknown 
frameshift substitution and 1 is an unknown nonsense variant.  Without performing 
functional analyses these can only be termed predicted deleterious variants and 
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therefore are variants of uncertain significance.  Variants of uncertain significance may 
or may not be clinically relevant. 
 
Figure 4.6 Sanger sequencing validation image of BRCA1 protein-truncating 
mutation.  Frameshift deletion c.1505_1509delTAAAG  
  
Figure 4.6 Sanger sequencing validation image of BRCA1 protein-truncating mutation. This image is 
a Sanger sequencing trace showing the frameshift deletion c.1505_1509delTAAAG.  The red arrow 
indicates deletion of the 5 nucleotides TAAAG in BRCA. 
 
All samples with NGS identified protein truncating and predicted protein truncating 
variants in BRCA1 are Sanger sequenced for validation purposes. Figure 4.6 is an 
example of 1 Sanger sequencing validation image for the frameshift deletion 
c.1506_1509delTAAAG. 
 
Figure 4.7 Read alignment of read with mutation185delAG 
 
Figure 4.7 Read alignment of read with mutation 185delAG.  The top read alignment is the actual one, 
the 3rd base from the 5’ end shows a SNP A>T where the mutation should be on the reverse sequence i.e. 
deletion of CT in forward sequence.  By simulating an increase in read length it is possible to see the 
deletion of the 2 bases (in the bottom sequence). 
 
1 frameshift deletion 185delAG is initially detected by NGS as a SNP not a deletion 
and the reason for this is that the read containing this mutation is misaligned by the 
aligner script because the mutation is located at the end of a read.  If reads are longer 
or if there is enough overlap of amplicons then misalignments should not happen.  The 
image (Figure 4.7) above describes this problem by simulating a longer read in the 
second example. 
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Table 4.7 Detailed results table of predicted deleterious variants detected in 
BRCA2 
Gene Function BIC cDNA Protein Exon Frequency 
On 
BIC 
Y/N 
BRCA2 FS Del 248_249delAG c.20_21delAG p.Glu7fs 2 1 N 
 FS Del 635delA c.407delA p.Asn136fs 4 1 Y 
 FS Del 0886delGT-ter220 c.658_659delGT p.Val220fs 8 1 Y 
 FS Del 982del4 c.755_758delACAG p.Asp252fs 9 3 Y 
 FS Del 1493delA c.1265delA p.Asn422fs 10 1 Y 
 NS 1684C>T (Q486X) c.1456C>T p.Gln486X 10 1 Y 
 FS Del 2157delG-ter659 c.1929delG p.Arg645fs 11 1 Y 
 FS Del 3773delTT-ter1182 c.3545_3546delTT p.Phe1182X 11 1 Y 
 FS Del 3908delTG-ter1231 c.3680_3681delTG p.Leu1227fs 11 1 Y 
 FS Del 3917delC c.3689delC p.Ser1230fs 11 1 Y 
 FS Del 4075_4076delGT(STOP1284) c.3847_3848delGT p.Val1283fs 11 2 Y 
 FS Del 4626del5 c.4398_4402del5 p.Leu1466fs 11 2 Y 
 FS Del 4638del4 c.4410_4413delAAGA p.Ile1470fs 11 1 N 
 FS Del 4705del4 c.4477_4480delGAAA p.Glu1493fs 11 1 Y 
 FS Del 5104delAA c.4876_4877delAA p.Asn1626fs 11 2 Y 
 FS Ins 5294_5295insA c.5066_5067insA p.Ala1689fs 11 3 Y 
 NS 5507C>G-Ser1760ter c.5279C>G p.Ser1760X 11 1 Y 
 FS Del 5531delTT-ter1772 c.5303_5304delTT p.Leu1768fs 11 3 Y 
 FS Del 5578delAA(STOP1785) c.5350_5351delAA p.Asn1784fs 11 1 Y 
 FS Del 6174delT c.5946delT p.Ser1982fs 11 4 Y 
 FS Del 6503delTT-ter2098 c.6275_6276delTT p.Leu2092fs 11 5 Y 
 FS Del 6926delC c.6698delC p.Ala2233fs 11 1 N 
 FS Del 7297delCT-ter2358 c.7069_7070delCT p.Leu2357fs 14 2 Y 
 FS Del 8803delC-ter2862 c.8575delC p.Gln2859fs 20 1 Y 
 NS 9610C>T(R3128X) c.9382C>T p.Arg3128X 25 1 Y 
 FS Del 2116delA c.1888delA p.Thr630fs 10 1 N 
 NS W2586X c.7757G>A p.Trp2586X 16 1 Y 
 NS W563X c.1689G>A p.Trp563Ter 10 2 Y 
 NS S1970X c.5909C>A p.Ser1970Ter 11 1 Y 
 NS-SNV E2663V c.7988A>T p.Glu2663Val 18 1 Y 
 Splice 8875delG c.8756delG P.Gly2919Valfs Intronic 1 Y 
Table 4.7 Detailed results table of predicted deleterious variants detected in BRCA2. This table 
describes details of predicted deleterious variants detected and validated in BRCA2, including mutation 
type, frequency, position and if known on BIC database.  NS = nonsense (Stop Gain), FS Del = Frameshift 
deletion, NS-SNV = non-synonymous single nucleotide variant. 4 variants were not previously recorded on 
the BIC database 
 
 
Table 4.7 gives detailed results for NGS in BRCA2 gene.  31 different variants are 
detected in BRCA2 with 4 of these not listed on the BIC database or on the NCBI 
dbSNP database; of these all 4 are unknown frameshift deletions.  Without performing 
functional analyses these can only be termed predicted deleterious variants and 
therefore are variants of uncertain significance with untested clinical relevance. 
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Figure 4.8 Sanger sequencing validation image of BRCA2 protein-truncating 
mutation. Nonsense mutation in BRCA2 c.1456C>T Q486X 
 
Figure 4.8 Sanger sequencing validation image of BRCA2 protein-truncating mutation. This image is 
a Sanger sequencing trace showing the nonsense mutation c.1456C>T, the red arrow indicates the single 
base change C>T in exon 10 of BRCA2 resulting in insertion of stop codon  
 
All samples with NGS identified variants in BRCA2 are Sanger sequenced for 
validation purposes. The image in Figure 4.8 is one example of a BRCA2 protein-
truncating mutation detected in exon 10 of the gene. 
 
Table 4.8 Detailed results table of protein-truncating mutations detected in  
BRIP1 
Gene Function cDNA Protein Exon Frequency Novel or Known 
BRIP1 FS Del c.2990_2993delCAAA p.Thr997fs 20 1 Novel 
 FS Del c.2255_2256delAA p.Lys752fs 15 1 Novel 
 FS Del c.890delA p.Lys297fs 7 1 Novel 
 FS Del c.128_131delTGTT p.Leu43fs 3 1 Novel 
 NS c.66C>A p.Tyr22X 2 1 Novel 
Table 4.8 Detailed results table of protein-truncating mutations detected in BRIP1.  This table 
describes detail of protein-truncating mutations detected in BRIP1, including mutation type, frequency, 
position and if previously identified in literature (novel or known). 
 
 
Table 4.8 gives detailed results of predicted protein-truncating variants in BRIP1.  
There are 4 different frameshift deletions and 1 nonsense variant.  All of these only 
occur once and all are novel variants not on dbSNP or previously published. 
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Figure 4.9 Sanger sequencing validation image of BRIP1 protein-truncating 
mutation. Nonsense mutation in exon 2 BRIP1 c.66C>A  
 
Figure 4.9 Sanger sequencing validation image of BRIP1 protein-truncating mutation.  This image is 
a Sanger sequencing trace showing the nonsense mutation in exon 2 of BRIP1 c.66C>A.  The red arrow 
indicates single base change C>A in exon 2 of BRIP1 resulting in insertion of stop codon  
 
All samples with BRIP1 predicted protein-truncating variants are Sanger sequenced for 
validation purposes.  The image in Figure 4.9 is one example of a BRIP1 predicted 
protein-truncating mutation detected in exon 2 of the gene. 
 
Table 4.9 Detailed results table of protein-truncating mutations detected in 
PALB2 
Gene Function cDNA Protein Exon No. Samples 
Novel or 
Known 
PALB2 FS Del c.2488delG p.Glu830fs 5 1 Novel 
 FS Del c.2167_2168delAT p.Met723fs 5 1 Novel 
 FS Del c.509_510delGA p.Arg170fs 4 1 rs515726124 known pathogenic                
 FS Del c.172_175delTTGT p.Leu58fs 3 1 rs180177143 known pathogenic 
Table 4.9 Detailed results table of protein-truncating mutations detected in PALB2. This table 
describes details of protein truncating mutations detected in PALB2, including mutation type, frequency, 
position and if previously identified in literature (novel or known).  
 
Table 4.9 gives a detailed description of predicted protein-truncating variants detected 
in PALB2.  4 frameshift deletions are detected with 2 being novel and not previously 
reported in literature or listed in dbSNP 2 frameshift deletions listed on dbSNP.  Both 
variants c.509_510delGA and c.172_175delTTGT are listed in dbSNP as short genetic 
variants that are known pathogenic and therefore are not given minor allele 
frequencies. Casadei et al (2011) published both of these mutations. They report 13 
different protein-truncating mutations in the gene in breast cancer patients with family 
history of the disease. 
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Figure 4.10 Sanger sequencing validation image of PALB2 protein-truncating 
mutation. Frameshift deletion in exon 5 of PALB2 c.2488delG 
 
Figure 4.10 Sanger sequencing validation image of PALB2 protein-truncating mutation. Frameshift 
deletion in exon 5 of PALB2 c.2488delG.  The red arrow indicates single base deletion of G in exon 5 of 
PALB2 resulting in a frameshift mutation 
 
All samples with PALB2 predicted protein-truncating variants are Sanger sequenced 
for validation purposes.  The image in Figure 4.10 is one example of a novel PALB2 
predicted protein-truncating mutation detected in exon 5 of the gene. 
 
Table 4.10 Detailed results table of predicted protein-truncating mutations 
detected in NBN 
Gene Function cDNA Protein Exon No. Samples 
Novel or 
Known 
NBN FS Del c.1142delC p.Pro381fs 10 2 Novel 
 FS Del c.657_661delACAAA p.Lys219fs 6 1 Novel 
 Splice c.481-1G>A  6 2 Novel 
Table 4.10 Detailed results table of protein truncating mutations detected in NBN.  This table 
describes details of protein truncating mutations detected in NBN, including mutation type, frequency, 
position and if previously identified in literature (novel or known). 
 
Table 4.10 details the predicted protein-truncating variants detected in NBN gene.  3 
different predicted protein-truncating variants (2 frameshift deletions and 1 splice site) 
are detected in 5 samples.  All variants are novel and not reported in literature or listed 
in dbSNP. 
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Figure 4.11 Sanger sequencing validation image of NBN predicted protein-
truncating variant.  Frameshift deletion in exon 10 of NBN c.1142delC 
 
Figure 4.11 Sanger sequencing validation image of NBN predicted protein-truncating variant.  
Frameshift deletion in exon 10 of NBN c.1142delC.  The red arrow indicates single base deletion of C in 
exon 10 of NBN resulting in a frameshift mutation 
 
All samples with NBN predicted protein-truncating variants are Sanger sequenced for 
validation purposes.  The image in Figure 4.11 shows the frameshift deletion in exon 
10 of the gene. 
 
Table 4.11 Detailed results table of predicted protein truncating variants detected 
in RAD51C, RAD51D and BARD1 
Gene Function cDNA Protein Exon 
No. 
Samples 
Novel or 
Known 
RAD51C FS Del c.158delC p.Ser53fs 2 1 Novel 
RAD51C FS Del c.731delT p.Ile244fs 5 2 Novel 
RAD51D FS Del c.748delC;c.808delC;c.412delC p.His250fs;p.His270fs;p.His138fs 9,9,6 1 Novel 
BARD1 FS Del c.2291_2294delTAGA p.Ile764fs 11 1 Novel 
Table 4.11 Detailed results table of protein truncating mutations detected in RAD51C, RAD51D and 
BARD1.  This table describes details of protein truncating mutations detected in RAD51C, RAD51D and 
BARD1 including mutation type, frequency, position and if previously identified in literature (novel or 
known). 
 
Table 4.11 gives detailed results of predicted protein-truncating variants detected in 
RAD51C, RAD51D and BARD1.  There are 2 different frameshift deletions in RAD51C 
in 3 samples and 1 frameshift deletion in each of RAD51D and BARD1 in 1 sample in 
each gene.  All of the variants in these 3 genes are novel and not previously published 
or listed in dbSNP.   
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Figure 4.12 Sanger sequencing validation image of BARD1 predicted protein-
truncating variant. Frameshift deletion in exon 11 c.2291_2294delTAGA 
 
 
Figure 4.12 Sanger sequencing validation image of BARD1 predicted protein-truncating variant. 
Frameshift deletion in exon 11 c.2291_2294delTAGA.  The red arrow indicates 4 base deletion in exon 
11 of BARD1 resulting in a frameshift mutation 
 
 
All samples with predicted protein-truncating variants in BARD1, RAC51C and 
RAD51D are Sanger sequenced for validation purposes.  The image in Figure 4.12 
shows the Sanger sequencing trace for the frameshift deletion in exon 11 of BARD1. 
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4.14 Epidemiological data 
 
Epidemiological data are available for 94 of the 121 samples with protein-truncating or 
predicted protein-truncating variants in each gene.  The tables 4.12 to 4.14 give detail 
on family history for each sample with an NGS detected variant and gives age at 
recruitment to the study.  This family history data includes the number of affected 
relatives and the type of cancer diagnosed.  If the volunteer has had a diagnosis of 
cancer then the age of diagnosis and cancer type are specified.  If the volunteer has 
been tested in an NHS clinic for BRCA1 or BRCA2 then the result of this test is given. 
 
Table 4.12 Epidemiological data for samples positive for BRCA1 gene variants 
Sample Variant type 
Variant 
BIC 
Epidemiological data 
Family 
History 
Age at 
recruitment 
Cancer 
Dx Y/N 
Age 
Cancer 
Dx 
NHS 
BRCA1/2 
1 FS Del 5083del19-ter1658 
2 ovarian 
2 breast 
1 stomach 
1 leukaemia 
54 No Na Not tested 
2 FS Del 4491_4507del17 (STOP1469) 
4 breast 
1 ovarian 
2 colon 
1 lung 
52 no Na Not tested 
3 FS Del 4232delG 
2 breast 
1 brain 
1 stomach 
1 uterus 
1 lung 
2 ovarian 
37 breast cancer 31 Not tested 
4 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
3 ovarian 
2 breast 39 no Na 
BRCA1 
positive 
5 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
3 breast 
2 ovarian 
1 leukaemia 
54 no Na Not tested 
6 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
4 ovarian 
6 breast 
4 brain 
1 unknown primary 
44 no Na Not tested 
7 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
3 breast 
1ovarian 
1 leukaemia 
1 oesophageal 
1 prostate 
44 No Na Not tested 
8 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
2 ovarian 
1 breast 
1 unknown primary 
42 No Na Not tested 
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9 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
2 breast 
1 ovarian 42 No No Not tested 
10 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
5 Liver 
1 ovarian 
3 breast 
1 oesophageal 
1 unknown primary 
39 Breast 40 BRCA1 positive 
11 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
2 breast 
1 ovarian 
1 endometrial 
1 stomach 
1 prostate 
51 No Na Not tested 
12 FS Del 
4184_4187del 
TCAA 
(STOP1364) 
3 ovarian 
1 alimentary tract 46 No Na Not tested 
13 FS Del 3875del4 (STOP1262) 
3 ovarian 
3 breast 
1 endometrial 
1 oropharynx 
1 lung/bronchial 
1 alimentary tract 
 
43 Breast cancer 40 
BRCA1 
positive 
14 FS Del 3875del4 (STOP1262) 
2 ovarian 
1 colorectal 
1 unknown primary 
41 No Na Not tested 
15 FS Del 3875del4 (STOP1262) 
1 ovarian 
2 alimentary tract 
2 unknown primary 
39 Breast cancer 29 Not tested 
16 FS Del 3875del4 (STOP1262) 
4 breast 
1 ovarian 
1 colorectal 
1 lung 
1 gastric 
38 Cervical cancer 40 Not tested 
17 FS Del 3875del4 (STOP1262) 
5 ovarian 
1 peritoneal 
1 breast 
1 gastric 
1 unknown primary 
60 No Na BRCA1 positive 
18 FS Del 3448del4 (STOP1115) 
1 ovarian 
1 breast 
1 prostate 
2 thyroid 
1 malignant 
melanoma 
1 unknown primary 
44 No Na Not tested 
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19 FS Del 3121delA (STOP1023) 
1 breast and 
ovarian 
1 breast 
42 No Na Not tested 
20 FS Del 3006delA (STOP999) 
2 breast 
1 pancreatic 
1 Hodgkin’s 
lymphoma 
1 liver 
1 parotid gland 
2 skin and nails 
1 neck and spine 
52 Breast cancer 41 Not tested 
21 FS Del 2823delG 5 breast 1 ovarian 42 No Na Not tested 
22 FS Del 2776_2777delCT 2 ovarian 1 cervical 41 No Na Not tested 
23 FS Del 2776_2777delCT 
1 ovarian 
1 breast 
1 osteosarcoma 
1 unknown primary 
38 No Na Not tested 
24 FS Del 2246delT 
2 ovarian 
7 breast 
1 neck and spine 
2 malignant 
melanoma 
2 lung/bronchial 
1 carcinoid 
bronchus 
1 heart 
1 testicular 
2 bladder 
2 Hodgkin’s 
lymphoma 
2 endometrial 
1 leukaemia 
46 Breast cancer 47 
BRCA1 
positive 
25 FS Del 1624_1628del4 1 breast 1 ovarian 54 
Breast 
cancer 39 
BRCA1 
positive 
26 FS Del 1624_1628del4 2 ovarian 2 breast 46 No Na 
BRCA1 
positive 
27 FS Del 1624_1628del4 
1 ovarian 
1 breast 
1 leukaemia 
1 cervical 
46 No Na Not tested 
28 Nonsense  1445T>A 
3 ovarian 
3 breast 43 Ovarian 45 
BRCA1 
positive 
29 FS Del 917delTT-ter285 
1 ovarian 
4 breast 
1 colorectal 
1 cervical 
39 No Na Not tested 
30 FS Del 795delT-ter233 
3 ovarian 
1 cervical 
1 lung/bronchial 
2 alimentary 
36 No Na Not tested  
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31 FS Del 795delT-ter233 
3 ovarian 
2 endometrial 
2 liver 
4 gastric 
38 No Na Not tested 
32 Nonsense 546G>T(E143X) 
3 ovarian 
1 breast 
1 pancreatic 
1 kidney 
1 lung/bronchial 
4 unknown primary 
60 No Na BRCA1 positive 
33 Nonsense 546G>T(E143X) 1 ovarian 3 breast 49 No Na Not tested 
34 Nonsense 546G>T(E143X) 
1 ovarian 
6 breast 
1 uterus 
2 prostate 
1 pancreatic 
2 malignant 
melanoma 
38 No Na Not tested 
35 FS Del 221delT 3 ovarian 1 breast 36 No Na Not tested 
36 FS Del 3274delA 
1 ovarian 
1 breast 
1 colorectal 
1 lung/bronchial 
38 No Na Not tested 
Table 4.12 Epidemiological data for samples positive for BRCA1 gene variants.  This table gives 
details on family history for 36 samples with protein-truncating variants in BRCA1 gene.  5 of these had 
prior breast cancer diagnoses; 4 are subsequently diagnosed with cancer (2 breast cancer, 1 ovarian 
cancer and 1 cervical cancer) fairly soon after joining the study. The remaining 27 samples do not report 
cancer diagnoses at the time of writing (July 2013). Dx = diagnosis 
 
Table 4.12 shows epidemiological data for 36 women positive for protein-truncating 
variants in BRCA1.  These data show that 27 women with BRCA1 variants are 
currently unaffected by breast or ovarian cancer and all of whom have a strong family 
history of various cancer types including breast and/or ovarian.  The ages of women 
range from 36 years to 60 years at recruitment, therefore, representing pre-, peri- and 
post-menopausal women; of the women with prior or subsequent cancer diagnoses the 
age of diagnosis ranges from 29 years to 47 years. 
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Table 4.13 Epidemiological data for samples positive for BRCA2 gene variants 
 
 
Sampl
e 
Variant 
Type Variant BIC 
Epidemiological Data 
Family 
History 
Age at 
recruitment 
Cancer 
Dx Y/N 
Age 
Cancer 
Dx 
NHS 
BRCA1/2 
37 FS Del 248_249delAG 
1 ovarian 
2 breast 
1 colorectal 
1 unknown primary 
35 No Na BRCA2 positive 
38 FS Del 635delA 
1 ovarian 
1 breast 
2 colorectal 
1 lymphoid 
1 parotid 
1 stomach 
47 Breast cancer 36 Not tested 
39 FS Del 0886delGT-ter220 1 ovarian 4 breast 66 
Breast 
cancer 59 Not tested 
40 FS Del 982del4 1 ovarian 4 breast 38 
Malignant 
melanoma 38 Not tested 
41 FS Del 982del4 1 ovarian 3 breast 39 No Na Not tested 
42 FS Del 982del4 
1 ovarian 
2 breast 
3 stomach 
1 alimentary tract 
1 lung/bronchial 
42 No Na Not tested 
43 FS Del 1493delA 
1 ovarian 
3 breast 
3 prostate 
1 unknown primary 
39 No Na Not tested 
44 Nonsense 1684C>T (Q486X) 
1 ovarian 
1 breast 
2 alimentary tract 
1 prostate 
39 No Na Not tested 
45 FS Del 2157delG-ter659 
1 ovarian 
3 breast 
1 liver 
1 pancreatic 
41 No Na Not tested 
46 FS Del 3773delTT-ter1182 
1 ovarian 
2 breast 
1 uterus 
1 colorectal 
1 lung 
49 No Na Not tested 
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47 FS Del 3908delTG-ter1231 3 ovarian 39 No Na Not tested 
48 FS Del 3917delC 
2 ovarian 
1 breast 
2 unknown primary 
47 
(Oophorectomy 
at 48) 
No Na Not tested 
49 FS Del 
4075_4076delG
T 
(STOP1284) 
2 ovarian 
1 breast 
1 lung/bronchial 
1 lymphoid 
1 unknown 
 
46 No Na Not tested 
50 FS Del 
4075_4076delG
T 
(STOP1284) 
1 ovarian 
2 breast 
1 bladder 
1 cervical 
1 unknown primary 
60 Breast cancer 48 Not tested 
51 FS Del 4626del5 
3 ovarian 
1 breast 
1 prostate 
1 lung/bronchial 
1 oesophageal 
 
52 No Na Not tested 
52 FS Del 4626del5 
1 unknown primary 
2 lung/bronchial 
1 skin tumour 
1 leukaemia 
38 Breast cancer 52 Not tested 
53 FS Del 4638del4 
1 ovarian 
2 breast 
1 lung/bronchial 
41 No Na Not tested 
54 FS Del 4705del4 
3 ovarian 
1 unknown primary 
1 lung/bronchial 
59 No Na Not tested 
55 FS Del 5104delAA  
2 ovarian 
2 breast 
1 endometrial 
2 colorectal 
1 stomach 
51 No Na Not tested 
56 FS Del 5104delAA 
2 ovarian 
1 breast 
1 gastric 
2 skin (basal cell) 
39 No Na Not tested 
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60 Nonsense 5507C>G-Ser1760ter 
2 ovarian 
1 breast 
1 brain 
1 lung 
1 stomach 
1 skin 
1 liver 
42 No Na Not tested 
61 
 FS Del 
5531delTT-
ter1772 
2 ovarian 
1 breast 
2 endometrial 
42 No Na Not tested 
62 FS Del 5531delTT-ter1772 
2 ovarian 
1 bladder 
1 brain 
1 unknown 
primary 
43 No Na Not tested 
63 FS Del 5578delAA (STOP1785) 
1 ovarian 
2 breast 
1 prostate 
1 unknown 
primary 
1 oropharyngeal 
44 No Na Not tested 
64 FS Del 6174delT 
1 ovarian 
7 breast 
1 prostate 
1 bone and 
chrondroid tissue 
50 No Na Not tested 
65 FS Del 6174delT 
2 ovarian 
1 breast 
1 prostate 
39 No Na Not tested 
66 FS Del 6174delT 
2 ovarian 
1 breast 
1 colorectal 
1 oropharyngeal 
53 No Na Not tested 
67 FS Del 6174delT 1 ovarian 4 breast 53 No Na Not tested 
57 FS Ins 5294_5295insA 
2 ovarian 
1 breast 
1 colon 
1 Hodgkin’s 
lymphoma 
1 bone marrow 
1 leukaemia 
54 No Na Not tested 
58 FS Ins 5294_5295insA 
2 ovarian 
3 breast 
1 colorectal 
2 alimentary tract 
1 stomach 
1 oropharyngeal 
1 pancreatic 
1 bladder 
42 No Na Not tested 
59 FS Ins 5294_5295insA 
1 ovarian 
1 breast 
2 colorectal 
1 stomach 
1 pancreatic 
51 Breast cancer 49 BRCA2 positive 
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68 FS Del 6503delTT-ter2098 
2 ovarian 
3 breast 56 Breast cancer 51 
BRCA2 
positive 
69 FS Del 6503delTT-ter2098 
2 ovarian 
3 breast 
1 endometrial 
1 colorectal 
1 prostate 
52 Breast cancer 52 BRCA2 positive 
70 FS Del 6503delTT-ter2098 
2 ovarian 
2 breast 58 No Na Not tested 
71 FS Del 6503delTT-ter2098 
1 ovarian 
3 breast 
1 brain 
2 oropharyngeal 
1 stomach 
36 No Na Not tested 
72 FS Del 6503delTT-ter2098 
1 ovarian 
4 breast 
1 alimentary tract 
1 lung/bronchial 
42 No Na Not tested 
73 FS Del 6926delC 
1 ovarian 
1 breast 
1 prostate 
1 bladder 
36 No Na Not tested 
74 FS Del 
7297delCT-
ter2358 
 
1 ovarian 
1 breast 
1 stomach 
1 skin tumour 
52 No Na BRCA2 positive 
75 FS Del 
7297delCT-
ter2358 
 
1 ovarian 
1 breast 
1 uterus 
1 stomach 
52 No Na Not tested 
76 FS Del 8803delC-ter2862 
3 ovarian 
1 unknown 
primary 
39 No Na Not tested 
77 
 Nonsense 
9610C>T 
(R3128X) 
3 ovarian 
1 uterus 
1 lung/bronchial 
68 No Na Not tested 
78 FS Del 2116delA 
1 ovarian 
2 breast 
1 lung/bronchial 
1 leukaemia 
41 No Na 
Not tested 
Table 4.13 Epidemiological data for samples positive for BRCA2 gene variants.  This table gives 
details on family history for 42 samples with protein-truncating variants in BRCA2 gene.  5 of these had 
prior breast cancer diagnoses; 3 are subsequently diagnosed with cancer (2 breast cancer, malignant 
melanoma) fairly soon after joining the study. The remaining 34 samples do not report cancer diagnoses at 
the time of writing (July 2013). 
 
Table 4.13 shows epidemiological data for 42 women positive for protein-truncating 
variants in BRCA2.  These data show that 34 women with BRCA2 variants are 
currently unaffected by breast or ovarian cancer and all of whom have a strong family 
history of various cancer types including breast and/or ovarian.  The ages of women 
range from 35 years to 60 years at recruitment, therefore, representing pre-, peri- and 
post-menopausal women; of the women with prior or subsequent cancer diagnoses the 
age of diagnosis ranges from 36 years to 59 years. 
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Table 4.14 Epidemiological data for samples positive for gene variants in BRIP1, 
PALB2, NBN, RAD51C, RAD51D and BARD1  
Sample Variant type Gene Variant 
Epidemiological data 
Family 
history 
Age at 
Recruitment 
Cancer 
Dx Y/N 
Age 
Cancer 
DX 
NHS 
Testing 
79 FS Del BRIP1 c.2990_2993delCAAA 
1 ovarian (71) 
1 breast (41) 46 No Na Not tested 
80 FS Del BRIP1 c.2255_2256delAA 
2 ovarian (50, 
74) 
3 breast 
2 lung/bronchial 
1 oesophageal 
1 brain 
44 No Na Not tested 
81 FS Del BRIP1 c.890delA 
3 ovarian 
(68,68,72) 
1 colorectal 
1 bladder 
1 gastric 
51 No Na Not tested 
82 FS Del BRIP1 c.128_131delTGTT 
2 ovarian (49, 
31)) 
1 lung 
1 colorectal 
38 No Na Not tested 
83 FS Del BRIP1 c.66C>A 
1 ovarian (34) 
6 breast (45, 
57) 
36 Breast cancer 39 Not tested 
84 FS Del PALB2 c.2488delG 
2 ovarian (55, 
66) 
3 breast (44, 
44, 45) 
1 lung/bronchial 
1 stomach 
1 leukaemia 
46 No Na Not tested 
85 FS Del PALB2 c.2167_2168delAT 
2 ovarian 
(64,83) 
1 breast (58) 
1 cervical 
1 unknown 
primary 
64 No Na Not tested 
86 FS Del PALB2 c.509_510delGA 
2 ovarian (43, 
89) 
1 breast (55) 
47 No Na Not tested 
87 FS Del PALB2 c.172_175delTTGT 
1 ovarian (62) 
5 breast (47, 
49, 83) 
1 stomach 
1 alimentary 
tract 
38 Breast cancer 39 
BRCA1/2 
test 
negative 
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88 FS Del NBN c.1142delC 
1 ovarian (56) 
1 breast (68) 
1 testicular 
2 lung/bronchial 
1 leukaemia 
1 alimentary 
tract 
1 oesophageal 
1 oropharynx 
1 unknown 
primary 
62 Breast cancer 47 Not tested 
89 FS Del NBN c.657_661delACAAA 
2 ovarian (40, 
56) 
4 breast (40, 48, 
77) 
1 stomach 
1 lymphoid 
39 No Na Not tested 
90 FS Del RAD51C c.158delC 
2 ovarian (54, 
70) 
1 lung/bronchial 
64 No Na Not tested 
91 FS Del RAD51C c.731delT 
3 ovarian (51, 
58, 76) 
1 Leukaemia 
1 Kidney 
2 unknown 
primary 
47 No Na Not tested 
92 FS Del RAD51C c.731delT 
2 ovarian (87) 
1 breast 
1 colorectal 
2 gastric 
1 prostate 
1 bone 
1 brain 
1 unknown 
primary 
60 Breast cancer 57 Not tested 
93 FS Del RAD51D c.748delC 
1 ovarian (54) 
3 breast 
(63,68,70) 
1 liver 
46 No Na Not tested 
94 FS Del BARD1 c.2291_2294delTAGA 
1 ovarian (63) 
1 breast (42) 
1 brain 
1 lung/bronchial 
1 cervical 
36 No Na Not tested 
Table 4.14 Epidemiological data for samples positive for gene variants in BRIP1, PALB2, NBN, 
RAD51C, RAD51D and BARD1. This table gives details on family history for 16 samples with protein-
truncating variants in PALB2, NBN, RAD51C, RAD51D or BARD1 genes.  2 of these had prior breast 
cancer diagnoses; 2 are subsequently diagnosed with breast cancer fairly soon after joining the study. The 
remaining 34 samples do not report cancer diagnoses at the time of writing (July 2013). 
 
Table 4.14 shows epidemiological data for 16 women positive for a predicted protein-
truncating variant in PALB2, NBN, RAD51C, RAD51D or BARD1 genes.  These data 
show that 12 of these women are currently unaffected by breast or ovarian cancer and 
all of whom have a strong family history of various cancer types including breast and/or 
ovarian.  The ages of women range from 36 years to 64 years at recruitment, therefore, 
representing pre-, peri- and post-menopausal women.  Of the women with prior or 
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subsequent cancer diagnoses the age of diagnosis ranges from 39 years to 57 years; 
Table 4.14 also includes the age at diagnosis for the affected relatives (where this is 
known).  This shows that for BRIP1 gene all those with gene variants show multiple 
ovarian and breast cancer cases in the family history and many of these are diagnosed 
under the age of 60 years. The family history includes both breast and ovarian cancer 
for every sample and in addition, many other cancer types are evident. 
 
4.15 Clinical Relevance of Results 
 
These results identify potential novel genes that could be targeted in follow-up studies.  
These data suggest that variants in BRIP1, PALB2, NBN and BARD1 should be 
investigated in new studies.  Whilst the frequencies of mutations in these genes are 
lower than BRCA1 and BRCA2, three new genes BRIP1, PALB2 and NBN show 
frequencies of 0.22%, 0.17% and 0.22% respectively and as these are in unaffected 
women with very strong family histories these gene variants suggest they are at a very 
high risk of developing ovarian or breast cancer. RAD51C and RAD51D have formerly 
been identified as breast and ovarian cancer susceptibility genes and these should 
continue to be characterised in large case-control studies. This study does not include 
a control group so population frequencies for variants in these genes cannot be 
examined, therefore positive predicted deleterious results must be interpreted with 
caution. Further studies are required, particularly because several of the volunteers are 
diagnosed with cancer very soon after recruitment in the study. 
 
4.16 Example Pedigree 
 
The example pedigree in Figure 4.13 demonstrates the transmission of gene variants 
from generation to generation.  
 
The volunteer, indicated by the red arrow in the pedigree diagram (Figure 4.13), has 
not been tested in an NHS clinic.  She has no living affected relatives and would 
therefore, not be eligible for NHS genetic testing.  She has a strong family history of 
breast and ovarian cancer, in which 3 prior generations of women have had diagnoses 
of breast and or ovarian cancer under the age of 60.  BRCA1 gene mutations are 
inherited in an autosomal-dominant pattern, which is clearly evident in this diagram 
(Figure 4.13).  This finding has clinical relevance in that the proband’s risk of 
developing breast and or ovarian cancer before the age of 60 is extremely high.  She is 
currently 50 years old with a family of 3 daughters.  If she is tested clinically she could 
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be offered risk-reducing surgery (RRSO).  In addition, she has 3 daughters, all of 
whom would have a high risk of testing positive for the same mutation.  If the daughters 
are tested and found to be negative, their lifetime risk for developing breast and/or 
ovarian cancer would be calculated at levels closer to that of general population.  If 
found to be positive they could be offered early screening until they have completed 
families after which they could be offered risk reducing surgery.   
 
Figure 4.13 Pedigree diagram for sample No. 7 with NGS detected BRCA1 
frameshift variant c.4184_4187delTCAA 
 
 
Figure 4.13 Pedigree diagram for sample No.7 with NGS detected BRCA1 frameshift variant 
c.4184_4187delTCAA.  This pedigree clearly shows BRCA1 transmission through the maternal side of the 
proband (indicated with a red arrow).  No generations are skipped and there are approximately as many 
affected as unaffected women on the maternal side of the family; characteristics of highly penetrant gene 
variants inherited in an autosomal-dominant pattern.  The proband’s daughters have a 50% chance of 
inheriting the genotype from the mother. 
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4.17 Discussion  
This study continues with the same high-throughput targeted sequencing approach and 
employs this to characterise the frequency of 4 known and 5 novel ovarian cancer 
susceptibility genes in unaffected women from high-risk breast-ovarian cancer families.  
Multiplexed PCR on the Fluidigm Access Array platform is scaled-up further to allow for 
target enrichment and library preparation in all 9 genes in 2,300 subject samples.   
4.18. Evaluation of the scaled-up targeted NGS approach used in this study 
4.18.1 Target enrichment and library preparation 
The target enrichment and library preparation are performed as 10 PCR reactions in 
each well of the Fluidigm Access Array.  The methodology chapter describes which 
amplicons are mixed in each well. This is a complex, laborious and time-consuming 
part of the experiment, but is crucial in successfully sequencing all coding regions. 
Once this step is complete the rest of the target enrichment and library preparation 
steps are relatively straightforward and streamlined.  In future experiments designing 
the primer mixing for highly multiplexed experiments could be improved by formulation 
of a computer program that could automate this process. A simple computer 
programming script could be written to follow the basic rules in mixing amplicons per 
well and that could also be applied to many different experiments. 
4.18.2 Sequencing Quality Controls (QC) – sequence coverage 
The importance of sequencing depth of coverage is discussed in the previous chapter.  
The minimum acceptable sequencing depth is previously established to be 30X and 
this level is used in filtering out reads. The excellent levels of coverage attained in this 
experiment allow for confidence in variant detection sensitivity and specificity. 
4.18.3 The importance and pitfalls of NGS data filtering 
Illumina sequencing uses sequencing by synthesis to determine the order of bases in 
the template DNA. Each DNA molecule is sequenced many times over and this 
sequencing depth allows for the accurate detection of single nucleotide variants and 
indels.  This methodology therefore, produces vast quantities of data and can lead to 
sequencing artefacts unless read and variant filtering are performed.   
If the first important step in NGS data analysis has already been identified as read 
alignment then the second most important step in variant annotation is filtering. The 
Genome Analysis Toolkit (GATK), described in previous chapters (McKenna et al 
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2010), includes tools for filtering variants, which will have the effect of reducing the vast 
number of variants detected in Illumina sequencing. Two of these tools from GATK, the 
Haplotype Score Test and the Read Pos Rank Sum test filtered out 11 of the 12 
missing mutations and the low QD test filtered out the final missing mutation. Where 
haplotype score results are high these are filtered out as potential errors and 
sequencing artefacts. High scores suggest regions of poor alignment as the algorithm 
calculates segregating haplotypes at specific loci for each sample. If there are more 
than 2 haplotypes for a given sample then these are filtered out. Since the study 
population is concerned specifically with subjects with a high incidence of familial 
ovarian cancer these do not represent a random general population as would be the 
situation in a case-control study. Thus, perhaps the Haplotype Score test was not 
relevant here. The ReadPosRankSum test filters out variants that are consistently 
identified in the alternate allele at the end of reads. However, one major drawback here 
is that if the majority of reads are the alternate allele then this cannot be calculated 
accurately and good variant calls might be eliminated. This disadvantage is also 
relevant in some other variant filtering tools such as the MQ RankSum test, which 
compares read mapping qualities of the alternate allele and the reference allele. As 
only two of the filtering tools appeared to show up as reasons for eliminating the 
missing mutations it can be concluded that the filtering was mostly successful and only 
minor adjustments need to be made to improve the data analysis pipeline 
4.18.4 Variant detection sensitivity  
As the study participants are female relatives of ovarian cancer patients and part of a 
UK screening trial some are previously tested for mutations in BRCA1 and BRCA2.  
This allows for further examination of NGS data to check for incorrect or missing 
mutation calls in these two genes. On inspection of clinical data 14 samples (out of a 
possible 73) are found to be discordant, i.e. those 14 samples were positive and were 
missed by NGS suggesting a poor variant detection sensitivity rate of 79.4%. Closer 
scrutiny in these 14 samples shows that these variants are in fact in the NGS data, but 
stringent filtering criteria removed the reads containing the variants.  
The method of target enrichment used here will not detect large rearrangements such 
as deletions or duplications of whole exons. Thus for the BRCA1/2 data these cannot 
be considered negatives neither can they be considered false negatives. These are the 
current limits of this particular methodology. 
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4.18.5 Variant detection specificity 
As a validation method all predicted deleterious variants are sequenced using Sanger 
sequencing.  99 of the NGS variants out of a total 116 are validated (85.34%) in this 
way meaning that there are 17 false positives. N.B. only Sanger sequencing data from 
the 1st analysis is available at the time of writing.  However, Sanger sequencing is still 
being conducted on the variants detected from the 2nd analysis with changed filtering 
parameters. In this study the filtering and QC levels are good, with 85.34% of positive 
samples being validated by Sanger sequencing. 
In BRCA1/2 genes there are several variants of uncertain significance (VUS).  These 
VUSs may or may not be clinically relevant and in these data these VUSs have not 
been included in the positive results.  In the clinical setting diagnostic laboratories 
detect around 5-10% of VUS (in BRCA1/2) even using Sanger sequencing. Clinics in 
these circumstances are still in debate around how these should be considered in 
terms of prediction of cancer risk.  Thus, the samples containing VUSs sequenced in 
this study cannot be classified as true negatives or false negatives.  Reassurance on 
the quality of these data can be taken from the accuracy estimates; as approximately 
85% accuracy rate is in keeping with current levels in recently published data. 
4.19 Evaluation of study design 
One of the main advantages of a family-based study design is in the genetic 
enrichment for all types of risk allele, meaning that very rare high-risk and rare 
moderate risk alleles should be detected using this study design.  This is in contrast to 
population-based case control studies that are unselected for family history and/or 
histological subtype that are more likely to detect the low risk common alleles.  
Additional advantages are in the circumvention of population stratification, a concept 
discussed in the previous chapter; and in the increase in statistical power and reduction 
in required sample sizes through using cases with a strong family history.  Required 
sample sizes reduce with samples selected for family history as well as reducing with 
increasing allele frequency; this is especially marked where there are affected mother 
and sister in the family (Antoniou & Easton 2003).    
4.20 Genetic variant prevalence and characteristics 
For the purposes of this analysis deleterious mutations are classified as frameshift, 
nonsense and splice site alterations that are predicted to result in protein-truncation.  
This study did not examine the predicted missense variants. In this study the combined 
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prevalence of a deleterious mutation in the 8 genes containing identified variants is 
5.26% (n=121) of which 4.39% (n=101) are BRCA1 or BRCA2 with the remaining 
0.83% (n=19) attributable to the additional 6 genes.  The ratio of BRCA1 to BRCA2 
mutations is roughly equal in this study at 1.06:1 (BRCA1:BRCA2). 
The prevalence figures in this study are strikingly low for the known breast/ovarian 
cancer susceptibility genes (BRCA1, BRCA2, RAD51C and RAD51D).  This is a 
particularly surprising result since the sample set is genetically enriched with subjects 
from families containing multiple cancers, many of which include high numbers of 
ovarian and breast cancer cases. If ~50% of familial ovarian cancer is considered 
attributable to BRCA1 and BRCA2 genes, then these figure would be expected to be 
higher than 4.39%. After taking into account that the gene mutation is probably 
inherited in an autosomal dominant fashion, meaning that each family member has a 
50% probability of inheriting the genotype, then this figure could be doubled to 8.78%.  
This figure is still relatively low and several factors may explain this. For example, 
these families may be Lynch Syndrome families with mutations in DNA mismatch repair 
genes or it may be because there are still additional ovarian cancer susceptibility genes 
yet to be discovered.  Another reason is that the cancer cases within these families 
may be sporadic cases that by chance happen to cluster within these families (Ramus 
& Gayther 2009). 
Large genomic rearrangements such as large insertions or deletions of whole exons 
could not be identified in these data due to the choice of target enrichment and library 
preparation system.  Mutations of this type could only be identified using genomic 
enrichment methods rather than one that creates tagged amplicons that only cover the 
coding sequence and splice sites of each gene.  The missing large genomic 
rearrangements could in part explain the low prevalence figures for BRCA1 and 
BRCA2. Ramus & Gayther (2009) analyse the prevalence of BRCA1 and BRCA2 
mutations in 283 epithelial ovarian cancer cases selected with family history of ovarian 
cancer.  They find that 37% of families have a mutation in BRCA1 and 9% have a 
mutation in BRCA2.  They perform MLPA analysis on a subset of the cases that have 
no detected coding sequence mutation; they identify 13 cases in the study with large 
genomic rearrangements. Ramus et al (2007) suggest that in UK ovarian cancer 
families around 18% are found to have large rearrangements in BRCA1 gene. Another 
important factor to take into account here are the number of ovarian/breast cancer 
cases in each family.  Ramus & Gayther (2009) report that the increasing number of 
cases in each family results in an increasing proportion of BRCA1 and BRCA2 
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mutations.  They report that in UK and US families with 2 ovarian cancer cases the 
prevalence of BRCA1 and BRCA2 mutations together is 27% rising to 63% in those 
where there are 3 or more ovarian cancer cases.  Since this study analyses women 
that are disease free at the time of volunteering, then perhaps these are women with 
less than 3 ovarian cancer cases in the family, thus lower expected levels of 
prevalence in this study. In addition, Ramus & Gayther (2009) report that there are 
marked differences in prevalence figures in the UK and US populations. Some variation 
in prevalence figures would be expected between different studies, especially taking 
into account differences in ethnicity and sample sizes of individual studies.  The most 
appropriate way to determine prevalence figures would be to combine data from many 
different studies conducted in different populations.  
Age is relevant here in that as individuals’ age and remain cancer free the probability 
that they have an inherited mutation diminishes. At a future date, it would be interesting 
to conduct analyses on these data examining the ages of individuals with detected 
mutations and the ages of individuals without mutations for those who develop cancer 
and those who remain cancer free.   
In BRIP1 Walsh et al (2011) detect 4 protein-truncating mutations in one peritoneal and 
3 ovarian cancer cases.  The ovarian cancer cases are 2 serous and 1 endometrioid 
histological subtypes.  The mutations detected by Walsh et al (2011) are not the same 
as those detected here.  In fact all BRIP1 mutations detected in this study are not 
previously cited in literature.  Certainly, this gene requires further investigation in very 
large case control studies and in family based studies in order to accurately estimate 
prevalence and penetrance levels and calculate odds ratios and relative risk. It is 
plausible that BRIP1 may be found to be moderate penetrance in breast cancer but a 
moderate to high penetrance in ovarian cancer; these data suggest that BRIP1 is 
potentially a novel ovarian cancer susceptibility gene. 
PALB2 is the third most prevalent of the candidate genes in the study with 4 frameshift 
deletions detected in 0.17% of samples in the study.  Two of these are previously 
reported in literature as connected with familial breast cancer c.509_510delGA 
(Casedei 2011) and c.172_175delTTGT (Hellebrand 2011).  Two frameshift deletions, 
both in exon 5 are novel mutations found only in this study interestingly, one of these 
individuals has developed breast cancer and the other has a family history of breast 
cancer. Only larger case control studies will determine if these variants are specific to 
breast cancer only.   
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NBN gene represents the second most prevalent candidate gene in the study.   This 
gene is not associated with ovarian cancer in previous studies and both of the 
mutations detected in this study are not previously reported in other studies as 
associated with either breast or ovarian cancer.  These data suggest that this gene 
should be further investigated in larger follow-on case control studies.   
The BARD1 gene is already considered a candidate susceptibility gene due to its 
biological association with BRCA1 (Ratajska et al 2013).  Ratajska et al (2013) detect 3 
probable deleterious variants in this gene in 109 non-BRCA1/2 breast and/or ovarian 
cancer patients. 1 predicted protein-truncating mutation, a frameshift deletion in exon 
11 is detected in this study and this novel variant is not previously reported in literature; 
as such these data suggest this is a future candidate gene in follow-up studies.  
In RAD51B no predicted protein truncating variants are detected and given that in the 
previous case-control study only 1 predicted deleterious variant is detected it is 
suggested that this gene is not a significant ovarian cancer susceptibility gene.  In 
RAD51C and RAD51D fewer mutations are detected than in the previous study with 
only 3 mutations in RAD51C (0.13%) and 1 in RAD51D (0.04%).  This study does not 
include a control group, which means that population frequencies cannot be assessed.  
These two genes were previously identified as breast and ovarian cancer susceptibility 
genes.  The frequency of RAD51C is only lower by one variant compared to the other 
genes. Certainly, variants in all of the genes in this study are rare. In addition, this 
study could result in frequency estimations of half of that expected due to an autosomal 
dominant inheritance pattern.  Or, the low frequencies could be due to the fact that 
these two genes are not predominant in familial ovarian cancer and may be more 
relevant to histological subtype and in the general population.  Case-control studies 
include women with cancer diagnoses that do not have family history of the disease 
and this type of study is useful in identifying alleles in non-familial ovarian cancer. 
Case-control studies are especially useful when combined with epidemiological data 
including age of onset and histological subtype.  This familial cohort study of unaffected 
women however, gives an indication of the likelihood of a woman harbouring gene 
mutations, within these candidates, with high familial risk.  
4.21 Analysis of clinical relevance of study findings 
Epidemiological data is gathered for 94 subject samples and includes, family history, 
age at recruitment, whether there is a cancer diagnosis, and if cancer is diagnosed at 
what age the diagnosis is made.  In subjects with a BRCA1 mutation 27 out of 36 study 
subjects are still unaffected at the time of follow-up.  Of these 36, 5 have breast cancer 
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diagnoses at recruitment and 4 are diagnosed subsequently with cancer (2 breast, 1 
ovarian and 1 cervical).  The ages at recruitment range from 29 to 47 years suggesting 
that early detection strategies and risk prediction using genetic screening are likely to 
be of immense value in reducing mortality and morbidity in ovarian cancer.  This is 
suggested as the women in this study are at a very high risk of developing ovarian 
cancer and the window of opportunity to identify these women will be during the pre- 
and peri-menopausal years.  No subjects had a diagnosis of ovarian cancer at study 
recruitment. Similar statistics are noted for BRCA2 in which the majority of women 
continue to be unaffected by cancer at follow-up.  Again with the remaining variants in 
the additional 6 genes, where data is available 12 out 16 women continue to be 
unaffected at the time of follow-up. 
Following this research, BRIP1 is a potential novel ovarian cancer susceptibility gene 
and warrants further analysis. This gene could exhibit high-penetrance amongst 
mutation carriers.  This discovery could have a major impact in the clinical diagnosis of 
prediction of risk of development of ovarian cancer. Furthermore, since these mutations 
were detected in those that were unaffected; then it would be plausible to extrapolate 
the prevalence found here and suggest that it could be doubled, this since this gene is 
likely to exhibit an autosomal dominant inheritance pattern.  
Together these data suggest that three genes BRIP1, PALB2 and NBN may potentially 
be novel ovarian cancer susceptibility genes and could be proposed for addition to 
clinical diagnostic screening for early detection and prediction of risk of ovarian cancer 
development. These could be included following further validation in large follow-up 
case control studies that examine the population frequencies of variants in these 
genes. In RAD51C 3 predicted pathogenic variants are detected supporting the 
significance of this gene in ovarian cancer.  These data indicate that the contribution of 
genes in addition to BRCA1 or BRCA2 is highly relevant and the search for the 
remaining genetic contribution to ovarian cancer development is a valuable strategy. 
These data suggest that women with moderate to high-risk mutations are very likely to 
develop ovarian cancer and this is inferred from family based data; therefore, targeting 
these women in future follow-up studies for early screening would be highly beneficial 
in early detection of disease.  
Large follow-up case-control studies will allow for the accurate prediction of the 
contribution of these novel ovarian cancer susceptibility alleles.  Large numbers of 
samples, perhaps from several combined studies in population-based research, will 
result in the accurate calculation of odds ratios and relative risk.  Only then can these 
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move to clinical genetic screening.  Even then women will require counselling on the 
level of lifetime risk of developing disease.  Discussion should centre on what risk is 
large enough to undergo RRSO. 
Ethical discussion on the women that are at substantially increased risk should centre 
on the fact that this is in the research stage and that there may be specific and 
immediate implications in terms of the clinical responsibility towards those women in 
the UKFOCSS screening study.  Ethical debate needs to urgently take place in order to 
be able to advise the women in this cohort that have been found to harbour genetic 
variants that are either currently known to increase risk of ovarian cancer development 
or could be found to increase ovarian cancer risk.  This is to allow for women taking 
part in UKFOCSS to be able to make informed choices about their current and future 
health.  
4.22 Conclusion 
In conclusion, these data suggest that there are likely to be additional alleles for 
epithelial ovarian cancer and these data give insight into which further genes could be 
examined, for example, those genes in the FA Pathway do appear to be especially 
relevant as do those in the BRCA1 pathway e.g. ATM, ATR, MRE11 and those 
associated with RAD50.  This reveals clues to further candidate genes.  These data 
indicate that BRIP1, PALB2 and NBN could potentially be included in clinical genetic 
screening, in the future, for early detection and improved risk prediction, which can only 
be introduced following further validation in large follow-up case-control studies.   
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Chapter Five 
 
General Discussion of thesis 
 
5.1 Next generation sequencing approaches for the identification of cancer 
susceptibility alleles 
 
The introduction of next generation sequencing approaches is heralding a new era in 
genetic association studies for complex diseases, including epithelial ovarian cancer. 
This rapidly advancing technology is expanding the potential of genetic studies and 
enabling affordable high-throughput research allowing for the identification of rare, 
moderate and common cancer risk alleles.  
 
5.1.1 Progress in technology during this thesis 
 
Chapters 2, 3 and 4 carefully chart the progress in NGS approaches since the start of 
this thesis in 2009.  Figure 5.1 is a flow diagram that depicts the progression of 
technology and the approaches used throughout the 3 years from 2009 to 2012.   
 
Figure 5.1 The development of NGS approaches in this thesis (2009-2012) 
 
Figure 5.1 The development of NGS approaches in this thesis.  This flow diagram charts the progress and 
development in the NGS approaches used through this thesis. This diagram shows how the increasing 
sequencing capacity of Illumina platforms is utilised to increase both throughput and genomic region 
investigated.  LR-PCR = Long Range PCR, GAIIx = Genome Analyser IIx, bp=base pairs.    
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During this progression the time it takes to prepare libraries has been reducing along 
with the cost per base to perform target enrichment, library preparation and sequencing 
runs.  Importantly, these improvements are not detrimental to depth of coverage levels 
due to the increasing capacity of NGS technology.   
 
Not only do technological improvements make large genetic association studies more 
feasible in terms of time and cost per sample; they also introduce novel approaches in 
the detection of rare, moderate and common variants. Large DNA sequencing studies 
targeting candidate genes, the whole exome or whole genome are now possible 
enabling the identification of rare variants (with minor allele frequencies <1%), which 
have been almost impossible to find previously using the GWAS approach (Cirulli & 
Goldstein 2010). 
 
5.2 Selecting the appropriate sequencing approach and study design in genetic 
studies 
 
The approaches discussed here can be applied to a variety of different genetic 
diseases not only cancer.  Most importantly, there are specific genetic characteristics 
that dictate the sequencing approach and study design most fit-for-purpose.  For 
example, different sequencing approaches and/or different study designs may be 
required whether investigating for causal or predisposing variants in Mendelian 
diseases or complex diseases (Cirulli & Goldstein 2010).  In addition, the mode of 
inheritance in the genetic disease may also be relevant in experimental design 
(Bamshad et al 2011). 
 
5.2.1 Whole exome sequencing 
 
Bamshad et al (2011) in a review paper describe both experimental design and 
analysis issues in using exome sequencing for the identification of genes in Mendelian 
diseases.  Mendelian disease can be defined as those that are inherited in either a 
dominant or recessive pattern; most often these diseases are caused by variants in a 
single gene leading to a high risk of developing the condition.  These same issues in 
design and analysis may also be relevant in complex diseases like cancer as alleles 
that predispose to cancer can be transmitted in a Mendelian fashion.  For example, the 
pedigree outlined in Chapter 4 with the BRCA1 mutation suggests that the mutation is 
inherited in an autosomal dominant pattern (refer to Figure 4.13).  Bamshad et al 
(2011) suggest that exome sequencing is useful in determining both very rare (MAF < 
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0.1%) and rare alleles (MAF <1%) as this method should be able to detect all of these 
alleles in the sample.  Tackling experimental design and data issues should also make 
exome sequencing more fruitful in dissecting these rare alleles in complex common 
disease and is thus not exclusively relevant to Mendelian or monogenic disease. 
  
The whole exome can be defined as the full set of known coding exons in the genome, 
which consists of around 1% of the whole genome (Cirulli & Goldstein 2010).  One of 
the predominant caveats in whole exome sequencing is the level of background noise. 
Background noise is derived from the abundant common polymorphic variants that 
have no effect on disease and the many sequencing artefacts found in NGS data.  For 
example, Bamshad et al (2011) report that in European American DNA samples as 
many as 20,000 single nucleotide variants are detected by exome sequencing, the 
majority of which are previously known.  They suggest that there are different 
approaches in identifying the relevant alleles within this context and consider 
differences in inheritance pattern, the population studied (i.e. family pedigrees or 
unselected cases and controls), how heterogeneous disease loci are and if the disease 
is caused by a transmitted variant or de novo variant.  In addition, these issues are 
important considerations in defining appropriate sample sizes for satisfactory statistical 
power.   
 
5.2.1.1 Filtering 
 
Many of the non-pathogenic single nucleotide variants present in the human genome 
can be filtered out in several ways. Firstly, by using data publicly available on dbSNP 
and 1000 Genomes databases. Secondly, by filtering according to minor allele 
frequency (MAF); Bamshad et al (2011) suggest including only variants with a MAF of 
0.1% or less in dominant inheritance disorders as these are likely to be very rare in the 
population.  Subsequent to filtering, the remaining variants can be separated further by 
gene function, role or relationship in a biological pathway or by prioritising according to 
variant type; for example those that are predicted to be deleterious (frameshift, 
nonsense, splice site) may be more relevant than the predicted missense variants.   
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5.2.1.2 Inheritance pattern 
 
Diseases that are inherited in a dominant or recessive pattern may require different 
levels of coverage. Intuitively, it may be expected that identifying homozygous alleles, 
using exome sequencing might be easier to detect and require lower sequencing 
coverage.  For example, 40X depth may be sufficient (for research purposes) for the 
detection of homozygous variants sought will be homozygous. It follows then that for 
dominant inheritance diseases a higher level of coverage would be necessary; perhaps 
80-100X since the variants sought will be heterozygous. However, in recessive 
disease, if variants were compound heterozygous the level of read depth required 
would be that of dominantly inherited disease. The reason for this is the proportion of 
reads for each allele.  In heterozygous variants 50% of the reads should be seen for 
each allele, whereas for homozygous 100% of the reads should be the same.  Sulonen 
et al (2011) in a study comparing exome capture techniques for exome sequencing 
suggest a coverage of 11X for 99% accuracy of calling heterozygous genotypes when 
these are compared to known SNPs from GWAS.  However, their data show that less 
than half the region covered shows coverage levels of >10X; and this is the case 
across the board for all target capture platforms.  As a rough estimate using exome 
sequencing for detection of novel SNPs a level of 20X coverage might expect to 
accurately detect ~95% of single nucleotide variants.  At 4X then, less than 50% would 
be likely to be detected.   
 
Conducting whole exome sequencing is still limited in terms of throughput and cost, so 
this type of experiment may not reveal the patients with the causative or predisposing 
mutations.  This is where experimental design can assist further by using a genetically 
enriched sample set to increase the probability of detecting variants and reduce the 
sample sizes required to reach statistical power.  Cirulli & Goldstein (2010) suggest two 
approaches in the identification of pathogenic alleles.  (1) Exome sequencing of the 
affected members of families with several cases of the disease (2) ‘Extreme trait 
sequencing’, also known as targeted genotyping, refers to the study of subjects from 
the two extremes in distribution for a phenotypic trait.  If using exome sequencing in 
ovarian cancer genetic association studies the most appropriate approach may require 
genetic enrichment by targeting those subjects with early onset disease in families with 
multiple cases (3 or more) of ovarian cancer only.  Thus, combining a family based 
approach with targeted genotyping. 
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5.3 Current research progress in the discovery of genetic risk alleles in epithelial 
ovarian cancer and clinical relevance 
 
In addition to BRCA1 and BRCA2 two new genes are identified as highly penetrant and 
predisposing to ovarian cancer, RAD51C (Meindl et al 2010) and RAD51D Loveday et 
al (2011).  Rafnar et al (2011) detect a frameshift mutation in BRIP1 that increases risk 
of ovarian cancer with an odds ratio of 8.13.  However, these new genes are very rare 
and still only represent around 40% of inherited ovarian cancer risk. In this thesis 3 
novel genes are identified as potential ovarian cancer predisposition genes (BRIP1, 
PALB2 and NBN) and these genes require targeting in follow-on studies.  This 
progress in identification of novel genes, suggests that continued searching for new 
alleles is worthwhile; whilst these are rare alleles, they could result in more than 10X 
increased lifetime risks of developing the disease (Gayther 2012).   As such these 
genes may have important relevance in the clinical management of ovarian cancer 
cases and in risk prediction and early detection.   
 
Pharoah et al (2002) suggest the genetic susceptibility to breast cancer is polygenic in 
nature and these multiple variants include rare (<1% MAF), uncommon (1% -5% MAF) 
and common (>5% MAF).  Identifying these alleles through large sequencing studies 
will contribute to risk prediction estimates and in the development of mathematical 
algorithms. 
 
Determining the functional role of these inherited risk alleles may be relevant in 
defining the biological mechanisms of ovarian cancer development and thus, these 
alleles are potentially novel targets for early disease detection.  For the coding variants 
in this research, this is easier as it is possible to assess the effect of these changes on 
the function of the encoded proteins.  In non-coding changes, such as SNPs found in 
GWAS studies, this will involve the use of further functional assays or fine mapping of 
genes.  In addition, the determination and understanding of the interactions between 
low-risk alleles and environmental factors and other genetic factors is important in 
assessing cancer susceptibility (Gayther 2012). When the full panel of ovarian cancer 
susceptibility genes are determined it will be possible to accurately estimate an 
individual’s specific ovarian cancer risk and offer the best most tailored and 
personalised medicine.   
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5.4 Personalised care in ovarian cancer: screening, early detection and targeted 
treatment 
 
Personalised cancer care involves prevention, via early detection and screening of 
high-risk patients as well as specific treatment regimen tailored to particular histological 
subtypes.  An in depth understanding of the molecular signatures and genetic 
pathways in ovarian cancer will certainly result in improved more targeted treatments 
for the disease similar to recent developments in breast cancer treatment. 
 
Since genetic screening in BRCA1/BRCA2 can steer decisions in both prevention and 
treatment of breast/ovarian cancer it is vital that this screening is the most 
comprehensive that technology allows.  Using next generation sequencing approaches 
will undoubtedly give greater accuracy and greater genomic coverage.  New 
technologies are faster and cheaper than those currently in use in clinical genetics 
laboratories, which will result in a larger proportion of women being offered genetic 
testing.  When the treatment option is the radical bilateral salpingo-oophorectomy it is 
important to ensure against false positive results and also to be sure which mutations 
pose the most risk in order to provide the most accurate risk assessment. 
 
This thesis has a significant impact on personalised medicine in several ways: 
 
1. It identifies potential novel cancer susceptibility genes that could be incorporated 
into clinical genetic screening once validated. 
2. It presents a viable screening approach in which high-risk women can be identified 
at a very early stage when prevention strategies can be implemented. 
3. It has identified likely targets for therapeutic approaches.  For example, those 
variants that are detected in genes with roles in homologous recombination may be 
sensitive to PARP inhibitors.   
4. It has established and refined robust protocols for both high-throughput research 
projects for the prediction of disease risk related susceptibility alleles for any 
complex disease, not only cancer; as well as establishing a rapid and affordable 
system for mutation detection in the clinical setting.  Thus, allowing for a much 
larger population of women to benefit from genetic screening for risk prediction and 
early detection of ovarian and/or breast cancer. 
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5.4.1 Personalised medicine 
 
Personalised medicine is a branch of medical practice that focuses on the specific 
genetic profile of an individual (or an individual’s disease) in order to guide the 
diagnosis and treatment of disease arising in that individual. In a paper produced by 
the European Science Foundation (ESF) Forward Look (2012) entitled ‘Personalised 
medicine for the European citizen’ at www.esf.org; the ESF suggests that personalised 
medicine is the provision of tailored healthcare specific to each person and that is 
conducted through prevention, diagnosis and treatment.  However, they suggest that 
the term is often defined differently and additional terminology can be used to describe 
similar medical practice.  There are distinct differences between the terms 
‘personalised medicine’, ‘genomic medicine’ or ‘stratified medicine’. Genomic medicine 
refers to sequenced genome data whereas the meaning of stratified medicine suggests 
specific populations of patients whom benefit from specific treatments.  For example, 
breast cancer patients with HER2 positive breast cancer respond to the drug 
Herceptin, whereas HER2 negative do not. As a treatment regimen the term ‘targeted 
treatment’ is often used. 
 
5.4.2 Predictive medicine 
 
By contrast, predictive medicine focuses on assessing the probability that individuals 
may develop disease at some point in their lives.  Often the result of this is an estimate 
of lifetime risk (i.e. the likelihood of disease developing by the age of 70 years). 
Predictive medicine includes genetic screening in high-risk groups and often involves 
DNA sequencing. In certain circumstances this can be conducted prenatally or on the 
neonate if early treatment strategies are important. For example for Familial 
Adenomatous Polyposis (FAP) preimplantation genetic diagnosis (PGD), prenatal 
diagnosis and neonatal or childhood DNA testing are available due to the autosomal 
dominant pattern of inheritance and almost complete penetrance (Douma et al 2010).  
Preimplantation genetic diagnostics (PGD) are conducted in very specific and rare 
circumstances; this is where embryos are screened for genetic diseases before 
implantation using in vitro fertilisation (IVF).  Specific reasons for conducting PGD are 
usually due to severe monogenic diseases and can circumvent anxieties around 
decision-making on termination of pregnancy.  PGD is now available for those with 
mutations in BRCA genes.  This is performed on embryos of patients positive for 
BRCA1 or BRCA2 and leads to the selection of embryos that are tested negative for 
BRCA mutations (Wilkinson 2012).   
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PGD is also used in determining sex of embryos in the specific circumstances of X-
linked genetic diseases in which female embryos are selected for implantation (Pray 
2008).  For example, the X-linked genetic disorder Duchene’s Muscular Dystrophy 
(DMD) is an X-linked Mendelian recessive disease, which almost never occurs in 
females due to the likelihood that offspring will not inherit two copies of the recessive 
mutant allele responsible for the disease. In the UK all PGD is closely monitored and 
agreed by the Human Fertilisation and Embryology Authority (HFEA).  The HFEA also 
regulate embryological research in the UK (www.hfea.gov.uk) 
 
5.4.4 Advantages and disadvantages of personalised and predictive medicine 
 
In practice predictive and personalised medicine often go hand in hand.  Many of the 
obvious advantages of this contemporary approach to medicine include focusing on 
prevention strategies reducing not only mortality rates, but also reducing morbidity and 
ultimately reducing cost of treatment.  This is found in the advice given to the 
population.  For example, if an individual is assessed to have a genetically elevated 
risk of heart disease that individual can make informed lifestyle decisions to help 
minimise that risk.  Diagnoses of single gene disorders, such as cystic fibrosis, are one 
of the successes of predictive medicine, in which early diagnosis results in improved 
and earlier treatment (Farrell et al 2008).  
 
Since many diseases particularly complex ones like cancer are not caused solely by a 
gene mutation, predicting the likelihood of developing a specific cancer is inherently 
problematic.  Other factors, including environmental and lifestyle issues play a major 
role in carcinogenesis.   
 
Genetic counselling prior to taking the decision to have a predictive genetic test is 
required; this must include how to deal with the results, whether these are positive or 
negative. Patients need to be fully informed in the consequences relevant to the 
specific test or disease.  Issues and questions that may need to be addressed in 
counselling might include the following: 
 
1. The test may not reveal any useful information at all – as only around half of the 
genetic predisposition to ovarian cancer has been currently elucidated 
2. If the test is positive, how will the patient deal with the possibility that the gene 
mutation has been (or could in the future) be inherited by offspring? 
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3. The current limitations of the technology employed to detect genetic mutations.  It is 
shown here that there are false positives and false negatives.  Patients need to be 
made aware of this. 
4. There may be data protection issues and other ethical issues in terms of 
employment or insurance policies. 
5. If found positive, how does the patient feel in terms of their responsibility to other 
relatives that may also harbour a faulty gene?  Should they share this information 
with them or not?  Is it their moral responsibility? 
6. If found positive, what can the patient be offered for reducing the risk of developing 
ovarian cancer?  Surgical options are radical personal choices. Is regular screening 
enough? And can regular early screening in fact increase anxiety by highlighting 
risk in daily life? 
 
Other disadvantages include concerns in the commercial ‘over-the-counter’ availability 
of genetic tests for genetic diagnosis that may hamper progress in this area.  These 
commercial tests threaten progress as they bypass health professional consultation.  
Current medical practice in genetic screening includes genetic counselling on the 
results, whether these are positive or negative.  Reduction in the price and the 
commercial race amongst private companies suggest that these ‘over-the-counter’ 
tests could be in place to those that request it (Hawkins & Ho 2012). 
 
5.5 The translation of NGS into clinical genetic screening 
 
The translation of NGS into the clinical setting for genetic diseases such as rare 
monogenic disorders is far in advance of cancer and other complex genetic diseases.  
In this area of genetics up to half of the causative genes have already been discovered 
for some 7,000 rare diseases that are caused by a single-gene.  In fact, Boycott et al 
(2013) in their recent review suggest that the remaining half will be discovered in less 
than 7 years.  
 
By contrast, in multi-gene analysis for cancer predisposition, the pace of progress is 
slower, but steady due to the complex nature of cancer syndromes (Domcheck et al 
2013).  The progress of the use of NGS technologies into diagnostics is assisted by the 
introduction of new personalised sequencers.  Illumina have introduced the new MiSeq 
sequencing system, which is a fast bench top personalised sequencer that can 
produce 15Gb data per run and 25 million sequencing reads in just 2 days.  This fully 
automated system (from sample to analysed data) produces 300 bp paired-end reads 
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making its use in clinical diagnostics very attractive and as such the technology is 
ready for use in this setting.  This introduces the potential of moving away from the 
current practice in clinical genetic testing, which involves testing one likely gene at time 
towards a multi-gene approach (Domcheck et al 2013).  Indeed, there are already 
commercially available tests, which are either cancer or disease specific that include a 
panel of genes.  These tests may be most useful in the better-defined areas of cancer 
predisposition, for example HPNCC, in which the causative genes are already 
discovered.  In this instance NGS technology provides a rapid cost-effective genetic 
screening method. In most breast and ovarian cancer this is not so clear-cut.  This is 
because there are still more genes to discover, the penetrance of these genes varies 
widely and because breast and ovarian cancer are highly heterogeneous.  Thus, 
clarification of the risks posed by novel alleles discovered in in epithelial ovarian cancer 
through this thesis and additional follow-on studies are vital before we can translate 
these into the clinical setting.  We are still in the research phase and the translation of 
this research into diagnostics, whilst may be the ultimate aim, is still some years away.  
In my view, the introduction of OvaNext (Ambry Genetics) is premature and could 
cause major anxieties in women found positive for these tests.  This panel of genes 
includes 17 genes with estimated increased cancer risks of 2-5 fold.  Many of those 
included are not yet fully defined in research, for example, BARD1, NBN, PTEN, 
PALB2 are included and these are not yet fully investigated in large studies.  In 
addition, many of these genes are implicated in other cancers and patients should be 
offered full pre-test counselling for these cancers as well.   
 
5.5.1 Pre-test counselling for multi-gene cancer predisposition clinical screening 
 
Specific pre-test counselling would be required if patients are going to undertake multi-
gene testing for cancer predisposition, which should be tailored to each individual.  The 
problem with pre-designed panels is that genes are included that are either not 
relevant or have far reaching implications. TP53 is often included and is known to be 
involved in many different cancers and therefore, is not specific.  Given the choice, 
would most patients decline this test? It is vital therefore, that patients are offered full 
counselling in a way that enables them to make informed choices about which of their 
own genes they want tested (Domcheck et al 2013).   Specific genes should be able to 
be excluded, rather than offering a set panel of genes designed as one size fits all 
approach. 
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5.6 Genetic Testing and Society 
 
5.6.1 Ethical, moral issues and legal issues 
 
5.6.1.1 The lifetime level of cancer risk:  at what level should we advise patients to take 
action? 
 
Is the answer to this question something that can be advised on or is this purely a 
subjective individual opinion? Within the scientific community questions like these 
warrant debate as they give insight into how best to advise patients in the clinic.  If it is 
possible to assess fairly accurately a person’s level of risk then it is necessary to 
consider this in terms of how this risk is managed. In clear high risk cases such as 
mutations in BRCA1 that can result in lifetime risks of up to 87% breast cancer and 
60% ovarian cancer this may be easier. However, if a person’s risk is estimated to be 
at 30%, 20% or 5% management options may be far less obvious.  For many, a 5% 
level of risk may be simply cause for increased anxiety for which no medical 
intervention is either available or useful.  Radical risk reducing surgery such as RRSO 
may be considered excessive by some women when their lifetime risk is 30% or less or 
this may be an attractive reassuring option for those with far lower risks.  The opinions 
will be very individual to each woman; whether they have children or not, age and other 
commitments may all influence a woman’s feelings on the appropriate level of risk for 
medical intervention to take place. On the other hand, many people may be interested 
in mapping out their entire genetic blueprint, although this is likely to be (in most cases) 
of very little medical benefit.  This is particularly relevant in the context of the abundant 
non-pathogenic variants previously noted in this chapter.   
 
If a healthy woman with a minimum of 2 FDR/SDR were considered to have a risk of 
10% of harbouring a mutation in a moderate-high penetrance gene would this level of 
risk be high enough to advise on risk reducing surgery or early monitoring of disease?  
The answer is probably not; but offering genetic testing could be useful in reducing 
anxiety (if found negative) or can give an accurate and specific estimate of lifetime risk 
if positive.  This would only be possible once the genetic susceptibility to ovarian 
cancer is fully defined and this could still be a long way into the future. 
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5.6.1.2 Public fear of genetics 
 
All too often genetic research presented in the media is centred on gene technologies 
and ‘designer babies’.  Scientists are banded as ‘playing god’; in reality genetic 
research has nothing to do with eugenics.  Media publicity can hamper scientific and 
medical progress by instilling such irrational fears in the wider population.  These fears 
can only be harmful to scientific and medical research.  Better, more informed and 
more accurate publicity is required to redress this balance; to allow the public to 
educate themselves on real genetic research which aims to improve and impact upon 
public health not create a supreme genetic composition of the human race. 
 
5.5.1.3 Insurance companies and genetic testing results 
 
The concordat and moratorium on genetics and insurance is a policy and practice 
document agreed between the government and the Association of British Insurers 
(ABI). The insurance genetics moratorium means that those buying insurance policies, 
apart from life insurance in excess of £500,000, will not have to declare results of a 
genetic test taken to predict disease.  In addition, insurance companies are not allowed 
to request that a person take a predictive genetic test before granting insurance.  
However, this does not prevent them from requesting information on family history of 
disease and information on any diagnostic tests taken within families and these could 
include diagnostic genetic tests.  Thus, if a close relative has been diagnosed with a 
genetic mutation in one of the known cancer predisposition genes, this could affect the 
ability to get insurance cover or the cost of that cover.  This moratorium revised in 
March 2013 will remain in place until 2017.  This moratorium is going to be reviewed in 
2014. 
 
As increasingly more knowledge is gained on the genetic susceptibility to disease the 
issues affecting insurance cover could become more complex.  In the future could 
insurance companies request a potential customer take certain predictive genetic 
tests?  How well will government safeguard the consumer in the future?  The answers 
to these questions are currently unknown and therefore, health policy to introduce 
genetic testing in the general population must carefully consider these ethical and legal 
issues.   
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5.6.1.4 Employment and workplace discrimination 
 
Issues within employment or the workplace concerning genetic testing are included in 
data protection legislation.  The Genetics Commission was an independent public body 
that was set up in 1999 to give advice to government concerning ethical, social and 
moral issues in genetic testing.  However, in 2010 this quasi-autonomous non-
governmental organisation (Quango) was closed through the government’s mass 
review on all Quangos.  Whether organisations such as these are necessary for the 
protection of those seeking predictive genetic testing will require debate.  These issues 
may simply be best addressed in government policies on employment and 
discrimination not require a separate genetics commission; indeed an organisation 
such as this may monitor and delay scientific progress in this area.  Perhaps the 
responsibility could lie with scientists becoming self-regulating.  These and related 
issues will require debate within the scientific community to allow for continued 
progression in and for the population to benefit from predictive genetic testing. 
 
5.7 Ethical and moral discussion on feedback of genetic testing results from this 
research 
 
The members of PROMISE (2016) agree that genetic testing results should not be 
returned to study volunteers and there are many reasons why these results could not 
be returned. (1) The novel variants detected in this study are not yet validated in follow-
on studies, meaning that the full clinical relevance of some of these variants is currently 
not known. (2) Accurate risk estimates cannot be calculated until many more studies 
are conducted and the results combined.  (3) Some of the BRCA1 and BRCA2 variants 
detected are variants of uncertain significance and it is not known how much these will 
affect cancer risk. (4) The clinical interpretation of moderate penetrance alleles is 
uncertain i.e. these may show relative risk between 2 and 5 (Domcheck et al 2013). (5) 
The study volunteers did not receive counselling in relation to genetic testing (as the 
trial is centred on screening) and these novel genes are identified following the end of 
the UKFOCSS screening study.   
 
However, whilst the ethics are clear there remains the moral issue in withholding 
important information on a few women in the study.  For example, the proband in the 
pedigree detailed in chapter 4 (Figure 4.13) has a mutation in BRCA1 gene, which 
means she has a very high risk of developing ovarian cancer.  In addition, she has 3 
daughters all of whom will have a 50% chance of inheriting the mutation.  If she had a 
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living affected relative she would be eligible for genetic testing and subsequently her 
daughters as well.  In a case as clear as this, the issue of our moral responsibility as 
researchers is raised.  Should we return to this debate amongst PROMISE members? 
The same could hold for the case-control study in that RAD51C and RAD51D are 
cancer susceptibility genes that result in a significantly elevated cancer risk.  One 
recommendation from this thesis is, that this is a question that needs to be addressed. 
 
5.8 Impact of this research on the health of the female population 
 
The findings in this thesis may in part contribute to novel medical strategies focused on 
risk prediction and early detection of ovarian cancer as well as all cancer.  In the near 
future more women will be able to be offered genetic testing for ovarian cancer (or 
breast cancer) susceptibility alleles as the cost of testing becomes increasingly more 
affordable.  This larger population of women would include those women with a strong 
family history, whether they have a living affected relative or not, and would include 
women with cancer diagnoses under 60 years.  The latter will become particularly 
relevant if those tumours of patients with novel DNA repair genes are found to be 
sensitive to specific chemotherapeutic agents such as PARP inhibitors.   
 
However, the full impact of these research studies may not become apparent for some 
years to come as more and similar follow-on studies are performed, published and the 
resulting data combined to allow us to fully define the genetic structure of ovarian 
cancer susceptibility.   
 
5.9 Conclusions and Future Work 
 
This thesis assists in guiding experimental design for future studies as well as giving an 
indication of which genes to prioritise.  Exome sequencing in genetically enriched 
sample sets from families affected by multiple cases of ovarian cancer and/or early 
onset disease will be extremely useful.  However, exome sequencing is still not cheap 
enough to be able to sequence the very large sample sizes to enable the identification 
of rare variants.  Therefore, the candidate gene approach will still be a valid and 
valuable one as this is the only way the appropriate level of coverage alongside the 
sample size can be achieved.  Likely candidates would continue to be those related to 
BRCA1 and BRCA2 in DNA repair and all genes in the homologous recombination 
repair pathway, the Fanconi anaemia genes and the RAD51 related genes. 
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Together the two high-throughput studies conducted here and reported on in this thesis 
probably represent the largest genetic studies in ovarian cancer to date, sequencing 
almost 5,000 DNA samples in total. Studies of this magnitude are now possible with 
next generation sequencing approaches.  In one single experiment it is conceivable 
that numerous genes can be investigated in sequencing studies of large sample sizes 
and this approach is fruitful in discovering rare susceptibility alleles for epithelial 
ovarian cancer.   
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Chapter Six 
Materials and Methods 
6.1 Methodology for Chapter Two 
Laboratory work was conducted at UCL and at Source Bioscience Plc in 
Nottingham. 
6.1.1 DNA Samples 
DNA samples from ovarian cancer cases are selected with known mutations in 
BRCA1.  Mutation identification was conducted blinded. 
6.1.2 Target Enrichment – Long Range PCR. 
6.1.2.1 Primer Design 
11 primer pairs are designed for BRCA1 using NCBI Primer-BLAST program 
This program uses Primer3 to design primers and runs a BLAST search to ensure 
primers returned are only those specific to the input template.  Primers are between 20 
and 30 nucleotides in length and have a GC content of 40-60%.   
Primers are generated using the GenBank sequences:  L78833.1 Homos sapiens 
BRCA1 (BRCA1) gene, complete cds; and NG_012772.1 Homo sapiens Breast 
Cancer 2, early onset (BRCA2). 
6.1.2.2 Search for the best performing DNA polymerase for Long Range PCR 
Several different commercially available DNA polymerases are tested to find the best 
performing product for Long Range PCR; these include several polymerases from 
Kapa Biosystems, Finnzymes, Fermentas Life Sciences and Invitrogen.  Enzymes are 
first tested using pooled genomic female DNA sourced from Promega.   
6.1.2.3 PCR Amplification 
Fragments ranging between 5kb and 10kb are generated using the Invitrogen 
SequalPrep™ Long PCR Kit with dNTPs following manufacturer’s protocols with an 
input DNA concentration of 25ng/20µl reaction volume.  Primers are included at a 
concentration of 0.5 µM for each forward and reverse primer.   Cycling Conditions are 
as follows: Initial Denature of 94oC for 2 min followed by 10 cycles of 94oC (denature) 
for 10 seconds, 65oC (variable dependent on primer annealing temperature) for 30 
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seconds and 68oC (extension) for 1min per Kb.  Then 25 cycles of 94oC (denature) for 
10 seconds then 65oC (variable) for 30 seconds and 68oC for 10 minutes + 20 seconds 
per cycle (auto extension); then a final extension at 72oC for 5 minutes and hold at 
15oC. Below is a table 6.1 detailing the size of the genomic region covered for each 
gene and the total size of PCR products including overlap. 
 
Table 6.1 Size of genomic region covered for BRCA1 and total PCR products 
including overlap 
Gene Size of Genomic Region Total Size of LR-PCR Products (includes overlap) 
 86.965 88.695 
Table 6.1. Size of genomic region covered for BRCA1 and total PCR products including overlap 
6.1.2.4 Capillary Electrophoresis 
Capillary sequencing is used to sequence a section of each LR-PCR fragment to verify 
fragments were the gene required.   
6.1.2.5 LR-PCR product clean up 
10 µl LR-PCR products per reaction are placed into wells of a 96 well plate. 4 µl 
EXOSAP-IT is placed into each well.  The plate is incubated for 15 minutes at 37oC; 
and incubated again at 80oC for a further 15 minutes.   
6.1.2.6 Sequencing reaction set up 
3 µl of cleaned up LR-PCR product is added to the wells of a 96 well plate.  3 µl the 
forward or reverse primers that are used for LR-PCR amplification are added to each 
well.  4 µl of Big Dye is added to each well.  A control well is used into which standard 
M13 primer is added.  The plate is vortexed and centrifuged briefly. 
6.1.2.7 PCR reaction 
The 96 well plate is sealed and placed on a thermal cycler with the following protocol: 
Initial denature:  
Rapid thermal ramp (10/second) to 960C, 960C for 5 min. 
25 cycles of:  
Rapid thermal ramp (10/second) to 960C, 960C for 10 seconds 
Rapid thermal ramp (10/second) to 500C, 500C for 5 seconds 
Rapid thermal ramp (10/second) to 600C, 600C for 5min 
Rapid thermal ramp (10/second) to 40C, hold at 40C for until purification 
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6.1.2.8 Sequencing reaction SEPHADEX®clean up 
10 µl PRESEQ_CL is added to samples in relevant wells of the sequencing reaction 
plate and centrifuged for 10 seconds.  The content of the sequencing reaction plate is 
added to the respective wells of the clean-up plate.  A 96 well semi skirted plate and is 
barcoded and clean up plate placed on top then centrifuged at 910g for 5 minutes to 
elute DNA. 10 µl of dH2O is added to each well in the sequencing reaction plate to 
increase the volume to 20 µl. 
6.1.2.9 Load ABI 3730 
The bar-coded plate is secured into one cassette and this cassette is loaded onto the 
input stacker before starting the ABI 3730 sequencer. 
The output sequencing trace (chromatogram) is analysed using software from Applied 
Biosystems (Sequence Scanner v1.0). 
6.1.3 Library Preparation 
One library is prepared for each sample analysed.  First 11 PCR products for each 
sample are purified using ZR-96 clean and concentrator (ZymoResearch) and 
quantified with the Quibit Fluorometer (Invitrogen); samples are then pooled in 
equimolar quantities.  Each sample is fragmented by sonication using a Bioruptor and 
purified again using Qiaquick Columns and a vacuum manifold (Qiagen).  
End repair is then performed on the fragmented DNA samples. T4 polymerase and 
klenow enzyme are used to remove the 3’ overhang and fill in the 5’ overhang and 
results in blunt ended fragments, ready for 3’ adenylation.  Samples are again purified 
on Qiaquick columns and a vacuum manifold.  An A base is then added to fragments 
using klenow fragment (3’-5’ exo minus); this allows for the fragments to be ligated to 
the adapters, which have a T overhang at their 3’ end.  Samples are then purified again 
using QiaQuick MinElute columns.  Subsequently, adapters are ligated to fragments to 
allow for them to be hybridised to the solid surface of the flow cell.  Samples are then 
purified again and at this point are stored at -20oC.   
Samples are next purified further and selected for size using an agarose gel.  This 
ensures that any un-ligated adapters are removed or those that may have ligated to 
each other; additionally this selects the appropriate size of fragments that will become 
the templates for cluster generation.  A 2% gel is prepared with 400ng/µl of Ethidium 
Bromide.  The whole of each sample (30µl) is added to wells of the gel leaving one 
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lane empty between the ladder and samples and between each sample.  The gel is run 
at 120 volts for 60 minutes.  Gel slices of 2mm are cut at ~300bp using the ladder as a 
guide.  Each gel slice is then purified using QiaQuick gel purification system.  The 
resulting purified samples are then enriched using PCR to amplify the size-selected 
fragments.  Multiplexing is achieved via the addition of a 6 base index sequence at this 
stage.  Therefore, for a paired end read 3 primers are required: one for each read and 
one for the index.  The individual index sequences are added to each sample so that 
12 samples can be sequenced in parallel.  Illumina provide 12 index primers and these 
can be used for each lane of the flow cell. Following addition of the index sequence 
and enrichment, the samples are then purified again using QiaQuick columns (Qiagen).   
6.1.4 Library validation 
Before cluster generation, the libraries require validation and quantification and this is 
performed using the Agilent Bioanalyzer 2100.  This system performs an automated 
sizing and quantitation step, delivering the information in a digital format.  DNA is 
analysed via on-chip gel electrophoresis using just 1µl of sample each time; and 
repeated in double or triplicate.  The data output reveals the size of fragments in bp 
and the concentration of DNA in nmol/l.   
6.1.5 Library normalisation and pooling 
The average concentration for each sample is calculated from the double/triplicate 
repeats.  Samples are then be pooled in appropriate quantities to ensure an equal 
concentration of DNA for each sample.   
6.2 Sequencing 
6.2.1 Cluster Generation 
Reagents for cluster generation are prepared, including hybridisation buffer, wash 
buffer, amplification buffer, linearization mix, blocking buffer and sequencing primer 
mix, as per Illumina GAII protocols (refer to the document supplied by Illumina: Single 
Read Sequencing User Guide GA2 1004831).  Reagents are then loaded into the 
cluster station and the flow cell is loaded.  Following cluster generation, sequencing 
primers are hybridised and sequencing is commenced within 4 hours. 
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6.2.2 Sequencing-by-synthesis 
76bp single read sequencing with the Genome Analyser IIx (GAIIx) involves preparing 
and installing reagents and starting the GAIIx and then checking the Quality Control 
Metrics before completing the sequencing run (full protocols are available in the 
document supplied by Illumina:  Single Read Sequencing User Guide GA2 1004831). 
6.3 Bioinformatics and Data Analysis 
6.3.1 Basic Local Alignment Search Tool (BLAST) 
DNA sequences from capillary electrophoresis are identified and confirmed as correctly 
amplified genes using the on line alignment program BLAST (Basic Local Alignment 
Search Tool).  This program searches for regions of homology between sequences, by 
matching an input nucleotide sequence to those in sequence databases.   
Bioinformatics for NGS sequencing data is performed by Bioinformaticians at Source 
BioScience Plc and involves first de-multiplexing samples to give 11 separate files.  
Then reads are aligned to the reference sequence and variants detected by software 
programs.  Two software programs are used on these data. 
6.3.2 CLC Genomics 
CLC genomics workbench is a commercially available software solution for next 
generation sequencing.  This software package performs read mapping and indel and 
SNP detection.  A trial version of this software is initially used to run a first data 
analysis on the pilot study data. 
6.3.3 CASAVA and SAMtools 
A second analysis of the data is performed as the first analysis only detected 3 indels.  
The parameters are altered so that reads are included that had coverage of <30 X.  
This means that reads are included that are in low coverage regions. 
6.3.4 Third analysis  
 
A third analysis is conducted for Exon 2 in sample Pr_B1 to ascertain why the 11bp 
deletion (189del11) is not detected. 
The FastQC program is first used to run basic quality control checks on this sample 
giving basic statistics, per base sequence quality, per sequence quality scores, per 
base sequence content, per base GC content, per sequence GC content, per base N 
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content, sequence length distribution, sequence duplication levels and overrepresented 
sequences.   
The Burrows Wheeler Aligner (BWA) program is used to align just sample Pr_B1. 
 
The SAM (Sequence Alignment Map) Format and SAMtools are used for storage and 
manipulation of sequencing reads. 
Picardtools is used to further manipulate files in SAM format, removing duplicate and 
overrepresented sequences including the indexes used to identify individual samples.  
Local realignment is performed using Picard using the Genome Analysis Toolkit 
developed by the Broad Institute.   
The Genome Analysis Toolkit (GATK) Broad Institute tools are used from GATK to 
perform data processing, variant calling and manipulation and variant QC.  These 
include the GATK IndelRealigner, multiple sequence alignment tool and the Unified 
Genotyper.    
The Integrative Genomics Viewer (IGV) program is used for data visualisation and is 
also from the Broad Institute  
Following QC checks, reads from sample Pr_B1 are aligned with BWA, and then 
duplicate sequences removed with Picard tools.  Then cleaned up sequences are re-
aligned with GATK IndelRealigner and variant detection performed on exon 2 Pr_B1 
using GATK and visualised with IGV. 
 
6.4 Methodology for Chapter Three 
Laboratory work was conducted myself at UCL, Great Ormond Street Molecular 
Genetics Laboratory and at Source Bioscience Plc. in Nottingham, UK.  Maria 
Intermaggio and Andre Kim also conducted laboratory work at University of 
Southern California (USC), USA. Dr Ed Dicks, at Strangeways Research 
Laboratory in Cambridge, UK conducted the Bioinformatics. 
6.4.1 DNA Samples 
Total number of samples available to sequence in this study is 1557 cancer cases and 
1131 controls and these are sourced from other case control studies and ovarian 
cancer registries as follows: 
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Gilda Radner Familial Ovarian Cancer Registry (GRFOCR) 
Some of these were previously screened for BRCA1/2 and in addition, there were 20 
samples that had not been screened for BRCA1/2 genes this allowed for estimation of 
false positive and false negative rates. 
MALOVA study provides early onset cases and cases with a family history or with 
serous histology and a set of healthy controls 
UKOPS (UK Ovarian Cancer Population Study) cases are samples with family history 
and serous histology and a large set of healthy controls. 
UKFOCR (UK Familial Ovarian cancer Registry) samples are ovarian cancer cases 
with a strong family history including at least one first degree relative with ovarian 
cancer.   
POL NCI ovarian case control study samples from Poland have at least one first 
degree relative with ovarian cancer. 
JAC Polish ovarian cancer study samples are healthy controls. 
AOCS (Australian Ovarian Cancer Study) cases are all serous histological subtype and 
include a set of age-matched healthy controls. 
Chapter 3 includes a summary table of all samples available for sequencing in the 
study and where they are sourced 
 
6.4.2 Target enrichment 
 
6.4.2.1 Primer Design for amplification of target regions 
Primers were designed by Fluidigm Access Array Design Team to cover the coding 
region of six candidate genes: SLX4, RAD51B, RAD51C, RAD51D, XRCC2 and 
XRCC3. Figure 6.1 shows a summary of the Fluidigm Access Arrays; the individual 
design summaries are in Appendix IV. 
.  
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Figure 6.1. Summary of the Fluidigm Access Array design   
 
Figure 6.1. Summary of Fluidigm Access Array design. This figure describes the number of amplicons 
prepared to include the coding region of each of the 6 genes.  This figure also demonstrates the overlap in 
base pairs (bp) upstream and downstream to ensure that splice sites are also included.  The figure also 
the number of amplicons (in red) in each gene with a GC% content >65%; this is flagged up as these 
amplicons may not amplify as efficiently as those with GC content <65%. 
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6.4.2.2 Wet validation  
Fluidigm, using the protocol (Figure 6.2), conduct wet validation of the primer pairs: 
Figure 6.2 Fluidigm wet validation protocol 
 
Figure 6.2 Fluidigm wet validation protocol. This figure shows the PCR reaction and cycling conditions 
for the wet validation protocol. 
6.4.2.3 Pooling of Primer Pairs  
Primer pairs are pooled at 3plex (i.e. 3 PCR reactions per well) and prepared so that 
half of a 96 well plate (48) is used.  Rows A-H are filled to column 6 with each row in 
the diagrams representing 1 well, as described in Figure 6.3. 
Figure 6.3 Pooling of primer pairs 
Column 1 
 
Column 2  
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Column 3 
 
Column 4 
 
 
 
Column 5 
 
 
 
 
Column 6 
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Figure 6.3 Pooling of primer pairs. Each image represents all rows in 1 column of the plate. Each row 
represents 1 well of a 96 well plate.  Pools are created to include columns 1-6 of a 96 well plate 
 
6.4.3 Target Enrichment and Library Preparation  
 
6.4.3.1 Overview of Multiplex Amplicon Tagging for Illumina on the 48.48 Access Array 
IFC 
 
Sequencer specific tagged amplicons are generated in two PCR reactions.  Each 
reaction is multiplexed at 3 pairs of primers in each well.  All 144 amplicons are created 
on one Access Array Integrated Fluidic Circuit (IFC).  Following the first PCR reaction, 
the products are harvested and used as a template in the second PCR reaction, during 
which the 384 barcode sequences are added along with the Illumina sequencing 
adaptors.  Each IFC produces 144 amplicons in each of 48 samples each one uniquely 
indexed to allow for the pooling of all 6,912 PCR products. 
 
Figure 6.4 Overview of Access Array System 
 
Figure 6.4 Overview of Access Array System.   
 
In summary, the Fluidigm Access Array is prepared as follows: 
• Prepare sample pre-mix and sample mix  
• Prime IFC  
• Load IFC and run Load Mix Script in IFC controller AX – pre-PCR (60 min) 
• Load IFC onto Biomark and run PCR (2.5 hours) 
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• Load harvesting reagents and run Harvest Script in IFC controller AX – post-
PCR (1 hour) 
• Transfer samples to a 96 well plate  
 
The sequence tags and sample barcodes are attached as follows: 
 
• Prepare sample pre-mix solution 
• Prepare 100 fold dilutions of harvested PCR products to be used as a template 
• Add sample pre-mix, 384 barcode and 1ul diluted harvested PCR products to 
48 wells of 96 well plate 
• Place PCR plate in FC1 thermal cycler ~ 40 min  
• Store at -200C 
 
6.4.3.2 Preparation of 20X primer solutions 
20X primer solutions for 144 primer pairs are prepared.  The table 6.2 below shows the 
primer dilution for one well (of 48 wells) with 3 primer pairs. 
 
Table 6.2 Preparation of 20X primer solutions 
Component Volume (μl) Final Concentration 
CS1-TS-F (50uM) 2.0 μl per primer 1uM 
CS2-TS-R  (50uM) 2.0 μl per primer 1uM 
20X Access Array loading reagent 5.0 μl 1X 
DNA Suspension Buffer (TE) 83.0 μl  
Total 100.0 μl  
Table 6.2 Preparation of 20X primer solutions. 
 
In a 96 well plate 4μl of each pooled forward and reverse primer pair are added at a 
mixture of 3 primer pairs in each well.  This produces enough for 20 IFC arrays.  The 
20X primer solutions are divided into 5μl aliquots.  This means that each 5μl aliquot is 
ready prepared for chip set up and to remove continued freeze/thaw cycles.  Only 4μl is 
loaded onto the access array, but 5μl prepared to allow for dead volume 
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6.4.3.3 Prime the 48.48 access array  
 
The Access Array is primed by injecting 300µl control line fluid into both of the 48.48 
access array Integrated Fluidics Circuit (IFC) accumulators, named Contaminant 
Accumulator and Interface Accumulator in Figure 6.5.  
 
Figure 6.5 The 48.48 Access Array Integrated Fluidic Circuit (IFC) 
  
Figure 6.5. The 48.48 Access Array IFC Chip. This image shows the IFC chip platform.  H = harvest 
reagent wells H1 to H4. Red arrows show were control line fluid is added to each accumulator.   
   
Then 500µl 1X Access Array Harvest reagent is added to the H1-H4 wells on the IFC 
and the Access Array is placed into the Pre-PCR IFC controller AX.  Then Prime (151x) 
script is run on the IFC controller. 
 
  
Interface 
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H
 
H
 
H
 
H
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6.4.3.4 Preparation of Sample Pre-mix Solution 
 
A master mix is prepared to a total volume sufficient for 60 reactions.  The following 
components (Table 6.3) are combined to make the master mix. 
 
Table 6.3 Preparation of sample pre-mix solution 
Component Volume (μl) Volume for 60 Reactions (μl) Final Concentration 
10X  FastStart High 
Fidelity Reaction 
Buffer without 
MgCl2 (Roche) 
0.5 30.0 1X 
25mM  MgCl2 
(Roche) 0.9 54.0 4.5mM 
DMSO (Roche) 0.25 15.0 5% 
10 mM PCR Grade 
Nucleotide Mix 
(Roche) 
0.1 6.0 200 μM 
5U/ul FastStart High 
Fidelity Enzyme 
Blend (Roche) 
0.05 3.0 0.05 U/μL 
20X Access Array 
Loading Reagent 
(Fluidigm) 
0.25 15.0 1X 
PCR Grade Water 1.95 117.0  
Total 4.0 240.0  
Table 6.3 Preparation of sample pre-mix solution. 
 
The sample pre- mix solution is vortexed for 20 seconds and centrifuged for 30 
seconds 
 
6.4.3.5 Preparation of Sample Mix Solution 
 
The sample mix solution is prepared by combining the following components (Table 
6.4) in a 96 well plate. 
 
Table 6.4 Preparation of sample mix solution 
Component Volume (μl) 
Sample Pre-Mix 4.0 
Genomic DNA (100ng/μL) 1.0 
Total 5.0 
Table 6.4 Preparation of sample mix solution 
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The sample mix solution is vortexed for 20 seconds and then centrifuged for 30 
seconds. 
 
6.4.3.6 Loading the IFC 
 
Samples and primers are pipetted to the wells of the IFC chip.  4μl of sample mix is 
pipetted to each of the 48 sample inlets on the left of the chip and 4μl of 20X primer mix 
solution is added to each of the 48 assay inlets on the right side of the chip.  The chip 
is placed into the Fluidigm Biomark and the C0t PCR protocol is run (Figure 6.6) 
 
Figure 6.6 C0t PCR protocol 
 
Figure 6.6 C0t PCR protocol.  
 
6.4.3.7 Harvesting PCR products from the 48.48 Access Array IFC 
 
In the post PCR lab 2 µl of 1X harvest reagent is pipetted into each of the sample inlets 
on the Access Array IFC.  The remaining harvest reagent is removed from the H1-H4 
wells.  600 µl of fresh 1X access array harvest reagent is added to H1-H4 wells.  The 
access array is placed into the post PCR IFC controller and the script Harvest (151x) is 
run.  When the harvest script is complete, the PCR products are removed and 
transferred from the sample inlets to the first 6 columns of a 96 well PCR plate. 
 
6.4.3.8 Attaching sequence tags and sample barcodes 
 
First, the sample pre-mix solution is prepared by combining the following components 
(Table 6.5) to produce enough sample pre-mix for 60 reactions.  Then the sample pre-
mix is vortexed for a minimum of 20 seconds and centrifuged for a minimum of 30 
seconds. 
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Table 6.5 Preparation of sample pre-mix (attaching sequence tags and barcodes) 
Component Volume (ul) Volume for 60 Reactions (ul) Final Concentration 
10X  FastStart High 
Fidelity Reaction 
Buffer without 
MgCl2 (Roche) 
2.0 120.0 1X 
25mM  MgCl2 
(Roche) 3.6 216.0 4.5mM 
DMSO (Roche) 1.0 60.0 5% 
10 mM PCR Grade 
Nucleotide Mix 
(Roche) 
0.4 24.0 200 nM each 
5U/ul FastStart High 
Fidelity Enzyme 
Blend (Roche) 
0.2 12.0 0.05 U/μL 
PCR Grade Water 7.8 468.0  
Total 15.0 900.0  
Table 6.5 Preparation of sample pre-mix. 
 
A 100-fold dilution of the harvested PCR products is then used as a template in the 
second PCR reaction.  In a 96 well plate 99 μl of PCR water is added to 48 wells.  Then 
1 μl of harvested PCR product is added to each well.  The PCR product dilutions are 
vortexed for a minimum of 20 seconds and centrifuged for a minimum of 30 seconds. 
 
6.4.3.9 Prepare sample mix solutions 
 
The following components (Table 6.6) are combined in a 96 well plate to prepare 48 
individual sample mix solutions. 
 
Table 6.6 Preparation of sample mix solutions (attaching sequence tags and 
barcodes) 
Component Volume (μL) 
Sample Pre-Mix 15.0 
Bidirectional 384 Barcode, Plate A1 (Fluidigm, PN 
100-3772) 4.0 
Diluted Harvested PCR Product Pool 1.0 
Total 20.0 
Table 6.6 Preparation of sample mix solutions 
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6.4.3.8 Thermal cycling 
 
Thermal cycling is conducted in a 96 well plate using the following protocol (Table 6.7) 
 
Table 6.7 Thermal cycling conditions to add sequence tags and sample barcodes 
PCR Stages Number of Cycles 
950C 10min 1 
950C 15 s 
600C 30 s 
720C 1 min 
15 
72720C 3 min 1 
Table 6.7 Thermal cycling conditions to add sequence tags and sample barcodes. 
 
6.4.4 Checking the barcoded PCR Products 
 
PCR products are checked using an Agilent Bioanalyzer 2100.  1 μl of each reaction is 
checked using a DNA 1000 chip from Agilent following the manufacturer’s instructions.  
The remaining products were stored at -200C 
 
6.4.5 Pooling the PCR products for each IFC array 
 
A harvest sample pool is created from each IFC array in order to prepare for 
purification and quantification.  8 pools are created, that is one pool for each IFC, by 
pooling 2 µl of each sample up to a total of 48 samples. 
 
6.4.6 Purification of the pools 
 
Purification of each individual pool is performed using AMPure XP beads.  AMPure XP 
beads are removed from the fridge and allowed to warm to room temperature for 30 
minutes. A fresh 70% ethanol solution is prepared by adding 3 mL of PCR water and 7 
mL of 100% ethanol to a 15 mL tube.  The tube of ethanol is vortexed for 5 seconds. 
The beads are vortexed for 10 seconds before adding the harvested pool and AMPure 
XP beads to one well of a 96 well plate (maximum capacity 300 μl) as detailed in Table 
6.8 
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Table 6.8 Volumes of harvest sample pool and AMPure XP beads 
Component Volume 
Harvest Sample Pool 96 μl 
AMPure XP beads 180 μl 
Table 6.8 Volumes of harvest sample pool and AMPure XP beads.  This table shows the proportions of 
harvest sample pool and AMPure XP beads used to purify the pools.  
 
The components, listed in Table 6.8, are mixed in the well by gentle pipetting and then 
vortexed for 10 minutes. The 96 well plate is then placed on the magnetic separator 
and allowed to sit for 3 to 5 minutes until the supernatant is clear and the beads are at 
the bottom of the well.  The supernatant is removed using a pipette without disturbing 
the beads.  290μL of 70% ethanol is added to the well and placed on the magnetic 
separator again and allowed to sit for 3 minutes.  The supernatant is removed without 
disturbing the beads, then a further 290μl 70% ethanol is added to each well and the 
plate left on the magnet and allowed to sit for 3 minutes.  The supernatant is removed 
without disturbing the beads and the plate centrifuged briefly, then the resulting 
supernatant removed carefully.  The plate is left to sit on the magnetic separator and 
allowed to air dry for a brief period of up to one minute.  The beads are re-suspended 
in 40 μl of nuclease free water and then vortexed for 2 minutes. The plate is then 
placed on the magnetic separator and allowed to sit for 1 minute.  The supernatant is 
removed and added to a fresh eppendorf tube ready for quantitation. 
 
6.4.7 Quantitation and normalisation of pools  
 
6.4.7.1 Quantitation 
 
Each of the pools created from individual Access Arrays are quantified using the 
Agilent Bioanalyzer 2100.  
 
6.4.7.2 Normalisation 
 
In sets of 8 these pools are pooled further in equimolar quantities to form a final pool 
for one lane of the Illumina Flow Cell.  Then each final pool (one lane) is quantified 
again using the Agilent Bioanlyzer 2100, in triplicate and the mean across these taken 
as the undiluted pool concentration. The required final concentration for sequencing 
libraries on Illumina HiSeq2000 is 10nM. Pools are diluted to this concentration ready 
for sequencing. 
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6.4.8 Dilution of pools to 10nM 
 
Pools are diluted by adding an appropriate volume of water to a volume of DNA to 
achieve the desired concentration of 10nM, using the following formula: 
 
Dilution factor = Initial Molarity ÷ Final Molarity (10nM) 
DNA volume = Final Volume (50μl) ÷ dilution factor 
 
6.4.9 Final quality control check 
 
A final QC check is performed and each diluted pool is quantified in triplicate using the 
Agilent Bioanalyzer 2100.  The actual final concentration is given as the mean across 
these triplicates. 
 
6.5 Sequencing  
 
6.5.1 Sequencing prepared tagged amplicons on the Illumina HiSeq2000. 
 
The following diagram (Figure 6.7) describes how paired end sequencing of Fluidigm 
prepared libraries is performed on the Illumina HiSeq2000 platform.  The amplicon 
produced on the Access Array contains Illumina paired end adaptors, Fluidigm custom 
sequencing primers primers and individual barcode sequences.  The paired end 
adaptors (PE1 and PE2) are required for the amplicon to hybridise to the flow cell 
surface in each of the forward and reverse directions during the sequencing procedure.  
Read 1 is the forward read (PE1 and CS1), read 2 is the index read (BC and CS2rc) 
and read 3 is the reverse read (PE2 and CS2). 
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Figure 6.7 Sequencing prepared tagged amplicons on the Illumina HiSeq2000 
 
Figure 6.7 Sequencing prepared tagged amplicons on the Illumina HiSeq2000. PE1=paired end 
adaptor, PE2=paired end adaptor 2, CS1=custom sequence tag 1, CS2=custom sequence tag 2, 
CS2rc=custom sequencing primer 2 reverse complement, BC=barcode.   
 
The diagram (Figure 6.8) overleaf describes the sequencing method further by adding 
details at the base pair level (bp). 
 
 
 
 
 
 
 
 272 
Figure 6.8 The sequencing method at the base pair (bp) level 
dsDNA construct (amplicon) 
PE1- acactgacgacatggttctaca[insert]-agaccaagtctctgcaccgta-[Index]-PE2 
PE1- tgtgactgctgtaccaagatgt[insert]-tacggtagcagagacttggtct-[Index]-PE2 
 
First read (forward) 
 
PE1-acactgacgacatggttctaca[insert]-agaccaagtctctgcaccgta-[Index]-PE2 
 
Second (Index) read 
 
PE1- acactgacgacatggttctaca[insert]-agaccaagtctctgcaccgta-[Index]-PE2 
 
Third read (reverse) 
PE1-tgtgactgctgtaccaagatgt[insert]-tacggtagcagagacttggtct-[Index]-PE2 
 
Figure 6.8 The sequencing method at the base pair (bp) level CS1 = custom sequencing primer 1, 
CS2= custom sequencing primer 2, CS2rc = custom sequencing primer 2 reverse complement.  
This diagram shows at the base pair level how sequencing is achieved. 
 
  
CS1 
CS2rc 
                                       CS2 
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6.5.2 Preparation of sequencing reagents 
 
Illumina TruSeq Reagents are used with the custom sequencing primers from Fluidigm 
(FL1 and FL2). 
 
FL1 is the sequencing primer and contains 50µM each of CS1 and CS2 primers 
(common sequence tags). 
 
FL2 is the barcode primer and contains 50µM each of the CS1rc and CS2rc primers 
 
Table 6.9 The sequences of CS1/CS2 primers. 
Primer Sequence 
CS1 5’-ACACTGACGACATGGTTCTACA-3’ 
CS2 5’-TACGGTAGCAGAGACTTGGTCT-3’ 
CS1rc 5’-TGTAGAACCATGTCGTCAGTGT-3’ 
CS2rc 5’-AGACCAAGTCTCTGCTACCGTA-3’ 
Table 6.9 The sequences of CS1/CS2 primers. 
 
Table 6.10 Preparation of reagents for read one (forward) 
Reagent Volume 
TruSeq reagent HP6 990 μl 
FL1 10 μl 
Total 1000 μl 
Table 6.10 Preparation of reagents for read one (forward) 
 
FL1 reagent is diluted according to the Table 6.10 above at a final concentration of 
0.50 µM in Illumna TruSeq reagent HP6 in a DNAse, RNAse free 0.5ml microcentrifuge 
tube.  The tube is vortexed for 30 seconds. 
 
Table 6.11 Preparation of reagents for read two (index) 
Reagent Volume 
TruSeq reagent HP8 990 μl 
FL2 10 μl 
Total 1000 μl 
Table 6.11 Preparation of reagents for read two (index) 
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The FL2 reagent is diluted according to the Table 6.11 above at a final concentration of 
0.50 µM in Illumina TruSeq reagent HP8 in a DNAse, RNAse free 0.5ml 
microcentrifuge tube.  The tube is vortexed for 30 seconds. 
 
Table 6.12 Preparation of reagents for read three (reverse) 
Reagent Volume 
TruSeq reagent HP7 990 μl 
FL1 10 μl 
Total 1000 μl 
Table 6.12 Preparation of reagents for read three (Reverse) 
 
The FL1 reagent is diluted according to the Table 6.12 above at a final concentration of 
0.50 µM in Illumina TruSeq reagent HP7 in a DNAse, RNAse free 0.5ml 
microcentrifuge tube.  The tube is then vortexed for 30 seconds. 
 
6.5.3 Cluster generation 
Cluster generation is performed on the cBot, which is a separate instrument from the 
HiSeq.  This step is performed following Illumina protocols for HiSeq2000 and is 
essentially a ‘plug and play’ process using pre-prepared Illumina reagents in sealed 96 
well plate.  This reduces any possibility of sample contamination and almost eliminates 
the hands on time for cluster generation.  Clustering takes 4 hours. 
 
First, the 96 well reagent plate is prepared by thawing and vortexing.  The foil over 
each tube in well 10 is pierced.  Then libraries are diluted to 20 pM with NaOH to 
denature; the libraries are then diluted to 10 pM with Illumina HT1 hybridisation buffer 
and 120 μl is placed into an 1 tube of an 8 tube strip (each tube represents 1 lane on 
the flow cell).  A pre-wash is performed following the instructions on the screen. The 
complete cluster generation run protocol is then selected (i.e. this performs 
amplification, linearisation, blocking and primer hybridisation).  The 96 well reagent 
plate is then loaded and following the steps on the screen.  The flow cell is then 
carefully slid into the path of the barcode scanner to be read then washed in deionised 
water and dried.  The flow cell is positioned onto the thermal stage in the cBot and the 
manifold loaded by positioning it over the flow cell and aligning it by the guide pins 
located on the thermal stage.  The manifold is then locked into position.  The outlet end 
of the manifold is connected to the outlet port and the rear clamp secured.  The sipper 
combs are aligned and secured into place.  The libraries in the 8-tube strip are loaded 
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into the ‘Template’ row on the cBot and finally the primers are loaded into the ‘Primer’ 
row.  A pre-run check is performed following on screen instructions and the run started. 
 
6.5.4 Sequencing on the HiSeq2000 
 
The prepared flow cell is now ready for loading into the HiSeq for sequencing.  The 
pre-prepared sequencing and indexing reagents are loaded into the HiSeq following 
the instructions on the screen on the instrument.  The reagents are loaded in the 
appropriate rack position inside the instrument according to the run being performed 
(i.e a dual indexed run on a paired-end flow cell).  The caps are removed from the 
reagent tubes and slid into position and aligned.  After closing the reagent door the 
reagents are set to ‘prime’.  The flow cell is then removed from the cBot and positioned 
in the HiSeq2000 by positioning the flow cell lever to position 1 and allowing the 
vacuum to engage the flow cell.  After 5 seconds the flow cell lever is moved to position 
2 and the sequencing run is started. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 276 
6.5.5 Bioinformatics and data analysis 
 
 
Figure 6.9 An overview of the bioinformatics and data analysis 
 
The pooled sequencing reads are first demultiplexed into 
separate sample files resulting in 384 samples files for each 
lane of sequencing. 
 
Primer sequences are clipped from the end of reads 
 
 
Using Burrows-Wheeler Alignment tool (BWA) the reads are 
mapped to the whole human genome sequence (hg19)  
 
The SAM format is used to store sequencing reads.  
 
Using SAMtools resulting alignments are manipulated in the 
bam format.  This enables the sorting merging and indexing of 
reads so that they can be accessed easily for further 
downstream analysis.   
 
 
 
 
 
Figure 6.9 Overview of the bioinformatics and data analysis 
Figure 6.9 shows an overview of the bioinformatics and data analysis performed by Ed 
Dicks at Strangeways Research Laboratory, Cambridge UK. 
6.5.5.1 Demultiplexing 
Demultiplexing of pooled sequencing reads is performed by Bioinformaticians at 
Source Bioscience Plc., Nottingham, UK.  This had to be conducted in four batches of 
96 samples for each sequencing lane.   
Demultiplexing 
of pooled 
sequencing 
reads 
Read Mapping 
Storage of 
aligned reads for 
downstream 
analysis 
Manipulate 
alignments -sort, 
merge, remove 
duplicates 
Variant Calling  
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and SNPs 
Variants 
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Clip primer 
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6.5.5.2 Read mapping with BWA. 
BWA (Li & Durbin 2009) is the chosen as the read alignment program and is performed 
by Ed Dicks, Strangeways Research Laboratory, Cambridge, UK. However, I tried this 
myself using the script presented here in Figure 6.10.  This program is fast and 
scalable for large numbers of samples and has the advantage of a smaller memory 
requirement compared to other read mapping programs.  BWA allows for gapped 
alignment of reads and this is essential in mapping reads containing indels.  The BWA 
output is in standard SAM (Sequence Alignment/Map) format.  This allows for the 
resulting sequencing files to use the SAMtools package for downstream analysis 
including variant calling. 
BWA is first downloaded from http://sourceforge.net/projects/bio-bwa/files/. Then the 
files are first unzipped.  Using the terminal the program required building using unix 
commands.  Directories are created so that BWA is accessible and placed in the 
correct PATH. 
The latest build of the whole human genome sequence was downloaded hg19 using 
the bundle provided by the Genome Anaysis Toolkit (GATK)  
http://www.broadinstitute.org/gsa/wiki/index.php/GATK_resource_bundle and this is 
used as the reference sequence. 
A bash shell script is written to perform the alignment against the whole human 
genome sequence in a loop to include all samples in order.  
Figure 6.10 Bash shell script written to perform the alignment against the whole 
human genome. 
#!/bin/bash 
 
#for loop run in Project_Jane_Hayward directory 
#find max depth 1 only directories 
for i in $(find /Users/janehayward/Documents/Project_Jane_Hayward -mindepth 1 -maxdepth 1 -type d); do 
echo $i 
cd "$i" 
#strip ./Sample_ from directory name 
sample=$(echo $i | awk -F'/' '{print $NF}') 
PU=$(head -n 1 L007_R1.fq | awk -F':' '{print $NF}') 
 
echo $sample $PU 
echo 
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#reference 
ref="/Users/janehayward/NGSapps/hg19/ucsc.hg19.fasta" 
 
# t = threads for quad core mac 
#bwa aln -t 3 "$ref" L007_R1.fq > L007_R1.sai 
#bwa aln -t 3 "$ref" L007_R2.fq > L007_R2.sai 
bwa aln "$ref" L007_R1.fq > L007_R1.sai 
bwa aln "$ref" L007_R2.fq > L007_R2.sai 
bwa sampe "$ref" L007_R1.sai L007_R2.sai L007_R1.fq L007_R2.fq > "$sample".sam 
 
##Convert sam to bam and add read groups 
java -Xmx2g -jar ~/NGSapps/bin/AddOrReplaceReadGroups.jar \ 
I="$sample".sam  \ 
O="$sample".sorted.RG.bam \ 
LB=Batch1 \ 
PL=illumina \ 
PU="$PU" \ 
SM="$sample" \ 
SORT_ORDER=coordinate \ 
CREATE_INDEX=true 
 
cd ../ 
 
done 
Figure 6.10 Bash shell script written to perform the alignment against the whole human genome.  
This is the script I used to learn how to perform read alignment for the first lane sequenced.  Daniel 
Leongamornlert at Institute of Cancer Research assisted with writing this script 
This script gave sorted BAM files as output.  These files sorted against the indexed 
hg19.fasta could then be viewed using Integrative Genome Viewer (IGV).  
6.5.5.3 Manipulate alignments using SAMtools 
SAM tools is downloaded from http://sourceforge.net/projects/samtools/files/ and the 
files first unzipped and using the terminal the package SAM tools is built using unix 
commands.  Again directories are created so that SAMtools is accessible and placed in 
the correct PATH.  SAMtools is chosen because the standard format is the SAM 
format; it is scalable and suitable for large sets of alignment files.  The SAM format is a 
tab delimited format with a header section and an alignment section.  The alignment 
section includes lines with 11 mandatory fields and variable optional fields.  The image 
(Figure 6.11) below shows those mandatory fields. 
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Figure 6.11 SAM tools mandatory fields  
 
Figure 6.11 SAM tools mandatory fields.  There are 11 mandatory fields in the SAM tools package 
6.5.5.4 Storage of reads for downstream analysis 
Raw sequencing files are converted to SAM format for storage of reads and 
accessibility of reads for downstream analysis. 
6.5.5.5 Manipulate alignments  
Manipulating alignments involves sorting, merging and indexing.  These manipulations 
are performed with SAM tools. 
6.5.5.6 Variant calling  
Variant calling (SNP and Indel discovery) is achieved with Genome Analysis Tool Kit, 
GATK (McKenna et al 2010). These are used for base quality score recalibration, local 
indel realignment, and SNP and INDEL discovery and genotyping across all 2,636 
samples simultaneously using standard hard filtering parameters or variant quality 
score recalibration 
GATK software and recommended practice for bam recalibration and read/base 
filtering are performed.  Quality score recalibration is conducted, however, local 
realignment and duplicate removal was not required as sequencing Fluidigm Access 
Array amplicons means that sequencing always starts from the same genomic position 
and at high depth coverage per exon; this compares to sequencing of amplicons 
generated via alternative enrichment technology (such as long range PCR and 
genomic capture) in which sequencing would begin from random points within 
amplicons so that sequences containing indels may require local realignment as in the 
pilot study.  All variants are checked in NCBI dbSNP database and where known the rs 
numbers are assigned to each. 
6.5.5.7 Variant annotation 
The final variants are annotated using ANNOVAR (Wang et al 2010).  This software 
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tool was designed by Wang et al (2010) to identify biologically important genetic 
variants.  It annotates single nucleotide variants as well as indels by assessing the 
significance of these on gene function.  This is done by calculating functional 
importance scores, distinguishing those variants previously found in 1000 Genomes 
Project data and on dbSNP 
6.5.5.8 Final filtering of variants 
This is performed to eliminate possible sequencing artefacts from real variants.  The 
following parameters are used to filter out spurious variant calls: 
• Variants detected are accepted if read depth is 15 X or more and the alternate 
allele frequency is 40% or more; or if the read depth is 30 X or more and the 
alternate allele frequency is 30% or more. 
If variants are detected in regions that did not meet these criteria then variants are 
rejected. 
6.5.5.9 Predicting which missense changes are deleterious 
 
Two programs PROVEAN and PolyPhen-2 are used to predict the functional effect of 
novel missense changes.  PROVEAN is chosen as it uses a substitution matrix, 
including 20 amino acid residues, which assesses the similarity between the subject 
sequence and the reference sequence.  PolyPhen-2 is chosen as an alternative 
comparison tool to evaluate concordance between the two programs and to ensure that 
those missense variants that are likely to be pathogenic are not missed.  
6.6 Methodology for Chapter Four 
Laboratory work was conducted myself in UCL and in the Great Ormond Street 
Molecular Genetics Laboratory.  Maria Intermaggio and Andre Kim also 
conducted laboratory work at University of Southern California (USC) 
Bioinformatics was conducted by Christopher K Edlund at USC. 
The same NGS analysis is conducted as described in the previous section detailing the 
methodology for chapter 3. This study started by including 10 candidate genes, 
however, 1 gene (TiPARP) is removed from the analysis, as this does not elicit any 
data. These remaining 9 genes are both known and unknown ovarian cancer 
susceptibility genes and are sequenced in 2,300 women that are part of a clinical 
screening trial for ovarian cancer, the UK Familial Ovarian Cancer Screening Study 
(UKFOCSS).  
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6.6.1 DNA Samples 
 
6.6.1.1 UK Familial Ovarian Cancer Screening Study (UK FOCSS) 
 
This study recruits women with an increased risk of developing ovarian cancer due to 
family history or an inherited predisposition to the disease. Screening takes the form of 
an annual CA125 blood test (a tumour marker) alongside annual transvaginal 
ultrasound scanning of the ovaries (Figure 6.12).  Later this would be increased to 3 
screening visits per year for blood and ultrasound tests. 
 
The primary aim of UK FOCSS is to establish an approach for screening for ovarian 
cancer. This approach requires examining parameters such as screening intervals, 
types of screening test and also includes assessments of cost and morbidity. In 
addition the study creates a serum bank, which will be invaluable in researching novel 
tumour markers. 
 
All of the women sequenced in this 9 gene candidate study are in the UKFOCSS study 
and therefore, were at a significantly increased risk of developing ovarian cancer.   
 
 
Figure 6.12 UK FOCSS study design 
  
Figure 6.12 UK FOCSS study design.  This flow diagram describes the UK FOCSS study design 
investigating screening strategy for high-risk women 
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6.6.2 Target enrichment 
 
The study sequences the coding regions only of known ovarian cancer susceptibility 
genes (BRCA1, BRCA2, RAD51C and RAD51D) and novel candidate genes BRIP1, 
PALB2, NBN, BARD1, and RAD51B.   
 
6.6.2.1 Primer design  
 
RAD51B, RAD51C, RAD51D primers are used from the previous study (Chapter 3 
Methodology) and designed by the Fluidigm Primer Design service.  BRCA1, BRCA2 
primers are designed by Honglin Song from Strangeways Research Laboratory in 
Cambridge University.  Primers for candidate genes BRIP1, PALB2, BARD1 and NBN 
are designed by myself using the NCBI Primer BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
6.6.2.2 Primer multiplexing and pooling 
 
Primers are multiplexed to a maximum of 10 amplicons per well on the Fluidigm 
Access Array platform meaning that PCR reactions amplifying all coding regions of all 
9 genes are conducted on one Access Array chip.   
 
The forward and reverse primer pairs are pooled following the recommended criteria 
suggested in the Fluidigm Access Array protocols as follows: 
 
1. Primer pairs that produce overlapping PCR products are not mixed in the same 
well.  This is especially relevant where more than one primer set is required to 
cover an exon in which case these primer sets are positioned in separate wells. 
2. Primer sets are amplifying regions that are at least 5Kb apart when mixed in the 
same well. 
3. Primer sets are mixed that are within an amplicon size range of 20% of the average 
size of the pool.  Generally, amplicons between 140bp and 210bp were aimed for. 
4. Primer pairs with a similar GC % content were mixed in the same well. 
5. Primers are designed to be specific to the desired regions, i.e. they do not have 
multiple annealing sites within the sample DNA template; this is verified by using 
NCBI BLAST on line tool to ensure that targets are specific. 
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6.6.2.3 Pooling of primer pairs on the Fluidigm Access Array 
 
48 pools were created from 406 amplicons the tables in Appendix X describe the 
location of each primer pair.  
 
6.6.3 Library preparation  
 
6.6.3.1 Multiplex amplicon tagging for Illumina on the 48.48 Access Array IFC 
 
Sequencer specific tagged amplicons are generated in two PCR reactions as in the 
previous study.  Each reaction is multiplexed at a maximum of 10 pairs of primers in 
each well.  406 amplicons are created on one Access Array Integrated Fluidic Circuit 
(IFC).  Following the first PCR reaction, the products are harvested and then used as a 
template in the second PCR reaction, during which the 384-barcode sequences are 
added along with the Illumina sequencing adaptors.  Each IFC produces 406 
amplicons in each of 48 samples, each one uniquely indexed to allow for the pooling of 
all 19,488 PCR products. 
 
Table 6.13 Preparation of 20X primer solutions 
Component Volume (μl) Final Concentration 
CS1-TS-F (50uM) 6.0 per primer 1μM 
CS2-TS-R  (50uM) 6.0 per primer 1μM 
20X Access Array loading 
reagent 15.0  1X 
DNA Suspension Buffer 
(TE) 165.0  
Total 300.0   
Table 6.13 Preparation of 20X primer solutions 
 
Where there are less than 10 primer pairs in the well additional DNA suspension buffer 
is added to maintain correct primer concentration.   
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6.6.3.2 Preparation of 20X primer solutions 
 
20X primer solutions for 406 primer pairs are prepared.  The Table 6.13 above shows 
the primer dilution for one well (of 48 wells) with 10 primer pairs. 
 
In a 96 well plate 12μl of each pooled forward and reverse primer pair are added at a 
mixture of up to 10 primer pairs in each well.  This produces enough for 60 Access 
Arrays.  The 20X primer solutions are divided into 5μl aliquots.  This means that each 
5μl aliquot is ready prepared for chip set up and to eliminate continued freeze/thaw 
cycles.  Only 4μl is loaded onto the access array, but 5μl prepared to allow for dead 
volume. 
 
The set-up of the Fluidigm Access Array system is described previously.  Access array 
chips are prepared in an identical manner as for Chapter 3 Methodology for the case-
control study. 
 
6.6.3.3 Priming, set up and running the 48.48 access array  
Priming the chips, setting up and running of each Access Array is performed in an 
identical manner to that in the former study and is previously described. 
 
6.6.3.4 Checking the barcoded PCR Products 
 
PCR products are checked using an Agilent Bioanalyzer 2100 as described in the 
previous study. 
 
6.6.3.5 Pooling and purification of PCR products for each Access Array 
 
Pooling and purification of PCR products for each Access Array is conducted in an 
identical manner to that described for the previous study. 
 
6.6.3.6 Quantitation and normalisation of pools  
 
Quantitation and normalisation of pooled PCR products is conducted in an identical 
manner to the previous study and is already described. 
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6.6.3.7 Dilution of pools to 10nM 
 
Dilution of pools is achieved in an identical manner to that previously described for the 
case-control study. 
 
6.6.3.8 Final quality control check 
 
A final QC check is performed.  Each diluted pool is quantified in triplicate using the 
Agilent Bioanalyzer 2100.  The actual final concentration is given as the mean across 
the triplicate repeats. 
 
6.6.4 Sequencing 
6.6.4.1 Sequencing prepared tagged amplicons on the Illumina HiSeq2000. 
 
Preparation of sequencing reagents (Illumina TruSeq) and sequencing on the Illumina 
HiSeq2000 are performed in an identical manner to that in the previous study. 
 
6.6.4.2 Cluster generation 
 
Clustering is performed on the CBot following Illumina protocols for HiSeq2000 
described in detail for the case-control study. 
 
6.6.5 Bioinformatics and data Analysis 
The Bioinformatics and data analysis are performed by Scientists at University of 
Southern California (USC) as follows, information provided by Christopher K 
Edlund (5-9-2013) 
Sequencing reads are generated by the USC Epigenome Center using the Illumina 
HiSeq2000 instrument. A total of six lanes are run using 384-barcoded samples pooled 
together in each lane. 
Sequencing reads are de-multiplexed and aligned to the hg19 genome (updated chrM, 
randoms included, haps removed) using BWA version 0.6.1-r104, resulting in one BAM 
file per sample. 
Reads mapping outside the targeted regions are removed using the intersectBed tool 
in the bedTools software. 
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Reads are aligned around indels using the GATK IndelRealigner tool and known indels 
used for realignment are obtained from the following VCF files: Mills_and 
1000G_gold_standard.indels.hg19.vcf and 1000G_phase1.indels.hg19.vcf. 
For each read starting inside a primer, all bases overlapping and on the same strand 
as the primer are soft-clipped. 
Samples are merged together by lane for running the GATK BaseRecalibrator too 
available:http://www.broadinstitute.org/gatk/gatkdocs/org_broadinstitute_sting_gatk_wa
lkers_bqsr_BaseRecalibrator.html. A recalibration table is generated for each lane 
using the default covariates in GATK. Known variants sites used in this process are 
obtained from the following VCF files: 
Mills_and_1000G_gold_standard.indels.hg19.vcf, 1000G_phase1.indels.hg19.vcf, and 
dbsnp_137.hg19.chrMT.vcf. Base quality scores are recalibrated for each sample 
using the recalibration table. Samples are then unmerged. 
The GATK ReduceReads tool is used to compress each BAM file. Default settings are 
used. 
The GATK UnifiedGenotyper tool is used to call variants with all reduced BAM files as 
input. The following settings are used: 
--dbsnp $GATK/resources/dbsnp_137.hg19.chrMT.vcf  
 -stand_call_conf 30.0 
 -stand_emit_conf 30.0 
-dcov 1000 
 --min_base_quality_score 20 
 --output_mode EMIT_VARIANTS_ONLY 
 --genotype_likelihoods_model BOTH 
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Appendix I  
 
Table of LR-PCR primer sequences and their position on the reference sequence 
L78833.1 
Fragment Primer Sequence Start  Stop 
Size 
Kb 
BRCA1_1 
Prom-intron 2 
Forward AGTGTCACCACCCCAAGGACTCTCT 122 146 
9.5  
Reverse ACGACTAACCTGGCAGTGTGACAAG 9623 9599 
BRCA1_2 
Intron 2-3 
Forward ACTGTCCACAAGCTTTTCTTGTGATCC 9415 9441 
9.5  
Reverse ACAATTCAGAGCAGGGGTAGGGAGG 19000 18976 
BRCA1_3BFint3 
BRCA1_3BRint6 
 
Forward TGTATAGACTACAGCACGAGACAGCTT 18898 18924 
5.009 
Reverse ACAGCACTTGAGTTGCATTCTTGGG 23906 23882 
BRCA1_3CFint6 
BRCA1_3DRint8 
Forward TGTGCTTTTCAGCTTGACACAGGT 23836 23859 
5.177 
Reverse AGCTCTTCTTAAAAGGCTTCCTCATCTAGT 29606 29577 
BRCA1_4A 
Intron 7-Exon 11 
Forward CCAGACATTTTAGTGTGTAAATTCCTGGGC 28686 28715 
8.415 
Reverse CACTGTGAAGAAAACAAGCTAGCAGAAC 37100 37073 
BRCA1_11BF 
BRCA1_13R 
Forward AGCCCTTTCACCCATACACA 36772 36791 
9.411 
Reverse CAGGTTATGTTGCATGGTATC 46162 46183 
BRCA1_5A 
Intron 12- 13 
 
Forward ACATCAAGTCTATTTGGGGGAATTTGAGG 45915 45943 
6.047 
Reverse TGCAACAGACAGATGCTAGCACCAAA 51961 51936 
BRCA1_6A 
Intron 13-16 
Forward AGCCTTGTCTCAGCTGGGTGTCT 51849 51871 
6.436 
Reverse GCAGGGCAGAAGTGGCAGGG 58284 58265 
BRCA1_7 
Intron 16-19 
Forward GGCTTGTAAGAATGCCCTGCCACTT 58251 58275 
9.2 
Reverse CCTAGTGCCCAGAACACAGTAGGCT 67271 67247 
BRCA1_8 
Intron 19-20 
Forward ATTGGGAGCCTACTGTGTTCTGGG 67241 67264 
10.0 
Reverse AGAGGCTTGGATGGCTAGAAACTCA 77242 77218 
BRCA1_9 
Intron 20 to 
beyond polyA 
tail 
Forward AGAGGAGACAAGGAGCATGTACACC 77102 77126 
10.0 
Reverse CAGGTTGCTGGCCCCACCTGTCTGG 87087 87063 
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Appendix II 
Agilent trace output of 12 samples 
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Appendix III  
Coverage Data for 11 Samples 
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Appendix IV 
Genomic co-ordinates of amplicons for 6-gene study  
The following tables are the genomic co-ordinates for each amplicon in each gene. The 
genomic co-ordinates refer to human genome build GRCh37/hg19 February 2009. 
 
RAD51B 
Gene Amplicon Chr Genomic Co-ordinates 
RAD51L1_t1_1 chr14 68290158 68290345 
RAD51L1_t1_2 chr14 68290283 68290477 
RAD51L1_t10_1 chr14 68944284 68944475 
RAD51L1_t11_1 chr14 68963773 68963971 
RAD51L1_t2_1 chr14 68292104 68292274 
RAD51L1_t2_2 chr14 68292189 68292377 
RAD51L1_t3_1 chr14 68301683 68301876 
RAD51L1_t3_2 chr14 68301803 68301977 
RAD51L1_t4_1 chr14 68331636 68331821 
RAD51L1_t4_2 chr14 68331731 68331930 
RAD51L1_t5_1 chr14 68352517 68352697 
RAD51L1_t5_2 chr14 68352596 68352785 
RAD51L1_t6_1 chr14 68353657 68353851 
RAD51L1_t6_3 chr14 68353821 68354017 
RAD51L1_t6r_2 chr14 68353747 68353920 
RAD51L1_t7_1 chr14 68758545 68758738 
RAD51L1_t8_1 chr14 68878090 68878285 
RAD51L1_t9_1 chr14 68934826 68935022 
 
RAD51C 
Gene Amplicon Chr Genomic Co-ordinates 
RAD51C_t1_1 chr17 56769915 56770114 
RAD51C_t1_2 chr17 56770032 56770219 
RAD51C_t2_1 chr17 56772177 56772374 
RAD51C_t2_3 chr17 56772293 56772491 
RAD51C_t2_4 chr17 56772391 56772583 
RAD51C_t3_1 chr17 56773965 56774164 
RAD51C_t3_3 chr17 56774099 56774288 
RAD51C_t4_1 chr17 56780503 56780687 
RAD51C_t4_2 chr17 56780547 56780744 
RAD51C_t5_1 chr17 56787127 56787308 
RAD51C_t5_2 chr17 56787219 56787398 
RAD51C_t6_1 chr17 56798064 56798180 
RAD51C_t6_2 chr17 56798116 56798237 
RAD51C_t7_1 chr17 56801334 56801532 
RAD51C_t8_1 chr17 56809766 56809950 
RAD51C_t9_1 chr17 56811368 56811546 
RAD51C_t9_2 chr17 56811471 56811649 
 
 
 320 
RAD51D 
Gene Amplicon Chr Genomic Co-ordinates 
RAD51L3_t1_1 chr17 33446493 33446664 
RAD51L3_t10_1 chr17 33428158 33428357 
RAD51L3_t10_2 chr17 33428224 33428419 
RAD51L3_t11_1 chr17 33427905 33428098 
RAD51L3_t2_1 chr17 33446066 33446256 
RAD51L3_t3_1 chr17 33445439 33445618 
RAD51L3_t3_2 chr17 33445486 33445684 
RAD51L3_t4_10 chr17 33443921 33444094 
RAD51L3_T4r_6 chr17 33443828 33444000 
RAD51L3_t5_1 chr17 33434328 33434525 
RAD51L3_t6_1 chr17 33433949 33434138 
RAD51L3_t6_2 chr17 33433991 33434187 
RAD51L3_t7_1 chr17 33433343 33433530 
RAD51L3_t8_1 chr17 33430401 33430599 
RAD51L3_t9_1 chr17 33430193 33430372 
 
XRCC2 
Gene Amplicon Chr Genomic Co-ordinates 
XRCC2_t1_1 chr7 152373031 152373227 
XRCC2_t2_1 chr7 152357715 152357901 
XRCC2_t3_1 chr7 152345680 152345871 
XRCC2_t3_1r_1 chr7 152345730 152345916 
XRCC2_t3_1r_3 chr7 152345919 152346111 
XRCC2_t3_4 chr7 152345847 152346021 
XRCC2_t3_6 chr7 152346023 152346203 
XRCC2_t3_6r_1 chr7 152346086 152346283 
XRCC2_t3_8 chr7 152346180 152346364 
XRCC2_t3_9 chr7 152346259 152346438 
XRCC2_t3s_1 chr7 152346296 152346494 
 
XRCC3 
Gene Amplicon Chr Genomic Co-ordinates 
XRCC3_t1_1 chr14 104177316 104177500 
XRCC3_t2_1 chr14 104174802 104174999 
XRCC3_t2_2 chr14 104174852 104175044 
XRCC3_t3_1 chr14 104173272 104173461 
XRCC3_t3_2 chr14 104173402 104173579 
XRCC3_t4_1 chr14 104169454 104169641 
XRCC3_t4_2 chr14 104169494 104169690 
XRCC3_t5_1 chr14 104165642 104165828 
XRCC3_t5_2 chr14 104165758 104165947 
XRCC3_t6_1 chr14 104165350 104165547 
XRCC3_t7_1 chr14 104165055 104165234 
XRCC3_t7_3 chr14 104165214 104165390 
XRCC3_t7r_2 chr14 104165179 104165355 
 
 
 
 321 
SLX4 
Gene Amplicon Chr Genomic Co-ordinates 
SLX4_13r_3 chr16 3634763 3634958 
SLX4_t10_1 chr16 3644414 3644589 
SLX4_t10_3 chr16 3644479 3644667 
SLX4_t11_1 chr16 3642631 3642817 
SLX4_t11_2 chr16 3642733 3642931 
SLX4_t12_1 chr16 3638929 3639127 
SLX4_t12_10 chr16 3639820 3640019 
SLX4_t12_10r_2 chr16 3639919 3640117 
SLX4_t12_13 chr16 3639997 3640181 
SLX4_t12_14 chr16 3640094 3640276 
SLX4_t12_15 chr16 3640185 3640381 
SLX4_t12_16 chr16 3640286 3640480 
SLX4_t12_17 chr16 3640387 3640568 
SLX4_t12_17r_1 chr16 3640475 3640656 
SLX4_t12_17r_2 chr16 3640583 3640768 
SLX4_t12_2 chr16 3639009 3639203 
SLX4_t12_20 chr16 3640687 3640859 
SLX4_t12_21 chr16 3640778 3640952 
SLX4_t12_22 chr16 3640864 3641063 
SLX4_t12_23 chr16 3640965 3641155 
SLX4_t12_23r_1 chr16 3641025 3641210 
SLX4_t12_23r_2 chr16 3641142 3641341 
SLX4_t12_23r_3 chr16 3641226 3641425 
SLX4_t12_9 chr16 3639719 3639896 
SLX4_t12s_1 chr16 3639108 3639299 
SLX4_t12s_2 chr16 3639209 3639394 
SLX4_t12s_3 chr16 3639307 3639497 
SLX4_t12s_4 chr16 3639401 3639587 
SLX4_t12s_5 chr16 3639519 3639718 
SLX4_t12s_6 chr16 3639614 3639790 
SLX4_t13_1 chr16 3633008 3633195 
SLX4_t13_2 chr16 3633116 3633286 
SLX4_t13_3 chr16 3633202 3633382 
SLX4_t13_4 chr16 3633301 3633480 
SLX4_t13_5 chr16 3633395 3633583 
SLX4_t13s_1 chr16 3634661 3634859 
SLX4_t14_1 chr16 3632272 3632444 
SLX4_t14_2 chr16 3632346 3632538 
SLX4_t14_3 chr16 3632465 3632664 
SLX4_t14_4 chr16 3632556 3632726 
SLX4_t2_29 chr16 3658392 3658564 
SLX4_t2_33 chr16 3658543 3658742 
SLX4_t2_34 chr16 3658660 3658835 
SLX4_t2_35 chr16 3658743 3658941 
SLX4_t2_37 chr16 3658897 3659079 
SLX4_t2r_2 chr16 3658507 3658692 
SLX4_t3_1 chr16 3656329 3656526 
SLX4_t3_2 chr16 3656444 3656623 
SLX4_t3_3 chr16 3656545 3656740 
SLX4_t3_4 chr16 3656647 3656846 
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SLX4_t4_1 chr16 3652019 3652216 
SLX4_t4_3 chr16 3652190 3652362 
SLX4_t4r_2 chr16 3652126 3652319 
SLX4_t5_1 chr16 3650883 3651078 
SLX4_t5_2 chr16 3650982 3651171 
SLX4_t5_3 chr16 3651083 3651257 
SLX4_t7_1 chr16 3647264 3647447 
SLX4_t7_2 chr16 3647351 3647550 
SLX4_t7_3 chr16 3647464 3647646 
SLX4_t7_4 chr16 3647556 3647727 
SLX4_t7_5 chr16 3647659 3647829 
SLX4_t7_6 chr16 3647750 3647935 
SLX4_t7_7 chr16 3647858 3648033 
SLX4_t7_8 chr16 3647946 3648116 
SLX4_t8_1 chr16 3646027 3646226 
SLX4_t8_3 chr16 3646204 3646403 
SLX4_t8_4 chr16 3646292 3646484 
SLX4_t8r_2 chr16 3646147 3646344 
SLX4_t9_1 chr16 3645475 3645671 
SLX4_t9_2 chr16 3645586 3645760 
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Appendix V 
Amplicon maps of target regions for 6-gene study 
The following diagrams are amplicon maps of target regions for each gene 
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Appendix VI 
Fluidigm Access Array PCR (6 gene study) results 
Agilent Bioanalyzer 2100 results 
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IFC 2 
 
 
IFC 3 
 
 327 
 
IFC 4 
 
 
 
 
 
 
 328 
IFC 5 
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Appendix VII  
Final concentration and dilutions for each lane  
ID Initial Molarity Vol DNA Vol H2O 
Required Final 
Molarity 
Lane 1 Pool 211.1 2.37 47.63 10 nM 
Lane 2 Pool 74.7 6.7 43.3 10 nM 
Lane 3 Pool 71.8 6.9 43.1 10 nM 
Lane 4 Pool 196.3 2.58 47.42 10 nM 
Lane 5 Pool 44.56 11.23 38.77 10 nm 
Lane 6 Pool 201.4 2.48 47.52 10 nM 
Lane 7 Pool 81.1 6.17 43.83 10 nM 
 
 Appendix VIII  
Dilution and final QC for flow cell 
Once diluted each final pool is quantified in triplicate using the Agilent Bioanalyzer.  
The mean is calculated and used as the actual final molarity for pools 
Lane ID Final Molarity (nM) 
Lane 1 7.0 
Lane 2 11.2 
Lane 3 9.5 
Lane 4 8.1 
Lane 5 8.7 
Lane 6 11.4 
Lane 7 9.9 
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Appendix IX  
 
 
Genomic co-ordinates of amplicons for additional genes for the 9-gene study 
 
The following tables and images give the genomic co-ordinates for each amplicon.  
Genomic co-ordinates refer to human genome build GRCh37/hg19 February 2009 
BRCA1 
Amplicon chr Start End 
BRCA1_ex2_1 chr17 41275935 41276143 
BRCA1_ex3_1 chr17 41267715 41267905 
BRCA1_ex5_1 chr17 41258424 41258631 
BRCA1_ex6_1 chr17 41256828 41257012 
BRCA1_ex7_1 chr17 41256179 41256380 
BRCA1_ex7_2 chr17 41256125 41256330 
BRCA1_ex8_1 chr17 41251822 41252016 
BRCA1_ex8_2 chr17 41251728 41251916 
BRCA1_ex9_1 chr17 41249269 41249472 
BRCA1_ex9_1r chr17 41249238 41249431 
BRCA1_ex9_2 chr17 41249204 41249333 
BRCA1_ex10_1 chr17 41247812 41248010 
BRCA1_ex11_1 chr17 41246725 41246923 
BRCA1_ex11_2 chr17 41246611 41246816 
BRCA1_ex11_3 chr17 41246489 41246698 
BRCA1_ex11_4 chr17 41246432 41246591 
BRCA1_ex11_5 chr17 41246346 41246517 
BRCA1_ex11_6 chr17 41246248 41246455 
BRCA1_ex11_7 chr17 41246143 41246351 
BRCA1_ex11_8 chr17 41246056 41246217 
BRCA1_ex11_9 chr17 41245978 41246135 
BRCA1_ex11_10 chr17 41245825 41246030 
BRCA1_ex11_11 chr17 41245726 41245932 
BRCA1_ex11_12 chr17 41245629 41245813 
BRCA1_ex11_13 chr17 41245504 41245713 
BRCA1_ex11_14 chr17 41245430 41245630 
BRCA1_ex11_15 chr17 41245358 41245542 
BRCA1_ex11_16 chr17 41245207 41245410 
BRCA1_ex11_17 chr17 41245129 41245318 
BRCA1_ex11_18 chr17 41245011 41245216 
BRCA1_ex11_19 chr17 41244921 41245120 
BRCA1_ex11_20 chr17 41244805 41245000 
BRCA1_ex11_21 chr17 41244689 41244891 
BRCA1_ex11_22 chr17 41244600 41244786 
BRCA1_ex11_23 chr17 41244473 41244682 
BRCA1_ex11_24 chr17 41244417 41244614 
BRCA1_ex11_25 chr17 41244293 41244481 
BRCA1_ex11_26 chr17 41244213 41244402 
BRCA1_ex11_27 chr17 41244102 41244295 
BRCA1_ex11_28 chr17 41243995 41244197 
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BRCA1_ex11_29 chr17 41243875 41244080 
BRCA1_ex11_31 chr17 41243852 41243983 
BRCA1_ex11_30 chr17 41243758 41243898 
BRCA1_ex11_32 chr17 41243670 41243879 
BRCA1_ex11_33 chr17 41243604 41243793 
BRCA1_ex11_34 chr17 41243455 41243655 
BRCA1_ex11_35 chr17 41243368 41243567 
BRCA1_ex12_1 chr17 41242904 41243110 
BRCA1_ex13_1 chr17 41234497 41234646 
BRCA1_ex13_2r chr17 41234400 41234556 
BRCA1_ex13_2 chr17 41234369 41234566 
BRCA1_in13_1 chr17 41231312 41231476 
BRCA1_ex14_1 chr17 41228464 41228653 
BRCA1_ex15_1 chr17 41226443 41226609 
BRCA1_ex15_2r chr17 41226316 41226503 
BRCA1_ex16_1r chr17 41223199 41223398 
BRCA1_ex16_1 chr17 41223130 41223311 
BRCA1_ex16_2 chr17 41223050 41223251 
BRCA1_ex16_3 chr17 41222901 41223096 
BRCA1_ex17_1 chr17 41219567 41219776 
BRCA1_ex18_1 chr17 41215840 41216029 
BRCA1_ex19_1 chr17 41215258 41215442 
BRCA1_ex20_1 chr17 41209045 41209232 
BRCA1_ex21_1 chr17 41203032 41203166 
BRCA1_ex22_1 chr17 41201071 41201275 
BRCA1_ex23_1 chr17 41199621 41199755 
BRCA1_ex24_1 chr17 41197714 41197895 
BRCA1_ex24_2 chr17 41197574 41197757 
 
BRCA2  
Amplicon chr Start End 
BRCA2_ex1_1 chr13 32890475 32890673 
BRCA2_ex1_2 chr13 32890571 32890753 
BRCA2_ex2_1 chr13 32893173 32893381 
BRCA2_ex2_2 chr13 32893249 32893426 
BRCA2_ex3_1 chr13 32899205 32899334 
BRCA2_ex4_1 chr13 32900202 32900400 
BRCA2_ex6_1 chr13 32900582 32900786 
BRCA2_ex7_1 chr13 32903475 32903668 
BRCA2_ex8_1 chr13 32904995 32905180 
BRCA2_ex9_1 chr13 32906365 32906514 
BRCA2_ex9_2 chr13 32906405 32906604 
BRCA2_ex9_3 chr13 32906512 32906710 
BRCA2_ex9_4 chr13 32906612 32906786 
BRCA2_ex9_5 chr13 32906717 32906879 
BRCA2_ex9_6 chr13 32906760 32906969 
BRCA2_ex9_7 chr13 32906848 32907051 
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BRCA2_ex9_8 chr13 32906967 32907169 
BRCA2_ex9_9 chr13 32907062 32907270 
BRCA2_ex9_10 chr13 32907219 32907384 
BRCA2_ex9_11 chr13 32907326 32907512 
BRCA2_ex9_11r chr13 32907328 32907512 
BRCA2_ex9_12 chr13 32907462 32907592 
BRCA2_ex10_1 chr13 32910341 32910505 
BRCA2_ex10_2 chr13 32910454 32910654 
BRCA2_ex10_3 chr13 32910583 32910749 
BRCA2_ex10_4 chr13 32910671 32910857 
BRCA2_ex10_5 chr13 32910787 32910992 
BRCA2_ex10_5r chr13 32910803 32911001 
BRCA2_ex10_6 chr13 32910906 32911074 
BRCA2_ex10_7 chr13 32910983 32911134 
BRCA2_ex10_8 chr13 32911192 32911396 
BRCA2_ex10_9 chr13 32911249 32911431 
BRCA2_ex10_10 chr13 32911360 32911557 
BRCA2_ex10_10r chr13 32911339 32911533 
BRCA2_ex10_11 chr13 32911509 32911678 
BRCA2_ex10_12 chr13 32911620 32911821 
BRCA2_ex10_12r chr13 32911622 32911812 
BRCA2_ex10_13 chr13 32911753 32911925 
BRCA2_ex10_14 chr13 32911796 32911940 
BRCA2_ex10_15 chr13 32911888 32912028 
BRCA2_ex10_16 chr13 32911986 32912151 
BRCA2_ex10_17 chr13 32912045 32912250 
BRCA2_ex10_18 chr13 32912247 32912443 
BRCA2_ex10_19 chr13 32912285 32912479 
BRCA2_ex10_20 chr13 32912423 32912571 
BRCA2_ex10_20r1 chr13 32912467 32912630 
BRCA2_ex10_20r2 chr13 32912384 32912516 
BRCA2_ex10_21 chr13 32912499 32912692 
BRCA2_ex10_22 chr13 32912642 32912809 
BRCA2_ex10_23 chr13 32912716 32912877 
BRCA2_ex10_24 chr13 32912830 32913015 
BRCA2_ex10_25 chr13 32912916 32913078 
BRCA2_ex10_26 chr13 32912977 32913156 
BRCA2_ex10_27 chr13 32913018 32913197 
BRCA2_ex10_28 chr13 32913133 32913333 
BRCA2_ex10_29 chr13 32913250 32913382 
BRCA2_ex10_30 chr13 32913318 32913454 
BRCA2_ex10_31 chr13 32913396 32913598 
BRCA2_ex10_32 chr13 32913491 32913669 
BRCA2_ex10_33 chr13 32913583 32913759 
BRCA2_ex10_33r chr13 32913566 32913758 
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BRCA2_ex10_34 chr13 32913674 32913883 
BRCA2_ex10_35 chr13 32913735 32913910 
BRCA2_ex10_36 chr13 32913854 32914019 
BRCA2_ex10_37 chr13 32913939 32914127 
BRCA2_ex10_38 chr13 32914006 32914206 
BRCA2_ex10_39 chr13 32914146 32914287 
BRCA2_ex10_40 chr13 32914225 32914408 
BRCA2_ex10_41 chr13 32914290 32914449 
BRCA2_ex10_42 chr13 32914394 32914573 
BRCA2_ex10_43 chr13 32914452 32914605 
BRCA2_ex10_44 chr13 32914560 32914689 
BRCA2_ex10_45 chr13 32914638 32914844 
BRCA2_ex10_46 chr13 32914795 32914971 
BRCA2_ex10_46r1 chr13 32914827 32914988 
BRCA2_ex10_46r2 chr13 32914755 32914924 
BRCA2_ex10_47 chr13 32914896 32915061 
BRCA2_ex10_48 chr13 32914946 32915095 
BRCA2_ex10_49 chr13 32915032 32915240 
BRCA2_ex10_50 chr13 32915157 32915364 
BRCA2_ex10_51 chr13 32915253 32915461 
BRCA2_ex11_1 chr13 32918555 32918763 
BRCA2_ex11_2 chr13 32918687 32918851 
BRCA2_ex12_1 chr13 32920895 32921044 
BRCA2_ex13_1 chr13 32928918 32929127 
BRCA2_ex13_2 chr13 32929074 32929253 
BRCA2_ex13_3 chr13 32929104 32929295 
BRCA2_ex13_4 chr13 32929240 32929397 
BRCA2_ex13_5 chr13 32929340 32929536 
BRCA2_ex14_1 chr13 32930503 32930636 
BRCA2_ex14_2 chr13 32930573 32930742 
BRCA2_ex14_3 chr13 32930661 32930870 
BRCA2_ex15_1 chr13 32931809 32932007 
BRCA2_ex15_2 chr13 32931904 32932113 
BRCA2_ex16_1 chr13 32936572 32936763 
BRCA2_ex16_2 chr13 32936649 32936821 
BRCA2_ex16_3 chr13 32936778 32936939 
BRCA2_ex17_1 chr13 32937215 32937401 
BRCA2_ex17_1r chr13 32937263 32937435 
BRCA2_ex17_2 chr13 32937347 32937512 
BRCA2_ex17_3 chr13 32937452 32937581 
BRCA2_ex17_4 chr13 32937537 32937668 
BRCA2_ex17_5 chr13 32937594 32937785 
BRCA2_ex18_1 chr13 32944422 32944613 
BRCA2_ex18_1r chr13 32944440 32944628 
BRCA2_ex18_2 chr13 32944546 32944696 
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BRCA2_ex18_3 chr13 32944603 32944733 
BRCA2_ex19_1 chr13 32945056 32945239 
BRCA2_ex19_2 chr13 32945140 32945279 
BRCA2_ex20_1 chr13 32950752 32950959 
BRCA2_ex21_1 chr13 32953401 32953606 
BRCA2_ex21_2 chr13 32953491 32953694 
BRCA2_ex22_1 chr13 32953773 32953978 
BRCA2_ex22_2 chr13 32953901 32954099 
BRCA2_ex22_1r1 chr13 32953850 32954025 
BRCA2_ex22_1r2 chr13 32953893 32954060 
BRCA2_ex22_1r3 chr13 32954003 32954185 
BRCA2_ex23_1 chr13 32954047 32954225 
BRCA2_ex23_2 chr13 32954179 32954375 
BRCA2_ex24_1 chr13 32968741 32968935 
BRCA2_ex24_2 chr13 32968827 32969028 
BRCA2_ex24_3 chr13 32968944 32969139 
BRCA2_ex25_1 chr13 32970909 32971109 
BRCA2_ex25_2 chr13 32971008 32971211 
BRCA2_ex26_1 chr13 32972189 32972375 
BRCA2_ex26_2 chr13 32972306 32972470 
BRCA2_ex26_3 chr13 32972421 32972628 
BRCA2_ex26_4 chr13 32972559 32972675 
BRCA2_ex26_5 chr13 32972600 32972774 
BRCA2_ex26_6 chr13 32972725 32972883 
BRCA2_ex26_7 chr13 32972817 32972988 
BRCA2_ex5_1 chr13 32900331 32900458 
 
BRIP1 
Amplicon chr Start End 
BRIP1_EX2_t1 chr17 59938820 59938979 
BRIP1_EX2_t2 chr17 59938723 59938909 
BRIP1_EX3_t1 chr17 59937113 59937296 
BRIP1_EX4_t1 chr17 59934461 59934660 
BRIP1_EX4_t2 chr17 59934388 59934533 
BRIP1_EX5_t1 chr17 59926496 59926667 
BRIP1_EX5_t2 chr17 59926404 59926580 
BRIP1_EX6_t1 chr17 59924424 59924617 
BRIP1_EX7_t1 chr17 59885975 59886147 
BRIP1_EX7_t2 chr17 59885877 59886071 
BRIP1_EX7_t3 chr17 59885825 59885997 
BRIP1_EX7_t4 chr17 59885725 59885923 
BRIP1_EX8_t1 chr17 59878683 59878879 
BRIP1_EX8_t2 chr17 59878566 59878762 
BRIP1_EX9_t1 chr17 59876535 59876721 
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BRIP1_EX9_t2 chr17 59876415 59876605 
BRIP1_EX10_t1 chr17 59870923 59871122 
BRIP1_EX11_t1 chr17 59861686 59861836 
BRIP1_EX11_t2 chr17 59861584 59861774 
BRIP1_EX12_t1 chr17 59858238 59858416 
BRIP1_EX12_t2 chr17 59858152 59858336 
BRIP1_EX13_t1 chr17 59857651 59857817 
BRIP1_EX13_t2 chr17 59857611 59857776 
BRIP1_EX14_t1 chr17 59853789 59853963 
BRIP1_EX14_t2 chr17 59853694 59853886 
BRIP1_EX15_t1 chr17 59821856 59822044 
BRIP1_EX15_t2 chr17 59821760 59821936 
BRIP1_EX16_t1 chr17 59820350 59820533 
BRIP1_EX17_t1 chr17 59793353 59793548 
BRIP1_EX17_t2 chr17 59793292 59793425 
BRIP1_EX18_t1 chr17 59770774 59770942 
BRIP1_EX18_t2 chr17 59770713 59770860 
BRIP1_EX19_t1 chr17 59763388 59763560 
BRIP1_EX19_t2 chr17 59763309 59763498 
BRIP1_EX19_t3 chr17 59763197 59763395 
BRIP1_EX19_t4 chr17 59763152 59763302 
BRIP1_EX20_t1 chr17 59761365 59761557 
BRIP1_EX20_t2 chr17 59761251 59761449 
BRIP1_EX20_t3 chr17 59761155 59761343 
BRIP1_EX20_t4 chr17 59761056 59761225 
BRIP1_EX20_t5 chr17 59760941 59761140 
BRIP1_EX20_t6 chr17 59760847 59761046 
BRIP1_EX20_t7 chr17 59760741 59760937 
BRIP1_EX20_t8 chr17 59760654 59760824 
BRIP1_EX20_t9 chr17 59760555 59760750 
 
PALB2 
Amplicon chr Start End 
PALB2_EX1_t1 chr16 23652356 23652513 
PALB2_EX2_t1 chr16 23649327 23649505 
PALB2_EX3_t1 chr16 23649139 23649301 
PALB2_EX4_t1 chr16 23647518 23647668 
PALB2_EX4_t2 chr16 23647424 23647609 
PALB2_EX4_t3 chr16 23647314 23647512 
PALB2_EX4_t4 chr16 23647214 23647389 
PALB2_EX4_t5 chr16 23647122 23647308 
PALB2_EX4_t6 chr16 23646995 23647194 
PALB2_EX4_t7 chr16 23646882 23647073 
PALB2_EX4_t8 chr16 23646775 23646969 
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PALB2_EX4_t9 chr16 23646670 23646869 
PALB2_EX4_t10 chr16 23646567 23646758 
PALB2_EX4_t11 chr16 23646460 23646640 
PALB2_EX4_t12 chr16 23646395 23646593 
PALB2_EX4_t13 chr16 23646244 23646443 
PALB2_EX4_t14 chr16 23646130 23646326 
PALB2_EX5_t1 chr16 23641636 23641834 
PALB2_EX5_t2 chr16 23641517 23641715 
PALB2-EX5_t3 chr16 23641394 23641587 
PALB2_EX5_t4 chr16 23641289 23641488 
PALB2_EX5_t5 chr16 23641188 23641387 
PALB2_EX5_t6 chr16 23641073 23641261 
PALB2_EX5_t7 chr16 23640967 23641161 
PALB2_EX5_t8 chr16 23640861 23641052 
PALB2_EX6_t1 chr16 23640491 23640672 
PALB2_EX7_t1 chr16 23637560 23637758 
PALB2_EX7_t2 chr16 23637455 23637645 
PALB2_EX8_t1 chr16 23635297 23635483 
PALB2_EX9_t1 chr16 23634292 23634489 
PALB2_EX9_t2 chr16 23634179 23634378 
PALB2_EX10_t1 chr16 23632650 23632848 
PALB2_EX11_t1 chr16 23625297 23625476 
PALB2_EX12_t1 chr16 23619192 23619361 
PALB2_EX12_t2 chr16 23619085 23619278 
PALB2_EX13_t1 chr16 23614894 23615081 
PALB2_EX13_t2 chr16 23614757 23614956 
PALB2_EX13_t3 chr16 23614654 23614832 
 
NBN 
Amplicon Chr Start End 
NBN_EX1_t1 chr8 90996705 90996847 
NBN_EX2_t1 chr8 90994951 90995147 
NBN_EX2_t2 chr8 90994896 90995067 
NBN_EX3_t1 chr8 90993644 90993809 
NBN_EX3_t2 chr8 90993553 90993744 
NBN_EX4_t1 chr8 90993024 90993175 
NBN_EX4_t2 chr8 90992902 90993100 
NBN_EX5_t1 chr8 90990451 90990650 
NBN_EX5_t2 chr8 90990354 90990550 
NBN_EX6_t1 chr8 90983400 90983598 
NBN_EX6_t2 chr8 90983302 90983486 
NBN_EX7_t1 chr8 90982634 90982808 
NBN_EX7_t2 chr8 90982539 90982736 
NBN_EX8_t1 chr8 90976650 90976820 
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NBN_EX8_t2 chr8 90976533 90976729 
NBN_EX9_t1 chr8 90970923 90971121 
NBN_EX10_t1 chr8 90967624 90967823 
NBN_EX10_t2 chr8 90967541 90967719 
NBN_EX10_t3 chr8 90967421 90967616 
NBN_EX11_t1 chr8 90965771 90965969 
NBN_EX11_t2 chr8 90965650 90965845 
NBN_EX11_t3 chr8 90965531 90965724 
NBN-EX11_t4 chr8 90965415 90965606 
NBN_EX12_t1 chr8 90960004 90960171 
NBN_EX13_t1 chr8 90958416 90958598 
NBN_EX13_t2 chr8 90958309 90958508 
NBN_EX14_t1 chr8 90955456 90955651 
NBN_EX15_t1 chr8 90949219 90949342 
NBN_EX16_t1 chr8 90947748 90947873 
 
BARD1 
Amplicon chr Start End 
BARD1_EX1_t1 chr2 215674121 215674320 
BARD1_EX2_t1 chr2 215661801 215661902 
BARD1_EX3_t1 chr2 215657067 215657218 
BARD1_EX4_ta1 chr2 215646097 215646293 
BARD1_EX4_t1 chr2 215646014 215646164 
BARD1_EX4_t2 chr2 215645889 215646084 
BARD1_EX4_t3 chr2 215645829 215646018 
BARD1_EX4_t4 chr2 215645744 215645925 
BARD1_EX4_t5 chr2 215645683 215645849 
BARD1_EX4_t6 chr2 215645617 215645781 
BARD1_EX4_t7 chr2 215645538 215645733 
BARD1_EX4_t8 chr2 215645464 215645636 
BARD1_EX4_t9 chr2 215645411 215645578 
BARD_ EX4_t10 chr2 215645346 215645522 
BARD1_EX4_t11 chr2 215645243 215645428 
BARD1_EX4_t12 chr2 215645150 215645320 
BARD1_EX5_t1 chr2 215633927 215634126 
BARD1_EX6_t1 chr2 215632220 215632418 
BARD_ EX6_t2 chr2 215632095 215632291 
BARD1_EX7_t1 chr2 215617142 215617328 
BARD_ EX8_t1 chr2 215610423 215610622 
BARD1_EX9_t1 chr2 215609757 215609929 
BARD1_EX10_t1 chr2 215595092 215595278 
BARD1_EX11_t1 chr2 215593566 215593765 
BARD1_EX11_t2 chr2 215593482 215593681 
BARD1_EX11_t3 chr2 215593354 215593553 
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Appendix X 
Amplicon maps of target regions for additional genes in 9-gene study 
The following diagrams are amplicon maps of target regions for each gene 
BRCA1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 343 
BRCA2  
 
  
 344 
BRIP1 
 
 
PALB2 
 
 
 
NBN 
 
 
 
 
BARD1 
 
 
